Download 2014 AES Program Book

ANNUAL MEETING
PROGRAM BOOK
2014
DECEMBER 5 - 9
Washington State Convention Center | Seattle, WA
Biennial North American Regional Epilepsy Congress
5th
Visit BOOTH
#405 to learn more
t
h
g
i
F
o
t
y
d
a
e
R
Bobby, age 47,
diagnosed with LGS.
ONFI® (clobazam) is FIERCELY DEDICATED
to helping Bobby & Julian fight their seizures.
ONFI is indicated for the adjunctive treatment of
seizures associated with Lennox-Gastaut syndrome (LGS)
in patients 2 years of age or older.
Julian, age 6,
diagnosed with LGS.
Important Safety Information
• ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was
dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued
treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central
nervous system (CNS) depressants. Prescribers should caution patients against engaging in hazardous activities that require mental
alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known.
• ONFI has a CNS depressant effect. Patients should be cautioned against the simultaneous use with other CNS depressant drugs
or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated.
• As with all antiepileptic drugs (AEDs), ONFI should be gradually withdrawn to minimize the risk of precipitating seizures, seizure
exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuation of ONFI; the risk
of withdrawal symptoms is greater with higher doses.
• Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been
reported with ONFI in both children and adults during the post-marketing period. ONFI should be discontinued at the first sign
of rash, unless the rash is clearly not drug-related.
• Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents
because of the predisposition of such patients to habituation and dependence. In clinical trials, cases of dependency were reported
following abrupt discontinuation of ONFI. The risk of dependence increases with increasing dose and duration of treatment.
• AEDs, including ONFI, increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be
informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or
any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider whether it may be related to
the AED or illness, because epilepsy itself can increase these risks.
• The most commonly observed adverse reactions reported in an LGS randomized, double-blind, placebo-controlled, parallel group
clinical trial who received clobazam as adjunctive therapy (≥10% in any treatment group and at least 5% greater than placebo,
respectively) were somnolence or sedation (32% vs. 15%), somnolence (25% vs. 12%), pyrexia (17% vs. 3%), lethargy (15% vs. 5%),
drooling (14% vs. 3%), aggression (14% vs. 5%), irritability (11% vs. 5%), ataxia (10% vs. 3%), and constipation (10% vs. 0%).
Please see Brief Summary of Prescribing Information on the following pages. For full Prescribing Information, Medication Guide, and Instructions for Use, go to www.ONFI.com.
©2014 Lundbeck. All rights reserved.
ONFI is a registered trademark of Lundbeck CLB-B-00123 09/2014
1
ONFI® (clobazam) tablets, for oral use,
ONFI® (clobazam) oral suspension,
Brief Summary of Prescribing Information
(See package insert for full Prescribing Information or visit www.ONFI.com)
Rx Only
INDICATIONS AND USAGE – ONFI® (clobazam) is indicated for the adjunctive
treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients
2 years of age or older.
CONTRAINDICATIONS – None [see Contraindications].
WARNINGS AND PRECAUTIONS – Somnolence or Sedation: ONFI causes
somnolence and sedation. In clinical trials, somnolence or sedation was reported
at all effective doses and was dose-related. In general, somnolence and sedation
begin within the first month of treatment and may diminish with continued
treatment. Prescribers should monitor patients for somnolence and sedation,
particularly with concomitant use of other central nervous system depressants.
Prescribers should caution patients against engaging in hazardous activities
requiring mental alertness, such as operating dangerous machinery or motor
vehicles, until the effect of ONFI is known [see Warnings and Precautions].
Potentiation of Sedation from Concomitant Use with Central Nervous System
Depressants: Since ONFI has a central nervous system (CNS) depressant effect,
patients or their caregivers should be cautioned against simultaneous use with
other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS
depressant drugs or alcohol may be potentiated [see Warnings and Precautions].
Withdrawal Symptoms: Abrupt discontinuation of ONFI should be avoided.
ONFI should be tapered by decreasing the dose every week by 5-10 mg/day
until discontinuation [see Dosage and Administration]. As with all antiepileptic
drugs, ONFI should be withdrawn gradually to minimize the risk of precipitating
seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms
have been reported following abrupt discontinuance of benzodiazepines. The
more severe withdrawal symptoms have usually been limited to patients who
received excessive doses over an extended period of time, followed by an
abrupt discontinuation. Generally milder withdrawal symptoms have been
reported following abrupt discontinuance of benzodiazepines taken continuously
at therapeutic doses for several months [see Warnings and Precautions].
Serious Dermatological Reactions: Serious skin reactions, including StevensJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported
with ONFI in both children and adults during the post-marketing period. Patients
should be closely monitored for signs or symptoms of SJS/TEN, especially during
the first 8 weeks of treatment initiation or when re-introducing therapy. ONFI should
be discontinued at the first sign of rash, unless the rash is clearly not drug-related.
If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed
and alternative therapy should be considered [see Warnings and Precautions].
Physical and Psychological Dependence: Patients with a history of substance
abuse should be under careful surveillance when receiving ONFI or other
psychotropic agents because of the predisposition of such patients to habituation
and dependence [see Drug Abuse and Dependence]. Suicidal Behavior and
Ideation: Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal
thoughts or behavior in patients taking these drugs for any indication. Patients
treated with any AED for any indication should be monitored for the emergence
or worsening of depression, suicidal thoughts or behavior, and/or any unusual
changes in mood or behavior. The increased risk of suicidal thoughts or behavior
with AEDs was observed as early as one week after starting drug treatment with
AEDs and persisted for the duration of treatment assessed. Because most trials
included in the analysis did not extend beyond 24 weeks, the risk of suicidal
thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal
thoughts or behavior was generally consistent among drugs in the data analyzed.
The finding of increased risk with AEDs of varying mechanisms of action and
across a range of indications suggests that the risk applies to all AEDs used for any
indication. The relative risk for suicidal thoughts or behavior was higher in clinical
trials for epilepsy than in clinical trials for psychiatric or other conditions, but the
absolute risk differences were similar for the epilepsy and psychiatric indications.
Anyone considering prescribing ONFI or any other AED must balance the risk of
suicidal thoughts or behavior with the risk of untreated illness. Should suicidal
thoughts and behavior emerge during treatment, the prescriber needs to consider
whether the emergence of these symptoms in any given patient may be related to
the illness being treated. Patients, their caregivers, and families should be informed
that AEDs increase the risk of suicidal thoughts and behavior and should be advised
of the need to be alert for the emergence or worsening of the signs and symptoms of
depression, any unusual changes in mood or behavior, or the emergence of suicidal
thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be
reported immediately to healthcare providers [see Warnings and Precautions].
ADVERSE REACTIONS – Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical trials of a
drug cannot be directly compared to rates in the clinical trials of another drug
2
and may not reflect the rates observed in practice. During its development
for the adjunctive treatment of seizures associated with LGS, ONFI was
administered to 333 healthy volunteers and 300 patients with a current
or prior diagnosis of LGS, including 197 patients treated for 12 months
or more. The conditions and duration of exposure varied greatly and
included single- and multiple-dose clinical pharmacology studies in healthy
volunteers and two double-blind studies in patients with LGS (Study 1 and 2)
[see Clinical Studies]. Only Study 1 included a placebo group, allowing comparison
of adverse reaction rates on ONFI at several doses to placebo. Adverse Reactions
Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1):
The adverse reactions associated with ONFI treatment discontinuation in ≥1%
of patients in decreasing order of frequency included lethargy, somnolence,
ataxia, aggression, fatigue, and insomnia. Most Common Adverse Reactions in
an LGS Placebo Controlled Clinical Trial (Study 1): Table 3 in the full Prescribing
Information lists the adverse reactions that occurred in ≥5% of ONFI treated
patients (at any dose), and at a rate greater than placebo treated patients, in the
randomized, double-blind, placebo-controlled, parallel group clinical study of
adjunctive AED therapy for 15 weeks (Study 1).
Table 3. Adverse Reactions Reported for ≥5% of Patients and More Frequently
than Placebo in Any Treatment Group
ONFI Dose Level
Placebo Lowa Mediumb Highc All ONFI
N=59
N=58
N=62
N=59
N=179
%
%
%
%
%
Gastrointestinal Disorders
Vomiting
5
9
5
7
7
Constipation
0
2
2
10
5
Dysphagia
0
0
0
5
2
General Disorders and Administration Site Conditions
Pyrexia
3
17
10
12
13
Irritability
5
3
11
5
7
Fatigue
2
5
5
3
5
Infections and Infestations
Upper respiratory
10
10
13
14
12
tract infection
Pneumonia
2
3
3
7
4
Urinary tract infection
0
2
5
5
4
Bronchitis
0
2
0
5
2
Metabolism and Nutrition Disorders
Decreased appetite
3
3
0
7
3
Increased appetite
0
2
3
5
3
Nervous System Disorders
Somnolence or Sedation
15
17
27
32
26
Somnolence
12
16
24
25
22
Sedation
3
2
3
9
5
Lethargy
5
10
5
15
10
Drooling
3
0
13
14
9
Ataxia
3
3
2
10
5
Psychomotor hyperactivity
3
3
3
5
4
Dysarthria
0
2
2
5
3
Psychiatric Disorders
Aggression
5
3
8
14
8
Insomnia
2
2
5
7
5
Respiratory Disorders
Cough
0
3
5
7
5
a
Maximum daily dose of 5 mg for ≤30 kg body weight; 10 mg for >30 kg body weight
b
Maximum daily dose of 10 mg for ≤30 kg body weight; 20 mg for >30 kg body weight
c
Maximum daily dose of 20 mg for ≤30 kg body weight; 40 mg for >30 kg body weight
Post Marketing Experience: These reactions are reported voluntarily from
a population of uncertain size; therefore, it is not possible to estimate their
frequency or establish a causal relationship to drug exposure. Adverse reactions
are categorized by system organ class. Blood Disorders: Anemia, eosinophilia,
leukopenia, thrombocytopenia; Eye Disorders: Diplopia, vision blurred;
Gastrointestinal Disorders: Abdominal distention; Investigations: Hepatic
enzyme increased; Musculoskeletal: Muscle spasms; Psychiatric Disorders:
Agitation, anxiety, apathy, confusional state, depression, delirium, delusion,
hallucination; Respiratory Disorders: Aspiration, respiratory depression;
Skin and Subcutaneous Tissue Disorders: Rash, Stevens-Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN), urticaria.
DRUG INTERACTIONS – Effect of ONFI on Other Drugs: ONFI is a weak CYP3A4
inducer. As some hormonal contraceptives are metabolized by CYP3A4,
their effectiveness may be diminished when given with ONFI. Additional
non-hormonal forms of contraception are recommended when using ONFI
[see Clinical Pharmacology, Patient Counseling Information]. ONFI inhibits
CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary
[see Clinical Pharmacology]. Effect of Other Drugs on ONFI: Strong and moderate
inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam,
the active metabolite of clobazam. This may increase the risk of dose-related
adverse reactions. Dosage adjustment of ONFI may be necessary when
coadministered with strong CYP2C19 inhibitors (e.g., fluconazole,
fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole)
[see Clinical Pharmacology]. CNS Depressants and Alcohol: Concomitant use of
ONFI with other CNS depressants may increase the risk of sedation and somnolence
[see Warnings and Precautions].
USE IN SPECIFIC POPULATIONS – Pregnancy - Pregnancy Registry: To provide
information regarding the effects of in utero exposure to ONFI, physicians are advised to
recommend that pregnant patients taking ONFI enroll in the North American Antiepileptic
Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number
1-888-233-2334, and must be done by patients themselves or their caregiver. Information
on the registry can also be found at the website http://www.aedpregnancyregistry.org/.
Pregnancy Category C: There are no adequate and well-controlled studies of ONFI
in pregnant women and no adequate developmental toxicity studies of clobazam in
animals. Although limited, the available animal data suggest developmental toxicity,
including an increased incidence of fetal abnormalities following oral administration
of clobazam to pregnant animals at doses similar to those used clinically. Data
for other benzodiazepines suggest the possibility of adverse effects in animals
and humans. Long-term effects on neurobehavioral and immunological function
have been reported in rodents following prenatal exposure to benzodiazepines.
Neonatal flaccidity, respiratory and feeding difficulties, hypothermia, and
withdrawal symptoms have been reported in infants born to mothers who
received benzodiazepines, including clobazam, late in pregnancy. Therefore, ONFI
should be used during pregnancy only if the potential benefit justifies the potential
risk to the fetus [see Use in Specific Populations]. Nursing Mothers: ONFI is
excreted in human milk. The effects of this exposure on infants are unknown
[see Use in Specific Populations]. Pediatric Use: The safety and effectiveness
in patients less than 2 years of age have not been established. In a study in
which clobazam (4, 36, or 120 mg/kg/day) was orally administered to rats
during the juvenile period of development (postnatal days 14 to 48), adverse
effects on growth (decreased bone density and bone length) and behavior
(altered motor activity and auditory startle response; learning deficit) were
observed at the high dose. The effect on bone density, but not on behavior,
was reversible when drug was discontinued. The no-effect level for juvenile
toxicity (36 mg/kg/day) was associated with plasma exposures (AUC) to
clobazam and its major active metabolite, N-desmethylclobazam, less than
those expected at therapeutic doses in pediatric patients. Geriatric Use:
Clinical studies of ONFI did not include sufficient numbers of subjects aged
65 and over to determine whether they respond differently from younger subjects.
However, elderly subjects appear to eliminate clobazam more slowly than younger
subjects based on population pharmacokinetic analysis. For these reasons, the
initial dose in elderly patients should be 5 mg/day. Patients should be titrated
initially to 10-20 mg/day. Patients may be titrated further to a maximum daily dose
of 40 mg if tolerated [see Dosage and Administration, Clinical Pharmacology].
CYP2C19 Poor Metabolizers: Concentrations of clobazam’s active metabolite,
N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in
extensive metabolizers. For this reason, the initial dose in patients known
to be CYP2C19 poor metabolizers should be 5 mg/day. Dose titration
should proceed slowly according to weight to 10-20 mg/day, and may be
titrated further to a maximum daily dose of 40 mg on day 21 based upon
clinical response [see Dosage and Administration, Clinical Pharmacology].
Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients with
mild and moderate renal impairment. There were no significant differences
in systemic exposure (AUC and Cmax) between patients with mild or moderate
renal impairment and healthy subjects. No dose adjustment is required for
patients with mild and moderate renal impairment. There is essentially no
experience with ONFI in patients with severe renal impairment or ESRD.
It is not known if clobazam or its active metabolite, N-desmethylclobazam,
is dialyzable [see Dosage and Administration, Clinical Pharmacology].
Hepatic Impairment: ONFI is hepatically metabolized; however, there are limited
data to characterize the effect of hepatic impairment on the pharmacokinetics of
ONFI. For this reason, the initial dose in patients with mild to moderate hepatic
impairment (Child-Pugh score 5-9) should be 5 mg/day. These patients should be
titrated according to weight to 10 to 20 mg/day, and may be titrated further to a
maximum daily dose of 40 mg on day 21 based upon clinical response. There is
inadequate information about metabolism of ONFI in patients with severe hepatic
impairment. Therefore no dosing recommendation in those patients can be given
[see Dosage and Administration, Clinical Pharmacology].
DRUG ABUSE AND DEPENDENCE – Controlled Substance: ONFI contains
clobazam which is a Schedule IV controlled substance. Abuse: ONFI can be
abused in a similar manner as other benzodiazepines, such as diazepam. The
pharmacological profile of ONFI is similar to that of other benzodiazepines
listed in Schedule IV of the Controlled Substance Act, particularly in its
potentiation of GABAergic transmission through its action on GABAA
receptors, which leads to sedation and somnolence. The World Health
Organization epidemiology database contains reports of drug abuse, misuse,
and overdoses associated with clobazam [see Drug Abuse and Dependence].
Dependence: In clinical trials, cases of dependency were reported following
abrupt discontinuation of ONFI. The risk of dependence is present even with use
of ONFI at the recommended dose range over periods of only a few weeks. The
risk of dependence increases with increasing dose and duration of treatment.
The risk of dependence is increased in patients with a history of alcohol or
drug abuse. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal
symptoms. As with other benzodiazepines, ONFI should be withdrawn
gradually [see Dosage and Administration, Warnings and Precautions].
In ONFI clinical pharmacology trials in healthy volunteers, the most common
withdrawal symptoms after abrupt discontinuation were headache, tremor,
insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations, and diarrhea
[see Warnings and Precautions]. Other withdrawal reactions to clobazam reported
in the literature include restlessness, panic attacks, profuse sweating, difficulty in
concentrating, nausea and dry retching, weight loss, blurred vision, photophobia,
and muscle pain and stiffness. In general, benzodiazepine withdrawal may cause
seizures, psychosis, and hallucinations [see Warnings and Precautions].
OVERDOSAGE – Signs and Symptoms of Overdosage: Overdose and
intoxication with benzodiazepines, including ONFI, may lead to CNS
depression, associated with drowsiness, confusion and lethargy, possibly
progressing to ataxia, respiratory depression, hypotension, and, rarely,
coma or death. The risk of a fatal outcome is increased in cases of combined
poisoning with other CNS depressants, including alcohol [see Overdosage].
Management of Overdosage: The management of ONFI overdose may include
gastric lavage and/or administration of activated charcoal, intravenous fluid
replenishment, early control of airway and general supportive measures, in addition
to monitoring level of consciousness and vital signs. Hypotension can be treated
by replenishment with plasma substitutes and, if necessary, with sympathomimetic
agents. The efficacy of supplementary administration of physostigmine
(a cholinergic agent) or of flumazenil (a benzodiazepine antagonist) in ONFI overdose
has not been assessed. The administration of flumazenil in cases of benzodiazepine
overdose can lead to withdrawal and adverse reactions. Its use in patients with
epilepsy is typically not recommended [see Management of Overdosage].
Lundbeck
Deerfield, IL 60015, U.S.A.
ONFI is a registered trademark of Lundbeck
November 2013
CLB-L-00001a
3
4
Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN 55369 | 1-800-654-2299
© 2014 Upsher-Smith Laboratories, Inc. 109864.01
Booth 823
5
FRIDAY November 30, 2007
UCB welcomes
you to AES
Visit us at booth 205 for exciting new
information on VIMPAT® for your patients.
VIMPAT is a registered trademark under license from Harris FRC Corporation.
©2014, UCB, Inc., Smyrna, GA 30080.
All rights reserved. LCM-PRM-035038-0914
®
6
Visit the
AES Booth
to…
1 in 3
readers take action as a result
of reading AES Connections
in their inbox every other Friday
Socialize
n Watch Video Interviews
n Review Publications
n See Live Demos
n Learn More About AES
n
See You at Booth #125
in the Exhibit Hall
AES Career Center
Your hub for hundreds of jobs, maximum
exposure to top opportunities, and highly
qualified applicants
• Clinical and research positions for epilepsy and
neurology professionals
• Easy-to-use and highly targeted resources for
online employment connections
• Access to the National Healthcare Career
Network (NHCN), connecting you to the career
centers of over 290 top healthcare associations
and professional organizations.
AES Connections
Become an Engaged Member
...Great Conversation
...Connected Community
...Different Perspectives
Share Yours Today
AES Connect
connect.aesnet.org
careers.aesnet.org
7
WELCOME MESSAGE
Welcome to Seattle and our 68th AES Annual Meeting!
To previous attendees, we are thrilled to have you back. To first time attendees, it is a pleasure to
welcome you into the AES Community. As you settle in and start off your week, I encourage you to take
notice of the energy within the convention center. I like to refer to the Annual Meeting as the Annual
“Reunion,” a time when colleagues, friends and even family, reunite under the common goal to cure the
epilepsies. I assure you that your time in Seattle will be filled with learning, networking and fun. Don’t
forget to connect with the larger AES Community on Twitter #aesmtg14.
Within this program book you will find a broad schedule of programs, exhibits, social events and
networking opportunities that invite your participation. Quality educational sessions have been organized
by your AES Annual Meeting and Scientific Program Committees targeted to the professional needs and
wide interests of meeting attendees. This year’s lineup of programs was carefully selected based on your
feedback:
n
Poster Walking Tours – Take a stroll through the Exhibit Hall and experience an enhanced learning
opportunity as authors present their posters throughout the week. Enjoy this feature of the AES
meeting by joining one of the popular Poster Walking Tours led by thought leaders. See page 15 for the
schedule.
n
Fellows Program – We are proud to continue the AES Epilepsy Fellows Program, which supports 95
trainees in epilepsy fellowships, and 10 Ph.D.s doing epilepsy research. Fellows are paired with mentors
for career guidance and support, giving them the opportunity to learn and connect with others
throughout the meeting.
n
Social Networking Groups – SIG, Investigators’ Workshops and symposium participants have a greater
opportunity to meet and continue group discussions during social networking hours on Sunday from
8:00 p.m. to 10:00 p.m.
n
Annual Meeting Mobile App – Access meeting information. Network with fellow attendees. Even
organize your schedule at your fingertips! If you have not done so already, download the AES Annual
Meeting App to your smartphone.
I invite you to join me at that this year’s Presidential Symposium, The AES International Biomarker Competition:
The Crowd, the Cloud, Detection and Prediction, taking place on Saturday, December 6 from 8:30 a.m. to
11:45 a.m. Together we will find out who the winners are and their novel solutions in seizure detection
and prediction. This session is a must see, I guarantee it!
Have a great meeting!
Elson So, M.D.
President, American Epilepsy Society
2014 AES BOARD OF DIRECTORS
PRESIDENT
Elson L. So, M.D.
FIRST VICE PRESIDENT
Amy Brooks-Kayal, M.D.
SECOND VICE PRESIDENT
Michael D. Privitera, M.D.
BOARD MEMBERS
Bruce E. Hermann, Ph.D.
EX-OFFICIO
Eileen M. Murray, MM, CAE, AES Executive Director
David M. Labiner, M.D.
Brandy Fureman, Ph.D. (NIH/NINDS)
Jack M. Parent, M.D., Ph.D.
Philip Gattone (Epilepsy Foundation)
Helen E. Scharfman, Ph.D.
Sheryl Haut, M.D. (North American Commission / ILAE)
Shlomo Shinnar, M.D., Ph.D.
Karen S. Wilcox, Ph.D.
Robert E. Hogan , M.D. (Education)
Jaideep Kapur, M.D., Ph.D. (Development)
TREASURER
William D. Gaillard, M.D.
Kimford J. Meador, M.D. (Research)
PAST PRESIDENT
Jacqueline A. French, M.D.
Carl E. Stafstrom, M.D., Ph.D. (Epilepsy Currents)
Joseph I. Sirven, M.D. (Epilepsy Foundation PAB)
William H. Theodore, M.D. (Communications & MOC Liaison)
James W. Wheless, M.D. (Clinical Council & AAN Liaison)
8
TABLE OF CONTENTS
FRIDAY
SATURDAY
SUNDAY
MONDAY
TUESDAY
Epilepsy Specialist Symposium ......................................................28
Annual Fundamentals of Epilepsy Symposium .................28
28th Annual Advances in the Management of
Epilepsy and the Epilepsy Clinic .................................................29
Professional Development in AES ...............................................29
Special Interest Group Meetings ................................................29
Hoyer Lecture ................................................................................................30
Spanish Symposium ..................................................................................30
Special Interest Group Meetings ................................................30
Mentoring Session for Junior Investigators .....................32
Special Interest Group Meetings ................................................32
Presidential Symposium........................................................................33
Antiepileptic Therapy Symposium ................................................33
Investigators’ Workshop ......................................................................34
Professionals in Epilepsy Care Symposium ........................34
North American Commission Symposium ............................35
Poster Session 1 ........................................................................................36
Investigators’ Workshops ...................................................................47
Annual Course ................................................................................................49
Special Interest Group Meetings ................................................50
Social Networking Groups ..................................................................50
Poster Session 2 ........................................................................................51
TABLE OF CONTENTS
Meeting
Information
Schedule-at-a-Glance ..............................................................................12
Poster Walking Tours ...............................................................................15
Poster Schedule .........................................................................................17
AES Special Recognition ......................................................................18
Berry, Grass and Nurse Awardees ............................................20
Young Investigator Awardees ..........................................................21
Special Interest Group Schedule .................................................22
Scientific Exhibit Schedule .................................................................23
Exhibitor Locations ...................................................................................82
Abstract Author Index ...........................................................................93
General Information ...............................................................................120
Faculty Ready Room and Photos ..............................................122
Watch for
these
2015 dates!
Annual Meeting
Call for Abstracts
Available
March 1, 2015
AES Research
Recognition
and Distinguished
Achievement Awards
Nominations
August 1, 2015
AES 2015
Annual Meeting
December 4 - 8
Philadelphia, PA
Pennsylvania Convention Center
Special Interest Group Meetings ................................................61
Merritt-Putnam Symposium .............................................................61
Special Interest Group Meetings ................................................62
Lennox and Lombroso Lecture .......................................................62
Investigators’ Workshop ......................................................................63
FDA Town Hall Update ............................................................................63
Pediatric Epilepsy Highlights Session......................................63
Pediatric State of the Art Symposium ..................................64
Platform Sessions ......................................................................................65
Poster Session 3 ........................................................................................66
Special Interest Group Meetings ................................................77
Hot Topics Symposium ...........................................................................78
Scientific Symposium ..............................................................................78
AES is an ACCME accredited provider.
9
Lighten your load and receive session handouts
and important meeting information electronically!
Accounts have been pre-created for all
pre-registered attendees.
On-site registrants may sign up online.
For instructions:
Please refer to the flyer provided in your
meeting bag or for further details go to
www.aesnet.org/meetings_events/
annual_meeting/general_info
Questions
virtualTotebag Support Desk: 410.402.1062
email: [email protected]
Go here:
www.aesnet.org/meetings_events/
annual_meeting/meeting_app
The AES Annual Meeting
is at your fingertips!
Stay up to the minute about sessions, schedules,
conversations and activities at the 68th Annual Meeting.
#AESMTG14 – official meeting hashtag
Wi-Fi available throughout Convention Center
(except in the Exhibit Hall and Poster Sessions)
American Epilepsy Society
10
is proud to recognize the following supporters
of the 2014 Annual Meeting.
Benefactor Level
$500,000 +
Sunovion Pharmaceuticals, Inc.
Leader Level
$250,000 – $499,999
Eisai, Inc.
UCB, Inc.
Partner Level
$100,000 – $249,999
Lundbeck Pharmaceuticals, Inc.
Upsher-Smith Laboratories, Inc.
Supporter Level
$50,000 – $99,999
Cyberonics, Inc.
Natus Neurology Incorporated
Supernus Pharmaceuticals, Inc.
Mallinckrodt Pharmaceuticals
Acorda Therapeutics
Contributor Level
$25,000 – $49,999
Nihon Kohden America, Inc.
Cadwell Laboratories, Inc
Compumedics Limited
Pfizer Inc.
Advocate Level
$10,000 – $24,999
Neuropace, Inc.
ELEKTA
Electrical Geodesics, Inc.
GW Pharmaceuticals
Medtronic, Inc.
Blackrock Microsystems, LLC
Patron Level
$5,000 – $9,999
Rhythm Link
Ad-Tech Medical Instrument Corp.
Monteris Medical, Inc.
Medical Neurogenetics, LLC
Nexstim, Inc.
Neurolynx, Inc.
PMT Corporation
Ripple LLC
Lifelines Neurodiagnostics Systems, Inc.
The Jack Pribaz Foundation
Listing is in order of support level as of October XX, 2014
Listing is in order of support level as of October 21, 2014
11
SCHEDULE-AT-A-GLANCE
THURSDAY
5:00 p.m. - 7:00 p.m.
December 4
Registration
Convention Center – South Lobby, Level 4
FRIDAY
7:00 a.m. - 6:00 p.m.
December 5
Registration
3:30 p.m. - 5:30 p.m.
Convention Center – South Lobby, Level 4
8:30 a.m. - 11:30 a.m.
Epilepsy Specialist Symposium:
The Generalized Epilepsies
3:30 p.m. - 6:00 p.m.
Convention Center – Ballroom 6E, Level 6
12:30 p.m. - 3:00 p.m.
1:30 p.m. - 3:00 p.m.
Hoyer Lecture
Convention Center – Ballroom 6E, Level 6
Spanish Symposium: Complementary and
Alternative Approaches to Epilepsy Treatments
Convention Center – Room 612, Level 6
Annual Fundamentals of Epilepsy Symposium:
The Side Effects of Epilepsy Treatment
5:30 p.m. - 6:15 p.m.
Convention Center – Ballroom 6E, Level 6
6:00 p.m. - 7:30 p.m.
Symposia Break
Convention Center – Level 6
Professional Development in AES: A Program
for Junior Members and Those in Transition
Special Interest Group Meetings
See page 30
Convention Center – Room 603, Level 6
Special Interest Group Meetings
See page 29
SATURDAY
6:30 a.m. - 6:00 p.m.
Registration
December 6
2:15 p.m. - 5:00 p.m.
Convention Center – South Lobby, Level 4
6:30 a.m. - 7:00 a.m.
Continental Breakfast
Convention Center – Level 6
7:00 a.m. - 8:30 a.m.
Mentoring Session for Junior Investigators
Convention Center – Room 307 / 308, Level 3
7:00 a.m. - 8:30 a.m.
5:00 p.m. - 6:00 p.m.
5:15 p.m. - 7:45 p.m.
SUNDAY
Registration
7:00 p.m. - 10:00 p.m.
December 7
8:45 a.m. - 5:15 p.m.
Poster Session 2
(includes late-breaking abstracts)
Continental Breakfast
10:00 a.m. - 6:00 p.m.
See page 47
12
Exhibit Hall
Reception: Suds for Science 5:00 p.m. - 6:00 p.m.
Convention Center – Hall 4B, Level 4
6:00 p.m. - 7:30 p.m.
Convention Center – Hall 4B, Level 4
Investigators’ Workshops
IW Posters / Boxed Lunch: Noon - 1:30 p.m.
Annual Course: Seizures and EEG in the
Critically Ill Patient
Convention Center – Ballroom 6C, Level 6
Scientific Exhibits
See page 23
Third Annual Wine Tasting and Silent Auction
See page 27
Convention Center – South Lobby, Level 4
8:45 a.m. - 4:45 p.m.
North American Commission Symposium:
Pediatric Epilepsy Surgery: Update on Current
Practice
Convention Center – Ballroom 6E, Level 6
Convention Center – Hall 4B, Level 4
Lunch: Noon - 1:00 p.m.
8:00 a.m. - 6:00 p.m.
Professionals in Epilepsy Care Symposium:
Practical Applications for the Comprehensive
Treatment of Epilepsy
Convention Center – Ballroom 6C, Level 6
5:30 p.m. - 7:30 p.m.
Exhibit Hall – Grand Opening
Poster Session 1
8:00 a.m. - 5:00 p.m.
Symposium Break
Convention Center – Hall 4B, Level 4
Convention Center – Hall 4B, Level 4
7:30 a.m. - 6:00 p.m.
Investigators’ Workshop
Convention Center – Ballroom 6E, Level 6
Presidential Symposium: The AES International
Biomarker Competition: The Crowd, the Cloud,
Detection and Prediction
Convention Center – Ballroom 6C, Level 6
Noon - 6:00 p.m.
Convention Center – Ballroom 6C, Level 6
2:30 p.m. - 4:00 p.m.
Special Interest Group Meetings
See page 32
8:30 a.m. - 11:45 a.m.
Antiepileptic Therapy Symposium:
The New AEDs: Where Do They Belong in
Your Armamentarium?
Special Interest Group Meetings
See page 50
8:00 p.m. - 10:00 p.m.
Social Networking Groups
Sheraton – Madrona, Second Floor
SCHEDULE-AT-A-GLANCE
MONDAY
Registration
2:15 p.m. - 3:00 p.m.
Convention Center – South Lobby, Level 4
6:30 a.m. - 7:00 a.m.
Continental Breakfast
3:00 p.m. - 4:30 p.m.
Convention Center – Level 6
7:00 a.m. - 8:30 a.m.
Special Interest Group Meetings
8:00 a.m. - 5:00 p.m.
8:45 a.m. - Noon
Poster Session 3
Continental Breakfast
3:00 p.m. - 5:00 p.m.
FDA Town Hall Update: SUDEP and
Clinical Trials
Convention Center – Room 612, Level 6
3:00 p.m. - 5:15 p.m.
Pediatric Epilepsy Highlights Session
Convention Center – Hall 4B, Level 4
Convention Center – Ballroom 6E, Level 6
Scientific Exhibits
Platform Sessions (3 Concurrent)
See page 23
See page 65
Merritt-Putnam Symposium: Stress,
Cannabinoids and Epilepsy: The Science
Behind the Buzz
Convention Center – Ballroom 6C, Level 6
9:00 a.m. - 10:30 a.m.
Investigators’ Workshop
Convention Center – Room 607, Level 6
See page 61
8:00 a.m. - 3:00 p.m.
Lennox and Lombroso Lecture
Convention Center – Ballroom 6C, Level 6
5:00 p.m. - 5:30 p.m.
Symposia Break
Convention Center – Level 6
5:30 p.m. - 8:00 p.m.
Special Interest Group Meetings
Pediatric State of the Art Symposium:
Long-term Outcomes of Neonatal Seizures
SCHEDULE-AT-A-GLANCE
6:30 a.m. - 6:00 p.m.
December 8
Convention Center – Ballroom 6C, Level 6
See page 62
10:00 a.m. - 3:00 p.m.
Exhibit Hall
Convention Center – Hall 4B, Level 4
TUESDAY
6:30 a.m. - 11:00 a.m.
6:30 a.m. - 7:00 a.m.
7:00 a.m. - 8:30 a.m.
Registration
December 9
8:45 a.m. - 10:45 a.m.
Hot Topics Symposium: Epilepsy Updates
Convention Center – South Lobby, Level 4
Convention Center – Ballroom 6C, Level 6
Continental Breakfast
Convention Center – Level 6
Scientific Symposium: The Epidemiology,
Pathophysiology & Prevention of SUDEP
Special Interest Group Meetings
Convention Center – Ballroom 6E, Level 6
See page 77
Suds for Science and
Exhibit Hall Reception
Sunday, December 7
5:00 p.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
Network with attendees from
around the world at the general
reception in the Exhibit Hall. Join
us for appetizers and visit
Sunovion Pharmaceuticals at
Booth #105 to receive your complimentary
drink tickets. A portion of the funds received
from support and beverage sales will benefit
the Lennox and Lombroso Trust.
EQUIPMENT AUCTION TO BENEFIT:
The Lennox and Lombroso Trust
for Research & Training
and The Susan S. Spencer Fund for
Clinical Education and Research
AES thanks Natus
for participating in the
equipment auction.
Supported by Sunovion Pharmaceuticals, Inc.
13
EQUIPMENT AUCTION TO BENEFIT:
The Lennox and Lombroso Trust for Research & Training
and
The Susan S. Spencer Fund for Clinical Education and Research
EEG Machine Becomes Research Dollars for AES
For six years, Nihon Kohden has pioneered a unique giving program by auctioning off its EEG-1200 machine and
donating 100 percent of the proceeds to the Lennox and Lombroso Trust for Research & Training and the Susan S.
Spencer Fund for Education and Research.
This year, Dignity Health Neurological Institute of Northern California (Sacramento) is the EEG-1200 Auction winner
at $23,263.75.
Nihon Kohden executives will present a check to the American Epilepsy Society on Saturday, December 6 at
1:00 p.m. on the floor of the Exhibit Hall.
AES thanks Nihon Kohden Booth #617 for their continued support and for again participating in the annual
equipment auction. We also thank those that participated in the bidding.
The American Epilepsy Society
is pleased to announce
INNOVATION PAVILIONS
located inside the Exhibit Hall Convention Center – Hall 4B, Level 4
These pavilions offer companies an opportunity to provide education and training
to Annual Meeting attendees in a convenient and more personal environment.
The Innovation Pavilions will be open on the following days:
Saturday, December 6: Noon – 6:00 p.m.
Sunovion Pharmaceuticals, Inc. (A) • Lundbeck Pharmaceuticals, Inc. (B)
NeuroPace, Inc. (C) • Cyberonics, Inc. (D)
Sunday, December 7: 10:00 a.m. – 6:00 p.m.
Sunovion Pharmaceuticals, Inc. (A) • Lundbeck Pharmaceuticals, Inc. (B)
NeuroPace, Inc. (C) • Cyberonics, Inc. (D)
Monday, December 8: 10:00 a.m. – 3:00 p.m.
Eisai, Inc. (C)
14
Poster Walking Tours
Convention Center – Exhibit Hall 4B, Level 4
The Poster Walking Tours will take place on the days noted below,
beginning at 12:15 p.m. each day, and tours will depart every 10 minutes.
Join AES leaders and visit interesting, compelling or novel posters and discuss perspectives on how the presented data is meaningful.
Leaders and participants will meet and gather at the Poster Information table near the front of the Poster Hall. Announcements will be made
in the Poster Hall prior to each tour departure. A schedule of topics and tour leaders will be available at the Poster Information Table.
POSTER SESSION 1: Saturday, December 6
Poster tour leaders: David Prince, Andres Kanner, Jean Gotman,
Bruce Hermann, Karen Wilcox
POSTER SESSION 2: Sunday, December 7
Poster tour leaders: Jackie French, Ilo Leppik, Steve Roper,
Joseph Sirven, Andrew Cole
POSTER SESSION 3: Monday, December 8
Poster tour leaders: Anne Anderson, Greg Bergey, Dennis Spencer,
Kimford Meador, Eric Kossoff
Poster tour leaders are subject to change
Participate in the AES
PASSPORT
TO PRIZES
PROGRAM
Join us in the Epilepsy Resource Center (located in the
Exhibit Hall) for daily prize drawings and a grand prize
drawing on Monday, December 8.
Prize Drawing Schedule:
SATURDAY, DECEMBER 6
Prize Drawing – 5:30 p.m.
SUNDAY, DECEMBER 7
Prize Drawing – 5:30 p.m.
MONDAY, DECEMBER 8
Prize Drawing & Grand Prize Drawing – 2:30 p.m.
In your AES Annual Meeting bag, as well as the virtualTotebag,
you will find a Passport brochure. To be included in the drawing
to win a variety of great prizes, visit the booths of participating
exhibitors to get your Passport validated. The more exhibitors
you visit, the better your chances.
Please complete your contact information and drop the passport
in the raffle drum located in the Epilepsy Resource Center.
Participants must be present to win. See your Passport for a
list of participating exhibitors.
15
colleague
COMMUNITYfriend
fellow inspire innovation
THANKYOU
COLLABORATION
applause
insight
catalyst
mentee
admiration
GRATITUDE
mentor
appreciation
CARING
Show your appreciation to
Someone Who.....
è Has influenced your career or your work in epilepsy
è Is someone you admire
è Has been a great colleague or collaborator
è Is celebrating a personal or professional milestone
The Community of Caring pin symbolizes the collaborative energy, the community
spirit and the supportive professional exchange among AES members.
Pins are available for sale at the AES Booth #125 in the Exhibit Hall.
All proceeds will benefit the AES New Initiatives Fund, supporting research and education
to advance the prevention, treatment and cure of epilepsy.
Those who purchase and receive pins will be recognized in a special way during the
Annual Meeting.
Community of Caring Pin
16
POSTER SCHEDULE
Detailed map of the Poster Hall is available in the virtualTotebag and at the Poster Information Table
Saturday, December 6
Translational Research
Behavior / Neuropsychology / Language
Genetics
Neuropathology of Epilepsy
Neurophysiology
Clinical Epilepsy
Neuroimaging
Comorbidity (Somatic and Psychiatric)
Antiepileptic Drugs
Surgery
1.001 – 1.078
1.079 – 1.101
1.102 – 1.121
1.122
1.123 – 1.180
1.181 – 1.232
1.233 - 1.269
1.270 – 1.293
1.294 – 1.345
1.346 – 1.377
POSTER SCHEDULE
Poster Session 1: Noon – 6:00 p.m. – Convention Center, Hall 4B, Level 4 (see pages 36-46)
Authors Present: Noon – 2:00 p.m.
Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 15)
Sunday, December 7
Poster Session 2: 8:00 a.m. – 6:00 p.m. – Convention Center, Hall 4B, Level 4 (see pages 51-60)
Authors Present: Noon – 2:00 p.m.
Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 15)
Behavior / Neuropsychology / Language
Health Services
Practice Resources
Epidemiology
Public Health
History of Epilepsy
Case Studies
Professionals in Epilepsy Care
Neurophysiology
Clinical Epilepsy
Neuroimaging
Comorbidity (Somatic and Psychiatric)
Antiepileptic Drugs
Surgery
2.001 –
2.031 – 2.060,
2.061 –
2.067 –
2.084 –
2.098 –
2.101 –
2.131 –
2.144 –
2.164 –
2.235 –
2.257 –
2.276 –
2.334 –
2.030
2.366
2.066
2.083
2.097
2.100
2.130
2.143
2.163
2.234
2.256
2.275
2.333
2.365
Investigators’ Workshop Lunch Poster Session
Noon – 1:30 p.m.
Convention Center – Room 6F, Level 6 (see pages 47-48)
Monday, December 8
Poster Session 3: 8:00 a.m. – 3:00 p.m. – Convention Center, Hall 4B, Level 4 (see pages 66-75)
Authors Present: Noon – 2:00 p.m.
Poster Walking Tours: 12:15 p.m. – 1:45 p.m. (see page 15)
Translational Research
Behavior / Neuropsychology / Language
Genetics
Neuropathology of Epilepsy
Epidemiology
Neurophysiology
Clinical Epilepsy
Neuroimaging
Antiepileptic Drugs
Non-AED / Non-Surgical Treatments
Surgery
3.001
3.075
3.086
3.108
3.126
3.146
3.196
3.254
3.288
3.318
3.343
–
–
–
–
–
–
–
–
–
–
–
3.074
3.085
3.107
3.125
3.145
3.195
3.253
3.287
3.317
3.342
3.375
Abstract Author Index – see pages 93-108
17
AES SPECIAL RECOGNITION
AES Service Award Co-Recipients
AES Service Award Co-Recipients
Friday, December 5 – 3:30 p.m.
Convention Center – Ballroom 6E, Level 6
(Immediately preceding the
Hoyer Lecture)
Friday, December 5 – 3:30 p.m.
Convention Center – Ballroom 6E, Level 6
(Immediately preceding the
Hoyer Lecture)
Robert L. Ruff, M.D., Ph.D.
Dr. Robert Ruff is a Professor of Neurology and Neurosciences at Case Western Reserve
University. He has been the VA’s National Director for Neurology for eight years. Dr. Ruff
received his M.D. and Ph.D. in Physiology and Biophysics from the University of Washington.
He did his Neurology Residency at New York Hospital Cornell Medical Center.
Served as Chief of Neurology at the Cleveland VAMC, Chairman of the Neurology Field
Advisory Committee, and oversaw the operations of the six Parkinson’s Disease Research,
Educational, and Clinical Centers (PADRECC), four Epilepsy Centers of Excellence (ECoE), and
the two Multiple Sclerosis Centers of Excellence (MSCoE). Under his direction, the ECoEs,
PADRECC and MSCoE developed into national neurology care networks with more than 50
sites in each of the networks. Dr. Ruff developed the ECoE program in response to a request
from Congress. Under his leadership, the ECoE program passed through a trail period which
demonstrated its value to veterans and the ECoE program will be continuously funded.
In addition, Dr. Ruff served as the VA’s Acting Director, Rehabilitation Research and
Development Service. Dr. Ruff is Medical Director of the Functional Stimulation Center at Case
Western Reserve University School of Medicine. He also serves as the Deputy Editor, Journal
of Rehabilitation Research and Development.
Karen L. Parko, M.D.
Dr. Karen Parko is a Professor of Neurology at the University of California, San Francisco
(UCSF), and the National Director of the Veterans Affairs Epilepsy Centers of Excellence. She
is a retired Commissioned Officer from the United States Public Health Service (USPHS).
Dr. Parko received a B.A. degree in Psychobiology from New York University and an M.D.
degree from the F. Edward Hebert School of Medicine at the Uniformed Services University
in Bethesda, M.D. Following an internship in Internal Medicine at the Washington Hospital
Center in Washington, D.C., she completed a residency in Neurology at UCSF. After residency
she worked in the Indian Health Service as a solo neurologist for ten years on the Navajo
reservation, where she established the reservation’s first neurology clinic, providing adult and
pediatric neurology services and neurodiagnostic testing to this population of nearly 300,000.
Dr. Parko has been involved in disaster and humanitarian relief medicine and served as a
medical officer aboard NOAA vessel McArthur during its Stenella Mission in the Eastern
Pacific. Dr. Parko serves on the National Professional Advisory Board of the Epilepsy
Foundation and previously chaired the Professional Advisory Board of the Northern
California Chapter.
She has received many awards for her work including being named the Public Health
Service Clinical Physician of the Year in 2001, was a finalist for The Frank Brown Berry
Prize in Federal Healthcare in 2003, and she received the Epilepsy Foundation of
Northern California’s Commitment to Progress Award in 2011.
The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research.
The awards are designed to recognize professional excellence reflected in a distinguished history of research of important promise for the improved understanding and
treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship program.
Award for Basic Science
Award for Clinical Science
(Immediately preceding the
Presidential Symposium)
(Immediately preceding the
Presidential Symposium)
Saturday, December 6 – 8:30 a.m.
Convention Center – Ballroom 6C, Level 6
Carolyn R. Houser, Ph.D.
Dr. Carolyn Houser is Professor of Neurobiology in the David Geffen School of Medicine at
the University of California, Los Angeles. She received her Doctoral degree in Anatomy from
UCLA, and completed postdoctoral training in the Division of Neuroscience at the City of Hope
Research Institute, Duarte, CA. Dr. Houser then joined the Comprehensive Epilepsy Program at
the VA Greater Los Angeles Healthcare System and the faculty of the Department of
Neurobiology at UCLA.
Dr. Houser’s research has focused on neuroanatomical alterations and plasticity in epilepsy.
Her studies provided the first descriptions of granule cell dispersion in patients with temporal
lobe epilepsy and contributed to the early descriptions of mossy fiber sprouting in humans
with epilepsy. Dr. Houser’s studies have been published in leading journals of neuroscience,
neurology and epilepsy, and have provided a neuroanatomical foundation for numerous
electrophysiological and neurochemical studies in the field.
Dr. Houser is strongly committed to education in neuroscience and has received numerous
teaching awards. Her service to the profession has includes AES Committees boards and
Committees of the Epilepsy Foundation, NIH and other epilepsy-related organizations, and
Chair of a recent Gordon Research Conference.
18
Saturday, December 6 – 8:30 a.m.
Convention Center – Ballroom 6C, Level 6
Ruth Ottman, Ph.D.
Dr. Ruth Ottman is Professor of Epidemiology (in Neurology and the Sergievsky Center),
Deputy Director for Research, Gertrude H. Sergievsky Center, Columbia University, and
Research Scientist, Division of Epidemiology, New York State Psychiatric Institute. She is also
Deputy Director of the Columbia Center for Research on Ethical, Legal, and Social Implications
of Psychiatric, Neurologic, and Behavioral Genetics. She received her B.A. in zoology and
Ph.D. in genetics from the University of California at Berkeley, and has been at Columbia
University throughout her career.
Dr. Ottman is a genetic epidemiologist whose research addresses the role of inherited factors
in susceptibility to neurologic disorders, primarily focusing on epilepsy. Her research group
was the first to recognize the epilepsy syndrome autosomal dominant epilepsy with auditory
features and to identify LGI1 as a major susceptibility gene for the disorder. She developed
and validated several research instruments for standardized data collection on epilepsy in
large-scale studies. She has recently begun to focus on the clinical and psychosocial impact
of genetic information on individuals with epilepsy and their family. She is a major
collaborator in the Epilepsy Phenome / Genome Project and in the Epi4K Center without
Walls for Collaborative Research in the Epilepsies.
AES SPECIAL RECOGNITION
J. Kiffin Penry Excellence in
Epilepsy Care Award
Joyce A. Cramer, B.S.
Joyce A. Cramer is now a consultant after a career in basic and clinical research at Yale
University School of Medicine. She also served as President and Chief Scientific Officer of
Epilepsy Therapy Project, a non-profit organization providing grants and investments for
new epilepsy therapies.
Joyce worked in pre-clinical research before initiating several decades of work in clinical
trials. She developed methods for the evaluation of drug efficacy and adverse effects,
study design and management, and enhancement of medication compliance and persistence,
as well as instruments to assess quality of life, treatment satisfaction and other patientreported outcomes for various medical disorders. The QOLIE quality of life instruments,
Seizure Severity Questionnaire (SSQ), and Systemic and Neurotoxicity Scales are widely
used in research around the world. A current focus is on development of the Personal
Impact of Epilepsy Scale (PIES).
Her publications include five books, more than 200 peer-reviewed papers, and numerous
book chapters covering a variety of topics. She is a frequent lecturer and consultant on
these topics.
Joyce served as AES Treasurer and on the AES Board of Directors. She was Chair of the
Board of Trustees of the Lennox Trust Fund. She has served on the Boards of Directors of
the International Society for Pharmacoeconomics and Outcomes Research and the Society
for Clinical Trials, as well as the Editorial Boards of Epilepsia and Epilepsy & Behavior and
currently of Acta Neurologica Scandinavica. She has received the ILAE International
Ambassador Award and the AES Service Award.
William G. Lennox Award
Monday, December 8 – 8:45 a.m.
Convention Center – Ballroom 6C, Level 6
(Immediately preceding the Merritt-Putnam
Symposium)
Monday, December 8 – 2:15 p.m.
Convention Center – Ballroom 6C, Level 6
(Immediately preceding the
Lennox and Lombroso Lecture)
Karen Gale, Ph.D.
Awarded posthumously
The AES community was saddened by the recent passing of, Karen Gale, Ph.D., Professor in
the Department of Pharmacology & Physiology at Georgetown University. During her more
than 35 years at Georgetown, Dr. Gale left an indelible mark as a researcher, educator and
stalwart advocate for faculty, students and staff.
Dr. Gale was a widely recognized expert in seizure circuitry, and the mechanisms of
seizure-induced brain damage and neuroprotection. She was an NIH-funded researcher for
more than 20 years, and the founding director of Georgetown’s Interdisciplinary Program in
Neuroscience (IPN) that has 50 faculty members from 11 departments campus-wide.
AES selected Dr. Gale for her pioneering research on the critical roles of subcortical structures,
including the substantia nigra, and on seizure control and propagation that has been seminal
in shaping the understanding about the distributed nature of seizures and how they might be
controlled, and her recent work on comorbidities of epilepsy including deleterious effects of
antiepileptic compounds on neural development.
Dr Gale was also recognized for her tireless commitment to the development of early career
investigators, women and minority scientists in the epilepsy community through mentorship
and advocacy.
AWARDEES
Saturday, December 6 – 2:15 p.m.
Convention Center – Ballroom 6C, Level 6
(Immediately preceding the AET Symposium)
Extraordinary Contributions Award
Lennox and Lombroso Lecturer
Monday, December 8 – 2:15 p.m.
Convention Center – Ballroom 6C, Level 6
A $10,000 award is provided by the
Lennox and Lombroso Trust Fund
Hans O. Lüders, M.D., Ph.D.
Dr. Hans O. Lüders is Professor of Neurology and staff at the Epilepsy Center, Case Medical
School, Cleveland, OH. He received his degree in medicine from the Catholic University,
Santiago, Chile and trained in neurology at the Neurological Institute, Kyushu University,
Fukuoka, Japan. He joined the Mayo Clinic as a clinical fellow in Electroencephalography
and received a Ph.D. in Neurophysiology from the University of Minnesota. He trained under
Prof. Eli Goldensohn at the Neurological Institute in New York. He became head of the
Epilepsy Center at the Department of Neurology, Cleveland Clinic Foundation where he
served as Chairman of Neurology until he moved to University Hospital, Case Medical Center,
to lead and develop the epilepsy program.
Dr. Lüders established the intensive course in Epilepsy and Clinical Neurophysiology and
developed the highly specialized Epilepsy Surgery Program which are now offered at the
Cleveland Clinic and at University Hospitals. He has edited of more than 19 books including
the most advanced “Textbook of Epilepsy Surgery”. Dr. Lüders established the “Cleveland
Clinic International Epilepsy Symposia” and the “International Epilepsy Colloquia” sponsored
by France, Germany, England and Cleveland, OH.
He developed an original, strictly semiological classification of epileptic seizures and the
original description of several semiological seizure types as well as identified several cortical
”centers” by electrical stimulation of the human brain. Dr. Lüders pioneered the use of
subdural electrodes in the presurgical evaluation of epilepsy surgery in the 1980s and is
supporting the introduction from Europe of depth electrodes in the U.S.
Anne Berg, Ph.D.
Dr. Anne Berg received her Ph.D. from Yale University in 1986. The focus of her research for
over 25 years has been in the area of pediatric seizures and epilepsy with
a specific emphasis on seizure outcomes, developmental and cognitive consequences, the
impact on quality of life and the implications of all of these considerations for care and
care-models. She is the lead investigator of the NINDS-funded Connecticut Study of Epilepsy
which spanned two decades and is providing an unprecedented understanding of the impact
of childhood epilepsy later in early adulthood. In 2007, she played a key role in focusing
NINDS research priorities on the cognitive, developmental, and behavioral comorbidities
of epilepsy and has organized sessions at American Epilepsy Society meetings to investigate
these areas and identify research opportunities for improving patients’ outcomes. Dr. Berg
was Co-Chair of the 2013 NINDS-sponsored Curing Epilepsies conference and also organized
and led the workshop, “Priorities in Pediatric Epilepsy Research: Improving Children’s Futures
Today” held in Chicago, November 2013. She helped spearhead the formation of the
Pediatric Epilepsy Research Consortium (PERC) which has grown to 37 centers nationwide and
is laying the foundation and creating the infrastructure for practice-changing clinical research
to improve the diagnosis, treatment, and outcomes of children with pediatric epilepsies.
Dr. Berg received a Jacob K. Javits Neuroscience Investigator Award from NINDS in 2007
and the American Epilepsy Society Research Recognition Award for Clinical Research, 2008.
19
SUZANNE AND PETER BERRY
INTERNATIONAL TRAVEL AWARDEES
This award is given to recognize and honor two young investigators doing research in clinical neuroscience related to epilepsy in Asia, Africa, Oceania,
Middle East or Latin America by supporting travel to present research at the AES Annual Meeting.
Contact Author
Abstract Title
Poster
Leyla Baysal Kirac, M.D.
Importance Of Routine Ictal Heart Rate Analysis In Drug Resistant Epilepsies:
Possible Prediction of Patients at Risk For SUDEP
1.128
Rie Sakuraba, M.H.Sc.
High-Rate REM Sleep High Frequency Oscillations (HFOs) Are Specific To Epileptogenicity
3.159
GRASS YOUNG INVESTIGATOR AWARDEES
This award is intended to recognize and honor outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy.
Awardees are selected from young investigators who submit an accepted abstract. The Grass Foundation and the American Epilepsy Society have combined
resources to present these awards to eight deserving candidates to help support travel costs to present their research at the Annual Meeting of the
American Epilepsy Society. The award is composed of a $1,000 travel stipend, a waiver of AES meeting registration fees and recognition during the Hoyer
Lecture on Friday, December 5. Congratulations to the following awardees:
Contact Author
Abstract Title
Poster / Platform
Chad R. Frasier, Ph.D.
Dravet Syndrome Patient-Derived Induced Pluripotent Stem Cell Cardiac Myocytes
Have Increased Sodium Current Density And Increased Beating Rate
C.02
Ethan M. Goldberg, M.D., Ph.D.
A Novel Mouse Model Of Chromosome Xq22.1 Deletion Syndrome Displays Epilepsy
And Cortical Circuit Dysfunction
C.06
SeokJun Hong, M.Sc.
Automated Detection Of Cortical Dysplasia In MRI-Negative Epilepsy:
Class II Diagnostic Evidence
B.04
Lawrence Hsieh, Ph.D.
New Model Of Focal Cortical Dysplasia Associated Epilepsy
3.030
Esther Krook-Magnuson, Ph.D.
Cerebellar Control Of Spontaneous Seizures In A Mouse Model Of Temporal Lobe Epilepsy
C.03
Lena H. Nguyen, B.S.
Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And Associated Neuropathology
In The NS-Pten KO Mouse Model Of Cortical Dysplasia
3.050
Vineet Punia, M.D., M.S.
Factors Influencing Driving Impairment In Persons With Refractory Epilepsy
A.02
Jacy Wagnon, Ph.D.
Seizures And SUDEP In A Mouse Knock-In Model Of SCN8A Related Epileptic Encephalopathy
C.09
NURSE AWARDEES
Contact Author
Abstract Title
Rachael Mealey, M.S.N., CRNP
Improving Quality Of Care Following EMU Discharge
2.135
Kimberly Orton, RN
To Coordinate Or Not To Coordinate?
2.134
Guinevere T. Que, NP
Pregnancy And Seizures: Review Of Practice At George Washington University
In The Past 5 Years
2.066
Patsy Ramey, MSN, RN
Unexplained Spikes In Lamotrigine Serum Concentration Suggest Nonlinear
Elimination Kinetics In Some Individuals
1.338
Acknowledgment: Nurse awards are supported by Eisai Inc.
20
Poster
YOUNG INVESTIGATOR AWARDEES
Poster /
Platform
Abstract Title
Karlene T. Barrett, Ph.D.
TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During
Development In Mice
1.025
Monica Dhakar, M.D.
Broadband Intracranial Ictal EEG Analysis In Lesional And Non-lesional Pharmacoresistant Epilepsy
3.174
Dario J. Englot, M.D., Ph.D.
Factors Associated With Failed Extra-Temporal Lobe Epilepsy Surgery
1.369
Alejandra M. Fernandez, B.S.
A 35% Triheptanoin Diet Reduces Spontaneous Electrographic Seizures In Pilocarpine-Induced
Epileptic Mice
3.342
Federica Frigerio, Ph.D.
Pro-Resolving Receptors ChemR23 and ALXR Expression During Epileptogenesis In Mice
1.020
Stephen Gliske, Ph.D.
Generalized, Automated Algorithm For Detecting HFOs And The Extent Of The Seizure Onset Zone
3.067
Abhijeet Gummadavelli, B.A.
Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures
1.044
Se Hee Kim, M.D.
Adaptive Function In Dravet Syndrome
3.244
Seongtaek Lee, M.S, B.S.
Investigation Of White Matter Integrity In Patients With Psychogenic Non-Epileptic Seizures
1.236
Tiffani L. McDonough, M.D.
Prediction Of Future Epilepsy In Neonates Who Received Selective Head Cooling For HIE
2.221
Rawad Obeid, M.D.
The Application Of Conventional EEG For Early Prognosis In Infants Born With Hypoxic
Ischemic Encephalopathy Undergoing Hypothermia
2.159
Reesha R. Patel, B.S.
Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current
Generation That Could Be Preferentially Targeted With Cannabidiol
1.294
Sandra Petty, M.B.B.S, FRACP Ph.D. Carbamazepine Inhibits Native Sodium Currents In Murine Osteoblasts
1.291
Craig A. Press, M.D., Ph.D.
Parental Reporting Of Response To Oral Cannabis Extracts As Adjunctive Treatment For
Medically Refractory Epilepsy
1.326
Rajsekar R. Rajaraman, M.D.
Predictive Model For Early Posttraumatic Seizures In The PICU
A.09
Udaya K. Seneviratne, FRACP
Electroencephalographic Correlates Of Seizure Freedom In Genetic Generalized Epilepsies
1.227
Kyle Thomson, Ph.D.
Use Of An Automated-Feeding System For The Testing Of Potential Anticonvulsant Compounds
In Chronic Epileptic Rats
1.050
Ebru Nur Vanli-Yavuz, M.D.
How Different Are Patients With Bilateral Hippocampal Sclerosis From The Unilateral Ones?
2.224
Matthew Weston, Ph.D.
Hyperactivation Of mTOR Signaling In A Two-Neuron Microcircuit Alters The Dynamics Of
Synaptic Transmission
1.013
Jennifer Wong, Ph.D.
Selective Targeting Of Scn8a Expression Confers Seizure Resistance In Two Mouse Models
Of Refractory Epilepsy
3.106
AWARDEES
Contact Author
Ackowledgment: Young Investigator Awards are supported by Eisai Inc. and Medtronic, Inc.
21
SPECIAL INTEREST GROUP SCHEDULE
Friday, December 5: 1:30 p.m. – 3:00 p.m.
n Basic Mechanisms: Inflammation, Microglia and Their Role in Neuronal
and Dendritic Homeostasis (Convention Center – Room 620, Level 6)
n Neuroimaging: MRI Normalcy – A Moving Target!
(Convention Center – Room 607, Level 6)
n Quality, Value and Safety: Improving the Epilepsy Monitoring Unit
(Convention Center – Room 617, Level 6)
Friday, December 5: 6:00 p.m. – 7:30 p.m.
n Cognitive and Behavioral Interventions for Epilepsy: PNES Case
Reports and Underlying Mechanisms
(Convention Center – Room 607, Level 6)
n EEG: Dense Array EEG and EEG Source Localization in Clinical Practice
(Convention Center – Room 609, Level 6)
n Head Trauma and Military Epilepsy Care: Practical Guide to Caring for
Epilepsy Patients in the VA System
(Convention Center – Room 620, Level 2)
n Junior Investigators: Mentorship
(Convention Center – Room 615, Level 6)
n Neuropharmacology: Medication Discontinuation Post Surgery: To Do
or Not to Do? (Convention Center – Room 617, Level 6)
n SUDEP: Hot Topics in SUDEP
(Convention Center – Room 603, Level 6)
Saturday, December 6: 7:00 a.m. – 8:30 a.m.
n Basic Neuroscience: Brain Mosaicism in Epilepsy (Convention Center –
Room 607, Level 6)
n Children’s Hour: Dravet Syndrome in 2014
(Convention Center – Room 609, Level 6)
n Ictal Semiology Cases: How Semiology Helps to Localize the Seizure
Onset Zone and Elucidate the Propagation Pattern
(Convention Center – Room 612, Level 6)
n Neurostimulation and Neuroengineering: New Developments
(Convention Center – Room 603, Level 6)
n Private Practice: How to Survive with Private Epilepsy Centers in the
Changing Health Care Environment
(Convention Center – Room 617, Level 6)
n Psychiatry in Epilepsy: Aggression in People with Epilepsy, Diagnosis
and Treatment Issues (Convention Center – Room 615, Level 6)
Sunday, December 7: 6:00 p.m. – 7:30 p.m.
n Drug Resistant Epilepsy – Definition, Epidemiology, Predictors,
Using Big Data for Epidemiological Research (Convention Center –
Room 617, Level 6)
n Frontal Lobe Epilepsy: Semiology and Cognitive Aspects
(Convention Center – Room 608, Level 6)
n MEG / MSI Source Imaging (MSI) Source Localization Results: Blind
Faith, Black Art, or Scientific Method?
(Convention Center – Room 620, Level 6)
n Neonatal Seizures: Should We Pursue Comparative Effectiveness
Studies for the Treatment of Neonatal Seizures?
(Convention Center – Room 609, Level 6)
22
n Neuroendocrinology: Sex Differences in Epileptogenesis
(Convention Center – Room 613, Level 6)
n Pediatric Case Discussions
(Convention Center – Room 612, Level 6)
n Psychogenic Nonepileptic Seizures: What Can We Learn From PNES
Semiology? (Convention Center – Room 615, Level 6)
Monday, December 8: 7:00 a.m. – 8:30 a.m.
n Ketogenic Diet: Does the Ketogenic Diet Offer a “Cure” for Epilepsy?
(Convention Center – Room 613, Level 6)
n Neuropsychology: Can We Spare Memory With Newer Surgical
Approaches for Temporal Lobe Epilepsy? Emergent Outcome Data
from Laser Ablation, Multiple Hippocampal Transection, and Fornix
DBS (Convention Center – Room 609, Level 6)
n NINDS and Non-Profit Research Resources
(Convention Center – Room 620, Level 6)
n Nursing (Convention Center – Room 608, Level 6)
n Status Epilepticus – Are We Over-Treating Status Epilepticus, and
Especially, Nonconvulsive Status Epilepticus?
(Convention Center – Room 612, Level 6)
Monday, December 8: 9:00 a.m. – 10:30 a.m.
n NEW – Epilepsy and Aging
(Convention Center – Room 620, Level 6)
n Surgery: Surgical Failure in Pediatric and Adult Epilepsy: ‘The Slam
Dunk Case that Wasn’t!’ (Convention Center – Room 609, Level 6)
n Tuberous Sclerosis: Thinking Outside the Tuber in TSC
(Convention Center – Room 612, Level 6)
Tuesday, December 9: 7:00 a.m. – 8:30 a.m.
n Critical Care (ICU EEG Monitoring): Controversies in ICU EEG
Interpretation and Management
(Convention Center – Room 612, Level 6)
n Genetics: Personalized Epilepsy Diagnosis and Treatment
(Convention Center – Room 613, Level 6)
n NEW – Global Health in Epilepsy: How Can You Get Involved?
(Convention Center – Room 603, Level 6)
n Practice Management (Convention Center – Room 618, Level 6)
n Sleep and Epilepsy: Sleep Polygraphy Monitoring in the EMU: Are We
Missing A Diagnostic / Therapeutic Opportunity?
(Convention Center – Room 606, Level 6)
n Temporal Lobe Club: The Thalamus in Epilepsy – Player or Bystander?
(Convention Center – Room 620, Level 6)
n Tumor Induced Epilepsy – Meningiomas
(Convention Center – Room 604, Level 6)
n Women’s Issues: Controversies in Caring for Women with Epilepsy
(Convention Center – Room 615, Level 6)
SCIENTIFIC EXHIBIT SCHEDULE
Scientific exhibits will be on display at this year’s annual meeting and will be located in
Rooms 603, 604, 607, 612 and 615 on Level 6 of the Washington State Convention Center.
These exhibits will provide meeting attendees an opportunity to update themselves on the
latest research. Authors will be present throughout the exhibit.
Sunday, December 7 • 8:00 a.m. – 11:00 a.m.
Cyberonics, Inc.
VNS Therapy®: Foundational Treatment for Drug-Resistant Epilepsy
Room
603
Lundbeck Pharmaceuticals, Inc.
Research Updates for Antiepileptic Therapies Clobazam, Vigabatrin, and IV Carbamazepine
607
UCB, Inc.
Continuing UCB’s Long-Term Commitment to Epilepsy Management
612
Sunday, December 7 • 8:00 a.m. – 5:00 p.m.
EQUIGEN
604
Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation
Monday, December 8 • 8:00 a.m. – 11:00 a.m.
Upsher-Smith Laboratories, Inc.
Upsher-Smith CNS Update
603
Sunovion Pharmaceuticals, Inc.
Aptiom® (eslicarbazepine acetate) Scientific Exhibit Room
607
Sage Therapeutics
Clinical Progress of SAGE-547 in Status Epilepticus and Advances in Next-Generation Neurosteroids
615
Monday, December 8 • 8:00 p.m. – 5:00 p.m.
EQUIGEN
604
Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation
23
S!
R
E
T
C
A
R
A
H
C
F
O
T
S
A
C
R
U
O
JOIN
WALK FOR AES
RESEARCH & TRAINING
RAISE FUNDS FOR EPILEPSY RESEARCH & TRAINING
The National Walk for Epilepsy
Washington, D.C. – April 11, 2015
Walk with your colleagues! Join Lorna Myers, Nathan Fountain, Patrice Jackson-Ayotunde,
Dennis Spencer, Martin Penry, Elson So, Jaideep Kapur, Mike Privitera, Jacqueline French, Patty Shafer,
and many others for the 2015 National Walk for Epilepsy.
All funds raised by AES Teams Support AES Research and Training efforts – even virtual teams
can participate! Teams can support any AES fund: Spencer, Lennox and Lombroso, Dreifuss,
Penry, Goldberg-Kaufman and New Initiatives Fund.
Raise the most money and win the AES trophy!
Sign up or get more information today!
Contact Kathy Hucks at 860-586-7505 x512 or [email protected].
24
Your place for ongoing professional education in epilepsy.
ELI is the new AES online tool offering quick
access to:
n
n
n
n
n
Relevant CME-based programs for epilepsy
Tailored Self-Assessments in Epilepsy (SAEs)
Rich archived educational content
Easy portal to AES partner projects for epilepsy
Organized records for self-directed learning
It’s all here at:
aesnet.org/professional_education
AES is an ACCME accredited provider.
25
n !
i
Jo day
o
T
WHY JOIN THE AMERICAN EPILEPSY SOCIETY?
The American Epilepsy Society serves as a resource for its membership and the epilepsy community by providing
access to data on the latest breakthroughs, technologies and methodologies in epilepsy research.
The American Epilepsy Society promotes interdisciplinary communication, scientific investigation and exchange of
clinical information about epilepsy. Membership in AES opens doors to educational sessions, networking and
knowledge-sharing among its members and Annual Meeting attendees.
Become a member today by going to www.AESnet.org or visit the AES Booth #125 at the AES Annual Meeting located in
the Exhibit Hall.
AES MEMBERS ARE:
n
n
n
n
n
n
n
n
n
n
n
Adult Neurologists
Advanced Practice Nurses
Basic Science Researchers
Clinical Researchers
Consultants
Doctors of Osteopathic Medicine
Doctors of Veterinary
Medicine
Emergency Room Physicians
Epileptologists
Fellows
Government/Regulatory
n
n
n
n
n
n
n
n
n
n
n
Internists
Licensed Practical Nurses
Neurosurgeons
Non-Profit Staff
Nutritionists
Office Managers
Pediatric Neurologists
Pharmacists
Pharmacologists
Presidents/CEOs in
Industry
Industry/Marketing
Professionals
n
n
n
n
n
n
n
n
n
Psychiatrists
Psychologists
Physicians Assistants
Registered Nurses
Residents
Social Workers
Students
Technologists
and Others
AES MEMBERS RECEIVE:
n
n
n
n
n
n
n
n
n
n
n
26
Epilepsy Currents, the official journal of AES
Epilepsia, the official journal of ILAE
Reduced annual meeting registration fees
Discounted subscriptions to scientific journals
Listing in Find-A-Doctor online directory
Network with members through AES Connect
Members-only discussion blogs
Research funding opportunities
Distinguished Achievement and Research Recognition Awards
Weekly e-newsletters with relevant, timely news
Full service career center
Raise Your Glass for the...
Third Annual Wine Tasting
& Silent Auction
Join your friends, colleagues and hosts – Mike Privitera, Greg Bergey and Dennis Spencer
in an evening to benefit the Susan S. Spencer Fund and Lennox and Lombroso Trust
Featuring locally sourced cuisine and hand-selected regional wines for your enjoyment.
Saturday, December 6th
7:00 PM to 10:00 PM
Where: 1927 EVENTS
n
1927 3rd Avenue, Seattle, WA
— a short stroll from the Convention Center!
Purchase your tickets today at the “solutions” counter at the
registration desk, Convention Center, South Lobby, Level 4.
More than 12,000 people visit the AES website each month
-- are you one of them?
The NEW AES website features:
•
•
•
•
•
Fresh news and daily updates
Dynamic content
Online community forum for AES members
Mobile friendly content
Learning and research opportunities
www.AESNET.org
JOIN US ON THE AES SITE TODAY!
27
AES Fellows Program •
Friday, December 5, 2014
The goal of the AES Fellows program is to encourage and support epilepsy fellows in training to attend the AES Annual Meeting where they will receive the
latest updates in clinical and basic science research. A breakfast and lunch will be provided to allow fellows the opportunity to meet and pair with mentors
who will provide guidance regarding career planning, potential research paths, and clinical endeavors. Following the breakfast the fellows will attend the
Epilepsy Specialist Symposium and the Annual Fundamentals of Epilepsy Symposium, as well as the Hoyer Lecture. A panel of experts will present and discuss
their experiences in the fields of research, and clinical and private practice. This program is supported by UCB, Inc., Eisai, Inc., Supernus Pharmaceuticals, Inc.,
Upsher-Smith Laboratories, Inc. and Acorda Therapeutics.
8:30 a.m. – 11:30 a.m.
Annual Fundamentals of Epilepsy Symposium:
The Side Effects of Epilepsy Treatment
(3.0 CME Credits) •Convention Center – Ballroom 6E, Level 6
(2.5 CME Credits) •Convention Center – Ballroom 6E, Level 6
Overview
This symposium will address current knowledge regarding generalized
epilepsies including idiopathic, symptomatic and progressive generalized
epilepsies. Faculty will address current understanding of their pathophysiology,
review data regarding prognosis and criteria for diagnosis, and discuss
management options for patients with generalized epilepsies.
Learning Objectives
u
u
u
12:30 p.m. – 3:00 p.m.
Epilepsy Specialist Symposium:
The Generalized Epilepsies
Develop treatment plans and provide counseling based on current
understanding of the pathophysiology of generalized epilepsies and their
prognosis
Apply current criteria in diagnosing generalized epilepsies
Recognize behavioral and cognitive comorbidities of generalized epilepsies
and provides appropriate interventions.
Target Audience
Basic and Intermediate (see page 120 for details)
Program
Chair: Michael R. Sperling, M.D.
Overview
This activity will provide comprehensive information about the potential side
effects of different epilepsy therapies, not limited to the usual side effects of
antiepileptic drugs. Included will be a synopsis of the adverse effects that can
be encountered from treatment of seizures and epilepsy providing a
comprehensive overview that will assist in tailoring treatment to individual
patients. The speakers will discuss antiepileptic drug side effects; side effects
of acute treatments for epilepsy (especially status epilepticus); side effects of
devices that provide neuromodulation (VNS, RNS, DBS); side effects of epilepsy
surgery evaluation and epilepsy surgery; and side effects of other treatments
(diet, hormones, cannabinoids, herbal medications).
Learning Objectives
u
u
u
u
Implement appropriate medical treatment based on improved understanding
of potential adverse effects of treatment options
Refer patients earlier in course of treatment for consideration of surgery or
for use of a device for seizure control
Counsel patients more knowledgeably about the potential adverse effects of
their treatment and helps identify potential hazards arising from treatment
Help patients communicate effectively about their care, including identifying
previously unrecognized adverse effects of their treatment
Identify treatment-related cognitive and emotional adverse effects of newly
emergent and alternative treatments.
8:30 a.m.
Introduction
Michael R. Sperling, M.D.
u
8:45 a.m.
Pathophysiology of the Generalized Epilepsies
Solomon L. Moshé, M.D.
Target Audience
9:15 a.m.
Seizure Types and Syndromes in the Generalized Epilepsies
Prakash Kotagal, M.D.
Program
9:45 a.m.
Prognosis of the Generalized Epilepsies
Katherine Nickels, M.D.
10:15 a.m. Treatment of the Idiopathic Generalized Epilepsies
Michael S. Duchowny, M.D.
10:45 a.m. Treatment of Symptomatic and Progressive Generalized
Epilepsies
Sandra L. Helmers, M.D., M.P.H.
11:15 a.m. Case Studies and Conclusions
Michael R. Sperling, M.D.
Basic and Intermediate (see page 120 for details)
Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D. and Tracy A. Glauser, M.D.
12:30 p.m. Introduction
Tracy A. Glauser, M.D.
12:40 p.m. Antiepileptic Drug Side Effects
Eugen Trinka, M.D., M.Sc.
1:05 p.m.
Side Effects of Acute Treatments for Epilepsy
David M. Treiman, M.D.
1:30 p.m.
Side Effects of Devices (VNS, RNS, DBS)
Robert S. Fisher, M.D., Ph.D.
1:55 p.m.
Side Effects of Epilepsy Surgery Evaluation and Epilepsy
Resective Surgery
Mary L. Zupanc, M.D.
2:20 p.m.
Side Effects of Other Treatments (Diet, Hormones,
Cannabinoids, Herbal Medications)
Kristen Park, M.D.
2:45 p.m.
Conclusions
Elinor Ben-Menachem, M.D., Ph.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 3.0 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-14-028-L01-P. Initial
Release Date: 12/5/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Epilepsy
Specialist Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS
as a necessary component of maintenance of certification.
Core Competencies: Practice-based Learning and Improvement, and Medical
Knowledge
Acknowledgment
This program is supported by an educational grant from Eisai, Inc.
28
Continued on page 29
FRIDAY December 5, 2014
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-029-L01-P.
Initial Release Date: 12/5/2014.
Special Interest Group Meetings
ABPN Core Competencies
Location listed under each session
1:30 p.m. – 3:00 p.m.
The American Board of Psychiatry and Neurology has reviewed the Annual
Fundamentals of Epilepsy Symposium and has approved this program as part
of a comprehensive lifelong learning program, which is mandated by the
ABMS as a necessary component of maintenance of certification.
Basic Mechanisms: Inflammation, Microglia and Their Role
in Neuronal and Dendritic Homeostasis
Core Competencies: Patient Care, Medical Knowledge and System-based
Practice
Coordinators: Amy L. Brewster, Ph.D., Dane M. Chetkovich, M.D., Ph.D.
Speakers: Sookyong Koh, M.D., Ph.D., Robert S. Fujinami, Ph.D.,
Viji Santhakumar, Ph.D.
Acknowledgment
This program is supported by an educational grant from UCB, Inc., Eisai, Inc.
and Lundbeck Pharmaceuticals, Inc. with additional support from Supernus
Pharmaceuticals, Inc. and Cyberonics, Inc.
separate registration required — see below for instructions
9:00 a.m. – 3:15 p.m.
28th Annual Advances in the Management of
Epilepsy and the Epilepsy Clinic
Sheraton – Metropolitan Ballroom A, Level 3
This intensive, one-day conference is designed for those professionals who
participate in the care of persons with epilepsy. The overall purpose is to improve
services to individuals and families affected by epilepsy. The conference is
presented by the Department of Neurology of Wake Forest University School of
Medicine, Winston-Salem, North Carolina, through an unrestricted grant
committed to the education of health professionals, in an effort to promote the
comprehensive care of those with epilepsy and their families.
Registration for this program is done separately from the AES Annual Meeting
and begins on September 1, 2014. You may register by calling Wake Forest
School of Medicine at 800.642.0500.
Convention Center – Room 620, Level 6
Activation of inflammatory mechanisms that include recruitment of reactive
microglia and associated signaling molecules such as cytokines and
complement cascade activation, among others, are often seen in surgical
resections from individuals with epilepsy and have been widely described
before, during, and after seizures in experimental models. The goal of this
session is to discuss potential mechanisms by which inflammatory mediators
may contribute to pathological epileptogenic changes in the brain.
Neuroimaging: MRI Normalcy – A Moving Target!
Convention Center – Room 607, Level 6
Coordinators: Matthias J. Koepp, M.D., Ph.D., Neda Bernasconi, M.D., Ph.D.
Speakers: Boris Bernhardt, M.D., R. Edward Hogan, M.D., William D. Gaillard, M.D.
About 30% of patients with electrographic evidence of temporal lobe epilepsy
(TLE) have normal MRI scans. The location of the seizure focus is unclear in this
patient population. Possibilities include (i) a subtle form of hippocampal sclerosis
that is not apparent on MRI; (ii) alterations in synaptic or receptor physiology not
visible on MRI; or (iii) pathology not detected by MRI, such as certain forms of
cortical dysplasia. Patients with MRI-“negative” TLE may be candidates for
additional neuroimaging techniques including advanced MR imaging with novel
acquisition or post-processing techniques, MRS, PET, and SPECT. Peri-ictal
imaging may increase the yield to detect abnormalities. This SIG will focus on the
management of MRI-normal TLE, emphasizing the neuroimaging perspective.
Up to 5.0 AMA Category 1 CME credit will be given.
Quality, Value and Safety: Improving the Epilepsy
Monitoring Unit
1:30 p.m. – 3:00 p.m.
Coordinator: Katherine Noe, M.D., Ph.D.
Speakers: Gabriel U. Martz, M.D., Nathalie Jetté, M.D., Khara M. Sauro, Ph.D.,
Janice Walbert, R.EEG/EPT
Professional Development in AES: A Program
for Junior Members and Those in Transition
Convention Center – Room 603, Level 6
The American Epilepsy Society invites all interested meeting attendees to come
to a special session on volunteer and leadership opportunities within the Society.
AES has a variety of programs year round to improve the care and treatment of
patients with epilepsy. These efforts include education for basic scientists and
clinicians, research grant programs, leadership and organizational activities,
community outreach and advocacy. Greater participation in the Society offers
members extensive career development opportunities by providing a chance to
hone leadership skills, to network with other AES members and outside funding
organizations, and most importantly, to make significant contributions to improve
the lives of patients with epilepsy.
FRIDAY
Nurse Practitioners may claim 1.5 hours of pharmacology for this session.
This session will be useful to trainees, basic scientists, clinicians and other allied
health professionals (nurses, psychologists, Pharm.D.s) who want to know more
about AES organizational structure or who want to become more involved. The
session will provide an overview of the professional development and volunteering
opportunities within the Society, followed by short presentations by members
active in AES leadership. The session will end with a chance to meet with AES
staff and committee leaders to learn more about available opportunities.
Convention Center – Room 617, Level 6
This year’s SIG will focus on current efforts to improve the quality, safety, and value
of care provided in epilepsy monitoring units. Reduction in 30-day readmission
rates is an ongoing focus of quality improvement efforts for all hospitalized patients,
and influences payments to hospitals from the Centers for Medicare and Medicaid
Services. Dr. Gabriel Martz, from the Medical University of South Carolina will
present his research into EMU readmissions. Continuing prior discussions on ways
to improve the patient experience in the EMU, Dr. Nathalie Jetté and colleague
Dr. Khara Sauro will discuss their unique experience with a multidisciplinary EMU
Quality Improvement Team at the University of Calgary. Finally, Janice Walbert,
Executive Director of ABRET, will describe their challenges / successes to date in
developing and implementing certification of EEG laboratories. Time will be
available for audience questions and discussion.
29
FRIDAY December 5, 2014
3:30 p.m. – 5:30 p.m.
4:10 p.m.
Dietary Measures, Vitamins and Other Supplements,
Herbal Therapies
Carlos Medina-Malo, M.D.
4:40 p.m.
Non-conventional Medical Treatments, Mind-body
Therapies
Blanca Vazquez, M.D.
Presentation: Robert L. Ruff, M.D., Ph.D. and
Karen L. Parko, M.D., AES Service Awards, NINDS Update
5:10 p.m.
Round Table
Mario A. Alonso-Vanegas, M.D., Patricio Abad, M.D.
Lecturer: Frances Jensen, M.D.
5:50 p.m.
Conclusions
Mario A. Alonso-Vanegas, M.D.
The 12th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer
Dr. Frances Jensen, is sponsored by the National Institute of Neurological
Disorders and Stroke. Dr. Jensen’s presentation is the twelfth in a series of
lectures highlighting the promise of epilepsy research. This series is held in
memory of Mrs. Judith Hoyer, an active member of the Board of Directors of
the Epilepsy Foundation and the late wife of Representative Steny Hoyer
(D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy
and promoting research into a cure and a better quality of life for those with
the disorder. The purpose of the lecture is to raise awareness of epilepsy
among researchers and the public and provide intellectual stimulation that will
encourage continuing progress toward finding a cure for epilepsy.
Credit Designation
Supported in part by Upsher-Smith Laboratories, Inc. and NINDS.
The American Board of Psychiatry and Neurology has reviewed the Spanish
Symposium and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
12th Judith Hoyer Lecture in Epilepsy:
Reshaping Epilepsy As a Spectrum Disorder:
Implications for Clinical Care, Research and
Education
Convention Center – Ballroom 6E, Level 6
3:30 p.m. – 6:00 p.m.
Spanish Symposium: Complementary and
Alternative Approaches to Epilepsy Treatments
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-030-L01-P.
Initial Release Date: 12/5/2014.
ABPN Core Competencies
Core Competencies: Patient Care, Medical Knowledge, Practice-based
Learning and System-based Practice
(2.5 CME Credits)
Convention Center – Room 612, Level 6
Overview
This symposium will present an overview on the role of neurostimulation, diet,
vitamins and other supplements, herbal therapies, non-conventional medical
treatments (acupuncture, cannabis, others), and psychological and Mind-body
therapies (biofeedback, meditation, yoga, relaxation techniques) in the
treatment of epilepsy. Treatment paradigms and evidence-based approach will
be addressed. As a result of attending this symposium, the attendee will
recognize alternative treatments when managing patients with medically
refractory epilepsy and become familiar with current evidence and rationale
for their use, allowing for consideration of neurostimulation and other available
alternative treatment options.
Learning Objectives
u
Utilize newer as well as established treatments such as neurostimulation,
dietary therapy and other alternative methods as therapeutic options in
refractory epilepsy
u
Counsel families regarding neurostimulation and alternative therapies
based on currently defined indications
u
Treat patients with refractory epilepsy through use of alternative
treatments not previously considered
u
Recognize the value of treating refractory epilepsy through use of new
techniques such as mind-body techniques and psychological therapy.
Target Audience
Basic and Intermediate (see page 120 for details)
Program
Co-Chairs: Patricio E. Abad, M.D. and Mario A. Alonso-Vanegas, M.D.
30
3:30 p.m.
Introduction
Patricio E. Abad, M.D.
3:40 p.m.
Neurostimulation for Epilepsy
David King-Stephens, M.D.
6:00 p.m. – 7:30 p.m.
Special Interest Group Meetings
Location listed under each session
Cognitive and Behavioral Interventions for Epilepsy:
PNES Case Reports and Underlying Mechanisms
Convention Center – Room 607, Level 6
Coordinators: Lauren Frey, M.D., Marcio Sotero de Menezes, M.D.,
Rosa Michaelis, M.D., Steven C. Schachter, M.D., Siegward M. Elsas, M.D.
Speakers: Ivan Osorio, M.D., W. Curt LaFrance, Jr., M.D., M.P.H.,
Janelle Wagner, Ph.D.
Cognitive–behavioral therapy, mind–body approaches, and multimodal
educational interventions have consistently demonstrated positive effects
on patient well-being. Nevertheless, the evidence for their effects on seizure
control remains inconsistent, which is partly attributable to the
methodological difficulties inherent in rigorously testing these interventions.
In the first part of this SIG, Dr. Osorio will present observations from invasive
EEG monitoring that inform the hypothesis for a possible physiological
antiseizure mechanism of cognitive tasks. In the second part, we will review
case-based tools that may help SIG participants identify suitable candidates
for behavioral interventions, select appropriate interventions and monitor
intervention outcomes. A number of experienced therapists will demonstrate
how their therapeutic approaches would work in practice.
Dense Array EEG and EEG Source Localization in Clinical
Practice
Convention Center – Room 609, Level 6
Coordinators: Kitti Kaiboriboon, M.D., Susan T. Herman, M.D.
Speakers: Susan T. Herman, M.D., Kitti Kaiboriboon, M.D.,
Serge Vulliemoz, M.D.
This SIG will review the use of dense array (64 or more channels) EEG and EEG
source localization for routine EEG and epilepsy monitoring. Routine EEG using
21 scalp electrodes has excellent temporal but relatively poor spatial resolution,
FRIDAY December 5, 2014
Head Trauma and Military Epilepsy Care: Practical Guide to
Caring for Epilepsy Patients in the VA System
Convention Center – Room 620, Level 6
Neuropharmacology: Medication Discontinuation Post
Surgery: To Do or Not to Do?
Convention Center – Room 617, Level 6
Coordinators: Jeannine Conway, Pharm.D., M.D. and Laura Strom, M.D.
Speakers: Laura Strom, M.D. and Pei Shieen Wang, Pharm.D.
This SIG brings together individuals in a debate format with an interest in
anticonvulsants and optimizing their use. This year’s session will address the
decision to discontinue anticonvulsants post surgery; encouraging audience
participation. We will also discuss the practical challenges that can occur as
medication is being withdrawn, including adverse reactions and medication
interactions. Upon completion of the session, the participant should be able to
present reasonable options to their patients about making a decision about
medication discontinuation.
FRIDAY
limiting its utility in localization of epileptiform activity and seizures. Recent
advances in amplifier technology and electrode technology now allow recording
of 128-256 channels of EEG. EEG source imaging (ESI) is a model-based imaging
technique that determines the “inverse EEG solution,” or the generating source
of electrical potentials recorded on the scalp. Improved ESI software can now
build realistic head models based on individual patients’ MRIs, perform source
localization, and co-register results to imaging studies in less time and without
need for programming skills. These advances now put dense array EEG and ESI
tools in the hands of clinical electroencephalographers, but the clinical utility of
these techniques has not yet been fully explored. Speakers will debate the pros
and cons of dense array EEG in comparison to other techniques used for
epilepsy diagnosis and localization.
SUDEP: Hot Topics in SUDEP
Coordinators: Tung Tran, M.D., Jonathan Halford, M.D.,
Enrique A. Feoli, M.D., Joseph Drazkowski, M.D.
Speakers: Tung Tran, M.D. and Kenneth R. Perrine, Ph.D.
Convention Center – Room 603, Level 6
We will discuss how epilepsy care in the VA system is different from epilepsy
care outside of a Veterans Affairs Medical Center (VAMC). Specifically, we
will discuss (1) how the VA medication formulary system works on a local
VAMC and national level and changes to the formulary for 2014 (2) technical
challenges to setting up a neurophysiology lab in a VAMC (3) the structure of
VA administration and how to request expansion of services for epilepsy care
at your VAMC and (4) an update on progress to develop the VA Epilepsy
Centers of Excellence (ECoEs) and what services they can provide non-ECoE
VAMCs. This SIG is designed to dovetail with a book, “VA Epilepsy Manual”
that is being prepared now (editor Aatif Husain, M.D.) and will be published a
few months before this SIG and will be handed out at this SIG meeting.
Our understanding of SUDEP is moving forward thanks to a broad range of
research including animal models, the search for clinical biomarkers, and
collaborative work with coroners, medical examiners and device developers.
This year, we will delve into hot topics with experts in the field. Speakers and
topics will be selected based on cutting-edge SUDEP-related research
presented at this AES meeting and at the recent Partners Against Mortality in
Epilepsy (PAME) conference. Ample time will be allowed for discussion with
audience members.
Coordinators: Elizabeth J. Donner, M.D. and Lawrence J. Hirsch, M.D.
Speakers: TBA
Supported by Sunovion Pharmaceuticals, Inc.
Junior Investigators: Mentorship
Convention Center – Room 615, Level 6
Coordinators: William Stacey, M.D., Ph.D. and Mackenzie Cervenka, M.D.
Speakers: Kevin J. Staley, M.D., Gregory K Bergey, M.D.,
Frances E. Jensen, M.D.
Whether you are a clinician, a researcher, or both, effective mentorship is
critical to your academic success. Our interactive panel will discuss and
answer questions about finding and utilizing mentors at this early stage in
your career. Topics will include the importance of mentorship in grant
proposals, finding faculty positions, and collaborations. This panel discussion
is independent of the AES mentoring program, which attendees are also
encouraged to attend.
Get Your Annual Meeting
CME / CE Credit Online
Go to www.AESnet.org
See page 120 for details
31
• AES 68TH ANNUAL MEETING
Seattle, WA •
SATURDAY December 6, 2014
www.AESnet.org
7:00 a.m. – 8:30 a.m.
Mentoring Session for Junior Investigators
Convention Center – Room 307 / 308, Level 3
Pre-application required
This program is targeted to fellows, postdoctoral researchers, instructors and
assistant professor level junior faculty. Epilepsy professionals at the Associate
Professor level will volunteer to serve as mentors. Accepted applicants will
meet with their assigned mentors during this time.
7:00 a.m. – 8:30 a.m.
Special Interest Group Meetings
Location listed under each session
Basic Neuroscience: Brain Mosaicism in Epilepsy
Convention Center – Room 607, Level 6
Coordinators: Martin Gallagher, M.D., Ph.D., Laura A. Jansen, M.D., Ph.D.
Speakers: Annapurna Poduri, M.D., Laura A. Jansen, M.D., Ph.D.,
Kathleen Millen, Ph.D., Franck K. Kalume, Ph.D.
The speakers will present an overview of genetic mosaicism in the brain,
studies of mosaic PI3K/AKT pathway mutations in human brain
malformations, and animal models of PI3K/AKT pathway activation.
Implications for the diagnosis and treatment of epilepsy in patients with
malformations of cortical development will be highlighted, and plenty of time
will be available for audience questions and discussion.
Children’s Hour: Dravet Syndrome in 2014
Convention Center – Room 609, Level 6
Coordinators: Elaine C. Wirrell M.D., Lieven Lagae, M.D., Ph.D.
Speakers: Joseph Sullivan, M.D., Sarah Weckhuysen, M.D.,
Rima Nabbout, M.D., Ph.D.
In recent years, considerable progress has been made in the diagnosis and
treatment of Dravet syndrome. The speakers will focus on these clinically
relevant new achievements and present the key clinical features, guide us
through the complex genetic background and discuss the newer treatment
options in this drug-resistant childhood epilepsy syndrome. The goal of this
SIG is to be able to recognize a young child with Dravet Syndrome, to order
the right genetic testing and to apply standard and newer treatment options.
Supported by Acorda Therapeutics and GW Pharmaceuticals.
Ictal Semiology Cases – How Semilogy Helps to Localize the
Seizure Onset Zone and Elucidate the Propagation Pattern
Convention Center – Room 612, Level 6
Coordinators: Phillipe Kahane, M.D., Ph.D., Charles A. Szabo, M.D.
Speakers: Charles A. Szabo, M.D., Philippe Kahane, M.D., Ph.D.,
Hans O. Lüders, M.D., Ph.D., Andrew Bleasel, M.D.
We will be presenting 4-8 cases of patients undergoing epilepsy surgery. The
cases will be primarily discussed in strong interaction with the audience
based on seizure semiology, to show how the careful analysis of subjective
and observable clinical elements help to localize the seizure onset zone and to
reconstruct the propagation pattern. The final explanation will be briefly given
at the end of each case presentation, based on intracranial EEG and / or
surgical result.
32
Neurostimulation and Neuroengineering: New Directions
Convention Center – Room 603, Level 6
Coordinators: Christopher DeGiorgio, M.D., Catherine Schevon, M.D., Ph.D.,
Steven J. Schiff, M.D., Ph.D.
Speakers: Marom Bikson, Ph.D., Robert Fisher, M.D., Ph.D.,
Selim Benbadis, M.D.
The SIG will focus on the following topics: Transcranial Magnetic Stimulation
for the Treatment of Epilepsy Seizure Detection Devices: Detection Strategies,
Sensitivity, and Clinical Impact; Controversies in Neurostimulation 2014-2015:
An Interactive Debate with Audience Participation. The topics will be followed
by a period of interactive discussion.
Private Practice: How to Survive with Private Epilepsy
Centers in the Changing Health Care Environment
Convention Center – Room 617, Level 6
Coordinators: Marcelo E. Lancman, M.D., Pavel Klein, M.D.
Speakers: John S. Ebersole, M.D., David J. Anschel, M.D.,
Thomas H. Swanson, M.D.
We will discuss several topics related to the ability of private practice centers
to survive and thrive in the fast-changing healthcare environment. First, we
will discuss the dramatic changes underway in many communities of large
academic institutions and hospital chains buying out private practice
physicians and how this may impact private epilepsy centers in terms of
competition, referral patterns, hospital access, and hospital and insurance
contract negotiations. Second, we will discuss the impact of ACA on the
practice of epilepsy at private centers — the competing forces of decreased
utilizations (increased co-pays and physician access restriction vs. potential
increased coverage of previously uninsured patients with epilepsy); and the
flux/chaos (changes in insurance policies and insurance among insured
patients). Third, we will address the increased burden on time and resources
of both insurance and governmental requirements of medication and
procedure authorizations and denials, which have accelerated remarkably in
the last 12-24 months. Fourth, to end on a positive note, we will highlight
possibilities for how to compete in this changing environment, e.g. by offering
highly specialized services such as MEG by virtue of greater control over
resources, and of routine services at better access by virtue of flexibility and
responsiveness; and how in in both areas, super-specialized epilepsy care and
the routine epilepsy care private centers can have a competitive advantage
over large academic centers and hospital chains.
Supported by Acorda Therapeutics.
Psychiatry in Epilepsy: Aggression in People with Epilepsy,
Diagnosis and Treatment Issues
Convention Center – Room 615, Level 6
Coordinators: John J. Barry, M.D., Rochelle Caplan, M.D.
Speakers: Mary Wojnaroski, Ph.D., Michael Kerr, M.B.ChB., FRCPSYCH
Aggressive behaviors in individuals with epilepsy have been a controversial
topic. The association of aggression or violence with epilepsy has been
debated despite being reproduced in some animal models and may have
significant psychological and environmental consequences. The Psychiatric
SIG will focus on 1) Evidence-based diagnostic and treatment options for
aggressive behaviors in children and adolescents and 2) Aggression in adults
appearing in the post-ictal state, especially affiliated with comorbid psychosis
and finally 3) Aggression seen in individuals with developmental delay. The
format of the SIG will utilize cases for both children and adults as a nidus for
group discussion.
Supported by Sunovion Pharmaceuticals, Inc.
SATURDAY December 6, 2014
8:30 a.m. – 11:45 a.m.
Presidential Symposium: The AES
International Biomarker Competition: The
Crowd, the Cloud, Detection and Prediction
(2.25 CME Credits)
Convention Center – Ballroom 6C, Level 6
Presentation: Carolyn R. Houser, Ph.D. and
Ruth Ottman, Ph.D., Research Awards, ILAE Update
Overview
Learning Objectives
u
Recognize the role of the International EEG Database in developing spatial
and temporal prediction of epilepsy and seizures
u
Understand the physiologic basis of epileptogenesis, understand impact of
localization on surgery outcomes and appreciate issues related to
research into seizure prediction
u
Researchers will utilize described approaches with quantitative analysis
using large NIH database for developing new research questions and
methodology.
Target Audience
Advanced (see page 120 for details)
Program
Co-Chairs: Brian Litt, M.D. and Gregory A. Worrell, M.D., Ph.D.
9:30 a.m.
Introduction
Elson So, M.D.
9:35 a.m.
Review Current State of the Art of Electrophysiological
Biomarkers
Gregory A. Worrell, M.D., Ph.D.
10:05 a.m. Review Current State of the Art of Seizure: Detection
and Devices
Kathryn Davis, M.D.
10:30 a.m. Review Current State of the Art: Prediction and Devices
Mark J. Cook, M.D.
10:55 a.m. NIH International Electrophysiology Database and the
Competition
Brian Litt, M.D.
11:20 a.m. The Seizure Detection & Prediction Contest
Benjamin Brinkmann, Ph.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.25 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.25 contact hours (0.25 CEUs). UAN 0077-9999-14-031-L01-P.
Initial Release Date: 12/6/2014.
Acknowledgment
The International Competition is co-sponsored by the American Epilepsy
Society, National Institute of Neurological Disorders and Stroke and the
Epilepsy Foundation.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the
Presidential Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
SATURDAY
This symposium will address the role of electrophysiological biomarkers in
diagnosis, localization, and prediction of focal seizures and epilepsy. We
review the current state of the art of electrophysiological biomarkers in
epilepsy. Utilizing a large electrophysiology database (NIH-sponsored
International EEG Database) the concepts of data-sharing, large-scale
computation, and reproducible research will be introduced. Specific
applications using electrophysiological biomarkers to predict epilepsy
(epileptogenesis), predict seizures (ictogenesis), and map the epileptogenic
zone will be presented. Algorithms for detection and spatiotemporal mapping
of electrophysiological biomarkers from multiple research groups will be
presented. The performance of these algorithms will be rigorously evaluated
in an open competition applied to large-scale clinical and basic research
datasets: 1) Prediction of epilepsy in animal models, 2) Seizure forecasting in
dogs and humans, and 3) Localization of epileptogenic zone in humans. The
results of the competition between multiple international research groups will
be reviewed and awards presented for the best performance for predicting
epilepsy, predicting seizures, and mapping the epileptogenic zone.
11:40 a.m. Conclusions
Brian Litt, M.D., Gregory A. Worrell, M.D., Elson So, M.D.
Core Competencies: Medical Knowledge
2:15 p.m. – 5:00 p.m.
Antiepileptic Therapy Symposium:
The New AEDs: Where Do They Belong in
Your Armamentarium?
(2.5 CME Credits)
Convention Center – Ballroom 6C, Level 6
Presentation: Joyce A. Cramer, J. Kiffin Penry Award
Overview
This symposium will present an overview of the 8 newest antiepileptic drugs
(AEDs) that include clobazam, eslicarbazepine, ezogabine, lacosamide,
perampanel, rufinamide, stiripentol, and vigabatrin. Discussion will cover the
developmental history of the drug, mechanisms of action, indications for use,
efficacy, safety issues, tolerability and ease of use to include drug
interactions, formulations and dosing. Treatment paradigms that demonstrate
the differential role of the medications will be presented. As a result of
attending this symposium, the attendee will have an understanding of how to
incorporate the newest AEDs into an integrative treatment algorithm for their
clinical practice and will be able to counsel patients and their families
regarding risks, benefits and alternatives.
Learning Objectives
u
Recognize opportunities in their clinical practice to use one or more of
the eight newest AEDs and appropriately counsel patients regarding
risks, benefits and alternatives
u
Participate in counseling patients and their families regarding use of one
or more of the eight newest AEDs
u
Assist clinicians in their prescribing of one or more of the eight newest
AEDs through an understanding of pharmacology and drug-to-drug
interactions
u
Assist in identifying tolerability of adverse effects in the use of one or
more of the eight newest AEDs, particularly in reference to cognitive
and behavioral outcomes.
33
SATURDAY December 6, 2014
Target Audience
5:15 p.m. – 7:45 p.m.
Programs
Co-Chairs: Angus A. Wilfong, M.D. and Jerry J. Shih, M.D.
Professionals in Epilepsy Care Symposium:
Practical Applications for the Comprehensive
Treatment of Epilepsy
2:30 p.m.
Introduction
Angus A. Wilfong, M.D.
(2.5 CME Credits)
2:45 p.m.
Ezogabine / Eslicarbazepine
Martin J. Brodie, M.D.
3:10 p.m.
Stiripentol / Vigabatrin
Elinor Ben-Menachem, M.D., Ph.D.
3:35 p.m.
Lacosamide / Perampanel
John Pollard, M.D.
4:00 p.m.
Clobazam / Rufinamide
Joan A. Conry, M.D.
4:25 p.m.
Integration of New AEDs Into Clinical Practice
William E. Rosenfeld, M.D.
4:50 p.m.
Conclusions
Jerry J. Shih, M.D.
Basic and Intermediate (see page 120 for details)
Convention Center – Ballroom 6C, Level 6
Overview
Learning Objectives
u
Recognize when to screen for comorbid epilepsy conditions, initiate
appropriate treatment, and refer to the appropriate health care professional
u
Participate in providing education, resources, and counseling to persons
with epilepsy and their families regarding the comprehensive treatment
needs of persons with epilepsy
u
Assist the epilepsy care team / provider in identifying and treating the
comorbid conditions and identifying antiepileptic medication issues for
children, men, women, and the elderly
u
Assist the epilepsy care team / provider in identifying and using best
screening instruments regarding epilepsy psychiatric / psychological /
neurodevelopmental comorbid conditions for persons with epilepsy and
their families. Learner will also assist in the practical provision of or
access to behavioral treatment of such comorbid conditions.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Nurse Practitioners may claim 2.5 hours of pharmacology for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-032-L01-P.
Initial Release Date: 12/6/2014.
Target Audience
Basic and Intermediate (see page 120 for details)
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the
Antiepileptic Therapy Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Program
Co-Chairs: Georgette Smith, Ph.D., APRN, CPNP and Janelle Wagner, Ph.D.
5:15 p.m.
Introduction and Case Presentation
Georgette Smith, Ph.D., APRN, CPNP
5:30 p.m.
Behavioral Health and Cognitive Screening as Part of the
Epilepsy Clinic Visit
Bruce P. Hermann, Ph.D.
5:50 p.m.
Finding Resources and Practical Solutions for Behavioral
Interventions
Loretta Carbone, M.S.W.
6:10 p.m.
Antiepileptic Therapy: Pediatric, Elderly, Women’s and
Men’s Issues
Jeannine Conway, Pharm.D.
6:30 p.m.
Moderator: Kamil Detyniecki, M.D.
Speakers: Charlotte Hill, Ph.D., Benjamin J. Whalley, BPharm, Ph.D.,
Orrin Devinsky, M.D.
Special Populations
Mary Jo Pugh, Ph.D., RN (Veterans)
Jonathan Edwards, M.D. (Adolescents)
7:10 p.m.
Review of Cases: Panel Discussion
Sandra Cushner Weinstein, M.S.W.
This Investigator Workshop is supported in part by GW Pharmaceuticals.
7:30 p.m.
Conclusions
Janelle Wagner, Ph.D.
Core Competencies: Patient Care and Medical Knowledge
Acknowledgment
This program is supported by an educational grant from Eisai, Inc., UCB, Inc.,
Lundbeck Pharmaceuticals Inc. and Sunovion Pharmaceuticals, Inc.
2:30 p.m. – 4:00 p.m.
Investigators’ Workshop
Convention Center – Ballroom 6E, Level 6
Cannabinoids in Epilepsy: Do They Work? If So, How?
34
SATURDAY
Recent research and practice recommendations include the comprehensive
care of persons with epilepsy and their families. Despite this recommendation
no guideline exists for comprehensive epilepsy care. This symposium will
present recent research and practice evidence to assist interdisciplinary
providers about practical ways to provide comprehensive care for persons with
epilepsy and their families through the lifespan. Cases will be used to apply
interventions to improve health outcomes through early comorbidity screening
and health outcomes including: behavioral health screening, behavioral
interventions and resources, antiepileptic medication through the lifespan, as
well as care of special populations such as veterans and adolescents.
SATURDAY December 6, 2014
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Programs
Chair: Gary W. Mathern, M.D.
Introduction
Gary W. Mathern, M.D.
5:40 p.m.
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-033-L01-P.
Initial Release Date: 12/6/2014.
What Is Pediatric Epilepsy Surgery?
Gary W. Mathern, M.D.
6:05 p.m.
What Is So Special About Children?
J. Helen Cross, M.D.
ABPN Core Competencies
6:30 p.m.
Pediatric Epilepsy Surgery: Is it Only Rare Syndromes?
William D. Gaillard, M.D.
6:55 p.m.
What is the Role of Social Media and Nonprofits?
Adam Hartman, M.D.
7:20 p.m.
Conclusions
Gary W. Mathern, M.D.
Nurses may claim up to 2.5 contact hours for this session.
Pharmacy Credit
The American Board of Psychiatry and Neurology has reviewed the
Professionals in Epilepsy Care Symposium and has approved this program as
part of a comprehensive lifelong learning program, which is mandated by the
ABMS as a necessary component of maintenance of certification.
Core Competencies: Professionalism, Practice-based Learning, Interpersonal
and Communication Skills and System-based Practice
Acknowledgment
This program is supported by an educational grant from Eisai, Inc., and
UCB, Inc.
5:30 p.m. – 7:30 p.m.
North American Commission Symposium:
Pediatric Epilepsy Surgery: Update on Current
Practice
(2.0 CME Credits)
Convention Center – Ballroom 6E, Level 6
Overview
This symposium will present an overview of pediatric epilepsy surgery
presenting, in part, data from the ILAE Pediatric Epilelpsy Surgery Task Force.
This symposium will address criteria for when to refer, what constitutes
pediatric epilepsy surgery, what are effective outcome measures, the social
impact and co-morbities of pediatric epilepsy surgery syndromes, and the
emergence of non-profit parent groups to influence care and practice in the
field. Learners will be provided with established criteria for diagnosis of
intractable pediatric epilepsy.
Learning Objectives
u
Determine which pediatric patients are candidates for epilepsy surgery
based on international standards suggested by the ILAE Pediatric Epilepsy
Surgery Task Force
u
Refer pediatric patients for epilepsy surgery based on international
experience
u
Counsel family regarding diagnosis of intractable epilepsy as currently
defined
u
Explain the process of evaluating a child for epilepsy surgery in view of
international experience
u
Assess children with intractable epilepsy in anticipation of referral for
surgical evaluation using current criteria, defining current psychological
and neuropsychological status.
Target Audience
Basic, Intermediate, and Advanced (see page 120 for details)
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
SATURDAY
5:30 p.m.
Nurses may claim up to 2.0 contact hours for this session.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the North
American Commission Symposium and has approved this program as part of
a comprehensive lifelong learning program, which is mandated by the ABMS
as a necessary component of maintenance of certification.
Core Competencies: Professionalism, Patient Care, Practice-based Learning,
Systems-based Practice
AES ANNUAL
BUSINESS MEETING
All AES members are encouraged
to attend this yearly meeting.
You’re invited to attend
Sunday, December 7
8:00 a.m. – 8:30 a.m.
Sheraton Seattle Hotel
Metropolitan Ballroom B, Third Floor
Coffee will be available
35
Saturday December 6, 2014
Poster Session 1
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
 Authors Present: Noon – 2:00 p.m.
 Poster Walking Tours begin at 12:15 (see page 15 for details)
Translational Research
Mechanisms
1.001 Enhanced Histamine Release
During The Pilocarpine-Induced Status
Epilepticus Is Associated To
Hippocampal Neuronal Damage In Rats:
Effects Of Sodium Cromoglycate/
L. Rocha, M. Valle-Dorado,
C. Santana-Gomez, S. Orozco-Suarez
1.002 PET Imaging Of Translocator
Protein In Temporal Lobe Epilepsy/
L. Dickstein, P. Zanotti-Fregonara,
I. Dustin, J. Liow, J. Hirvonen,
W. Kreisl, K. Jenko, S. Inati, M. Fujita,
C. Morse, J. Hong, V. Pike, S. Zoghbi,
R. Innis, W. Theodore
1.003 Time- And Region-Specific
Alterations In Cyclin D1 Expression
Following STAT3 Inhibition In A Rat
Model Of Temporal Lobe Epilepsy/
Y. Cruz Del Angel, D. Strode,
A. Brooks-Kayal, H. L. Grabenstatter
1.004 Basic Mechanisms Of Acute
And Chronic Neocortical Epilepsy
Revealed By Multi-Electrodes
Extracellular Field Recordings In Brain
Slices/R. Serafini, J. Loeb
1.005 Adenosine Kinase Expression In
Cortical Dysplasia With Balloon Cells:
A Developmental Lineage Of Cell Types
Analysis Epilepsy Center, Beijing
Sanbo Brain Hospital, Capital Medical
University, Beijing 100093, China/
T. Li, G. Luan
1.006 Proteomic Analysis Of TrkBMediated Synaptic Changes Following
Status Epilepticus/E. B. Ludmir,
Y. Huang, B. Gu, E. J. Soderblom,
M. Moseley, J. O. McNamara
1.007 Differential Toll-Like Receptor 4
Modulation Of Dentate Excitability In
The Normal And Injured Brain/
A. A. Korgaonkar, Y. Li, V. Santhakumar
1.008 T Cells Rapidly Relocate From
Spleen And Accumulate During
Epileptogenesis In A Rat Brain Of
Cortical Dysplasia Following A Second
Hit/K. Ayasoufi, A. Nemes,
A. Valujskikh, Z. Ying, I. Najm
1.009 Developmental Plasticity Of
Dentate Gyrus Granule Cells Following
Epileptiform Activity In Vitro/
K. P. Patterson, Y. Chen, G. P. Brennan,
C. Ly, T. Baram
1.010 New Animal Model Of SUDEP:
Brainstem Ictal EEG Is Associated
With Respiratory Arrest/T. Salam,
G. Montandon, R. Genov, J. Perez
Velazquez, P. Carlen
1.011 Mechanisms Underlying
Transitions Between Bursting And
Seizing In A Computational Network
Model/W. Swiercz, K. Lillis, K. Staley
1.012 Increased Expression Of
Growth Associated Protein 43 After
Seizures In Rodent Model Of
Irradiation-Induced Cortical
Dysplasia/A. Nemes, Z. Ying, I. Najm
36
1.013 Hyperactivation Of mTOR
Signaling In A Two-Neuron Microcircuit
Alters The Dynamics Of Synaptic
Transmission/M. Weston, H. Chen,
J. Swann
1.014 Unit Activity Of Subicular, CA1,
CA3, And Dentate Gyrus Principal
Cells And Interneurons Before
Spontaneous Seizures In A Rat Model
Of Temporal Lobe Epilepsy/
P. Buckmaster, I. Toyoda, S. Fujita,
A. Thamattoor
1.015 GABAB Receptors Regulate
Trafficking Of Extrasynaptic GABAA
Receptors In Dentate Gyrus Granule
Cells Via PKA- And PKC-Dependent
Signaling Pathways/W. Tao, W. Spain,
C. Ransom
1.016 Potassium Concentration
Bidirectionally Modulates Seizure-Like
Events In The 4-AP Epilepsy Model In
Vitro And In Vivo/P. Bazzigaluppi,
L. Wang, S. Dufour, T. Valiante,
P. Carlen
1.017 Onset Of Spontaneous Limbic
Seizures Is Associated With Changes
In Firing Dynamics Of Neuronal
Ensembles In Hippocampus And
Parietal Association Cortex/
A. Neumann, A. Luczak, M. Sprengers,
H. Steenland, K. Bzymek, J. Xie,
V. Lapointe, Z. Navratilova,
F. Kloosterman, K. Vonck, P. Boon,
B. L. McNaughton, R. Raedt
1.018 Human Single Neuron
Correlates Of High Frequency
Oscillations During Seizures/
O. J. Ahmed, E. N. Eskandar,
L. R. Hochberg, S. S. Cash
1.019 Invited Speaker Abstract
Submission
1.020 Pro-Resolving Receptors
ChemR23 And ALXR Expression
During Epileptogenesis In Mice/
F. Frigerio, A. Torello, M. Neveux,
K. Leclercq, A. del Prete, S. Sozzani,
R. Kaminski, A. Vezzani
1.021 Impermeant Anions Are
Involved In Setting The Neuronal
Chloride Concentration, Implications
For Seizure Treatment/J. Glykys,
V. Dzhala, K. Egawa, T. Balena,
Y. Saponjian, K. Kuchibhotla,
B. Bacskai, K. T. Kahle, T. Zeuthen,
K. Staley
1.022 Adenosinergic Pathway
Involvement In Protective Effect Of
Atorvastatin In PentylenetetrazolInduced Seizures In Rats/A. Goyal,
R. Kumar, Y. K. Gupta
1.023 Does Enhancement Of
Ventilation Reduce Respiratory Arrest
In DBA/1 Mice?/C. Zeng, X. Long,
J. Cotten, S. Forman, K. Solt,
C. Faingold, H. Feng
1.024 The mTOR Inhibitor, Rapamycin,
Attenuates Acute Seizure-Induced
Dendritic Injury In Mice/D. Guo,
N. Rensing, M. Wong
1.025 TRPV1 Receptors Modulate
The Expression Of Experimental
Febrile Seizures During Development
In Mice/K. Barrett, L. Scott,
S. Mandadi, P. Whelan, M. Scantlebury
1.026 Hypothermia Prevents The
Development Of The Calcium Plateau
Following Status Epilepticus/
K. Phillips, L. Deshpande, R. DeLorenzo
Models
1.027 Tonic GABAergic Inhibitory
Signaling To Dentate Granule Cells In
Mice Following Controlled Cortical
Impact/J. Boychuk, C. Butler, B. Smith
1.028 The Action Potential Firing
Frequency Of Fast-Spiking Basket
Cells Is Reduced After Status
Epilepticus/H. Sun, H. Goodkin
1.029 Benzodiazepine Resistant
Status Epilepticus And Brain Injury In
DFP Model Of OP Intoxication/
R. Kuruba, X. Wu, D. Reddy
1.030 Postnatal Disruption Of The
Cytoskeletal Protein Ndel1 Induces
Hippocampal Structural Pathology And
Spontaneous Recurrent Seizures/
C. Gavrilovici, Y. Jiang, M. Chansard,
R. Liu, K. Parsons, S. Park,
M. Scantlebury, G. Teskey, J. M. Rho,
M. Nguyen
1.031 Midazolam Refractory Seizures
And Brain Injury Following Acute
Organophosphate Intoxication/X. Wu,
R. Kuruba, D. Reddy
1.032 Diminished Antiepileptogenic
Effects Of Neurosteroids In Mice
Lacking Delta-Subunit Extrasynaptic
GABA-A Receptors/B. Clossen,
D. Reddy
1.033 Perimenstrual Upregulation Of
Delta-Subunit Extrasynaptic GABA-A
Receptors Mediating Tonic Inhibition
And Neurosteroid Sensitivity/
C. Carver, X. Wu, O. Gangisetty,
D. Reddy
1.034 Alcohol And SUDEP In
Genetically Epilepsy Prone Rats
(GEPR-9s)/C. Faingold, M. Randall,
S. P. Kommajosyula
1.035 Hyperthermic Seizures And
Seizure Susceptibility: A Novel
Approach Using Zebrafish/J. Ullmann,
G. Leanage, D. Reutens
1.036 Alterations Of
Neurometabolites And Fear
Responses After NMDA-Induced
Spasms In Infant Rats/M. Lee,
M. Yum, D. Woo, T. Ko
1.037 Progesterone Increases AMPA
Receptor Cell Surface Expression Via
Mechanisms Involving Progesterone
Receptors/J. Kapur, S. Joshi,
C. Passmore, J. Williamson
1.038 Antiseizure Effects Of TrkB
Kinase Inhibition/R. Kotloski, G. Liu,
J. McNamara
Saturday December 6, 2014
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.052 Early-Life Clonazepam
Exposure Leads To Persistent
Alteration Of Seizure Susceptibility/
H. Kubova, G. Tsenov, J. Virta,
P. Mares
1.053 Blood-Brain Barrier Integrity In
Epileptic WAG/Rij rats with rotational
movements/C. Gurses, D. Sahin,
C. Ugur Yilmaz, N. Orhan, B. Ahishali,
M. Kucuk, N. Arican, N. Ates,
M. Kaya
1.054 Treatment Of Convulsive
Status Epilepticus In An Animal Model
Of Glucose Transporter Type 1
Deficiency (G1D) Syndrome/C. Trent,
L. Good, D. Kelly, S. Kayani,
J. Pascual, K. Rajasekaran
1.055 Minocycline Reverses ProEpileptogenic Effect Of Viral-Like Brain
Inflammation In The Mature And
Immature Rat Brain/N. Dupuis,
A. Mazarati, B. Desnous, S. Auvin
1.056 Systemic TLR3 Agonist
Injection Enhances Epileptogenesis In
Rat Pups But Does Not Affect The
Adult Rats/B. Desnous, A. Mazarati,
N. Dupuis, S. Auvin
Human Studies
1.057 Improving Seizure Outcomes In
Patients With Neocortical Epilepsy By
Resecting Brain Regions Generating
Ictal Phase Locked High-Frequency
Oscillations (HFOs)/S. A. Weiss,
R. Connors, G. Banks, E. Smith,
A. Lemesiou, B. Zhao, C. Filippi,
R. Emerson, L. Bateman, M. Nowell,
R. Rudoinov, B. Diehl, M. Walker,
C. Schevon
1.058 The Gamma Band Effect For
Episodic Memory Encoding Is Absent
In Epileptogenic Hippocampi/B. Lega,
A. Dionisio, W. Bingaman, I. Najm,
J. Gonzalez-Martinez
1.059 Structure And Risk Factors of
Epileptic Seizures At Patients With
Severe Head Injury/I. Trifonov, V.
Krylov, A. Talypov
1.060 Alternation Of Cross
Frequency Coupling In The Pre-Ictal
iEEG Of Epileptic Patients/K. Edakawa,
H. Kishima, T. Yanagisawa, S. Oshino,
Y. Inoue, H. Khoo, T. Maruo,
M. Kobayashi, M. Hirata, T. Yoshimine
1.061 Brain State Dynamics And The
Role Of The Epileptogenic Zone/
S. Burns, S. Santaniello,
W. Anderson, S. V. Sarma
1.062 Prospective Evaluation Of The
Effects Of Clinical And Subclinical
Epileptoform Discharges On Driving
Safety/Y. Si, E. Gudbranson, W. Chen,
M. Midura, R. Wu, B. Geng,
P. Vitkovskiy, A. Sivaraju, R. Sainju,
A. Fernandez, A. Alareddy, I. Quraishi,
R. Duckrow, L. Hirsch, H. Blumenfeld
1.063 The Frontal And Insular
Network: A Corticocortical Evoked
Potentials Study/R. Enatsu,
J. Gonzalez-Martinez, J. Bulacio,
Y. Kubota, J. Mosher, R. Burgess,
I. Najm, D. Nair
1.064 Seizure Propagation Across
Micro Domains In Epileptic Patients
Undergoing Intracranial Monitoring/
I. Basu, W. S. Anderson
1.065 Why Do Placebos Decrease
Seizures In Clinical Trials?/
D. Goldenholz, R. Moss, W. Theodore
Devices, Technologies, Stem Cells
1.066 Commercial Development Of
Advanced Wireless Technologies In
Implantable Neurostimulators For The
Treatment Of Epilepsy/E. Chow,
C. Warren, A. Shen, K. Venkatraman,
A. Jones, A. Adkins, O. Abdel-Latief,
D. Thompson, B. Byerman
1.067 Cardiac-Based Seizure
Detection: Long-Term Patient FollowUp From The AspireSR E-36 Trial/
P. Boon, K. van Rijckevorsel,
R. El Tahry, C. Elger, N. Mullatti,
A. Schulze-Bonhage, K. Vonck,
G. Wagner, W. Van Grunderbeek,
R. McGuire
1.068 VNS Therapy Automatic
Magnet Mode Outcomes Study In
Epilepsy Patients Exhibiting Ictal
Tachycardia/R. Fisher, J. Harvey,
P. Afra, B. Najimipour
1.069 Immunomodulation For LongLasting Anticonvulsant Effects After
Neural Xenografting In Rats –
Neonatal Induction Of Tolerance
Versus Pharmacological
Immunosuppression/A. Handreck,
B. Backofen-Wehrhahn, E. M. Mall,
B. Petersen, H. Niemann, M. Gernert
1.070 Chronic Delivery Of Vigabatrin
Into The Subthalamic Nucleus Is
Anticonvulsant In A Rat Seizure
Model/L. Gey, M. Gernert, W. Loscher
1.071 Development Of A Technique
For Assessing The Effects Of
Selective Sleep Restriction In Mice/
S. Sunderam, F. Yaghouby, C. Schildt,
K. D. Donohue, B. F. O’Hara
1.072 Multichannel Portable fNIRSEEG System For Long-Term
Monitoring Of Seizures/A. Kassab,
P. Vannasing, J. Tremblay, D. Safi,
F. Lesage, M. Sawan, D. Nguyen
1.073 Sensing-Enabled Hippocampal
Deep Brain Stimulation In Idiopathic
Nonhuman Primate Epilepsy/
W. J. Lipski, V. DeStefino,
S. Stanslaski, A. Antony, J. Cameron,
M. Richardson
1.074 Development Of A Depth
Electrode Placement Planning System
For Direct Cortical Stimulation
Therapy/L. Cendejas, R. Dawe,
M. A. Rossi
1.075 Performance Of Limb-Based
Accelerometers In The Detection Of
Hypermotor Seizures/G. Carlson,
S. Sabesan, K. Rose, I. Chekhovtsov
SATURDAY
1.039 GABA Agonists Restore
Inhibitory GABA Neurotransmission In
Mesiotemporal Lobe Epilepsy: In Vivo
And In Silico Modeling Evidence/
S. Stamboulian-Platel, A. Legendre,
T. Chabrol, P. Polack, J. Platel,
F. Pernot, V. Duveau, C. Roucard,
S. Charpier, M. Baudry, A. Depaulis
1.040 Higher Seizure Susceptibility In
Rats With Cortical Dysplasia: A
Feedback Systems Perspective/
B. Krishnan, A. Nemes, Z. Ying,
Z. I. Wang, I. Najm, A. Alexopoulos
1.041 Early Structural Changes In
The Methionine Sulfoximine Model of
Mesial Temporal Lobe Epilepsy/
H. Wang, Y. Huang, R. Dhaher,
D. Coman, H. Zaveri, F. Hyder, T. Eid
1.042 Changes In Neurotransmitter
Gene Expression Correlated With EEG
Stages During Lithium/PilocarpineInduced Experimental Status
Epilepticus/D. M. Treiman,
D. E. Schooley, S. T. Marsh,
L. J. Treiman
1.043 Modeling PIK3CA-Related
Malformations Of Cortical
Development And Epilepsy In Mice/
A. Roy, J. Ni, J. Skibo, S. Rankin,
W. Dobyns, S. Baker, J. Zhao,
F. Kalume, K. J. Millen
1.044 Thalamic Deep Brain
Stimulation To Improve Consciousness
After Seizures/A. Gummadavelli,
J. Motelow, N. Smith, Q. Zhan,
N. Schiff, H. Blumenfeld
1.045 Electrical Stimulation Of The
Cerebral Cortex With A Disk
Electrode: A Modeling Study/P. Kudela,
W. Anderson
1.046 Examining The Roles Of SCN3A
And SCN9A In Epilepsy/T. Lamar,
J. Wong, L. Papale, A. Escayg
1.047 Neuroanatomical And
Neurodevelopmental White Matter
Differences Between Rat Strains
With Differing Vulnerability To
Epileptogenesis And Behavioural
Comorbidities/P. Sharma, M. E. Wlodek,
L. A. Johnston, K. L. Powell, K. Gilby,
T. J. O’Brien
1.048 PTEN Deletion From AdultGenerated Dentate Granule Cells
Disrupts Granule Cell Mossy Fiber
Axon Structure/C. L. LaSarge,
V. R. Santos, S. C. Danzer
1.049 Effects Of Seizures On
Breathing And Survival Are Dependent
On Vigilance State/K. I. Claycomb,
M. A. Hajek, D. A. Rappoport,
G. Buchanan
1.050 Use Of An Automated-Feeding
System For The Testing of Potential
Anticonvulsant Compounds in Chronic
Epileptic Rats/K. Thomson,
C. H. Rueda, M. Barker-Haliski,
H. White
1.051 Analysis Of Postictal Period In
Developing Rats/Z. Ben Salem,
H. Hanáková, J. Otáhal, P. Mares
Poster Session 1
37
Saturday December 6, 2014
1.076 Prospective Driving
Performance Evaluation Using A
Portable Handheld Device In The
Epilepsy Monitoring Unit/N. Li,
J. Thomson, W. Chen, D. Kluger,
C. Cunningham, R. Gebre, Y. Si,
J. Blumenfeld, E. Chen, M. Johnson,
P. Vitkovskiy, Y. Baykara, E. Gudbranson,
A. Morawo, H. Blumenfeld
1.077 Scoring Sleep In Interictal
Electrocorticographic Recordings/
F. Yaghouby, P. Modur, S. Sunderam
1.078 Medial Septal Theta
Stimulation Increases Seizure
Threshold And Improves Cognition In A
Rat Model Of Epilepsy/A. Izadi,
S. Seidl, D. Lee, A. Ekstrom,
K. Shahlaie, G. Gurkoff
Behavior/Neuropsychology/
Language
Adult
1.079 Direct Physiologic Evidence For
A Heteromodal Convergence Region
For Proper Naming In The Left
Anterior Temporal Lobe/T. J. Abel,
A. E. Rhone, K. V. Nourski,
H. Kawasaki, H. Oya, T. Ando,
M. Howard, D. Tranel
1.080 Executive Functioning Changes
In A Clinical Sample Of Older Adult
Patients With Temporal Lobe
Epilepsy/C. Sylvester, G. Risse,
R. Doss
1.081 Factors Analysis Of Korean
Version Of Liverpool Adverse Event
Profile (K-LAEP): Factors Explaining
The Scores Of K-LAEP And Their
Association With Drug Load And Drug
Number Of Antiepileptic Drugs/
O. Kwon, S. Kim, S. Park
1.082 The Influence Of Gender On
Personality Assessment Inventory
Scores Used To Support The
Diagnosis Of Psychogenic Nonepileptic
Seizures/M. Hoerth, K. Corallo,
D. Locke, R. Lanyon
1.083 Stress Coping Strategies In
Patients With Epilepsy And How They
Relate To Mood/K. Isaacs Lebeau,
L. Myers, M. Lancman, M. E. Lancman
1.084 Barriers And Facilitators To
Self-Management Among Persons
With Epilepsy And Mental Illness/
M. Sajatovic, R. K. Ramsey, E. Welter,
K. Colón-Zimmermann, A. T. Perzynski
1.085 Effects Of Adjunctive
Lacosamide On Mood And Quality Of
Life In Adult Patients With
Localization Related Epilepsy/
L. Nakhutina, S. D. Kunnakkat,
M. Coleman, C. Lushbough, V. Arnedo,
N. Soni, A. C. Grant
1.086 A Randomized Controlled Trial
Of HOBSCOTCH: A Self-Management
Intervention For Cognitive Impairment
In Epilepsy/T. A. Caller, K. L. Secore,
R. J. Ferguson, R. M. Roth,
F. P. Alexandre, J. Kleen,
J. Harrington, P. L. Henegan,
B. C. Jobst
38
Poster Session 1
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.087 Effect Of Seizures On Sleep
Quality In Patients With Chronic
Epilepsy/K. Hwang, S. Cho, J. Kim,
E. Joo, S. Hong
1.088 Depression, Anxiety And
Quality Of Life In Hispanic SpanishSpeaking Patients With Psychogenic
Non-Epileptic Seizures (PNES)
Compared To Those With Epilepsy/
L. Myers, R. Zeng
1.089 Correlation Of Pre-Diagnosis
Illness Perception And Clinical
Outcome In Patients With
Psychogenic Non-Epileptic Seizures/
S. Majmudar, D. K. Chen
Pediatrics
1.090 Development Of The PedsQLEpilepsy Module/A. Modi, K. Junger,
A. Arnett, K. Mann, S. Guilfoyle,
D. Morita, J. Varni
1.091 Behavioral Medicine Services
Integrated Into Pediatric Epilepsy
Care/S. Guilfoyle, K. Junger,
A. Arnett, A. Modi
1.092 Children With Early Onset
Epilepsy Display Thalamic
Abnormalities At Diagnosis/M. Yoong,
M. Hunter, J. Shetty, M. McPhillips,
A. McLellan, R. F. Chin
1.093 Impact Of Epilepsy Surgery On
Behavior In Children/L. Ferguson,
R. M. Busch, K. Kim, J. Haut,
P. Klaas, W. Bingaman, D. Lachhwani,
T. Lineweaver
1.094 Treatment Of Psychogenic
Non-Epileptic Seizures In The
Pediatric Population/J. Doss,
E. Adams, M. Palmquist
1.095 Memory Functioning In LongTerm Outcome After Epilepsy Surgery
In Childhood/M. Smith, K. Puka
1.096 Epilepsy Education: Parents
And Adolescents Learn Differently/
L. Carbone, R. Derry, M. Plegue,
S. Rau, R. Shellhaas
1.097 Behavioral Co-Morbidities In
Pediatric Epilepsy: What Is The Role
Of Cognition?/S. Eom, R. Caplan,
A. Berg
1.098 Continuous spikes And Waves
During Sleep (CSWS). Changes In
Seizure Frequency, Epileptiform
Activity And Cognition After HighDose Clobazam Treatment/J. Klehm,
I. Sánchez Fernández, C. Vega,
J. Peters, S. Thome-Souza, C. Harini,
M. Takeoka, G. Wilkening, K. Chapman,
T. Loddenkemper
1.099 Intellectual And Memory
Outcome Following Pediatric Epilepsy
Surgery Using Reliable Change
Methods/J. Haut, L. Ferguson,
T. Lineweaver, P. Klaas, D. Lachhwani,
W. Bingaman, R. M. Busch
1.100 Predictors Of Quality Of Life In
Childhood Epilepsy: The Child’s
Perspective/N. Fayed, A. M. Davis,
D. L. Streiner, P. L. Rosenbaum,
L. Lach, C. E. Cunningham, M. Boyle,
G. Ronen
1.101 Support For Use Of The
Meyers Neuropsychological System
With Pediatric Patients With Epilepsy/
Y. C. Leon, S. Benbadis, D. Lisicki,
C. Ramirez, J. Ferreira
Genetics
Human Studies
1.102 WITHDRAWN
1.103 The Expanding Role For
Chromatin Remodeling In Epilepsy:
Gene Discovery To Pathogenic
Mechanisms/G. L. Carvill, J. McMahon,
H. Wang, J. Stamatoyannopoulos,
I. Scheffer, H. Mefford
1.104 Mutations In WWOX Gene In
Early Infantile Epileptic Encephalopathy:
Expansion Of The Phenotype And
Genotype Disease Spectrum/
B. Melaiki, F. ALMutairi, A. ALHashem
1.105 Distinct Phenotypes And
Genotypes Of SPTAN1 Encephalopathy/
J. Tohyama, M. Nakashima, Z. Rener
Primec, C. Gaik-Siew, S. Nabatame,
M. Kato, N. Matsumoto, H. Saitsu
1.106 Cornelia de Lange
Syndrome:Clinical Features & Course
of The Largest SMC1A Deletion/
L. R. Kaplan, N. Zadeh, A. Spitz,
G. Fernandez
1.107 De Novo Mutation In Sodium
Channel Gene SCN8A Causes Delay In
Neuromuscular Junction Development
In Early Onset Epileptic
Encephalopathy /N. Barisic
1.108 Familial Focal Epilepsy With
Paroxysmal Arousals Due To A Novel
CHRNA2 Loss Of Function Mutation/
V. Conti, P. Aracri, L. Chiti, S. Brusco,
F. Mari, C. Marini, A. Romigi,
A. Becchetti, R. Guerrini
1.109 WITHDRAWN
1.110 Presenilin 1 Mutation In A
Sporadic, Early-Onset Dementia With
Myoclonus And Epilepsy/M. Kinoshita,
H. Nakano, K. Park, H. Yamashita,
T. Kondo, R. Takahashi, A. Ikeda
1.111 A Novel LGI1 Variant In
Autosomal Dominant Lateral Temporal
Lobe Epilepsy/W. O. Pickrell, C. Hope,
J. G. Mullins, P. E. Smith, M. I. Rees,
S. Chung
1.112 Antecollis And LevodopaResponsive Parkinsonism Are Late
Features Of Dravet Syndrome/
A. Fasano, F. Borlot, A. E. Lang,
D. Andrade
1.113 DEPDC5 Mutations In Familial
Temporal Lobe Epilepsies/C. Nobile,
E. Serioli, E. Dazzo, P. Striano,
S. Striano, R. Michelucci
1.114 De Novo Mutations In Synaptic
Transmission Genes Including DNM1
Cause Epileptic Encephalopathies/
S. Weckhuysen
1.115 Copy Number Variations In
Early Onset Absence Epilepsies/
H. Muhle, M. Pendziwiat, P. Striano,
R. S. Møller, C. Marini, A. Suls,
P. De Jonghe, B. Neubauer,
M. von Deimling, J. Jähn,
S. von Spiczak, Y. Weber,
G. Kurlemann, T. Polster, I. Vater,
I. Scheffer, T. Sander, R. Siebert,
U. Stephani, I. Helbig
Saturday December 6, 2014
Neuropathology of Epilepsy
Human Studies
1.122 Temporal Lobe Epilepsy With
Hippocampal Sclerosis: The Role Of
5HT1A and 5HT2A Receptos In
Human Epileptogenesis/N. Fonseca,
H. P. Joaquim, V. D. de Paula,
S. Vincentiis, L. L. Talib, W. F. Gattaz,
K. Valente
Neurophysiology
Video EEG Epilepsy-Monitoring
1.123 Electroencephalographic
Patterns During Sleep In Children
With Chromosome 15q11.2-13.1
Duplications (Dup15q)/D. Arkilo,
O. Devinsky, R. Thibert
1.124 A Reduction Of Sleep Spindles
Precedes Seizures In Focal Epilepsy
By Minutes/J. Remi, F. Tezer-Filik,
S. Noachtar
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.125 How Long Is A Single, Scalp
Video EEG Monitoring Evaluation Valid
In The Pre-Surgical Evaluation For
Focal Epilepsy?/D. M. Bonno,
A. Fessler
1.126 Representation Of Memory
Strength And Subjective Confidence
By Individual Neurons In The Human
Medial Temporal Lobe/U. Rutishauser,
S. Ye, M. Koroma, J. Chung,
A. Mamelak
1.127 Synergy Between Epileptogenic
Cortex And Thalamus Projecting
Generalized Paroxysmal Fast Activity
(GPFA) In Children With Intractable
Localization-Related Epilepsy/S. Baba,
M. Mohammadi, T. Okanishi,
K. Okanari, S. Sakuma, A. Ochi,
E. Widjaja, C. Go, O. C. Snead III,
H. Otsubo
1.128 Importance Of Routine Ictal
Heart Rate Analysis In Drug
Resistant Epilepsies: Possible
Prediction Of Patients At Risk For
SUDEP/L. Baysal Kirac, B. Baykan,
C. Gurses, N. Bebek, A. Gokyigit
1.129 Scalp High Frequency
Oscillations Help To Identify Patients
With Poor Postsurgical Seizure
Outcome/C. Klus, M. Duempelmann,
M. Mader, A. Schulze-Bonhage,
J. Jacobs
1.130 A Study On Clinical Usefulness
Of 3D EEG Source Localization
Analysis/C. Park, D. Kim, B. Abibullaev,
H. Kwon, J. Seo, E. Joo, D. Seo,
Y. Lee, S. Hong
1.131 The Diagnostic Yield Of VideoEEG in the inpatient versus
Ambulatory Settings In Adults With
Episodes Of Unclear Nature/E. Fertig,
E. Feoli, J. Sabri, C. Lambrakis,
O. Laban-Grant, S. Mesad,
J. Politsky, M. Lancman
1.132 Electroencephalogram
Characteristics In Pediatric Patients
With Anti-NMDA Receptor
Encephalitis/E. Cruz, S. Manganaro,
L. Bello, M. Andriola, L. Manganas
1.133 Interictal And Ictal Video EEG
Findings In Patients With Epilepsy And
Autism Spectrum Disorder/
J. Avallone, J. Misajon, S. Iyer,
O. Devinsky
1.134 Pathognomonic
Electroencephalogram Findings In A
Case Of Isodicentric Chromosome
15/V. S. Vajjala, J. B. Wollack,
S. A. Hosain
ICU EEG
1.135 Clinical Correlates And
Outcome Of Lateralized Periodic
Discharges In Patients Without Acute
Brain Injury: A Case-Control Study/
R. Sainju, L. Manganas, E. Gilmore,
O. Petroff, N. Rampal, L. Hirsch,
N. Gaspard
1.136 Interrater Agreement In The
Interpretation Of Neonatal
Electroencephalography/C. J. Wusthoff,
J. Sullivan, H. C. Glass, R. Shellhaas,
N. Abend, T. Chang, T. Tsuchida
1.137 Development Of Epilepsy In
Neonates With Hypoxic Ischemic
Encephalopathy (HIE) Receiving Whole
Body Therapeutic Hypothermia(TH)
Compared To A Non-TH Group/
K. Khusiwilai, M. Cordeiro, T. Czech,
K. Harris, A. Massaro, T. Chang,
T. Tsuchida
1.138 Seizure Detection In Adults
Using Feature Baseline Correction On
A Neonatal EEG Trained Classifier/
G. Bogaarts, E. Gommer, D. Hilkman,
V. van Kranen-Mastenbroek
1.139 Comparison Of Seizures
Captured With Extended Versus
Reduced EEG Electrode Arrays In
Neonates Undergoing Therapeutic
Hypothermia/G. Diaz-Medina, Y. Lai,
A. L. Thompson, W. Laura, A. Anderson
1.140 Early Identification Of Patients
With PRES Using Continuous EEG
Reduces The Comorbidity Of SAH And
Impacts its Treatment Approach/ J.
Politsky, I. Ugorec, D. Baker,
P. Rodgers, E. Fertig
1.141 Prognostic Value Of
Continuous EEG During And After
Therapeutic Hypothermia In Patients
With Cardiac Arrest/B. Legros,
M. Lamartine Sabido Monteiro,
C. Depondt, I. Lamanna, N. Ligot,
N. Mavroudakis, G. Naeije, J. Vincent,
F. Taccone
1.142 Analysis Of Pediatric
Electroencephalogram Characteristics
During Therapeutic Hypothermia In
Post Cardiac Arrest Patients/L. Bello,
E. Cruz, S. Manganaro, M. Andriola
SATURDAY
1.116 Epilepsy In STXBP1
Encephalopathy: Clinical Delineation Of
32 Japanese Patients Including 14
Novel Patients/M. Kato, H. Saitsu,
H. Osaka, K. Nakamura, T. Watanabe,
H. Terashima, T. Ikeda, T. Kumada,
H. Matsumoto, T. Yamaguchi,
J. Azuma, Y. Tominaga, M. Shinpoo,
H. Arai, S. Hirai, S. Takeshita,
E. Nakagawa, H. Uchio, Y. Nonoda,
T. Iwasaki, T. Chiyonobu, A. Sudo,
1.117 Familial Focal Seizures And
Anterior Pachyghria In A Large Family
With A Novel DCX Mutation Combined
With A TUBB1 Mutation That Might
Be A Modifier For The Phenotype Of
Cognitive Deficit/Y. Kim, M. Kim,
S. Choi, Y. Woo
1.118 Distinctive Electro-Clinical
Features Of Epilepsy In Severe Early
Onset SCN8A Encephalopathy/
E. Gardella, J. Larsen, M. Wolff,
G. Schmiedel, M. Kirkpatrick,
N. Barisic, C. Depienne, M. Troncoso,
B. Jepsen, M. Nikanorova,
L. Troncoso, A. Bevot, H. Hjalgrim,
S. Beniczky, R. S. Møller
1.119 Targeted Massively Parallel
Sequencing Of Infantile Onset
Epileptic Encephalopathy/B. Lim,
H. Kim, H. Hwang, J. Chae, K. Kim,
Y. Hwang
1.120 Familial Epilepsy Due To A Point
Mutation In LIS1/D. E. Crompton,
M. S. Hildebrand, R. J. Leventer,
Y. Perchyonok, J. A. Damiano,
C. A. Wise, I. E. Scheffer,
G. D. Jackson, S. Berkovic
1.121 The Subcortical Band
Heterotopia/Lissencephaly Spectrum
And Epilepsy: Phenotypic, Molecular,
Functional, And Structural Analysis Of
Novel Causative DCX And LIS1
Mutations/D. Amrom, G. Brouhard,
S. Bechstedt, K. Toropova,
F. Andermann, F. Dubeau,
D. Melanson, D. Tampieri,
S. Reck-Peterson, E. Andermann
Poster Session 1
MEG
1.143 Pre-Ictal And Ictal Pathological
High Frequency Oscillations (HFOs) In
Focal Epilepsy: Analysis Of MEG
Recording/J. Velmurugan, S. Sinha,
N. Mariyappa, P. Satishchandra
1.144 Magnetoencephalographic
Characteristics Of Cortical Dysplasia
In Children/N. Agarwal, U. Thome
Costa, B. Krishnan, R. Burgess,
R. Prayson, A. Alexopoulos, A. Gupta
1.145 Volume And Location Of Focal
Cortical Dysplasia Type Ii Correlating
With Magnetoencephalography;
Convexity Vs. Bottom Of Sulcus/
M. Nakajima, Y. Sato, S. Wong,
K. Okanari, S. Sakuma, C. Boelman,
S. Baba, A. Ochi, S. Doesburg,
H. Otsubo
1.146 Automatic Detection Of Focal
Slow Waves In Patients After Epilepsy
Surgery Is Related To Recurring
Seizures/S. Rampp, M. Schönherr,
K. Roessler, M. Buchfelder, H. Hamer,
H. Stefan
1.147 Comparative Analysis Of Spike
Source Between High-Density EEG
And MEG/R. Honda, Y. Kaneko,
Y. Saito, E. Nakagawa, K. Sugai,
M. Sasaki, T. Kaido, A. Takahashi,
T. Otsuki
39
Saturday December 6, 2014
1.148 Coherence And Source
Localisation In Reflex-Eating Epilepsy:
A MEG Based Analysis/S. Sinha,
V. Jayabal, M. Narayanan,
S. Parthasarathy
1.149 Application Of Multiple
Equivalent Current Dipole Modeling
And Minimum Norm Modeling For
Analyzing Magnetoencephalography
Activities Of An Unusual Form Of
Benign Childhood Epilepsy With
Occipito-Frontal Sharp Waves/
H. Murakami, J. Mosher, A. Naduvil
Valappil, E. Wyllie, A. Alexopoulos,
R. Burgess
1.150 MEG Source Imaging Of
Interictal Spikes Using Samepi:
Comparison With Area Of Surgical
Resection And Seizure Outcomes/
J. Scott, S. Robinson, K. Zaghloul,
J. Heiss, S. Sato, W. Theodore,
S. Inati
1.151 Epileptic Networks In Genetic
Generalized Epilepsy: A MEG Study/
A. Zillgitt, B. Assaad, J. Moran,
K. Mason, D. Burdette,
J. Constantinou, G. L. Barkley,
S. Bowyer
1.152 Comparison Of Ictal And
Interictal Source Localization Using
MEG And dEEG In Pediatric Drug
Resistant Epilepsy/H. Fujiwara,
H. Greiner, J. Tenney, D. Rose
Brain Stimulation
1.153 Cortical-Cortical Evoked
Potentials (CCEPs) Distinguish Early
Versus Late Seizure Spread In
Stereoelectroencephalography/
A. Dionisio, B. Lega,
J. Gonzalez-Martinez, P. Flanagan,
D. Nair
1.154 Physiological Consequences Of
Abnormal Connectivity In A
Developmental Epilepsy/M. Shafi,
M. Vernet, D. Klooster, M. E. Barnard,
K. Romatoski, M. Westover,
J. Christodoulou, J. D. Gabrieli,
S. Whitfield-Gabrieli, A. Pascual-Leone,
B. S. Chang
1.155 Chronic Cortical Optogenetic
Stimulation For The Prevention Of
Posttraumatic Epileptogenesis In
Mice/X. Ping, W. Xiong, G. Chavez,
J. Gao, X. Jin
1.156 (DYS) Functional Connectivity
Of The Seizure Onset Zone: Low
Frequency Stimulation And CorticoCortical Evoked Responses Study/
R. Alkawadri, H. Zaveri, R. Duckrow,
D. Spencer, J. Gerrard, L. Hirsch
1.157 Exploring Seizure Networks
Using Cortico-Cortical Evoked
Potentials: Internally Hyperconnected,
Externally Hypoconnected?/L. Entz,
P. Megevand, D. Groppe, E. Toth,
D. Fabo, Z. Fallil, C. Harden,
S. Hwang, S. Bickel, C. Keller,
A. Mehta
1.158 Paired-Pulse Transcranial
Magnetic Stimulation (ppTMS) In
Measures Of Cortical Inhibition During
Propofol Infusion/C. F. Paredes Saenz,
R. Gersner, J. Goldie, A. Rotenberg
40
Poster Session 1
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.159 State-Dependent Modulation
Of Cortical Activity By Intracranial
Stimulation/S. Alagapan, S. Schmidt,
D. Bernardo, F. Frohlich, H. Shin
1.160 Sleep, Seizures And CorticoCortical Evoked Potentials: A
Dynamical System Perspective/
J. Slater, G. Kalamangalam
Animal Studies
1.161 Short-Term Synaptic
Reorganization In The Rat Neocortex
After Perinatal Hypoxia-Ischemia/
J. Bastar, J. Spampanato, F. Dudek
1.162 Supramammillary Hypothalamic
Neurons That Co-Release GABA And
Glutamate Promote Wakefulness And
Hippocampal Theta Rhythm/
N. P. Pedersen, L. Ferrrari,
J. L. Wang, E. Arrigoni, P. M. Fuller,
C. B. Saper
1.163 Electroconvulsive Seizure
Induces The Changes Of NMDAR,
AMPAR, And STEP61 Protein In Rat
Hippocampus/S. Jang
1.164 Peri-Ictal Impairment Of
Brainstem 5-HT Neurons: Insight Into
Depressed Arousal, Reduced
Ventilation And Sudden Unexpected
Death In Epilepsy (SUDEP)/Q. Zhan,
G. Buchanan, J. Motelow, F. Serout,
W. Chen, A. Gummadavelli,
J. Andrews, P. Vitkovskiy, M. Furman,
W. Li, G. Richerson, H. Blumenfeld
1.165 Seizure-Induced Kcnq
Upregulation Alters The Functional
Properties Of Hippocampal M
Currents In The Pilocarpine Model Of
Temporal Lobe Epilepsy/C. T. Taylor,
D. B. Jaffe, M. S. Shapiro
1.166 Selective, Unilateral Ablation
Of Hippocampal Interneurons Causes
Acute Seizures/J. Spampanato,
F. E. Dudek
Computational Analysis & Modeling
Of EEG
1.167 Power-Weighted Narrowband
Changes During Epileptic Bursts In
Invasive EEG Identify The Epileptogenic
Zone/M. Heers, X. Wang,
M. Duempelmann, J. Jacobs,
A. Schulze-Bonhage, T. Ball
1.168 An Interictal EEG Spectral
Metric For Temporal Lobe Epilepsy
Lateralization/L. Cara, G. Kalamangalam
1.169 Correlation Of EEG Spectra
With Quantitative Measures Of
Intelligence And Attention In Children
With Idiopathic Epilepsy/D. Hsu,
K. Rayer, M. Hsu, P. Ferrazzano,
K. Dabbs, D. Jackson, C. Stafstrom,
G. Worrell, J. Jones, B. Hermann
1.170 Lateralizing Shift Of Current
Source Of Generalized Spikes In
Childhood Absence Epilepsy:
Relationship Between The Shift And
Response To Valproic Acid/O. Kwon,
T. Yang, S. Jung, J. Yeom
1.171 High Frequency Oscillations
And Spikes: Separating Oscillations
From Broad Band Activities/M. Amiri,
J. Gotman
1.172 Spatial Relationship Between
The Fast And Slow Components Of
Ictal Activities And Interictal
Epileptiform Discharges In Children
With Epileptic Spasms/T. Akiyama,
M. Akiyama, K. Kobayashi, T. Okanishi,
C. Boelman, D. A. Nita, A. Ochi,
C. Go, C. Snead, J. Rutka, J. Drake,
S. Chuang, H. Otsubo
1.173 Dynamic Measures Applied To
A Cohort Of Children With Childhood
Absence Seizures/M. J. Schwabe,
K. C. Hecox
1.174 Epileptogenic Networks
Revealed By Varying Patterns Of
Propagation Of High Frequency Ictal
Activity (70-175 Hz)/A. Korzeniewska,
P. Franaszczuk, M. Cervenka,
C. Jouny, G. Bergey, N. Crone
1.175 Pathologic Generation Of High
Frequency Oscillations In The Seizure
Onset Zone During A Motor Task/
P. A. Peters, J. Cimbalnik,
B. Brinkmann, V. Svehlik, V. Vasoli,
M. T. Kucewicz, R. Marsh, F. Meyer,
M. Stead, G. Worrell, J. Matsumoto
1.176 WITHDRAWN
1.177 Modulation Of Neuronal
Activity And Functional Connectivity In
Transition To Ictus/T. Matsuo,
R. Staba, A. Bragin, I. Fried
1.178 Scale-Free Properties Of
Intracerebral EEG Improve Seizure
Prediction In Mesial Temporal Lobe
Epilepsy/K. Gadhoumi, J. Gotman, J. Lina
1.179 Coherence Analysis Of Diffuse
Bisynchronous Ictal iEEG Discharges
For Seizure Localization/P. Chen,
M. Korostenskaja, E. Castillo, J. Seo,
J. Baumgartner, K. Lee
1.180 Noninvasive Dense Array
Electroencephalography For Localizing
The Seizure Onset Zone/C. Kuo,
D. Tucker, P. Luu, K. Jenson, M. D. Holmes
Clinical Epilepsy
Clinical Diagnosis
1.181 A Case Of Takotsubo
Cardiomyopathy Due To Status
Epilepticus – An Underreported And
Lethal Sequela/N. Mirchandani,
I. Khan, G. Pushchinska
1.182 Development And Validation Of
A Seizure Prediction Model In
Critically Ill Children/A. Yang, D. Arndt,
R. Berg, J. Carpenter, K. Chapman,
D. Dlugos, W. Gallentine, C. Giza,
J. Goldstein, C. Hahn, J. Lerner,
T. Loddenkemper, J. Matsumoto,
K. Nash, E. Payne,
I. Sánchez Fernández, J. Shults,
A. Topjian, K. Williams, C. Wusthoff,
N. Abend
1.183 Obesity In Adult Patients With
Psychogenic Non-Epileptic Seizures/
A. Abubakr, I. Wambacq
1.184 Ambulatory EEG In Epilepsy
Diagnosis For Adults Aged 65 And
Older/K. Upchurch, D. McCarthy,
E. Baker, J. Pathmanathan
Saturday December 6, 2014
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.197 A Retrospective Study Of
Continuous EEG Monitoring In A
Single Tertiary Care Pediatric Site/
L. St. Louis, A. Sansevere,
I. Sánchez Fernández, E. Nagarajan,
J. Klehm, P. Pearl, R. Tasker,
T. Loddenkemper
1.198 Comparison Of Number Of
Patient-Reported Allergies In Adult
Patients With Epileptic And NonEpileptic Seizures/A. Fu, D. Denny,
S. Cerven, N. Moorley, S. S. Chung
1.199 Prevalence Of Headache In
Patients With Epileptic Versus NonEpileptic Seizures/S. Cerven, A. Fu,
N. Moorley, D. denny, S. S. Chung
1.200 Comparing Duration To
Diagnosis Made Via VideoElectroencephalography For NonEpileptic Seizures And Epileptic
Seizures/D. denny, A. Fu, S. Cerven,
N. Moorley, S. S. Chung
1.201 Comparison Of Number Of
Events Captured In Epilepsy
Monitoring Unit Between Patients
With Epileptic Versus Non-Epileptic
Seizures/N. Moorley, A. Fu, D. Denny,
S. Cerven, S. S. Chung
1.202 Cefepime Induced
Encephalopathy In A Tertiary Medical
Center In Korea/J. Jeon, H. Moon,
G. Motamedi, Y. Cho
Clinical Treatments
1.203 What Do Epileptologists
Recommend About Discontinuing
AEDs For A Second Time In SeizureFree Children When The First
Attempt Failed?/A. McCarthy,
C. Camfield, P. Camfield, I. Valencia
1.204 Clinical Predictors For Delirium
Tremens In Patients With AlcoholWithdrawal Seizures/D. Kim
1.205 Repetitive Transcranial
Magnetic Stimulation For Refractory
Focal Status Epilepticus/
S. VanHaerents, S. Herman, T. Pang,
A. Pascual-Leone, M. Shafi
1.206 Why Do Patients Get Admitted
For ACTH For Infantile Spasms?A
Survey Of ACTH Delivery Across
United States/C. Joshi, A. Berg,
E. Wirrell
1.207 Ictal Religious Speech In
Temporal Lobe Epilepsy/I. Yildirim
Capraz, M. Mercan, E. Bilir
1.208 Maximizing The Efficacy Of The
Ketogenic Diet Treatment For SuperRefractory Status Epilepticus/
Y. C. Liu, H. Lowe, S. C. Shen,
M. Zak, V. Chan, J. Kobayashi,
E. J. Donner
1.209 Interrater Reliability In
Interpretation Of
Electrocorticographic Seizure
Detections Of The Responsive
Neurostimulator/M. Quigg, B. Jobst,
N. Fountain, V. S. Wong, F. Sun,
E. Mirro, S. Brown, D. Spencer
1.210 Hereditary Hyperekplexia
And Generalized Epilepsy In A Child
Responsive To Levetiracetam/
A. Lowden, J. Munoz, R. Said
1.211 Comparison Of Efficacy
Between A Modified Atkins Diet And A
Classic Ketogenic Diet In Childhood
Intractable Epilepsy/J. Kim, J. Yoon,
E. Lee, J. Lee, H. Kim, H. Kang
1.212 WITHDRAWN
1.213 Clinical Characteristics And
Treatment Pattern In Cluster
Seizures: A Preliminary Chart Review
Analysis/B. Vazquez, E. Wu,
D. Macaulay, M. Sidovar, H. Roberts,
D. Squillacote, A. L. Rabinowicz, A. Guo
1.214 IV Lacosamide As Adjunctive
Therapy In Treatment Of Refractory
Status Epilepticus/S. Kohli, P. Li,
B. Teter, K. Kavak, A. Weinstock
1.215 Effectiveness Of Routine
Management Of Status Epilepticus In
Dravet Syndrome/S. N. Misra,
S. Agadi
1.216 Responsive Neurostimulation
in Patients with Mesial Temporal Lobe
Epilepsy and Prior Temporal
Lobectomy/T. Crowder Skarpaas,
R. Duckrow, A. Herekar, C. Heck,
C. Skidmore, D. Spencer, G. Bergey,
D. Shields, D. Nair, D. King-Stephens,
M. Morrell
1.217 The Effects Of Experimental
Febrile Seizures On The Expression Of
Forelimb Motor Maps In A Rodent
Model Of Mesial Temporal Lobe
Epilepsy/K. B. Rivard, K. Scullion,
G. Teskey, M. Scantlebury
SATURDAY
1.185 Coprolalia As A Manifestation
Of Epileptic Seizures/A. Massot-Tarrús,
C. Dove, R. McLachlan, J. G. Burneo,
S. Mirsattari
1.186 Comparison Of Patients With
Coexisting Epileptic Seizures And
Psychogenic Nonepileptic Spells To
Patients With Psychogenic
Nonepileptic Spells Only: A Search For
Unique Clinical Characteristics/
S. C. Block, B. Abou-Khalil,
H. Sonmezturk
1.187 Which Clinical Features Help In
Differentiating Epileptic From
Nonepileptic Convulsive Seizures? A
Systematic Review Of Initial Clinic
Encounters/K. Kleinfeld, A. Peltier,
N. Azar
1.188 Delays In Diagnosis And
Treatment Of Acute Seizures/
S. VanHaerents, E. Bachman,
K. Romatoski, L. Knopf, M. Ebril,
T. Pang
1.189 Clinical, EEG, MRI And Surgical
Outcomes Of Pediatric Epilepsy With
Astrocytic Inclusions Versus Focal
Cortical Dysplasia/L. Alshafai, A. Ochi,
C. Go, B. McCoy, C. Hawkins,
H. Otsubo, O. Snead, J. Rutka,
E. Widjaja
1.190 Sleep Homeostasis In Children
With Focal Epilepsy Following Sleep
Deprivation: Relationship To Seizure
Propensity/S. Chan, C. Chevalier-Riffard,
T. Baldeweg, J. Cross
1.191 Networks Of Laughing Seizures
– A Stereoelectroencephalographic
Study/I. Mindruta, L. Minotti, A. Job,
D. Hoffmann, S. Chabardes,
A. Barborica, J. Ciurea, P. Kahane
1.192 Super Refractory Status
Epilepticus: A Case Report/
I. Noviawaty, A. Naduvil Valappil,
A. Zeft, D. Lachhwani
1.193 Predictors Of Length Of Stay
In Children Admitted For A PreSurgical Evaluation/P. Y. Sun,
K. Wyatt, K. Nickels, L. Wong-Kisiel,
E. Wirrell
1.194 Navigating The Benefits And
Limitations Of Current Molecular
Testing Options For The Clinical
Identification Of Disease-Causing
PCDH19 Mutations/S. Gandomi,
M. Parra, K. D. Farwell Gonzalez,
K. Waller, R. Baxter, B. Tippin Davis
1.195 Electroencephalographic
Findings By Stage In Rasmussen’s
Encephalitis/H. Kim, H. Ryu, B. Lim,
H. Hwang, J. Chae, J. Choi, K. Kim,
Y. Hwang
1.196 Type I Interferon Levels In
Cerebrospinal Fluid Samples From
Newborn Infants With Seizures,
Rotavirus Infections, And Diffuse
Cerebral White Matter Lesions/
K. Lee, C. Moon
Poster Session 1
Prognosis
1.218 Family Factors Contributing To
Depression In People With Epilepsy/
S. Han, B. Kim, E. Koh, M. Kim,
D. Shin, J. Lee, K. Ji, S. Park,
H. Nam, Y. Cho, E. Joo, S. Kim,
D. Kim, K. Park, S. Han, Y. Sohn,
K. Heo, E. Lee, H. Han, K. Kim,
W. Shin, G. Kim, J. Lee, S. Koh,
W. Kim, Y. Cho, J. Kim, S. Lee
1.219 Early Intensive Care Is Critical
For The Outcome Of The Refractory
Status Epilepticus/Y. Choi, K. Kang,
S. Lee, M. Kim
1.220 Demographics And Outcomes
Of Pediatric Febrile Convulsive Status
Epilepticus/M. Nishiyama, T. Tanaka,
K. Fujita, A. Maruyama, H. Nagase,
D. Toyoshima, T. Nakagawa,
N. Morisada, S. Takada, K. Iijima
1.221 Predictors Of Recurrent
Febrile Seizure/M. Oh, S. Kim
1.222 Early Anatomical Injury
Patterns Predict Post-neonatal
Epilepsy In Infants Treated With
Selective Head Cooling For Neonatal
Hypoxic Ischemic Injury/D. Jung,
C. Venkatesan, D. Nordli,
D. G. Ritacco, S. Koh
1.223 Gender Alters The Prognosis
Of Cryptogenic Epilepsy/F. Babtain,
M. Abu Abthan, S. Al Ghamdi,
H. Bhatia, M. Velmurugan
41
Saturday December 6, 2014
1.224 Epilepsy In Childhood After
Acute Encephalopathy With Reduced
Subcortical Diffusion/Y. Ito,
J. Natsume, H. Kidokoro, N. Ishihara,
Y. Azuma, T. Tsuji, A. Okumura,
T. Kubota, N. Ando, K. Miura,
T. Negoro, K. Watanabe
1.225 Succinic Semialdehyde
Dehydrogenase Deficiency And
Worsening Epilepsy In Adulthood/
S. LaPalme-Remis, E. Lewis,
W. Theodore, M. Gibson, P. Pearl
1.226 The Relevance Of
Somatosensory Auras In Refractory
Temporal Lobe Epilepsies/G. Perven,
L. Jehi, R. Yardi
1.227 Electroencephalographic
Correlates Of Seizure Freedom In
Genetic Generalized Epilepsies/
U. Seneviratne, M. Cook, W. D’Souza
1.228 How Many Patients With
Temporal Lobe Epilepsy Are Well
Controlled With Medications?/
J. Tellez-Zenteno, L. Hernandez
Ronquillo, S. Buckley, L. D. Ladino
1.229 The Evaluation Of Left
Ventricular Diastolic Function Of
Newly Diagnosed Idiopatic Generalized
Epilepsy Patients With Tissue Doppler
Imaging/O. Dokgoz, C. Yilmaz,
A. Ünalp, T. Mese, U. Karaarslan
1.230 Clinical Outcome Following
Medical Treatment In Drug-Naïve
Epilepsy Patients With Cavernous
Malformation/K. Cho, Y. Lee, Y. Cho,
K. Heo, B. Lee
1.231 Mortality In Patients Assessed
For Suspected New-Onset Seizures/
T. O’Brien, T. Hakami, M. Todaro,
L. Danny, P. Kwan, S. Yerra, M. Tan,
C. French, S. Li, Z. Matkovic,
A. McIntosh
1.232 Long Term Surgical Outcome
Of Non-Lesional Temporal Lobe
Epilepsy (NLTLE)/J. Chu, W. D’Souza,
M. Murphy, S. Schachter, M. Cook
Neuroimaging
Animal Studies
1.233 Intrinsic Optical Signal Imaging
Of Afterdischarges Induced By Acute
Kindling Of The Rat Hippocampus/
K. Tsuchiya, A. Kobayashi, N. Inoue,
S. Kogure, M. Nemoto
1.234 The Effect Of De Novo KCNQ2
Epileptic Encephalopathy Mutations
On KCNQ2/3 Channel Trafficking And
Hippocampal Neuronal Excitability/
J. Cavaretta, K. Lee, H. Chung
Structural Imaging
1.235 Diffusion Tensor Imaging Study
In Dravet Syndrome/J. Natsume,
O. Chikako, H. Yamamoto, Y. Ito,
T. Takeuchi, S. Yokoi, Y. Sakaguchi,
Y. Azuma, N. Ishihara, H. Kidokoro,
K. Miura, T. Negoro, K. Watanabe
1.236 Investigation Of White Matter
Integrity In Patients With Psychogenic
Non-Epileptic Seizures/S. Lee,
J. Allendorfer, T. Gaston, K. Hernando,
R. C. Knowlton, J. Szaflarski,
L. W. Ver Hoef
42
Poster Session 1
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.237 The Severity Of Brain Atrophy
In Temporal Lobe Epilepsy Is Unrelated
To The Side Of The Focus: An Engel
Class I Study/M. Liu, N. Bernasconi,
A. Bernasconi, B. Bernhardt
1.238 Epileptogenic Tubers:
Conventional MRI Findings/Y. Hirata,
A. Yogi, R. Harris, B. Ellingson,
N. Salamon
1.239 Unilateral Brain Oedema
Related To Focal Status Epilepticus/
N. Ali, S. Palat Chirakkara, J. Reddy,
S. Sinha
1.240 Voxel-Based Morphometric MRI
Post-Processing May Provide Relevant
Targets For Reoperation In
Nonlesional Epilepsies/Z. Wang,
P. Suwanpakdee, S. E. Jones,
Z. Jaisani, B. Krishnan, R. Prayson,
R. Burgess, I. Najm,
J. Gonzalez-Martinez, W. Bingaman,
A. Alexopoulos
1.241 Callosal And Diffusion Features
In High-Functioning Subjects With
Pyridoxine-Dependent Epilepsy/
S. D. Friedman, G. E. Ishak,
A. V. Poliakov, S. L. Poliachik,
C. B. Budech, D. W. Shaw,
S. M. Gospe
1.242 A Case Of Periodic Lateralized
Epileptiform Discharges (PLEDs)
Causing Concordant Reversible MRI
Changes/S. Chen, S. Schmitt,
K. Davis
1.243 Longitudinal Diffusion Tensor
Imaging Study In Cryptogenic West
Syndrome/C. Ogawa, J. Natsume,
T. Fukasawa, H. Kidokoro,
H. Yamamoto, Y. Sakaguchi, Y. Ito,
T. Takeuchi, S. Yokoi, Y. Azuma,
N. Ishihara, K. Miura, T. Kubota,
N. Ando, T. Negoro, K. Watanabe
1.244 MRI Spectrum Of Unilateral
Temporal Lobe Epilepsy: A SurfaceBased Pattern Analysis Of
Mesiotemporal Sub-structures/
B. Bernhardt, H. Kim, A. Bernasconi,
N. Bernasconi
1.245 Usefulness Of DTI Analysis Of
Brain Tissue Surrounding The Cortical
Tuber For Predicting Epileptogenicity
In Tuberous Sclerosis Patients/A. Yogi,
Y. Hirata, E. Karavaeva, J. Wu,
S. Yudovin, B. Ellingson, G. Mathern,
N. Salamon
1.246 Impaired Perception Of Anxiety
In Others Is Related To Right Superior
Temporal Gyrus Volume In Temporal
Lobe Epilepsy/G. P. Thomas,
K. Bujarski
1.247 Hippocampal Internal
Architecture Asymmetry In WellControlled And Drug-Resistant
Temporal Lobe Epilepsy/T. E. Gaston,
L. Perry, L. Ver Hoef
1.248 Evidence Of Regional Thinning
Of The Cerebral Cortex In
Asymptomatic Siblings Of Patients
With Mesial Temporal Lobe Epilepsy/
S. Alhusaini, C. Doherty,
M. Fitzsimons, G. Cavalleri,
N. Delanty
1.249 Toward A Quantitative
Measure Of Hippocampal Internal
Architecture Clarity: A Proposed
Method And Its Utility In Predicting
Seizure Laterality In Temporal Lobe
Epilepsy/L. Perry, T. E. Gaston,
L. Ver Hoef
1.250 Volume Renderings Of
Intraoperative Electrocorticography In
Epilepsy/S. Poliachik, R. Hevner,
E. Novotny, A. V. Poliakov, G. Ishak,
H. Eslamy, J. Kuratani, R. Saneto,
J. Ojemann
1.251 Cortical Thickness And
Surgical Outcome In Patients With
Non-Lesional Neocortical Epilepsy/
V. Pilli, D. Kamson, C. Juhasz,
J. Jeong, E. Asano, S. Sood, H. Chugani
1.252 Psychopathology, Cortical
Thickness And Sulcal Depth In
Pediatric Epilepsy/R. Caplan,
P. Siddarth, D. Tosun, S. Gurbani,
J. Levitt
1.253 Loss Of Hippocampal Internal
Architecture In Temporal Lobe
Epilepsy Demonstrated With High
Resolution 4.7-T Fast Spin Echo
Imaging/T. A. Steve, Y. Huang,
N. V. Malykhin, A. H. Wilman,
D. W. Gross
1.254 Pediatric Epilepsy:
Developmental Vulnerability Of
Cortical Thickness And Sulcal Depth/
P. Siddarth, D. Tosun, S. Gurbani,
J. Levitt, R. Caplan
Functional Imaging
1.255 Can Resting-State Functional
Connectivity Predict Seizure Outcome
After Anterior Temporal
Lobectomy?/G. Doucet, D. Pustina,
P. Barnett, A. Ghani, C. Skidmore,
A. Sharan, J. Evans, M. Sperling,
J. Tracy
1.256 Spatiotemporal Mapping Of
Multiple Spikes Using Distributed
Source Analysis/N. Tanaka, N. Suzuki,
S. Stufflebeam
1.257 Stress Perception And Seizure
Control Modulate The Neural
Response To Psychosocial Stress In
Patients With Left Temporal Lobe
Epilepsy/J. B. Allendorfer, H. Heyse,
B. A. Szaflarski, L. Mendoza,
N. Cohen, E. B. Nelson,
J. C. Eliassen, J. M. Storrs,
J. Szaflarski
1.258 Language Mapping In Epileptic
Patients Represented By
Magnetoencephalography: Utility Of
Movement Compensation Algorithm/
N. Suzuki, N. Tanaka, S. Stufflebeam
1.259 Temporal Lobe Spikes: EEGfMRI Contributions to the “Mesial Vs.
Lateral” Debate/S. Watanabe,
F. Dubeau, J. Gotman
1.260 Modeling Channel-Specific
Hemodynamic Response Function In
Epilepsy With EEG-fNIRS Data/
K. Peng, D. K. Nguyen, T. Tayah,
P. Vannasing, J. Tremblay, M. Sawan,
F. Lesage, P. Pouliot
Saturday December 6, 2014
Comorbidity (Somatic and
Psychiatric)
Medical Conditions
1.270 Analgesic Opioid Use In A
Health-Insured Epilepsy Population
During 2012/A. Wilner, B. Sharma,
A. Soucy, A. Krueger
1.271 Prevalence Of Restless Leg
Syndrome In Patients With Epilepsy/
N. K. Sethi, T. Tropea, L. Katus
1.272 Prevalence Of Epilepsy As A
Comorbidity With Stroke In The U.S./
A. K. Birnbaum, I. E. Leppik,
K. H. Svendsen, L. E. Eberly
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.273 Association Between
Depressive Symptoms And Seizure
Response Among Subjects With
Refractory Partial-Onset Seizures In
Clinical Trials Of Eslicarbazepine
Acetate/F. F. Velez, T. C. Bond,
X. Wang, K. P. Anastassopoulos,
R. Sousa, D. Blum, F. Rocha,
J. A. Cramer
1.274 Non-Epileptic Seizures In A
Population Of Diagnosed Pediatric
Epilepsy Patients/R. Villalobos,
E. Gonzales
1.275 Reproductive Health In Indian
Women With Epilepsy – A Cross
Sectional Quantitative Survey/
M. Singh, A. EB, M. Agarwal,
R. Pandey
Psychiatric Conditions
1.276 Paroxysmal Non-Epileptic
Events In A Pediatric Population/
T. Sawchuk, J. D. Smith, S. D’Alfonso,
J. Buchhalter
1.277 Medications Implicated In
Psychogenic Seizures: Insights From
The OpenFDA Initiative/V. S. Wong,
P. Motika
1.278 Differentiating Epileptic From
Non-Epileptic Seizures Through
Patterns Of Comorbidities And
Pharmacologic Management/
W. T. Kerr, E. A. Janio, C. T. Braesch,
J. M. Hori, J. M. Le, K. R. Raman,
A. B. Patel, S. E. Barritt,
E. S. Hwang, E. C. Davis,
D. Torres-Barba, N. Salamon,
J. Engel, J. Stern, M. S. Cohen
1.279 Psychiatric Comorbidity In
Idiopathic Generalised Epilepsies/
A. Loughman, N. Bendrups,
S. C. Bowden, W. D’Souza
1.280 Stress-Triggered Seizures: A
Focus On Anxiety, Depression, And
Childhood Trauma/H. R. McKee,
A. Linane, R. Azzam, B. Abou-Khalil
1.281 Personalities Of Patients With
Psychogenic Non-Epileptic Seizures/
P. Rawal, M. Szaflarski, J. Saenz,
Z. Richardson, B. Dworetzky,
J. Szaflarski
1.282 The Impacts Of AttentionDeficit Hyperactivity Disorder On
Epilepsy Children/S. Park
1.283 Behavioural Features Of
Patients With Psychogenic NonEpileptic Seizures (PNES)/
C. Helmstaedter
1.284 Why Are We Excluding
Patients With Epilepsy From Clinical
Trials Of Transcranial Magnetic
Stimulation To Treat Depression?/
S. D. Forman, J. Roberts,
B. A. Congedo, B. H. Hanusa,
A. C. Van Cott
1.285 Patterns And Frequency Of
The Treatment Of Depression In
Persons With Epilepsy/K. M. Fiest,
S. B. Patten, C. Altura, A. G. Bulloch,
C. Maxwell, S. Wiebe, S. Macrodimitris,
N. Jetté
1.286 Reducing Severity Of Comorbid
Psychiatric Symptoms In An Epilepsy
Clinic Using A Co-Location Model/
J. J. Chen, T. Caller, J. N. Mecchella,
D. S. Thakur, K. A. Homa, C. Finn,
E. Kobylarz, K. Bujarski, V. Thadani,
B. Jobst
1.287 Seizure Severity Among
Subjects With Refractory PartialOnset Seizures: Analysis Of The
Seizure Severity Questionnaire In A
Phase III Trial Of Eslicarbazepine
Acetate/J. A. Cramer, T. C. Bond,
F. F. Velez, X. Wang,
K. P. Anastassopoulos, R. Sousa,
F. Rocha, D. Blum
1.288 New Risk Factor
Considerations In The Nonepileptic
Patient Population: A Medication Use
Review/S. Mason, P. Penovich,
R. Lyons
Animal Studies
1.289 Interaction Between Recurrent
Seizures And Autism-Like Behavior In
A Mouse Model Of Maternal Immune
Activation/A. Mazarati,
J. Washington III, R. Sankar, D. Shin,
U. Kumar
1.290 Seizures Amplify Autistic
Behavioral Deficits In Mouse Models
Of 15q Duplication: A Potential Role
For Heightened PI3K/AKT Signaling/
V. Krishnan, M. Anderson
1.291 Carbamazepine Inhibits Native
Sodium Currents In Murine
Osteoblasts/S. J. Petty,
C. J. Milligan, M. Todaro, T. J. O’Brien,
J. D. Wark, E. J. Mackie, S. Petrou
1.292 A Single Acute Pre-Training
Seizure Impairs Long Term Fear
Memory In Mice/A. Holley, J. Lugo
1.293 Seizure Propagation To Sleep
Triggers In The Lateral Hypothalamus
Of Kcna1-Null Knockout Mice/
K. Simeone, T. Simeone
SATURDAY
1.261 Can FDG-PET Find
Epileptogenic Tuber In Tuberous
Sclerosis Complex?/Y. Hirata, A. Yogi,
E. Karavaeva, R. Harris, B. Ellingson,
N. Salamon
1.262 Studies In Epilepsy Patients
Using Simultaneous PET/MR:
Preliminary Results/Y. S. Ding,
B. Chen, C. Glielmi, K. Friedman,
O. Devinsky
1.263 Electric Source Imaging (ESI)
In Presurgical Epilepsy Investigations:
The Importance Of High Electrode
Density And Temporal Lobe Coverage
In Patients With Mesiotemporal And
Neocortical Temporal Foci/G. Lantz,
M. Terrill, T. Gilbert, P. Luu,
A. Bunnenberg, D. Tucker
1.264 Widespread BOLD Activation In
MR Negative Patients With Bi-Temporal
Epileptiform Discharges Studied With
Simultaneous Intracranial EEG fMRI/
C. Beers, I. Gaxiola Valdez,
D. J. Pittman, Y. Aghakhani,
P. Federico
1.265 Evaluation Of The Changes In
Interictal Magnetoencephalography
(MEG) Spikes By Gradient Magnetic
Field Topography (GMFT) Analysis
Before And After Anterior Corpus
Callosotomy For Symptomatic
Generalized Epilepsy With DropAttacks/K. Kagawa, K. Iida,
A. Hashizume, M. Kartagiri, Y. Kiura,
R. Hanaya, K. Arita, K. Kurisu
1.266 Quantitative FDG-PET
Neuroimaging In Medically Refractory
Epilepsy: UPenn Experience/
A. A. Thaker, J. G. Dubroff, M. Brown,
K. A. Davis
1.267 MRI, PET, SPECT, And
Pathology Results Do Not Predict
Seizure Outcome Following Epilepsy
Surgery In Children With Focal
Cortical Dysplasia/R. W. Dudley,
B. Badesch, V. Allen, A. White,
D. Mirsky, S. Nick, B. O’Neill, S. Koh,
M. Handler, P. Laoprasert
1.268 Effect Of EEG Electrode
Number On Epileptic Source
Localization In Pediatric Patients/
A. Sohrabpour, Y. Lu, P.
Kankirawatana, B. He
1.269 Dynamic FRET-FLIM Imaging Of
TrkB Activation In Living Cells/
S. C. Harward, N. G. Hedrick,
R. Yasuda, J. McNamara
Poster Session 1
Antiepileptic Drugs
Mechanisms Of Action
1.294 Epilepsy-Associated Mutant
Voltage-Gated Sodium Channels Alter
Resurgent Current Generation That
Could Be Preferentially Targeted With
Cannabidiol/R. Patel, C. Barbosa-Nunez,
T. R. Cummins
1.295 Levetiracetam Modify Synaptic
Vesicle Protein Expression And
Reduce Abnormally Augmented
Presynaptic Vesicular Release After
Pilocarpine-Induced Status
Epilepticus/E. Garrido, L. Pacheco,
V. Funck, N. Ruvalcaba, J. Rodriguez,
D. Taylor, R. Garcia, J. Martinez,
C. Castro, C. Upreti, P. Stanton
1.296 Novel GABAA Positive
Alllosteric Modulator Neuroactive
Steroids As Potential Therapies For
Epilepsy/A. J. Robichaud, J. Doherty,
R. Hammond, G. Belfort, F. Salituro,
G. Martinez, M. Ackley
43
Saturday December 6, 2014
Animal Studies
1.297 Inhibitory Effect Of Cys LT
Receptor Antagonist Pranlukast On
MES And PTZ Induced Seizures/
Y. Ueda, L. Willmore
1.298 Consistent Seizure
Suppression By Brivaracetam In
Animal Models Of Partial Epilepsy
Includes Protection Against
Pilocarpine- And Kainic Acid-Induced
Partial Seizures In Rats/A. Matagne,
H. Klitgaard
1.299 TrkB Receptor Activation
Improves Interneuronal Function And
Suppresses Epileptiform Activity
Following Traumatic Brain Injury/F. Gu,
Y. Ma, I. Parada, L. Faria, F. M. Longo,
D. A. Prince
1.300 High Dose Levetiracetam
Could Be Used Prophylactically To
Reduce The Severity Of Brain
Damages Associated With Status
Epileptics In Pilo Model/K. Itoh,
Y. Ishihara, Y. Chiba, M. Ueno
1.301 Lacosamide And Levetiracetam
Modulate The Development Of
Interictal Spikes And High-Frequency
Oscillations During Epileptogenesis/
M. Lévesque, C. Behr, M. Avoli
1.302 Huperzine A Increases Cortical
Inhibition And Prevents
Pentylenetetrazole-Induced Seizures
In Rat/R. Gersner, D. Ekstein,
S. Schachter, A. Rotenberg
1.303 Neuroactive Steroids Halt
Electrographic Seizures In The
Lithium-Pilocarpine Model Of
Pharmaco-Resistant Status
Epilepticus/G. Belfort, R. Hammond,
E. Christian, M. Ackley, C. Maciag,
A. Robichaud, J. Doherty
1.304 Acute Spasm Reduction With
Celastrol In The Multiple-Hit Rat
Model Of Infantile Spasms/
O. Shandra, W. Mowrey,
A. S. Galanopoulou
1.305 Efficacy And Tolerability Of An
Interleukin 1 Receptor Antagonist
(IL-1Ra) In The Multiple- Hit Rat Model
Of Refractory Infantile Spasms/T.
Brima, W. Mowrey, S. Moshé,
A. S. Galanopoulou
Clinical Trials
1.306 An Evaluation Of The Impact Of
Memory On Antiepileptic Drug
Adherence/J. McAuley, N. Passen,
C. Prusa, J. Jih, S. Hart, B. Shneker
1.307 Efficacy Of USL255 (Qudexy™
XR; Extended-Release Topiramate) In
Patients With Refractory PartialOnset Seizures: PREVAIL and
PREVAIL OLE/A. M. Clark,
S. S. Chung, I. Blatt, B. Anders,
M. B. Halvorsen, R. E. Hogan
1.308 Long-Term Efficacy Of USL255
(Qudexy™ XR; Extended-Release
Topiramate) In Patients With
Refractory Partial-Onset Seizures:
PREVAIL OLE/R. Hogan, I. Blatt,
A. M. Clark, B. Anders,
M. B. Halvorsen, S. S. Chung
44
Poster Session 1
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.309 Effects Of Topiramate On
Growth And Development In Children
With New Or Recent- Onset Epilepsy:
A Phase-4 Randomized, ActiveControlled Study/L. Ford, Y. Shi,
P. Manitpisitkul
1.310 Prospective Randomized
Single-Blinded Trial Of Lacosamide
Versus Fosphenytoin For Seizure
Prophylaxis In Traumatic Brain
Injury/J. Szaflarski, L. A. Shutter,
L. Mendoza, M. Szaflarski
1.311 Treatment Of Refractory
Status Epilepticus With Enteral
Topiramate/A. Asadi-Pooya
1.312 Relationship Between
Eslicarbazepine Exposure And Safety
Endpoints For Eslicarbazepine
Acetate Monotherapy/T. Fakhoury,
J. Harvey, R. T. Wechsler, J.
Passarell, J. Fiedler-Kelly, E. Ludwig,
D. Blum, S. Sunkaraneni
1.313 The Impact Of Anticonvulsants
On Neurological Outcomes In
Neonatal Seizures/J. Han, I. Lee,
E. Kim, S. Park
1.314 Relationship Between
Exposure And Efficacy Of
Eslicarbazepine Acetate
Monotherapy/J. Rogin, A. J. Cole,
L. Strom, J. Passarell, J. Fiedler-Kelly,
E. Ludwig, D. Blum, S. Sunkaraneni
1.315 Incidence Of Falls, Fractures,
And Injuries With Adjunctive
Eslicarbazepine Acetate In Patients
With Refractory Partial-Onset
Seizures: A Pooled Analysis Of Three
Placebo-Controlled Trials/
W. Rosenfeld, S. Benbadis, P. Klein,
L. Specchio, P. Kowacs, H. Gama,
F. Rocha, R. Claus, D. Blum
1.316 Hepatic Safety Of
Eslicarbazepine Acetate: Summary Of
Five Phase II And Three Phase III
Adjunctive Trials/D. Blum, P. Van Ness,
G. Krauss, S. Chung, C. Elger,
C. Galimberti, H. Gama, F. Rocha,
R. Claus
1.317 Eslicarbazepine Acetate As
Adjunctive Therapy For Refractory
Partial-Onset Seizures: Analysis Of
Cognitive Adverse Events/
E. Andermann, S. Benbadis, A. Shah,
E. Trinka, A. Biraben, R. Sousa,
H. Gama, D. Blum, R. Claus
1.318 Eslicarbazepine Acetate
Monotherapy In Adults With PartialOnset Seizures: A Pooled Analysis Of
Two Randomized Double-Blind Studies
With Use Of A Historical Control/
L. Pazdera, J. French, M. Sperling,
M. Jacobson, H. Cheng, D. Blum
1.319 Relationship Between
Eslicarbazepine Exposure And Efficacy
Of Eslicarbazepine Acetate Adjunctive
Therapy/J. Harvey, E. Andermann,
S. Chung, E. Trinka, F. Cendes,
J. Passarell, J. Fiedler-Kelly,
E. Ludwig, S. Sunkaraneni, R. Sousa,
F. Rocha, D. Blum
1.320 Relationship Between
Eslicarbazepine Exposure And Safety
Endpoints For Eslicarbazepine
Acetate Adjunctive Therapy/
P. Penovich, G. Krauss,
M. R. Sperling, S. Striano, C. Elger,
J. Passarell, J. Fiedler-Kelly,
E. Ludwig, S. Sunkaraneni, R. Sousa,
F. Rocha, D. Blum
1.321 Eslicarbazepine Acetate
Monotherapy: A Population
Pharmacokinetic Analysis/
B. Abou-Khalil, I. Ali, A. Shah,
J. Fiedler-Kelly, E. Ludwig,
S. Sunkaraneni, D. Blum
1.322 Lack Of Exacerbation Of
Partial-onset Seizures During
Adjunctive Treatment With
Eslicarbazepine Acetate: A Pooled
Analysis Of Three Phase III Controlled
Trials/S. Benbadis, M. Carreño,
S. Striano, R. Sousa, F. Rocha,
D. Blum, H. Cheng
1.323 Evaluation Of Physical
Dependence Potential Following
Abrupt Discontinuation Of Adjunctive
Eslicarbazepine Acetate: A Pooled
Analysis Of Adverse Events From Ten
Studies/K. A. Schoedel,
M. R. Sperling, M. Bensalem-Owen,
D. Blum, R. Sousa, H. Gama, R. Claus
1.324 Bioequivalence Testing Of
Disparate Generic Lamotrigine
Products Using Chronic Dosing In
People With Epilepsy: The Equigen
Study/M. Privitera, F. Diaz,
B. Dworetzky, P. Bolger, R. Krebill,
B. Gidal, E. Elder, A. Paige,
J. Szaflarski, T. Welty, J. Pollard,
W. Jiang, N. McBee, M. Berg
1.325 Assessment Of Renal Toxicity
In Perampanel-Treated Subjects:
Pooled Results From Phase III Clinical
Studies/I. Leppik, H. Yang, B. Williams,
D. Xing, A. Laurenza
Cohort Studies
1.326 Parental Reporting Of
Response To Oral Cannabis Extracts
As Adjunctive Treatment For Medically
Refractory Epilepsy/C. Press,
K. Knupp, K. Chapman
1.327 Lacosamide Efficacy And
Tolerability In Clinical Practice – Post
Marketing Analysis/M. Baker,
H. Sonmezturk, A. Arain, K. Haas,
N. Azar, B. Abou-Khalil
1.328 Efficacy And Tolerability Of
Intravenous Levetiracetam Versus
Phenobarbital In Children With Status
Epilepticus Or Acute Repetitive
Seizures/Y. Lee, M. Yum, E. Kim,
T. Ko
1.329 Clobazam Higher-Evening
Differential Dosing As An Add-On
Therapy In Refractory Epilepsy/
M. Jackson, S. Thome-Souza,
J. Klehm, N. E. Kadish, I. Sánchez
Fernández, T. Loddenkemper
Saturday December 6, 2014
Other
1.337 Population Pharmacokinetic
Modeling Of Immediate And ExtendedRelease Topiramate (SPN-538,
Trokendi XR®) In Adults With Epilepsy:
Characterization f Different
Absorption Rates/E. Roers,
S. T. Brittain, J. D. Stocks,
J. K. Johnson
1.338 Unexplained Spikes In
Lamotrigine Serum Concentration
Suggest Nonlinear Elimination
Kinetics In Some Individuals/P. Ramey,
M. Osborn, K. Lowen, B. Abou-Khalil
1.339 A New Method To Determine
Linear Non-Steady State
Pharmacokinetic Parameters In The
Acute Care Setting/L. Olson
1.340 A Comparison Among The
Various Carbamazepine-Related
Antiepileptic Drugs/E. Vernier,
S. R. Benbadis, M. Giarratano
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.341 Acute Seizure Management
With Intravenous Levetiracetam In
Neonates And Children/B. Kirmani,
W. Hastings, O. Khan, P. Patel,
A. Sarode, R. Castillo,
M. Kempapura, S. Agadi, J. Aceves
1.342 A Systematic Review And
Network Meta-Analysis Of
Eslicarbazepine Acetate And Other
Recently-Approved Anti-Epileptic
Drugs For Adjunctive Treatment Of
Partial-Onset Seizures In Adults/
K. Betts, V. Bollu, G. De, D. Blum,
F. Velez
1.343 Once-Daily Trokendi XR®
(SPN-538) Dosing In Children With
Epilepsy/J. D. Stocks, S. T. Brittain,
J. K. Johnson
1.344 Cost-Effectiveness Of
Eslicarbazepine Acetate In Refractory
Partial-Onset Epilepsy/K. O’Day,
F. Velez, K. Meyer
1.345 Ezogabine Usage In Pediatric
Patients: A Retrospective Review Of
Safety And Efficacy From Two
Academic Institutions/J. Toler,
K. Chapman, T. Loddenkemper,
J. Klehm
Surgery
Adult
1.346 MagnetoencephalographyGuided Surgery In MRI Negative Or
Ill-Defined Frontal Lobe Epilepsy Using
Neuronavigation And Intraoperative
MR Imaging/B. Sommer, K. Roessler,
I. Blumcke, S. Rampp, H. Hamer,
M. Buchfelder, H. Stefan
1.347 Effects Of Invasive EEG
Monitoring On Memory And Language
After Left Anterior Temporal
Lobectomy: A Propensity Model
Analysis/R. M. Busch, T. E. Love,
L. E. Jehi, L. Ferguson, R. Yardi,
W. Bingaman, J. Gonzalez-Martinez
1.348 Temporal Plus Seizures Are
The Main Prognostic Factor For
Unfavourable Surgical Outcome In
Patients With Temporal Lobe
Epilepsy/C. Barba, S. Rheims,
L. Minotti, J. Isnard, D. Hoffmann,
S. Chabardes, M. Guenot, P. Ryvlin,
P. Kahane
1.349 Stereotactic Laser Ablation Is
A Potentially Curative Procedure After
Unsuccessful VNS Or RNS For Mesial
Temporal Lobe Epilepsy/J. J. Shih,
R. Wharen, W. Tatum, R. Gross,
J. Willie, D. Labiner, M. Weinand,
A. Sharan, M. Sperling
1.350 Intraoperative Supplementary
Motor Area (SMA) Monitoring For
Medial Frontal Lesions/S. Shibata,
T. Kunieda, R. Matsumoto, Y. Yamao,
R. Inano, S. Nishida, T. Nakae,
T. Kikuchi, Y. Arakawa, Y. Takagi,
A. Ikeda, R. Takahashi, S. Miyamoto
1.351 Postoperative Interictal
Epileptiform Discharges Within One
Month After Selective
Amygdalohippocampectomy For Mesial
Temporal Sclerosis/H. Yu, S. Hsu,
C. Lin, Y. Shih
1.352 Individualized Epilepsy Surgical
Outcome Prediction Based On Neural
Network Architecture/L. Bonilha,
J. Lin, D. Drane, J. Jensen,
R. Kuzniecky
Pediatrics
1.353 Language Mapping By
Spontaneous Conversation Related
High-γ Synchronization And
Comparison With Conventional
Electrical Cortical Stimulation/
R. Arya, J. A. Wilson, J. Vannest,
A. W. Byars, H. Greiner, J. Buroker,
H. Fujiwara, F. Mangano, K. Holland,
N. Crone, D. Rose
1.354 The Influence Of Lesion Volume,
Perilesional Resection Volume And
Completeness Of Resection On
Seizure Outcome Following Resective
Epilepsy Surgery For Cortical
Dysplasia In Children/C. Oluigbo,
D. Depositario-Cabacar, S. Magge,
J. Myseros, M. Whitehead,
R. Keating, W. Gaillard
1.355 Yield And Predictors Of
Epilepsy Surgery Candidacy In Children
Admitted For Surgical Workup/
O. Haque, K. Nickels, N. Wetjen,
L. Wong-Kisiel, E. Wirrell
1.356 Epilepsy Surgery Outcomes
For Lesionectomy In Non-Dysplastic
Lesions In Children With Intractable
Epilepsy/R. Villalobos, E. Gonzales,
J. Torrez-Corzo
1.357 A Circuitous Journey: Parent
Perspectives Of Getting To Pediatric
Resective Epilepsy Surgery/C. Bower
Baca, H. Pieters, T. Iwaki,
G. Mathern, B. Vickrey
1.358 Posterior Quadrant
Disconnection Surgery For
Sturge-Weber Syndrome/H. Sugano
1.359 Central Cortex-Preserving
Multilobar Surgery: An Alternative
Option For Patients With Hemispheric
Pathology And Minimal Motor
Deficit/T. Ono, H. Baba, K. Toda,
R. Honda
1.360 The Impact Of Epilepsy Surgery
On Paediatric Quality Of Life/W. Hader,
L. Ruttle-Soon, H. Carlson, D. Slick,
L. Bello-Espinosa, E. Sherman
1.361 Is Diffusion Tensor Imaging
Useful To Localize The Epileptic Focus
In Children With MRI-Negative
Epilepsy?/K. Toda, H. Baba, T. Ono,
R. Honda
1.362 Seizure Outcomes After
Resective Epilepsy Surgery In Children
With Lennox-Gastaut Syndrome/
P. Suwanpakdee, A. Naduvil Valappil,
L. Jehi, A. Gupta, W. Bingaman,
J. Gonzalez-Martinez, I. Najm,
E. Wyllie
1.363 Analysis Of Epileptic
Discharges Using Implanted Subdural
Electrodes In Patients With SturgeWeber syndrome/Y. Iimura, H. Sugano,
M. Nakajima, T. Higo, H. Arai
SATURDAY
1.330 The Effects Of Antiepileptic
Drugs On Cortical Irritability In
Patients With Tumoral Epilepsies/
P. Warren, L. B. Nabors, J. Szaflarski
1.331 Adjunctive Perampanel For
Focal-Onset Seizures – An Interim
Analysis/K. Kelly, L. Stephen,
P. Parker, M. Brodie
1.332 Fydata Study: Retrospective
Analysis Of Perampanel In A Real-Life
Setting/V. Villanueva, M. Garces,
F. López Gonzalez,
X. Rodriguez-Osorio, J. Rodriguez
Uranga, E. López-Gomáriz, J.
Montoya, J. Poza Aldea, A. Molins,
R. Saiz-Diaz, J. González de la Aleja,
J. Mauri, A. Castillo, F. Lopez-Trigo
Picho, M. Toledo, J. Salas Puig,
D. Campos Blance, J. Flores
1.333 Intravenous Intiation Of
Lacosamide For Status Epilepticus
And Following Video EEG Monitoring/
G. Morris, J. Burgos, A. Van Kampen,
M. Hanson, J. Dagam
1.334 Clobazam Vs. Clonazepam For
Adults With Epilepsy: Long-Term
Results From A UK Primary Care
Database/M. Brodie, S. S. Chung,
A. G. Wade, C. Quelen,
A. Guiraud-Diawara, C. François,
P. Verpillat, V. Shen, D. Jones,
J. Isojarvi
1.335 Long-Term Utilization
Differences Between Children Treated
With Clobazam Vs. Clonazepam For
Epilepsy In The UK/S. S. Chung,
M. Brodie, A. G. Wade, C. Quelen,
A. Guiraud-Diawara, C. François,
P. Verpillat, V. Shen, D. Jones,
J. Isojarvi
1.336 Evolution Of Clobazam,
Clonazepam, And Diazepam Usage In
The UK For Epilepsy And Other
Diseases/D. Jones, S. S. Chung,
M. Brodie, A. G. Wade, C. Quelen,
A. Guiraud-Diawara, P. Verpillat,
V. Shen, J. Isojarvi, C. François
Poster Session 1
45
Saturday December 6, 2014
1.364 Risk Of Seizure Recurrence In
Children With Pathology Confirmed
Focal Cortical Dysplasia Undergoing
Surgical Resection/A. Mrelashvili,
E. Wirrell, K. Nickels, L. Wong-Kisiel
1.365 Surgical Versus Medical
Treatment For Children With Epileptic
Encephalopathy In Infancy And Early
Childhood. An Observational Cohort
Study By Far-East Asia Catastrophic
Epilepsy (FACE) Study Group/T. Otsuki,
H. Kim, G. Luan, Y. Inoue, H. Baba,
H. Oguni, S. Hong, S. Kameyama,
K. Kobayashi, S. Hirose, H. Yamamoto,
S. Hamano, K. Baba, A. Takahashi,
T. Kaido, K. Sugai
1.366 Visualization Of Epileptogenic
Networks From Interictal iEEG Using
Granger Causality/J. R. Madsen,
E. Park
1.367 Clinical Factors For Long-Term
Seizure Remission And Developmental
Outcome After One-Stage Total
Corpus Callosotomy/M. Iwasaki,
M. Uematsu, T. Nakayama,
N. Hino-Fukuyo, K. Haginoya,
S. Osawa, Y. Shimoda, K. Jin,
N. Nakasato, T. Tominaga
All Ages
1.368 Long-Term EEG And Clinical
Outcome Of Laser Thermal Ablation In
Large Series Of Lesional And NonLesional Epileptic Foci In Adults And
Children/M. Chez, A. Ghassemi,
S. Ciricillo
46
Poster Session 1
Noon - 6:00 p.m.
Convention Center – Hall 4B, Level 4
1.369 Factors Associated With Failed
Extra-Temporal Lobe Epilepsy
Surgery/D. J. Englot, K. Raygor,
P. Garcia, R. C. Knowlton,
K. I. Auguste, E. Chang
1.370 Inflammatory Mediators Role In
Epileptogenesis Caused By Cavernous
Angioma/M. Nakajima, H. Sugano,
Y. Iimura, T. Higo, Y. Harada, H. Arai
1.371 The Role Of Corpus
Callosotomy And Vagus Nerve
Stimulation For Medically Refractory
Epilepsy And Their Future As Palliation
In Epilepsy Surgery/T. Yamamoto,
A. Fujimoto, T. Yamazoe, T. Okanishi,
T. Yokota, H. Enoki
1.372 Temperatures Achieved In
Human And Canine Neocortex During
Intraoperative Passive Or Active Focal
Cooling/R. Han, C. Yarbrough,
S. Rothman, E. Patterson, X. Yang,
J. Miller, R. D’Ambrosio, M. Smyth
1.373 Medical Cost Reduction By
Vagus Nerve Stimulation/A. Onomura,
T. Yamamoto, H. Iseki, K. Iwasaki,
M. Umezu
1.374 Surgical Outcome Of
Lesionectomy Vs Lesionectomy +
Temporal Lobectomy For Lesional
Temporal Lobe Epilepsy/V. Rajasekaran,
D. B. Burkholder, G. Worrell,
R. Marsh, F. Meyer, J. Mandrekar,
J. Britton
1.375 Long-Term Product Reliability
For Implantable VNS Therapy
Generators And Leads/C. M. Gordon,
M. T. Bunker
1.376 Conformal Laser Ablation: A
Safe & Effective Treatment For Focal,
Non-Mesial Temporal Lobe Epilepsy/
S. Bandt, A. H. Hawasli, R. E. Hogan,
E. Leuthardt
1.377 Development And Validation Of
A Prognostic Nomogram Of SeizureFreedom After Resective Epilepsy
Surgery/L. Jehi, R. Yardi, K. Chagin,
L. Tassi, G. Worrell, F. Cendes,
M. Morita, F. Bartolomei, P. Chauvel,
I. Najm, J. Gonzalez-Martinez,
W. Bingaman, M. Kattan
• AES 68TH ANNUAL MEETING
Seattle, WA •
SUNDAY December 7, 2014
www.AESnet.org
8:45 a.m. – 4:45 p.m.
Investigators’ Workshops
Location listed under each session
Overview
These workshops, conducted informally and designed to encourage
interaction, will address several important areas of rapidly-emerging
knowledge in clinical and basic research in epilepsy. The workshops are
intended to identify challenges in current research, propose methods to
overcome those challenges, and encourage areas for future investigation.
The Basic Science Investigator Workshops will highlight a number of research
areas that have been developing rapidly over the last year. Participants include
established and junior epilepsy investigators as well as researchers outside
the epilepsy community who have specialized expertise that may be applied
to epilepsy basic science. In addition, one of the workshops features
presentations by junior investigators in cutting-edge areas of research.
Most of the workshops will run as concurrent sessions on Sunday, with a
single workshop on Saturday afternoon on cannabis and epilepsy and another
Monday afternoon on stem cells.
Target Audience
Basic scientists, neurologists, neuroscientists, pharmacologists,
neuropsychologists and neurosurgeons who are performing research in
epilepsy
Program
Investigators’ Workshop Chair: Michael Wong, M.D., Ph.D.
Clinical Investigators’ Workshop Chair: Hal Blumenfeld, M.D., Ph.D.
Morning Session I – 8:45 a.m. - 10:15 a.m.
1. Yes, Focal Epilepsy Is a Network, But Does it Matter?
Convention Center – Room 608, Level 6
Moderator: Jean Gotman, Ph.D.
Speakers: Christophe Grova, Ph.D., Philippe Kahane, M.D., Ph.D.,
Michael R. Sperling, M.D.
This Investigator Workshop is supported in part by Acorda
Therapeutics.
2. How Does Status Epilepticus Provoke the Generation of
'Epileptic Neurons'?
Convention Center – Room 613, Level 6
Moderator: Tallie Z. Baram, M.D., Ph.D.
Speakers: Katja Kobow, Ph.D., Jong M. Rho, M.D., Ph.D.,
Gary P. Brennan, Ph.D.
3. Unraveling the Basis of Heterogeneity in Genetic Epilepsy
Convention Center – Room 609, Level 6
Moderator: Samuel F. Berkovic, M.D.
Speakers: Christopher Reid, Ph.D., Dennis Dlugos, M.D.,
Peter B. Crino, M.D., Ph.D.
Break: 10:15 a.m. - 10:30 a.m.
4. Teratogenesis of Antiepileptic Drugs
Convention Center – Room 608, Level 6
Moderator: Kimford J. Meador, M.D.
Speakers: Patrick Forcelli, Ph.D., Page B. Pennell, M.D.,
Kimford J. Meador, M.D.
5. Hot Topics and Late-breaking Research from Young Investigators in
the Epilepsy Community
Convention Center – Room 613, Level 6
Moderators: Chris Dulla, Ph.D., Michael Wong, M.D., Ph.D.
Speakers:
Gemma Carvill, Ph.D.: The Expanding Role for Chromatin Remodeling
in Epilepsy: Gene Discovery to Pathogenic Mechanisms
Bethany Hosford, Ph.D.: Impact of Targeted Ablation Of Developing
Dentate Granule Cells On Temporal Lobe Epileptogenesis
Matt Weston, Ph.D.: Hyperactivation of mTOR Signaling in a TwoNeuron Microcircuit Alters the Dynamics of Synaptic Transmission”
Dan Xu, Ph.D.: A Novel Therapy for Status Epilepticus Using
Biodegradable Immune-Modifying Nanoparticles
6. Low-frequency Stimulation in Epilepsy
Convention Center – Room 609, Level 6
Moderator: Mohamad Koubeissi, M.D.
Speakers: Mohamad Koubeissi, M.D., Dominique Durand, Ph.D.,
G. Campbell Teskey, Ph.D.
SUNDAY
The Clinical Investigators’ Workshops provide a series of working seminars in
matters of active clinical investigation and controversy. Speakers present
results from their ongoing research and place their findings in the context of
current understanding.
Morning Session II – 10:30 a.m. - Noon
Noon - 1:30 p.m. Poster Session (Lunch)
Convention Center – Room 6F, Level 6
Note: Number below refers to poster assignment
1.001 Enhanced Histamine Release During The Pilocarpine-Induced Status
Epilepticus Is Associated To Hippocampal Neuronal Damage In Rats:
Effects Of Sodium Cromoglycate/Luisa Rocha
1.003 Time- And Region-Specific Alterations In Cyclin D1 Expression
Following STAT3 Inhibition In A Rat Model Of Temporal Lobe Epilepsy/
Y Cruz Del Angel
1.007 Differential Toll-Like Receptor 4 Modulation Of Dentate Excitability
In The Normal And Injured Brain/Viji Santhakumar
1.014 Unit Activity Of Subicular, CA1, CA3, And Dentate Gyrus Principal
Cells And Interneurons Before Spontaneous Seizures In A Rat Model Of
Temporal Lobe Epilepsy/Paul Buckmaster
1.018 Human Single Neuron Correlates Of High Frequency Oscillations
During Seizures/Omar Ahmed
1.024 The mTOR Inhibitor, Rapamycin, Attenuates Acute Seizure-Induced
Dendritic Injury In Mice/Dongjun Guo
1.025 TRPV1 Receptors Modulate The Expression Of Experimental Febrile
Seizures During Development In Mice/Karlene Barrett
1.026 Hypothermia Prevents The Development Of The Calcium Plateau
Following Status Epilepticus/Kristin Phillips
1.027 Tonic GABAergic Inhibitory Signaling To Dentate Granule Cells In
Mice Following Controlled Cortical Impact/Jeffery Boychuk
1.030 Postnatal Disruption Of The Cytoskeletal Protein Ndel1 Induces
Hippocampal Structural Pathology And Spontaneous Recurrent
Seizures/Cezar Gavrilovici
1.039 GABA Agonists Restore Inhibitory GABA Neurotransmission in
Mesiotemporal Lobe Epilepsy: In Vivo And In Silico Modeling Evidence/
Antoine Depaulis
1.043 Modeling PIK3CA-Related Malformations Of Cortical Development
And Epilepsy In Mice/Franck Kalume
1.044 Thalamic Deep Brain Stimulation To Improve Consciousness After
Seizures/Abhijeet Gummadavelli
47
SUNDAY December 7, 2014
1.054 Treatment Of Convulsive Status Epilepticus In An Animal Model Of
Glucose Transporter Type 1 Deficiency (G1D) Syndrome/Cary Trent
1.055 Minocycline Reverses Pro-Epileptogenic Effect Of Viral-Like Brain
Inflammation In The Mature And Immature Rat Brain/Nina Dupuis
1.056 Systemic TLR3 Agonist Injection Enhances Epileptogenesis In Rat
Pups But Does Not Affect The Adult Rats/Stephane Auvin
1.105 Distinct Phenotypes And Genotypes Of SPTAN1 Encephalopathy/
Jun Tohyama
1.294 Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter
Resurgent Current Generation That Could Be Preferentially Targeted With
Cannabidiol/Reesha Patel
1.303 Neuroactive Steroids Halt Electrographic Seizures In The
Lithium-Pilocarpine Model Of Pharmaco-Resistant Status Epilepticus/
James Doherty
1.377 Development And Validation Of A Prognostic Nomogram Of
Seizure-Freedom After Resective Epilepsy Surgery/Lara Jehi
3.001 Increase In Dendritic Spines Correlates With Increased Synapses In
Hippocampal CA1 Following Hypoxia-Induced Neonatal Seizures/
Jocelyn Lippman-Bell
3.005 Retrograde Monosynaptic Tracing Of Inputs To Neonatal- Vs. AdultBorn Dentate Granule Cells In A Rodent Temporal Lobe Epilepsy Model/
Xi Du
3.006 Disabled 1-Deficient Mice Exhibit Hippocampal Structural
Abnormalities And A Reduced Seizure Threshold/Matthew Korn
3.014 Functional Evaluation Of A De Novo GRIN2A Mutation In A Patient
With CSWSS, Continuous Spike And Waves During Slow-Wave Sleep
Syndrome/Hongjie Yuan
3.016 Mechanisms Of Epilepsy And Epileptic Encephalopathy Due To
KCNT1 Mutations/Imran Quraishi
3.017 A KCNQ2/3 Mutation Causing Severe Epilepsy Disrupts Channel
Targeting To The Axon Initial Segment/Baouyen Tran
3.022 Modulation Of NKCC1 And KCC2 Co-Transporters For Control Of
Drug-Resistant Seizures/Volodymyr Dzhala
3.027 Unravelling The EEG Footprints That Develop Into Spontaneous
Recurrent Seizures (SRS) During Epileptogenesis In C57BL6/J Mouse
Model Of Temporal Lobe Epilepsy (TLE)/Thimmasettappa Thippeswamy
3.030 New Model Of Focal Cortical Dysplasia Associated Epilepsy/
Lawrence Hsieh
3.032 Oxidative Stress-Mediated Mitochondrial Dysfunction And Neuronal
Loss Contribute To Cognitive Deficits In Experimental Temporal Lobe
Epilepsy/Jennifer Pearson
3.035 Enhancing KCC2 By Acute TrkB Inhibition Rescues PhenobarbitalResistant Seizures In A Model Of Neonatal Ischemia/Shilpa Kadam
3.036 Cardiac Consequences Of Repeated Brief Seizures In Chronic
Experimental Temporal Lobe Epilepsy/John Jefferys
3.039 Flupirtine Is More Efficacious Than Phenobarbital In The Treatment
Of Hypoxia-Ischemia Induced Neonatal Seizures In A Rodent Model/
Dayalan Sampath
3.043 Lithium-Pilocarpine And DFP-Induced Status Epilepticus In
Immature Rats: Behavioral, Electrographic, And Neuropathological
Characteristics/Erika Scholl
3.047 Comparison Of Spike-Wave Discharges And Other Oscillatory
Activity In Normal Animals With Spontaneous Recurrent Seizures Across
Several Animal Models Of Acquired Epilepsy/F. Edward Dudek
3.050 Late Inhibition Of mTOR Suppresses Fully Established Epilepsy And
Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical
Dysplasia/Lena Nguyen
3.063 Tracking Inflammation In Epileptogenic Brain Tissue In The Rat By
Nanoparticles/Sara Eyal
3.070 Early Seizure Detection Using Relative Gamma And Ripple Band
Phase Decoherence/Zoltan Nadasdy
3.089 Whole-Exome Sequencing In 84 Cases Of Unsolved Progressive
Myoclonus Epilepsy/Mikko Muona
3.145 Etiologies And Yield Of Investigations For Infantile Spasms: Results
Of A US Multicenter, Prospective Study/Elaine Wirrell
48
Afternoon Session I – 1:30 p.m. - 3:00 p.m.
7. Brain Connectivity in Health and Epilepsy
Convention Center – Room 608, Level 6
Moderator: Jeffrey G. Ojemann, M.D.
Speakers: Catherine Chu-Shore, M.D., Luigi Maccotta, M.D., Ph.D.,
Kurt Weaver, M.D.
8. SUDEP Mechanisms: A Basic Science Perspective
Convention Center – Room 613, Level 6
Moderators: Gordon F. Buchanan, M.D., Ph.D.
Speakers: Gordon F. Buchanan, M.D., Ph.D., Isamu Alba, Ph.D.,
Carl L. Faingold, Ph.D.
9. Finding Risk Alleles in Generalized Epilepsies: Next Generation
Sequencing and the Virtues of Large Collaborations
Convention Center – Room 609, Level 6
Moderator: Slavé Petrovski, Ph.D.
Speakers: Slavé Petrovski, Ph.D., Roland Krause, Dr. Sci.,
Patrick Cossette, M.D.
Break: 3:00 p.m. - 3:15 p.m.
Afternoon Session II – 3:15 p.m. - 4:45 p.m.
10. Stress and Seizures
Convention Center – Room 608, Level 6
Moderators: Michael D. Privitera, M.D.
Speakers: Jane B. Allendorfer, Ph.D., James Herman, Ph.D.,
Michael D. Privitera, M.D.
11. Understanding Infantile Spasms: A Pathogenic Perspective
Convention Center – Room 613, Level 6
Moderators: Chris Dulla, Ph.D., Aristea S. Galanopoulou, M.D., Ph.D.
Speakers: Chris Dulla, Ph.D., Jeffrey L. Noebels, M.D., Ph.D.,
John W. Swann, Ph.D.
12. Which Parts of the Brain Participate in Seizures, and Why
Does It Matter?
Convention Center – Room 609, Level 6
Moderator: Catherine Schevon, M.D., Ph.D.
Speakers: Andrew Trevelyan, M.D., Ph.D., Hal Blumenfeld, M.D., Ph.D.,
Catherine Schevon, M.D., Ph.D.
SUNDAY December 7, 2014
8:45 a.m. – 5:15 p.m.
Annual Course: Seizures and EEG in the
Critically Ill Patient (6.0 CME Credits)
Convention Center – Ballroom 6C, Level 6
11:50 a.m.
Noon-2:00 p.m.
Overview
Who Should be Reading cEEGs? The Role of the
Neurointensivist
Edward M. Manno, M.D.
Morning Wrap-Up
Eric Kossoff, M.D.
Lunch Break in Exhibit Hall
The Annual Course will focus on diagnosis and management of seizures in
patients admitted to intensive care units (ICU), both those with known epilepsy
and those with seizures due to systemic illnesses or infection. Topics include:
diagnostic challenges, initially regarding etiologies of seizures in ICU patients;
how routine and / or continuous EEG can help (or hinder) management. Financial
issues and management options for patients having seizures as well as Status
Epilepticus in ICU settings. Lectures will cover standard anticonvulsants,
sedative and coma-inducing agents, as well as non-standard treatments such
as surgery, diet, immunomodulatory agents, and TMS. The Annual Course will
conclude with a discussion of prognosis and outcomes from seizures as well as
status epilepticus. The course will include case presentation, debate and use of
audience response system.
Treatment Challenges
Learning Objectives
2:55 p.m.
Recognize interictal and ictal EEG patterns in critically ill patients
u
Define intervention strategies for critically ill patients with both subclinical
and refractory clinical Status Epilepticus
u
Implements rational medical therapy for seizures in critically ill patients
u
Counsel families regarding implications and prognosis of sub-clinical and
clinical Status Epilepticus
u
Assist physicians in treating subclinical and clinical seizures through use
of appropriate medications
u
Recognize the implications of seizures in a critically ill patient who
survived and is now facing neuropsychological difficulties.
2:05 p.m.
2:10 p.m.
2:30 p.m.
3:25 p.m.
3:40 p.m.
3:55 p.m.
Target Audience
Intermediate and Advanced (see page 120 for details)
Program
Chair: Eric Kossoff, M.D.
Diagnostic Challenges
8:45 a.m.
8:55 a.m.
9:00 a.m.
9:25 a.m.
9:50 a.m.
10:20 a.m.
10:35 a.m.
10:40 a.m.
11:05 a.m.
11:30 a.m.
Introduction to Morning Session
Eric Kossoff, M.D.
Case Presentation (Johnny, Part 1)
Andreas Alexopoulos, M.D., M.P.H.
Lecture: Etiologic Considerations in Seizure
Screening
Nicholas S. Abend, M.D.
Lecture: EEG in the ICU: Nomenclature and
Current Trends
Susan T. Herman, M.D.
Debate: Utility of Continuous EEG – Monitor All
vs. Be Selective?
Lawrence J. Hirsch, M.D. (Pro) / Paul Vespa, M.D. (Con)
Break
Case (Johnny, Part 2)
Lily Wong-Kisiel, M.D.
Lecture: Neonates and Children: Are They
Different?
Cecil Hahn, M.D.
Lecture: NORSE, FIRES, and Encephalitis
Nicolas Gaspard, M.D., Ph.D.
Flash Panel: Financial and Logistical Issues
Is Continuous EEG Worth the Cost and Use of
Resources?
Thomas P. Bleck, M.D.
4:35 p.m.
4:55 p.m.
5:00 p.m.
Introduction to Afternoon Session
Eric Kossoff, M.D.
Case (Johnny, Part 3)
Jack Lin, M.D.
Lecture: Pharmacologic Treatment of Status
Epilepticus in the ICU
Daniel H. Lowenstein, M.D.
Lecture: Pharmacologic Treatment of
Super-refractory Status Epilepticus
Joseph I. Sirven, M.D.
Debate: Should We Treat Anoxic / Myoclonic
Seizures?
David M. Ficker, M.D. (Pro) / Jennifer L. Hopp, M.D. (Con)
Lecture: AES Treatment Guidelines for Status
Epilepticus
Tracy A. Glauser, M.D.
Break
Flash Panel: Other Treatments to Try When
Nothing Else Works
Surgery
Yu-tze Ng, M.D.
Ketogenic Diet
Mackenzie Cervenka, M.D.
Steroids / IVIG – How Do They Work?
Annamaria Vezzani, Ph.D.
Transcranial Magnetic Stimulation
Alexander Rotenberg, M.D., Ph.D.
Lecture: Long-term Prognosis and Outcomes
Elizabeth J. Waterhouse, M.D.
Case (Johnny, Part 4 and Conclusion)
Jerzy P. Szaflarski, M.D., Ph.D.
Conclusions
Eric Kossoff, M.D.
SUNDAY
u
2:00 p.m.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum
of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 6.0 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 6.0 contact hours (0.6 CEUs). UAN 0077-9999-14-034-L01-P.
Initial Release Date: 12/7/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Annual
Course Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Core Competencies: Patient Care, Medical Knowledge and Practice-based
Learning
Acknowledgment
This program is supported in part by an educational grant from Electrical
Geodesics, Inc.
49
SUNDAY December 7, 2014
6:00 p.m. – 7:30 p.m.
Special Interest Group Meetings
Location listed under each session
Drug Resistant Epilepsy – Definition, Epidemiology,
Predictors, Using Big Data for Epidemiological Research
Convention Center – Room 617, Level 6
Coordinator: Nathalie Jetté, M.D., FRCPC
Speakers: Samuel Wiebe, M.D., Martin J. Brodie, M.D.,
Elaine C. Wirrell, M.D., Jakob Christensen, M.D., Ph.D.
This SIG will provide participants with an up to date review about drug-resistant
epilepsy. We will begin by reviewing the latest definition of drug resistant
epilepsy and consider the evidence behind it. We will review the epidemiology of
drug-resistant epilepsy and whether patterns are changing over time, discuss
risk factors for pharmaco-resistance in children with epilepsy and will examine
whether big data can be exploited to study drug-resistance in epilepsy.
Frontal Lobe Epilepsy: Semiology and Cognitive Aspects
Convention Center – Room 608, Level 6
Coordinators: Andrea Bernasconi, M.D., Fernando Cendes, M.D., Ph.D.
Speakers: Prof. Patrick Chauvel, Bruce Hermann, Ph.D.
Frontal lobe epilepsy is the second most common type of localization-related
epilepsy that undergoes surgical treatment, and probably the most challenging in
terms of medical and surgical management. The causes are diverse and often
undetected by current standards of neuroimaging investigation, and a large
proportion of patients need invasive EEG investigation. Despite advances in
technology, many patients with frontal lobe epilepsy cannot undergo surgery either
due to the seizure onset zone being close to or involving eloquent areas (motor and
language) or because there is a lack of clear localization of epileptogenic lesion /
seizure focus. We will discuss the pathophysiological aspects of the complex
seizure semiology and cognitive changes in frontal lobe epilepsy.
Coordinator: D. Samba Reddy, Ph.D., RPh
Speakers: Aristea S. Galanopoulou, M.D., Ph.D., Cynthia L. Harden, M.D.,
D. Samba Reddy, Ph.D., RPh, Asla Pitkanen, M.D., Ph.D.
Sex difference in seizure susceptibility is one of the long-standing issues of
epilepsy. Clinical evidence shows gender- and age-related expression of many
seizure syndromes. The incidence of epilepsy is generally higher in males than
in females. More women than men are diagnosed with idiopathic generalized
epilepsy, but localization-related symptomatic epilepsies are more frequent in
men, and cryptogenic localization-related epilepsies are more frequent in
women. Changes in seizure sensitivity are also evident at puberty, which is
associated with rigorous changes in reproductive hormones and behavioral
patterns. Overall, there is considerable evidence indicating that men exhibit
greater seizure susceptibility than females, while many females exhibit greater
fluctuations in susceptibility to seizures, including menstrual cycle-related
changes in seizure activity. Although sex differences in epileptogenesis are
widely recognized, there is little discussion on their mechanisms and
therapeutic implications. In this SIG, sex-based differences in seizure sensitivity
and epileptogenesis will be discussed, with emphasis on variations between
men and women in factors such as steroid hormones, gender-specific
developmental consequences, biologic differences in neuronal networks in the
brain and gender-based differential therapeutic interventions.
Pediatric Case Discussions
Convention Center – Room 612, Level 6
Coordinator: Elaine Wyllie, M.D.
Speakers: TBA
Six expert faculty will present impactful cases illustrating important clinical
points in diverse topics including pediatric epilepsy diagnosis, seizure
semiology, EEG, antiepileptic medications, surgery, genetics, comorbidities, and
other topics.
Magnetoencephalography (MEG) / Magnetic Source Imaging
(MSI) Source Localization Results: Blind Faith, Black Art, or
Scientific Method?
Psychogenic Nonepileptic Seizures: What Can We Learn from
PNES Semiology?
Convention Center – Room 620, Level 6
Coordinators: Markus Reuber, M.D., Ph.D., FRCP, Sigita Plioplys, M.D.
Speakers: Roderick Duncan, M.D., Ph.D., FRCP, Gaston C. Baslet, M.D.,
Julia Doss, Psy.D., LPN
Coordinators: Anto I. Bagic, M.D., Ph.D.
Speakers: Steven Stufflebeam, M.D., Ph.D., Richard C. Burgess, M.D., Ph.D.,
Michael Funke, M.D., Ph.D., John S. Ebersole, M.D.
Although MEG is an established tool for localizing normal and pathological fields,
and clinical MEG is a recognized diagnostic subspecialty, there is a need to
improve the understanding and thus usefulness of MEG source modeling results for
the practitioner to facilitate further growth of the field. To this end, it is essential to
review the concepts of source localization accuracy based not only on the
equivalent current dipole (ECD) but also on various extended models. Thus,
Dr. Stufflebeam will introduce distributed source localization methods; Dr. Burgess
will scrutinize the criteria for acceptance of a dipole fit; Dr. Funke will discuss the
methods for improving source localization yield and accuracy (spike averaging,
tSSS, region of interest sub-selection, etc.) and Dr. Ebersole will elucidate on the
concept of dipole-worthiness.
Neonatal Seizures: Should We Pursue Comparative
Effectiveness Studies for the Treatment of Neonatal
Seizures?
Convention Center – Room 609, Level 6
Coordinators: Renee A. Shellhaas, M.D., M.S., Courtney Wusthoff, M.D.
Speakers: Ronnie Guillet, Tracy A. Glauser, M.D.
There remains a paucity of evidence regarding optimal treatment for neonatal
seizures. While there are a few ongoing RCTs for specific agents in the
treatment of neonatal seizures, all have faced significant challenges. Some
have proposed the solution to this knowledge gap lies in comparative
effectiveness research, using the existing wide variation in clinical practice to
study impact on outcomes. Others argue that a well-designed and executed
RCT remains feasible and is preferable as the gold standard to provide an
evidence basis in this area. Following presentation of three relevant posters,
our speakers will debate the sides of this issue.
50
Neuroendocrinology: Sex Differences in Epileptogenesis
Convention Center – Room 613, Level 6
Convention Center – Room 615, Level 6
This SIG will focus on the visible and subjective symptomatology of PNES in
adults and children and explore whether different semiological features can tell
us anything about the etiology, course or optimal management of patients with
PNES. A wide range of subjective semiological features have been reported
during PNES, including sensory experiences from different modalities,
symptoms indicative of hyperarousal, distressing experiences and varying
degrees of preserved awareness. Similarly, the objectively observable
semiology of PNES has been studied extensively, and characteristic features
have been described. Some PNES experiences have been linked to antecedent
trauma and better or worse outcome. Other than this, little is known about how
PNES semiology might relate to etiology or mechanism, and whether some
elements of it might have implications for choice of therapy. Drs. Duncan and
Baslet will summarize published observations of PNES subjective and objective
semiology in adults, will discuss the implication of these observations and will
explore possibilities for future research. While PNES in children shares similar
semiological features to those in adults, there are few studies assessing
subjective experience and how this may inform treatment choice or treatment
outcome. Dr. Doss will discuss PNES semiology in the pediatric population.
8:00 p.m. – 10:00 p.m.
Social Networking Groups
Sheraton – Madrona, Second Floor
(registration is not required)
Informal gathering and networking for SIG participants. Space is limited so
participants are welcome on a first-come, first-served basis. Roundtable topics
include: Adolescent Epilepsy and Transitional Clinics.
Sunday December 7, 2014
Poster Session 2
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
 Authors Present: Noon – 2:00 p.m.
 Poster Walking Tours begin at 12:15 p.m. (see page 15 for details)
Behavior/Neuropsychology/
Language
Pediatrics
2.012 Neuropsychological Outcome In
Children With Focal Cortical Dysplasia
Following Surgical Resection For
Intractable Epilepsy/R. Boada,
G. Berrios-Siervo, D. L. Cohen,
G. Wilkening, P. Laoprasert
2.013 Memory And Executive
Functioning In Monolingual And
Bilingual Children With Epilepsy/
A. Veenstra, J. Riley, J. Romain,
M. Muhonen, J. Lin, M. Zupanc,
G. Mucci
All Ages
2.025 Cognitive Consequences Of
Interictal Spikes/L. Groomes,
R. Madhavan, H. Tang, N. E. Crone,
J. Madsen, A. Golby, F. Lenz,
G. Kreiman, W. Anderson
2.026 Use Of Magnetic Source
Imaging Language Mapping To Predict
Language Decline Following Left
Temporal Lobe Epilepsy Surgery/
R. Doss, G. Risse, W. Zhang, R. Lyons
2.027 Spatial Dissociation Between
Phonological And Semantic Speech
Processing In The Lateral Temporal
Lobe/M. J. Hamberger,
G. M. McKhann, II, M. Miozzo
2.028 Pre- And Post-Neurosurgical
Longitudinal Psychiatric Outcome In
Intractable Mesial Temporal Lobe
Epilepsy Patients Receiving
Psychiatric Care/R. Pella, A. Velez,
O. Lie, L. Morgan, K. Karkar, C. Szabo
2.029 The Impact Of Mood On
Memory Complaints And Memory
Performance In Patients With
Epilepsy/Y. Cukier, K. Janke,
B. Rabinovitz, D. Hwang, D. Mehta,
C. Harden, D. Schaffer
2.030 Complication Rates During The
WADA Test: One Center’s
Experience/N. J. Beimer, H. Buchtel,
S. Glynn
Health Services
Delivery of Care
2.031 Survey Of Online Patient
Communities To Analyze Perceptions
Of Healthcare Value/G. Cohen,
B. Leymon-Porter, J. Fishman
2.032 Epilepsy Surgery Trends In A
Universal Health System: Ontario,
Canada (1999-2010)/J. G. Burneo,
K. Liu, S. Shariff, S. Leonard,
A. Garg, G. Saposnik
2.033 Antiepileptic Drug Therapy And
Model Predictions Of Treatment
Success/C. Dilley, M. Rozen-Zvi,
J. Harrington, Y. Goldschmidt,
C. Clark, P. Fritz, O. Devinsky
2.034 Outpatient Education Reduces
Emergency Room Use By Epilepsy
Patients/F. T. Pascual, K. Hoang,
C. Hollen, R. Swearingen, A. Hakimi,
J. King, D. M. Thompson
2.035 Time Elapsed From Onset Of
Infantile Spasms To Diagnosis And
Treatment/S. An, E. Nagarajan,
I. Sánchez Fernández, C. Joshi,
K. Knupp, I. Valencia, E. Wirrell,
A. Berg, T. Loddenkemper
2.036 Review Of Outpatient Home
Clinical Video Telehealth (CVT) In
Epilepsy And Pilot Experience Within
The Veterans Health Administration
(VHA)/T. T. Tran, P. Kelly, A. Husain
2.037 Standardized Seizure
Assessment In The EMU/O. Hope,
M. Tapia, A. Balabanov
2.038 Impact Of Psychogenic NonEpileptic Seizure (PNES) Diagnosis On
Acute Care Resource Utilization, Role
For Psychiatric Consultation, And
Follow-Up Within A Dallas County
Hospital System/C. B. Culver,
J. J. Konikkara, L. Howe-Martin,
P. Van Ness, M. Agostini, R. Hays,
P. Modur, K. Ding, P. Gupta
SUNDAY
Adult
2.001 Utility Of RBANS In Intractable
Epilepsy Patients In A Arab Cohort/
N. A. Moussa, S. A. Al Jarrah,
K. A. Siddiqui
2.002 Quality Of Life And Mood
Status Of New Patients In Outpatient
Clinic For Epilepsy/R. Hanaya,
Y. Kashida, H. Hosoyama, K. Iida,
T. Otsubo, K. Arita
2.003 Long-Term Follow-Up Of
Memory Functions In Patients With
Chronic Vagal Nerve Stimulation/I.
Tyrlikova, Z. Hummelova, R. Kubikova,
S. Telecka, M. Tyrlik, R. Kuba,
M. Brazdil, J. Chrastina, J. Hemza,
Z. Novak, I. Rektor
2.004 Mapping The Cognitive
Network In Adults With Temporal Lobe
Epilepsy/T. Kellermann, J. Lin,
L. Bonilha, B. Hermann
2.005 Better Executive Function
Associated With Higher
Frontoparietal Functional Connectivity
In The Spared Hemisphere In Left
Mesial TLE/N. Kucukboyaci, K. Leyden,
N. Kemmotsu, E. Tecoma, R. Q. Loi,
D. Lee, C. McDonald
2.006 The Social Experience Of
Stigma In A Midwestern Epilepsy
Population/J. L. Moore,
C. Bosler Walton
2.007 Mediators Of Quality Of Life In
An Underserved Population Of
Epilepsy Patients/D. Becker,
A. Shallcross, D. Friedman, A. Singh,
J. French, R. Jurd, T. Spruill,
O. Devinsky
2.008 Unprovoked Seizures In
Patients Diagnosed With Dementia:
Clinical And Neurophysiologic
Characteristics/R. Sarkis,
B. Dickerson, Z. Chemali
2.009 A Randomized Efficacy Trial Of
A Clinic-Based Decision Support
System For Epilepsy Self-Management/
R. Shegog, C. Begley
2.010 Reinstatement Of Distributed
Spatiotemporal Patterns Of
Oscillatory Power During Associative
Memory/K. A. Zaghloul, R. B. Yaffe,
M. S. Kerr, S. Damera, S. V. Sarma,
S. K. Inati
2.011 Relations Between Social
Cognition And Quality Of Life In
Epilepsy/K. Janke, Y. Cukier, S. Hwang,
A. Mehta, C. Harden, S. Schaffer
2.014 Language Localization In
Pediatric Epilepsy: Comparison
Between Functional Magnetic
Resonance Imaging (fMRI) And
Electrical Stimulation Mapping
(ESM)/C. M. Salinas, P. Chen,
M. Korostenskaja, E. Castillo,
J. Baumgartner, J. Seo, K. Lee,
M. Westerveld
2.015 Neurodevelopment In
Preschool Children Of Fife And Lothian
Epilepsy Study: Neuroprofiles – A
Population-Based Study/M. B. Hunter,
K. Verity, R. Sumpter, A. McLellan,
J. Shetty, M. Yoong, R. Chin
2.016 Unexpected Subclinical Spikes:
Clinical And Neurophysiological
Correlations/M. Mintz, L. Szklarski,
M. Chadehumbe, G. Alberts,
S. Woldoff, M. Mohamadpour,
J. Keating
2.017 Neuropsychological Profiles Of
Children With Benign Rolandic Epilepsy
Highlight Vulnerability In Cognitive
Efficiency, Learning And Memory/
K. Boyer, J. Girard, C. Vega,
D. P. Waber, M. Takeoka
2.018 Psychiatric Disturbance In
Children With Epilepsy/F. Besag,
A. Aldenkamp, R. Caplan, D. Dunn,
G. Gobbi, M. Sillanpaa
2.019 Computerized Training Of
Working Memory In Children With
Epilepsy Update/V. Terwilliger, M. Berl,
E. Fisher, L. Sepeta
2.020 Gender Differences And ADHD
Among Children With Epilepsy/R.
Trobliger, M. E. Lancman, M. Lancman
2.021 Minnesota Epilepsy Group’s
Multidisciplinary Clinic for New Onset
Pediatric Epilepsy (NOPE)/E. Adams,
J. Doss, K. Berg, C. Opperman,
F. Ritter
2.022 Postoperative
Neuropsychological Outcomes in
Pediatric Patients Undergoing
Temporal Lobe Epilepsy Surgery/
L. Bailey, T. Parsons, H. Blumenthal,
A. Boals, M. Perry
2.023 Psychiatric Comorbidity In
Children With Recent-Onset Epilepsy:
A 2-Year Prospective Controlled
Investigation/J. Jones, D. Almane,
D. Jackson, D. Hsu, L. Zawadzki,
C. Stafstrom, M. Seidenberg,
B. Hermann
2.024 Left Centrotemporal Spikes
Affect Language Function In BECTS/
J. Vannest, T. Maloney, J. Tenney,
J. Szaflarski, K. Hibbard, D. Morita,
T. Glauser
51
Sunday December 7, 2014
2.039 PACES In Epilepsy: Results Of
A Self-Management Randomized
Controlled Trial/R. T. Fraser,
E. K. Johnson, S. Lashley, J. Barber,
N. Chaytor, J. Miller, P. Ciechanowski,
N. Temkin, L. Caylor
2.040 A Survey Of Family
Satisfaction Of Pediatric Epilepsy
Care Via Telemedicine In British
Columbia (BC)/A. Faber, S. Peinhof,
S. Richards, Y. Pan, M. Connolly
2.041 Yield Of Monitoring In An Adult
Epilepsy Monitoring Unit/S. Agrawal,
L. Turco, S. Goswami, M. Faulkner,
S. P. Singh
2.042 Reducing Urgent Hospital
Re-Encounters Following Epilepsy
Monitoring Unit Discharge/K. Secore,
J. J. Chen, A. F. Van Straten,
S. P. Wei, K. A. Birney,
J. J. Harrington, B. Jobst,
K. Bujarski, E. J. Kobylarz, V. Thadani,
T. A. Caller
2.043 Hospital Crossover Increases
Utilization For People With Epilepsy:
A Retrospective Cohort Study/
Z. Grinspan, J. S. Shapiro,
E. L. Abramson, H. Jung, R. Kaushal,
L. M. Kern
2.044 Health Care Resource
Utilization And Costs Of Immediate
vs. Delayed Second-Line Treatment
Initiation Among Patients With
Epilepsy/V. Divino, V. Bollu, C. Makin,
F. Velez
2.045 Does Adherence To Epilepsy
Quality Measures Predict Seizure
Control?/L. V. Moura, D. Mendez,
B. Vickrey, D. Hoch
2.046 Quality Of Life Outcomes After
Referral To A Tertiary Epilepsy
Center/M. Tom, P. Penovich, R. Doss,
A. Olson
2.047 Improving The Standard Of
Care For Patients With Epilepsy:
Factors Influencing Hospitalization
Rates/C. Begley, S. Helmers,
D. Thurman, C. Dilley, C. Clark,
P. Fritz, E. Faught
Access to Care
2.048 Leveraging Technology To
Improve Access - Epilepsy Centers Of
Excellence (ECoE) Capitalizes On The
Telemedicine Opportunity/P. Kelly,
R. Rehman, A. Husain
2.049 Reduction Of ED Visits By
Implementation Of An Urgent Clinic
For Children With Established
Epilepsy/D. Terry, J. Pacheco-Phillips
2.050 The Michigan Pediatric Epilepsy
Telemedicine Project- Innovative
Subspecialty Care Within A Medical
Home/S. Joshi, S. Clark, L. Fletcher,
S. Jordan
2.051 Patterns Of Neurological And
Neurosurgical Care For Persons With
Epilepsy/K. Sauro, S. Mah, B. Li,
L. Svenson, C. DeCoster, S. Wiebe,
N. Jetté
2.052 Gaps In Medicaid Coverage
Among Persons With Epilepsy/
P. Bakaki, S. Koroukian, J. Albert,
K. Kaiboriboon
52
Poster Session 2
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.053 Process Improvement To
Reduce Time To Epilepsy Surgery/
C. Drees, R. DeBello, L. Frey, P. Korb,
A. Shrestha, L. Strom, M. Spitz,
C. O’Brien
2.054 Assessment Of Knowledge And
Attitudes As Well As Patterns Of
Referral About Epilepsy Surgery
Among Family Doctors In Ontario,
Canada/N. Cothros, J. G. Burneo,
S. Brown, D. Steven
Health Care Models
2.055 Comorbidities Associated With
Frequent Emergency Department
Visits Among Children With
Epilepsy/A. Patel, B. Haridas,
Z. Grinspan
2.056 Using The Measure Of
Processes Of Care (MPOC-20) To
Assess Family-Centred Care In
Children With Epilepsy: Evaluating This
Application/K. C. Joachim, P. Wilk,
B. Ryan, K. Speechley
2.057 Changing Practice Pattern
Before And After The Modification Of
EMU At UNC/R. Davis, N. Odom,
S. Sutton, B. Vaughn, A. Hinn,
E. Ryan, H. Ritchie, H. Shin
2.058 The POEM Study: Patient
Usage And Satisfaction With An
Online Health Management Platform
For Epilepsy/J. Hixson, D. Barnes,
K. Parko, T. Durgin, S. Van Bebber,
P. Wicks, A. Graham
2.059 Mapping Epilepsy Subspecialty
Care By Physician Networks/H. Hamid,
J. Bates, M. Pugh, J. Neil, C. Brandt
2.060 Developing An Effective
Vocational Rehabilitation Model For
Individuals With Epilepsy And
Comorbid Disabilities In Japan: A New
Hospital-Based Service Delivery
System/Y. Namihisa, M. Sakata,
M. Ohshima, M. Osako, M. Fujikawa
Practice Resources
2.061 Characteristics Of Pediatric
Inpatients In Whom Clinical Decision
Making Is Changed By Continuous
Video EEG Monitoring/
M. C. Spiciarich, K. Ballaban-Gil,
J. C. Beal
2.062 Utility, Applications, Validity
And Reliability Of The Inventory Of
Neppe of Symptoms of Epilepsy and
the Temporal Lobe (INSET) Compared
With Ambulatory
Electroencephalographic Parameters,
Longitudinal Clinical Features,
Anticonvulsant Responsiveness/
V. M. Neppe
2.063 Frequency, Findings, And
Comparisons Of Seizure Montage
Polysomnography/A. Slansky,
S. Manganaro, R. Ribot, L. Tornes
2.064 Designing And Assessing
Digital Patient Education Materials In
An Outpatient Epilepsy Practice
Setting/F. Blezin, H. Quinn,
L. Ponticello, J. Richardson,
J. Stribling
2.065 SUDEP: What Do Patients
Want To Know?/R. RamachandranNair,
A. Rama Madhava, S. M. Jack,
M. J. Shapiro
2.066 Pregnancy And Seizures:
Review Of Practice At George
Washington University In The Past 5
Years/G. T. Que, C. Agha, U. Menon,
R. Aly
Epidemiology
2.067 Epilepsy In The Elderly: A
Distinct Entity?/C. Josephson,
N. Jette, Y. Aghakhani, P. Federico,
A. Hanson, W. Murphy, N. Pillay,
S. Wiebe
2.068 Mortality In Adult Epilepsy
Patients Decreased Over 3 Decades:
A Hospital-Based Cohort/
C. Granbichler, W. Oberaigner,
G. Kuchukhidze, G. Bauer, J.
Ndayisaba, K. Seppi, E. Trinka
2.069 Research Project Management
In Multi-Centre Long-Term Follow-Up
Studies: Meeting The Challenges/
J. Terhaerdt, K. Speechley
2.070 A Survey Of Medical Examiner
Death Certification Of Vignettes On
Death In Epilepsy: Gaps In Identifying
SUDEP/D. Atherton, G. G. Davis,
C. Wright, D. Hesdorffer
2.071 Quality Of Life In Persons With
Epilepsy/N. Jette, S. Patten,
S. Wiebe, A. G. Bulloch,
S. Macrodimitris, K. Fiest
2.072 Epilepsy In Young Children: A
Nationwide Population-Based Study/
K. Aaberg, P. Suren, C. Soraas,
I. Bakken, M. Lossius, C. Stoltenberg,
R. Chin
2.073 Mortality In Patients With
Epilepsy And Psychogenic
Nonepileptic Seizures/
C. Garcia Gracia, K. Unnwongse,
K. Shea, R. Burgess, I. Najm, L. Jehi
2.074 Cause-Specific Mortality
Among Children And Young Adults
With Epilepsy: Results From The
United States National Child Death
Review Case Reporting System/
N. Tian, E. C. Shaw, M. Zack,
R. Kobau, H. Dykstra, D. Thurman,
T. M. Covington
2.075 The Epidemiology, Management
And Outcome Of Convulsive Status
Epilepticus In Children/M. Uzun
2.076 TBI Study In Moscow –
Predictors Of Seizures And
Outcomes/A. Guekht, V. Krylov,
N. Gulyaeva, E. Gusev, I. Kaimovsky,
I. Trifonov, A. Talypov, S. Asratyan,
A. Yakovlev, A. Lebedeva, A. Hauser
2.077 Creation Of An Epilepsy
Registry In The Veterans Health
Administration/R. Rehman, P. Kelly,
A. Husain
2.078 A Community-Based Study Of
The Sociodemographic Risk Factors Of
Epilepsy Among Adults In The Province
Of Alicante (Spain)/S. Palao-Duarte
Sunday December 7, 2014
2.079 Prevalence And Risk Factors
Of Peri-Ictal Autonomic Changes In
Children With Temporal And
Frontotemporal Lobe Seizures/
M. A. Whealy, E. Wirrell,
L. Wong-Kisiel, K. Nickels
2.080 Epileptic Seizures In Japanese
Patients With Lacunar Infarction And
Branch Atheromatous Disease/
K. Obata, M. Kinoshita, K. Sato,
M. Chin, S. Yamagata, K. Shindo
2.081 Evidence Mesial TLE Is Not
Always Medically Refractory/P. Tseng,
M. Liu, N. Fountain
2.082 Resective Focal Epilepsy
Surgery – Has Selection Of
Candidates Changed?/C. Kwon,
J. Neal, J. Tellez-Zenteno,
A. Metcalfe, W. Hader, S. Wiebe,
N. Jetté
2.083 The Clinical Characteristics Of
Preschool-Aged Children Visited
Emergency Room By Epileptic
Seizures/B. Cha, G. Noh
Public Health
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.094 Antiepileptic Drug And
Cardiovascular Risk In Patients With
Epilepsy/C. Huang, C. Hsieh,
Y. Yang Kao
2.095 Epilepsy Transition: Challenges
Of Caring For Adults With ChildhoodOnset Seizures/F. Borlot,
J. Tellez-Zenteno, A. Allen, A. Ali,
O. Snead III, D. Andrade
2.096 Epilepsy Knowledge And
Understanding Among
Parents/Caregivers Of Children With
Epilepsy/L. Sanchez-Ortiz,
R. Rios-Motta, M. Rios-Motta
2.097 Implicit Attitudes Toward
Epilepsy In Japan/S. Tohma, K. Hara,
A. Tabata, S. Tanaka, M. Hara,
M. Matsuura, K. Ohta, M. Inaji,
T. Maehara, Y. Sumi
History of Epilepsy
2.098 Diet And Epilepsy – A
Historical Review 1875-1938/
S. Goswami, S. P. Singh
2.099 Otto Löwenstein (18891995): The Forgotten Pioneer Of
Video-Monitoring In Epilepsy/
G. Kraemer
2.100 The Birth Of Stigma In
Antiquity: Phaedrus As Disabling
Text/A. Swenson
Case Studies
2.101 Refractory Partial Seizures As
Manifestation Of Polymerase Gamma
(POLG) Mutation In Pediatric
Patients/N. Dalvi, L. Vargas,
S. Karkare
2.102 Pre- And Post-Ictal Body
Positions In Patients With Generalized
Convulsive Seizures/S. Graf, S. Wu,
J. Liebenthal, S. Rose, J. Tao
2.103 Alexia Without Agraphia In A
Child – An Unusual Complication Of
Epilepsy Surgical Resection In The
Left Posterior Head Region/
G. Wilkening, N. Stence, M. Handler,
P. Laoprasert
2.104 Resolution Of Seizures And
Normalization Of EEG After Initiation
Of CBD In A Patient With Doose
Syndrome/J. Gold, S. Sattar,
S. Wang, M. Nespeca
2.105 EEG-Based Identification Of
Command-Following After Cardiac
Arrest In The Minimally Conscious
State/P. B. Forgacs, N. Schiff
2.106 Prolonged Propofol Infusion In
Pregnant Women With Refractory
Status Epileptics/N. O. Al Matrooshi,
N. Ali, S. Sinha
2.107 Super Refractory Status
Epilepticus In An 8 Year Old Female
With Congenital Brain Anomalies,
Metabolic Myopathy, And Progressive
Epilepsy – Brain Autopsy And Genetic
Testing Correlates/F. Khan, E. Ramsay,
H. Dave, V. Sabharwal, L. Finger
2.108 Photosensitive Epilepsy With
OCD Type Behavior: A Case Series
Report/N. Olney, R. Rajaraman,
R. Sankar, S. A. Hussain
2.109 Case Report: Seizure As The
First Clinical Presentation In Adult
With Childhood Genetic Disorder
(Tuberous Sclerosis Complex)/T. Aung
2.110 Use Of Nicotine Patch For
Drug-Resistant ADNFLE In Children:
A Case Study/C. Gonsalves, K. Lee,
J. Seo, B. Pullum, J. L. Norman
2.111 Surgical Treatment Of
Recurrent Super-Refractory Status
Epilepticus: A Case Report/U. Uysal,
M. Mittal, N. Hammond
2.112 Eye Closure Sensitivity In An
Adult With Suspected Temporal Lobe
Epilepsy/B. Chapman, J. Vidaurre
2.113 Ischemic Epilepsia Partialis
Continua And Age Of Onset: A Tale Of
Two Patients And Review Of The
Literature/T. Gholipour, M. Ng
2.114 Baclofen Induced NonConvulsive Status Epilepticus/
R. C. Martinez, W. Richeh, E. Mader
2.115 Bizarre Visual Hallucinations In
A Child With PRES Syndrome/
P. Maertens, M. Bramhall, M. Cobia
2.116 Child Youth Epilepsy (CYE)
TeleECHO – Innovative Tele-Mentoring
Clinic For Child & Youth Epilepsy
Care/M. Yamada
2.117 Small Temporal Encephaloceles:
An Under-Recognized Cause Of “NonLesional” Temporal Lobe Epilepsy/
R. Azzam, P. Singh, A. Arain,
V. Morgan, J. Neimat, B. Abou-Khalil
2.118 The Ictal Guardian Angel: A
Case Report Of An Ictal Spiritual
Visual Hallucination/M. A. Kellogg,
V. S. Wong
2.119 Hemimegalencephaly In
Tuberous Sclerosis Complex: Is
Surgery The Only Treatment?/
P. B. Cerqueira, E. V. Caetano,
M. G. Manreza, U. C. Reed,
L. B. Sampaio, E. C. Miotto,
F. A. Costa, P. S. Mendes, B. J. Correa
2.120 Asynchronous Leg Jerking
With Normal Sensorium As A
Presentation Of Frontal Lobe
Seizures/L. Vargas, N. Dalvi,
S. Karkare
2.121 Case Report Of A 24-Year-Old
Patient Suffering From Seizures With
G13513A Mutation In The ND5 Gene
Of Mitochondrial DNA/M. Prieschl,
W. Nachbauer, P. Lackner,
B. Matosevic, I. Unterberger,
U. Athing, G. Luef, B. Frauscher
2.122 Are Interictal Epileptiform
Discharges Always Subclinical? A
Study Of Cognitive Function During
Interictal Epileptiform Discharges/
A. Serafini, M. Gubernale, M. Da Rold,
S. Negrin, P. Bonanni
2.123 WITHDRAWN
2.124 A Case Of Neonatal Epilepsy
With KCNQ2 And SCN1A Mutations/
F. Baumer, L. Rodan, J. Heath,
D. Harris, J. Soul
2.125 Sudden Onset Alexia Without
Agraphia Caused By A Reversible
Splenial Lesion (RSL); Two Cases Of
RSL In Non Epileptic Patients On
Lamotrigine And Topomax/R. K. Gupta,
P. Sofat, P. Li, T. Guttuso, R. Sawer, Jr.
2.126 Lesion Negative Anterior
Cingulate Epilepsy/N. Lacuey
Lecumberri, J. Chapa Davila,
M. Pelayo, S. Amina, J. Turnbull,
J. Miller, H. Luders, S. Lhatoo
SUNDAY
2.084 Effects Of Epilepsy In ADHD
And Quality Of Life/M. Salam,
K. Works
2.085 A Mobile Health-Intensive
Comprehensive Care Delivery Model
For Amplifying Outreach For
Refractory Epilepsy And Comorbid
Mood Disorders/M. A. Rossi,
N. Monica, K. Babiarz, L. Cendejas,
R. Hanson, M. Tshionyi, J. Endres,
M. Jain
2.086 Attitude Of Neurologists In
The United Arab Emirates Towards
Epilepsy And Motor Vehicle
Accidents/A. Shatila, O. Khaddam,
N. O. Al Matrooshi, T. Alsaadi
2.087 Trends In Healthcare Charges
And Length Of Stay For People With
Epilepsy, South Carolina, 20002011/D. A. Wilson, A. Selassie
2.088 Engaging Primary Care
Providers In Epilepsy Quality
Measures/S. T. Arnold, R. R. Said,
D. Sirsi, E. A. Burch
2.089 BE- Beyond Epilepsy,
Education, Awareness And Advocacy
Program For Frontline Healthcare
Providers In Tanzania/L. Jurasek,
S. Mbelwa
2.090 Premature Mortality In Poor
Health And Low Income Adults With
Epilepsy/K. Kaiboriboon, N. Schiltz,
P. Bakaki, S. Lhatoo, S. Koroukian
2.091 What Affects The Self-Stigma
And Self-Esteem Of Persons With
Epilepsy?/A. Tabata, K. Hara, S.
Tohma, S. Tanaka, M. Hara, K. Ohta,
M. Matsuura, M. Inaji, T. Maehara,
Y. Sumi
2.092 Do Drivers With Epilepsy Have
Higher Rates Of Motor Vehicle
Accidents Than Those Without
Epilepsy?/P. Naik, M. Fleming,
P. Bhatia, C. Harden
2.093 The Effects Of Reports Of Car
Accidents Caused By Persons With
Epilepsy On Its Stigma In Japan/
K. Hara, S. Tanaka, Y. Hirose,
S. Tohma, M. Matsuura, K. Ohta,
M. Inaji, M. Hara, T. Maehara, Y. Sumi
Poster Session 2
53
Sunday December 7, 2014
2.127 Refractory Focal-Onset
Seizures As A Consequence Of
Cerebral Amyloid Angiopathy-Related
Inflammation: A Case Study/
B. Appavu, H. Seif Eddeine
2.128 Desmoplastic Infantile
Ganglioglioma Presenting With
Neonatal Status Epilepticus/E. Ng,
S. Karkare, M. Laureta, J. Maytal,
S. Schneider
2.129 Seizure After Laminectomy
Associated With Pneumocephalus/
N. Cinar, M. Cakmak, S. Sahin,
B. Kelten, S. Karsidag
2.130 Insight Into The Precuneus: A
Novel Seizure Semiology In A Child
With Epilepsy Arising From The Mesial
Parietal Region/J. A. Mailo
Professionals in Epilepsy Care
Nursing
2.131 Quality Assurance In The
Epilepsy Monitoring Unit: Time To
Seizure Recognition And
Intervention/D. Nelson, D. Briggs,
J. Shen, K. Lovell, E. Harrell,
E. Wedberg, P. Modur
2.132 Seizure-Related Falls In The
Epilepsy Monitoring Unit/E. Yagiri,
H. Arai, H. Suzuki, K. Jin, M. Fujikawa,
K. Kato, Y. Kakisaka, M. Iwasaki,
K. Yamauchi, N. Nakasato
2.133 Role Of A Nurse Program
Coordinator: Comprehensive Epilepsy
Clinic/M. Gustafson, K. Gugler
2.134 To Coordinate Or Not To
Coordinate?/K. Orton, G. R. Nelson,
C. Van Orman
2.135 Improving Quality Of Care
Following EMU Discharge/R. Mealey,
J. Pollard, K. Davis, C. Kohler,
R. Shmuts, S. Chen, B. Oommen,
C. Hill
2.136 Creating A Standard Of Care
For Epilepsy Patients: Starting with
Nursing Staff in the Adult Epilepsy
Monitoring Unit/R. Ward-Mitchell,
M. Bensalem-Owen, G. Plank,
R. Woodward
2.137 Epilepsy Nurse Led Vagus
Nerve Stimulator Program:
Comprehensive Epilepsy Center/
K. J. Gugler, M. Gustafson
Psychosocial
2.138 Perception Of Happiness In
Adults With Epilepsy/J. Cohen,
D. F. Tovar Quiroga
2.139 Driving Safety In People With
Non-Epileptic Events/K. S. Ziemba,
J. F. Drazkowski
Education
2.140 A Case Report - Importance
Of Early Treatment In Anti-NMDA
Receptor Encephalitis/T. Aung
2.141 What’s In A Year? EEGs
Encountered In An ACGME-Accredited
Clinical Neurophysiology Fellowship/
E. C. Lewis
2.142 SUDEP Experience And
Practice In A Large Group Of Child
Neurologists/J. Reese, Jr,
D. Friedman, W. Gaillard
54
Poster Session 2
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.143 A Single Center Survery Of
Pediatric Neurologists’ Views On
Epilepsy Surgery And Medically
Refractory Epilepsy/J. Bolton,
G. Dabscheck
Neurophysiology
Video EEG Epilepsy-Monitoring
2.144 Spread Of The Ictal Discharge
From Hippocampus And Cortex To
Scalp EEG Electrodes In Temporal
Lobe Epilepsy/D. G. Vossler, A. J. Bell,
D. L. Kraemer
2.145 WITHDRAWN
2.146 The Prognostic Value Of Early
EEG Background During Hypothermia
On MRI And Neurodevelopmental
Outcome In Neonates With HypoxicIschemic Encephalopathy/M. Balestri,
M. Lispi, S. Pro, D. Longo,
F. Vigevano, M. Cilio
2.147 Microseizures Recorded With
Clinical EEG Acquisition System/
L. Higdon, G. Ghearing,
M. Richardson, C. Plummer
2.148 Prevalence Of Ictal Infraslow
Potentials (IISPs) In Scalp EEG/
N. Dorland, J. Lavingia, C. Carlson,
M. Raghavan
2.149 Right Temporal Lobe Seizure
Frequently Induces Precipitous Heart
Rate Increase/K. Kato, K. Jin,
Y. Kakisaka, M. Iwasaki, M. Fujikawa,
M. Aoki, N. Nakasato
2.150 Intracranial Ictal EEG Patterns
And Seizure Onset Zone: A
Systematic Review/S. SINGH,
S. Sandy, Y. Aghakhani, N. Pillay,
S. Wiebe
2.151 Evidence For A Multi-Night
Improving Trend In Sleep During
Intracranial EEG Monitoring/R. Joshi,
N. Gaspard, I. Goncharova,
M. Pavlova, R. Duckrow, J. Gerrard,
D. Spencer, L. Hirsch, H. Zaveri
2.152 Interictal Epileptiform
Discharges Before And After A
Generalized Tonic Clonic Seizure In A
Patient With Generalized Epilepsy –
Case Report/D. Sabau, D. W. Harvey,
M. Mehrizi
2.153 Semiological Characterization
And Clinical Profile Of Patients With
Psychogenic Non-Epileptic Seizures/
S. Cieza, P. Amaro, I. Marcotegui,
C. Viteri Torres, M. Alegre, J. Iriarte,
E. Urrestarazu
2.154 Cardiac Sympathetic Nerve
Activity Is Abnormally Suppressed
During Wakefulness In Patients With
Epilepsy/N. Suzuki, K. Jin, K. Kato,
Y. Kakisaka, M. Iwasaki, N. Nakasato
2.155 Texting in Epilepsy: Activation
or Distraction?/B. DiCaccio,
K. H. Yelvington, W. Tatum
ICU EEG
2.156 High Frequency Oscillations
Are Associated With Cognitive
Processing In Human Recognition
Memory/M. T. Kucewicz, J. Cimbalnik,
J. Matsumoto, B. Brinkmann,
M. Bower, V. Vasoli, V. Sulc, F. Meyer,
R. Marsh, M. Stead, G. Worrell
2.157 Misleading EEG Lateralization
Associated With Midline Shift/
S. Abramovici, G. Ghearing
2.158 The Adequacy Of Density
Spectral Array (DSA) And AmplitudeIntegrated EEG (aEEG) For Neonatal
And Pediatric Seizure Identification/
H. Yamamoto, J. Natsume,
H. Kidokoro
2.159 The Application Of Conventional
EEG For Early Prognosis In Infants
Born With Hypoxic Ischemic
Encephalopathy Undergoing
Hypothermia/R. Obeid, M. Naik,
M. Painter, R. Telesco, Y. Sogawa,
S. Gedela, V. Lee, J. Wisnowski,
A. Panigrahy
2.160 Inter-Rater Agreement For
Identification Of Electrographic
Seizures And Periodic Discharges In
Critically Ill Patients/D. Shiau,
J. A. Desrochers, J. J. Halford,
B. J. Kolls, G. U. Martz, S. R. Sinha,
K. F. Haas, E. E. Kutluay, N. J. Azar,
R. T. Kern, K. M. Kelly,
J. C. Sackellares, S. M. LaRoche
2.161 EEG Predictors Of
Antiepileptic Drug Adjustments In
Critically Ill Patients – A Prospective
Observational Study/G. Wang,
A. M. Khawaja, G. Cutter,
J. Szaflarski
2.162 Skin Breakdown In Patients
Undergoing EEG Monitoring In The
NICU/S. Manganaro, E. Cruz,
M. Andriola, A. Slansky, L. Manganas
2.163 EEG Predictors Of Outcomes
In Critically Ill Patients – A
Prospective Observational Study/
A. M. Khawaja, G. Wang, G. Cutter,
J. P. Szaflarski
Clinical Epilepsy
Classification and Syndromes
2.164 Clinical Characteristics Of
Benign Convulsions With Mild
Gastroenteritis/H. Kim, S. Kim,
Y. Kim, J. Kim, W. Kim
2.165 Ictal And Postictal Aphasia Are
Most Common In Temporal Lobe
Epilepsy/A. M. Loesch, H. Steger,
C. Losher, C. Vollmar, J. Remi,
E. Hartl, S. Noachtar
2.166 Comparing EMU Staffing
Models For Spell Classification
Admissions/S. D. Spritzer,
B. D. Pirotte, S. Agostini, K. Noe,
J. Drazkowski
2.167 Seizure Semiology In Pediatric
Posttraumatic Epilepsy/J. T. Park,
H. T. Chugani
2.168 Incidence And Seizure
Characteristics In Autoimmune
Epilepsy Patients/J. Byun, J. Sunwoo,
J. Moon, J. Shin, K. Jung, S. Lee,
K. Jung, S. Lee, K. Chu, J. Jun
2.169 Familial Ring Chromosome 20
Syndrome – A Case Report/
I. Unterberger, H. Schober, D. Kotzot,
C. Fauth
Sunday December 7, 2014
Clinical Diagnosis
2.177 Impact Of Specialty Epilepsy
Consultation On Management And
Outcomes Among Veterans/
A. Panduranga, E. Boudreau,
M. Salinsky
2.178 Radiological And Pathological
Discordance Of Mesial Temporal Lobe
Sclerosis In Pediatric Temporal
Lobectomy/J. Kassiri, D. Sinclair,
M. Wheatley
2.179 Left Temporal Lobe Epilepsy
Presenting As Apparent LifeThreatening Events In Infants/
J. Kassiri, R. Tang-Wai
2.180 Longer Seizure Duration
Terminates A Seizure Cluster During
Epilepsy Monitoring/V. Ferastraoaru,
S. R. Haut, R. B. Lipton,
A. D. Legatt, J. Blumberg,
M. Dumpelmann, A. Schulze-Bonhage
2.181 Initial Involvement Of The
Posterior Orbital Gyrus In Prolonged
Panic Attack Associated With Simple
Partial Status Epilepticus On Depth
Electrodes/J. M. Chung, C. M. Reed,
U. Rutishauser, A. N. Mamelak
2.182 Seizure Types And
Electrographic Patterns Of Angelman
Syndrome In South Indian Children/
V. Puthenveettil, A. G. Roy,
S. Nampoothiri
2.183 Epileptic Pain As A Rare
Symptom Of Seizures/N. Pazarci,
N. Bebek, B. BAYKAN, C. Gurses,
A. Gokyigit
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.184 Bitemporal Epilepsy: AnatomoElectro-Clinical Features And
Comparison With Unitemporal
Epilepsy/G. Didato, V. Chiesa, F. Villani,
V. Pelliccia, F. Deleo, F. Gozzo,
M. Canevini, R. Mai, R. Spreafico,
M. Cossu, L. Tassi
2.185 Predictors For Seizure
Recurrence In 228 Developmentally
And Neurologically Normal Children
With A Newly Diagnosed, Unprovoked
Seizure/H. Kim, A. Oh, X. de Grauw,
A. de Grauw
2.186 Drug-Resistant Epilepsy With
Neurocysticercosis And Mesial
Temporal Lobe Sclerosis/
L. M. Espaillat Solano,
A. Martinez-Perez, M. Leon-Vazquez,
J. Perez-Ruiz, R. Carrillo,
M. Alonso-Vanegas, A. Fleury,
I. E. Martinez-Juarez
2.187 TOSCA – Tuberous Sclerosis
Registry To Increase Disease
Awareness: First Interim Data On
Epilepsy/R. Nabbout, C. Hertzberg,
P. Curatolo, P. de Vries, M. Feucht,
E. Belousova, M. Dahlin, J. Ferreira,
J. lawson, A. Macaya, F. O’ Callaghan,
M. Benedik, V. Sander, S. Youroukos,
A. Jansen, S. Jozwiak
2.188 Concordance Between History
And Epilepsy Monitoring Unit
Evaluation For Diagnosing Seizures/
K. Siddiqui, E. Khalid, R. S. Siddiqui,
S. Sinha
2.189 Autoimmune Epilepsy: Clinical
Features, Management And
Outcomes/D. Dubey, R. Hays,
P. Gupta, K. Ding, M. Agostini,
P. Van Ness, S. Vernino
2.190 Electroclinical Correlation Of
Typical Absence In Idiopathic
Generalized Epilepsies (IGE)/
W. S. Sanchez Barrera
2.191 Is Treatment-Resistant Focal
Epilepsy Less Frequent In
Veterans?/M. Lopez, A. Kanner
2.192 New Onset Temporal Lobe
Epilepsy And REM Sleep Behavior
Disorder: Further Demonstration Of A
Possible Association?/M. Junna,
E. St. Louis, E. Duwell
2.193 Rhythmic ictal Nonclonic
Extremity Movements In Temporal
Lobe Epilepsy: A Reappraisal/K. Ding,
M. Agostini, P. Gupta, R. Hays,
P. Van Ness, P. Modur
2.194 Predictors Of Postneonatal
Epilepsy And Sensitivity Of The First
Hour Of EEG Monitoring In Predicting
Risk Of Seizures In The Neonatal
Period/A. J. Hani, K. Cornett,
B. Smith, W. Gallentine
2.195 Improving Long-Term
Management Of Epilepsy Using
Wearable Multi-Modal Seizure
Detection System/S. Sabesan,
K. Rose, G. Carlson, A. Mueller,
R. Sankar, J. Wheless
2.196 Ambulatory EEG In Children:
When Is It Most Helpful?/S. Adhami,
K. Singh, C. Harini
2.197 Siblings with Juvenile
Huntington’s Disease having two
different Seizure Types: A Case
report/C. Srikanth Mysore,
D. Madhavan, D. Mudugal, T. Jasinski
Clinical Treatments
2.198 Surgical Outcomes Of Patients
With Focal Epilepsy Evaluated By
Intracranial EEG Monitoring/S. Sandy,
S. Singh, Y. Agha-Khani, N. Pillay,
S. Wiebe
2.199 Efficacy And Tolerability Of
Intravenous Lacosamide In Daily
Practice – Results Of A Large
Independent Registry/N. Lang,
U. Stephani
2.200 Successful Treatment Of
Febrile Illness-Related Epilepsy
Syndrome (FIRES) And New Onset
Refractory Status Epilepticus
(NORSE) With Plasma Exchange And
Rituximab/J. Berkeley, P. Foreman,
A. Foroughi, F. Tirol
2.201 Efficacy And Safety Of
Intravenous Lacosamide In Pediatric
Status Epilepticus/K. Poddar,
R. Sharma, Y. Ng
2.202 Application Of A EEG To Severe
Motor And Intellectual Disability
(SMID) – Utility In Control Of
Seizures/T. Nagasawa, Y. Okoshi,
S. Atsumi, N. Tanuma, M. Fukumizu,
K. Tominaga
2.203 Acetazolamide For Spike-Wave
Index Reduction In Electrical Status
Epilepticus In Slow Wave Sleep/
A. Fine, E. Wirrell, L. Wong-Kisiel,
K. Nickels
2.204 A Double-Blinded, Randomized
Evaluation Of Neuropsychological And
Behavioral Changes In Children With
Benign Epilepsy With Centrotemporal
Spikes Treated Either With
Levetiracetam Or Sulthiame/
I. Borggraefe, M. Bonfert, L. Gerstl,
F. Heinen, B. Neubauer
2.205 Efficacy And Tolerability Of
Modified Atkins Diet (MAD) And Low
Glycemic Index Diet (LGID) Among
Adults With Medically Intractable
Epilepsy/A. Balabanov, K. Roehl
2.206 Glioma Associated Epilepsy/
M. Fiol, M. Qureshi, M. Hunt, A. Malik
2.207 Epilepsy And Bicycle:
Observation In The Epilepsy
Monitoring Unit/J. Kim, K. Hwang,
E. Joo, S. Hong, D. Seo
2.208 Outcomes Of Vagal Nerve
Stimulation (VNS) For Intractable
Epilepsy/V. S. Wasade,
K. Mohanarangan, A. Gaddam,
L. Schultz, J. Schwalb, M. Spanaki
2.209 Responsive Neurostimulation
In Patients With Periventricular
Nodular Heterotopia (PNH)/P. Rutecki,
A. Herekar, P. Van Ness, G. Bergey,
C. Bazil, D. King-Stephens, F. Sun,
R. Kapur, M. Morrell
2.210 High Dose Oral Steroids For
Treatment Of Infantile Spasms: The
Wake Forest Baptist Medical Center
(WFBMC) Experience/I. Khaytin,
M. Silvia, G. Popli, A. Grefe, C. Lee
SUNDAY
2.170 SUDEP Awareness Among
Pediatric Practitioners: A Descriptive
Survey of United States Physicians/
S. Massey, D. Friedman, N. Berberi,
O. Devinsky, S. Kothare
2.171 Epilepsy Syndrome, MRI
Pathologies and Treatment Response
In Patients With First Seizure And
New-Onset Epilepsy – A Comparison
Of Patients Of Middle Age (50-60
Years) Versus Elderly Patients
(> Older 60 Years)/B. Pohlmann-Eden,
C. Crocker, K. Legg, M. Schmidt
2.172 Semiology Of Hypermotor
Seizures/K. Alqadi, R. R. Sankaraneni,
U. Thome Costa, P. Kotagal
2.173 Participant Eligibility In The
Human Epilepsy Project/S. Cristofaro,
C. Freyer, V. Mays, O. HEP
Investigators
2.174 Not All But The Most Patients
With CSWS Are Atypical Benign
Partial Epilepsy In Childhood/
H. Shiraishi, K. Egawa, K. Otsuka,
M. Nakajima, T. Ito, M. Narugami,
S. Nakane, K. Takahashi
2.175 Patterns Of Disease
Progression In Epilepsy/D. Ekstein,
M. Nassar, T. Ben Hur, R. Bar Yossef,
M. Benifla, O. Bennett
2.176 Delay To Initiation Of
Treatment: Data From The Human
Epilepsy Project/R. Hennessy,
M. Mendoza, J. French, S. Haut,
J. Hixson, K. Detyniecki, O. HEP
Investigators
Poster Session 2
55
Sunday December 7, 2014
2.211 Evaluation Of Clobazam
Conversion Therapy Replacing
Clonazepam In Patients With Medically
Refractory Epilepsy/S. Marsh,
S. S. Chung
2.212 Responsive Stimulation Of
Eloquent Cortex/R. Kapur, R. Duckrow,
C. Heck, S. Eisenschenk, R. Gwinn,
E. Geller, M. Smith, A. M. Murro,
G. Worrell, R. Wharen, V. Salanova,
G. L. Barkley, R. Gross, B. Jobst,
C. Bazil, D. Nair, D. King-Stevens,
E. Mizrahi, T. Crowder Skarpaas,
M. Morrell
Prognosis
2.213 Electrodermal Activity During
Complex Partial Seizures Is
Dependent Of Age And MRI Lesions/
S. Thome-Souza, J. Klehm, R. Sarkis,
K. kapur, E. Nagarajan, R. Picard,
M. Jackson, C. Doshi, C. Papadelis,
B. Dworetzky, C. Reinsberger,
T. Loddenkemper
2.214 Predictive Risk Factors Of
Seizure-Related Injury And Postictal
Behavioral Changes/C. Maideniuc,
A. Stino, M. Basha
2.215 Outcomes Of Genetic
Generalized Epilepsy At A
Comprehensive Epilepsy Center/
S. Maturu, T. Dayyoub, B. Assaad,
L. Schultz, V. S. Wasade, E. Muma,
T. Howard, J. Snyder, S. Gaddam,
N. Mahmood, J. Constantinou,
G. L. Barkley, M. Spanaki, A. Zillgitt
2.216 Latency To Treatment Of
Status Epilepticus: Long-Term
Outcomes/J. Cheng
2.217 Prognosis Of Idiopathic
Generalized Epilepsy Patients Who
Had At Least 10 Years Follow Up And
Predictors Of At Least 5 Years
Seizure Remission Off Medication/
H. Hosny
2.218 Relationship Between
Biomarkers Of Vascular And Metabolic
Health And Cognition In Aging Persons
With Chronic Epilepsy/B. Hermann,
M. Sager, R. Koscik
2.219 WITHDRAWN
2.220 Comparison Between Febrile
And Afebrile Convulsion With Mild
Gastroenteritis/S. Kim, I. Lee, T. Eom
2.221 Prediction of Future Epilepsy in
Neonates Who Received Selective
Head Cooling for HIE/T. McDonough,
J. Paolicchi, L. A. Heier, N. Das,
M. Engel, J. M. Perlman, Z. Grinspan
2.222 Treatment Resistance
Correlates With ECG Abnormalities In
A Pilot Clinical Surveillance Of Epilepsy
Patients/P. Zohrevand, M. Diaz,
A. Amador, A. Goldman
2.223 Detrimental Impact Of
Convulsive Status Epilepticus On
Health-Related Quality Of Life
Apparent At 24 Months after
Epilepsy Diagnosis In Children: A
Longitudinal Population-Based
Study/M. Ferro, S. Levin, S. Wiebe,
R. Chin, C. Camfield, K. Speechley
56
Poster Session 2
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.224 How Different Are Patients
With Bilateral Hippocampal Sclerosis
From The Unilateral Ones?/
E. Vanli- Yavuz, B. Baykan, S. Sencer,
Z. Matur, N. Bebek, A. Gokyigit,
O. Oktem, C. Gurses
2.225 N20 Of Median Nerve SSEP Is
An Early Predictor For Developmental
Outcome After Hemispherotomy In
Patients With Ohtahara Syndrome
With Hemimegalencephaly/K. Sugai,
R. Honda, T. Saito, E. Nakagawa,
H. Komaki, M. Sasaki, A. Takahashi,
T. Kaido, Y. Kaneko, T. Otsuki
2.226 Risk Factors Of Postictal
Generalized Electroencephalographic
Suppression In Generalized Convulsive
Seizures/V. Alexandre, B. Mercedes,
L. Valton, L. Maillard, J. Petit,
A. Biraben, F. Chassoux, P. Kahane,
B. De Toffol, F. Bartolomei, P.
Derambure, V. Navarro, E. Hirsch,
A. Crespel, C. Marchal, P. Thomas,
P. Ryvlin, S. Rheims
2.227 Initial EEG Patterns As An
Adjunctive Prognostic Indicator In
Cardiac Arrest Patients Undergoing
Therapeutic Hypothermia/
E. Tsimerinov, D. Maher, H. Tran,
M. Nuno, D. Eliashiv, D. Palestrant,
A. Moheet, W. Yu, J. Chung
Women’s Issues
2.228 Improving The Prescription Of
Folic Acid To Women Taking
Antiepileptic Drugs/A. Sharma,
J. Cavitt, M. Privitera, B. D. Moseley
2.229 A Transdisciplinary Professional
Clinic For Pregnant Adolescents And
Young Adults With Epilepsy In A
Midwest Children’s Hospital/M. Turner,
L. Garrity, K. Junger, S. Standridge
2.230 Epilepsy And Reproductive
Issues In Women With Epilepsy:
Survey Of An Unselected Community
Of Women With Epilepsy/
O. Laban-Grant, E. Fertig, M. Malik,
C. B. de la Pena, M. Fleming,
M. E. Lancman, P. Klein, M. Lancman
2.231 Occurrence Of Obstetric
Complications In Women With Epilepsy
Results From The Oppland Perinatal
Database In Norway/A. Farmen,
T. Tomson, K. Nakken, M. Lossius
2.232 Quality Of Life In Women With
Epilepsy In Pregnancy: Experience At
A Tertiary Care Centre/J. Qiang, E. Bui
2.233 Menstrual Cycle Length In
Women With Epilepsy Trying To
Conceive Compared To Healthy
Controls/C. Harden, C. Lau, P. Pennell,
E. Bagliella, J. Huynh, R. Kashambwa,
N. Llewellyn, B. Kaufman, A. Davis,
J. French
2.234 Seizure Control, Acceptability,
And Drug Interactions During Use Of
The Levonorgestrel Intrauterine
System In Women With Epilepsy/
A. Davis, A. Pack, H. Saadatmand
Neuroimaging
Functional Imaging
2.235 MSI/MEG And DTI Tractography
In Tuberous Sclerosis Complex/
W. Zhang, D. Dickens, J. Doescher,
T. Passe, F. Ritter, M. Dunn, M. Frost
2.236 Individual-Subject Frontolimbic
Neurocircuit Activations During
Emotional Processing And Behavioral
Inhibition In Psychogenic Non-Epileptic
Seizures/D. L. Perez, B. A. Dworetzky,
H. Pan, G. Baslet, D. R. Vago, L. Leung,
J. Epstein, D. A. Silbersweig, E. Stern
2.237 The Temporal Instability Of The
Ventral Default Mode Network
Connectivity In Intractable Epilepsy/
L. Robinson, P. Barnett, G. Doucet,
D. Pustina, A. Ghani, J. Tracy
2.238 In Vivo Optical Signal Changes
Observed With Optical Coherence
Tomography In A Focal Cortical
Seizure Model/J. Szu, M. Eberle,
C. Rodriguez, M. Hsu, B. Park,
D. Binder
2.239 Simultaneous EEG-NIRS (Near
InfraRed Spectroscopy) Guided By
MEEG And EEG-fMRI To Assess The
Neurovascular Coupling In Focal
Epilepsy: A New, Non-Invasive,
Multimodal Approach/G. Pellegrino,
A. Machado, S. Watanabe, N. Drouin,
L. Allard, J. Lina, J. Hall,
E. Kobayashi, C. Grova
2.240 Computer-Automated Focus
Lateralization Of Temporal Lobe
Epilepsy Using fMRI/S. Chiang,
H. Levin, Z. Haneef
2.241 Moving Towards New
Techniques In The Evaluation Of The
Ictal Onset Zone: Ratio Ictal SPECT
(RISCOM) Using A 72-Detector
Focused Collimator Ring SPECT
Scanner System/M. Jain, K. Krug,
P. Balaguera, C. M. Millan, A. Jalota,
V. Pylypyuk, R. W. Byrne, M. A. Rossi
2.242 Frequency Dependent Evolution
Of Functional Networks Over Years Of
Duration In Temporal Lobe Epilepsy/
V. L. Morgan, B. Abou-Khalil,
B. P. Rogers
2.243 Classification Of Individuals
With Temporal Lobe Epilepsy Using
Network Analysis Of Resting-State
Functional MRI/D. Vaughan,
M. Pedersen, C. Tailby, G. Jackson
2.244 Components Of Epileptic
Networks Show Pathological Coherent
Fluctuations Even In The Absence Of
Scalp Spikes/F. Pittau, G. Iannotti,
E. Abela, F. Grouiller, M. Seeck,
C. Michel, S. Vulliemoz
2.245 Nonverbal Memory In Patients
With Mesial Temporal Lobe Epilepsy
And Amygdala Lesions/G. Kuchukhidze,
L. Zamarian, E. Schmid,
F. Koppelstaetter, C. Siedentopf,
M. Delazer, H. Jokeit, E. Gizewski,
G. Luef, I. Unterberger, E. Trinka
2.246 Inter-Hemispheric
Asymmetries In Resting-State fMRI
Activity For Identifying Seizure Onset
And Irritative Zones/D. Groppe,
P. Mégevand, Z. Fallil, S. Hwang,
J. Hira, A. Abisogun, C. Yan,
R. C. Craddock, M. Milham, S. Bickel,
C. Harden, A. Mehta
Sunday December 7, 2014
2.247 Brain Graph Theory Topology
Changes Associated With
Antiepileptic Drug Use/Z. Haneef,
H. Levin, S. Chiang
2.248 Real-Time Functional Mapping
(RTFM) Of Language Function In
Patients With Intractable Epilepsy/
B. Edmonds, M. Korostenskaja,
P. Chen, A. Schaal, C. M. Salinas,
M. Westerveld, E. Castillo, G. Schalk,
P. Brunner, J. Baumgartner, K. Lee
2.249 Comparing Four Connectivity
Measures: From Simultaneous Direct
Intracranial Stimulation And fMRI,
EEG, DWI, And rs-fMRI/S. E. Jones,
A. Alexopoulos, J. Bulacio,
J. Gonzalez-Martinez, J. Mosher,
D. Nair, I. Najm, M. Zhang
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
Cormorbidity (Somatic and
Psychiatric)
Medical Conditions
2.257 Mortality In Elderly Veterans
With New And Chronic Epilepsy/
P. J. Foreman, A. VanCott, M. Pugh
2.258 Post Ictal Headache Phenotype
In Epileptic Seizures And NonEpileptic Spells/S. Kapoor,
A. Swaminathan
2.259 Diagnosis Of Pnes In
Childhood: Is It Possible To Suspect Of
Non Epileptic Seizures In The First
Standard Neurological Interview For
Epilepsy?/R. Alessi, P. Rzezak,
S. Vincentiis, K. Valente
2.260 Delay In Diagnosis Of
Psychogenic Non-Epileptic Seizures In
Children And Adolescents: Age
Matters/K. Valente, R. Alessi,
S. Vincentiis
2.261 Post Ictal Cardiac Asystole In
A Series Of Pediatric Cases With
Epilepsy Refractory To Medical
Treatment/E. Andrade, Z. Liu
2.262 Sleep Disorders And Circadian
Rhythm In Epilepsy Revisited: A
Prospective Controlled Study/G. Luef,
B. Frauscher, D. Gabelia, M. Prieschl,
K. Chea, M. Hofer, B. Hoegl,
I. Unterberger
Psychiatric Conditions
2.263 ADHD In Childhood Epilepsy:
Clinical Determinants Of Severity And
Of Response To Methylphenidate/
S. Rheims, V. Herbillon, M. Milh,
S. Auvin, S. Napuri, C. Cances,
P. Berquin, P. Castelnau, S. N. Guyen,
The Tich, F. Villega, H. Isnard,
R. Nabbout, B. Kassai,
A. Arzimanoglou
2.264 Recognition Of Mood And
Anxiety Disorders In Patients With
Epilepsy By General Neurologists: A
Comedy Of Contradictions/R. Ribot,
A. Kanner
2.265 Does Screening For Major
Depressive Episodes And Generalized
Anxiety Disorder By Epileptologists
Translate In Their Remission?/
A. Kanner, J. Kozupsky
2.266 Comorbidity Between Epilepsy
And Psychiatric Disorders – A
Population-Based Study/
J. Christensen, C. Petersen,
M. Vestergaard
2.267 Stigma Is Uncommonly
Reported By Adolescents With
Epilepsy/J. Langer, M. Thompson,
D. Taplinger
2.268 Autism Spectrum Disorder
And Neurocognitive Comorbidities In
Patients With Epilepsy And ESES/
M. El-Hagrassy, R. C. Gunasekara,
K. Mehrotra, C. Mohan, D. Francois,
L. Probst, Y. Eksioglu
2.269 Health Care Utilization
Following Diagnosis Of Psychogenic
Seizures In U.S. Veterans/M. Salinsky,
C. Evrard, D. Storzbach, E. Goy,
E. Boudreau
2.270 Sleep Problems, Risk Factors,
And Clinical Implications Among
Children At A Tertiary Care Epilepsy
Center/K. Fehr, E. Adams, K. Berg,
M. Frost
2.271 Depression Screening In Youth
With Epilepsy: The NDDI-E-Y/
J. Wagner, G. Smith, B. Brooks,
M. Mueller
2.272 Subjective Forgetfullness In
People With Epilepsy/I. Elmenshawi,
M. A. Mohamed, A. Zaher
2.273 Psychiatric Assessment Of
Psychogenic Nonepileptic Seizures:
A Comparison Of Approaches/
X. F. Jimenez, J. Bautista
2.274 Psychosis In Temporal Lobe
Epilepsy With Hippocampal Sclerosis:
Corroborating The Relevance of
Laterality/
K. Rodrigues Ximenes Goldberg,
S. de Vincentiis, S. E. de Melo-Souza,
F. J. Arruda, P. C. Ragazzo,
H. van der Linden Jr.,
K. Dualibi Ramos Valente
2.275 Predictors Of Major
Depression In Multiplex Epilepsy
Families/S. T. Sorge, J. O. Okeke,
V. Tangel, S. Shostak, J. C. Phelan,
J. Goldsmith, M. Winawer,
D. Hesdorffer, W. K. Chung,
R. Ottman
Antiepileptic Drugs
SUNDAY
Other Emerging Techniques
2.250 Impact Of coregistered
Multimodal Neuroimaging On Pediatric
Epilepsy Surgery Planning And
Postoperative Outcome/D. Freedman,
L. Bailey, A. Hernandez, S. Malik,
C. Keator, D. Donahue, M. Perry
2.251 White Matter Compromise
Modulates Verbal Fluency
Performance In Patients With Atypical
Language Dominance/N. Kemmotsu,
K. Leyden, N. Kucukboyaci,
V. Iragui-Madoz, E. Tecoma,
C. McDonald
2.252 Detection Of The Dominant
Brain Network In Bitemporal Lobe
Epilepsy With MEG/S. Bowyer,
A. Zillgitt, M. Spanaki, K. Mason,
V. S. Wasade
2.253 Clinical Validity Of MEG-Guided
Tractography (MEG-GT) To
Characterize Networks Supporting
Word Comprehension/E. Castillo,
T. Kleineschay, C. M. Salinas,
M. Korostenskaja, P. Chen,
J. Baumgartner, J. Seo, K. Lee
2.254 Regional Cerebral
Hypoperfusion From Arterial Spin
Labeling Correlates With EEG
Lateralization In Patients With
Epilepsy/H. Kadiwala, A. Verma,
S. H. Fung
2.255 Predicting Post-Surgical
Language Outcome With ECoG-Based
Real-Time Functional Mapping
(RTFM)/M. Korostenskaja, P. Chen,
C. M. Salinas, M. Westerveld, J. Seo,
E. Castillo, A. Schaal, B. Edmonds,
G. Schalk, P. Brunner, M. Elsayed,
J. Baumgartner, K. Lee
2.256 Stereotactic Laser Ablation:
How Much Hippocampus And
Amygdala Ablation Volume Optimizes
Seizure Freedom?/A. Sharan, C. Wu,
M. Sperling, R. Gross, J. Willie,
D. Labiner, M. Weinand, R. Marsh,
G. Worrell, G. Cascino, G. Popli,
D. Couture, J. J. Shih, W. Tatum,
A. Mehta, C. Harden, R. Patwardhan,
B. Fernald, A. Shetty, A. Gowda
Poster Session 2
Clinical Trials
2.276 Review Of Suicidality Events In
Perampanel Clinical Studies/
A. B. Ettinger, C. Dobrinsky, H. Yang,
B. Williams, D. Xing, R. Fain,
A. Laurenza
2.277 Safety Of Levetiracetam
Among Infants Younger Than 12
months – Results From A European
Multicenter Observational Study/
A. Arzimanoglou, P. Berquin, C. Lösch,
J. Bentz
2.278 Analysis Of Psychiatric
Adverse Events In Three Phase III
Controlled Trials Of Eslicarbazepine
Acetate As Adjunctive Therapy For
Refractory Partial-Onset Seizures/
V. Biton, B. Shneker, M. Carreño,
E. Ben-Menachem, F. Rocha,
H. Gama, D. Blum, R. Claus
2.279 Perampanel Discontinuation Is
Not Associated With Self-Reported
Withdrawal Symptoms in Patients
Completing Phase III Clinical
Studies/M. A. Rogawski, H. Yang,
R. V. Fant, B. Williams, D. Xing,
C. Dobrinsky, A. Laurenza
2.280 Clinical And Quality Of Life
Assessments Following Long-Term
Treatment With USL255 (Qudexy™
XR; Extended-Release Topiramate) In
Patients With Refractory PartialOnset Seizures: PREVAIL OLE/
B. Anders, R. Hogan, S. S. Chung,
A. M. Clark, I. Blatt
57
Sunday December 7, 2014
2.281 Long-Term Safety And
Tolerability Of USL255 (Qudexy™ XR;
Extended-Release Topiramate) In
Patients With Refractory PartialOnset Seizures: PREVAIL OLE/I. Blatt,
S. S. Chung, B. Anders, A. M. Clark,
R. Hogan
2.282 High Retention Rate In
Patients With Refractory Epilepsy
Treated With Eslicarbazepine
Acetate/T. Svendsen, E. Brodtkorb,
A. Reimers, E. Sætre,
S. Johannessen, C. J. Landmark
2.283 High Predictability Of Plasma
Lacosamide And No Differences By
Different Age And Gender Through
Normalization Processes/C. Schaefer,
W. Cawello, J. Andreas
2.284 Is Half-Life A Clinically Relevant
Measure For Extended-Release
Drugs? Data Comparing IR Vs XR
Topiramate (USL255; Qudexy™ XR)/
B. Gidal, A. M. Clark, B. Anders
2.285 Patients Reporting Problems
After Generic Antiepileptic Drug
Switches Are Unlikely To Participate In
A Generic Bioequivalence Trial
D. Ficker, M. Berg, P. Bolger, F. Diaz,
B. Dworetzky, E. Elder, B. Gidal,
W. Jiang, R. Krebill, N. McBee,
A. Paige, J. Pollard, M. Privitera,
J. Szaflarski, T. Welty
2.286 Subject-Unrecognized
Medication Adherence Errors In The
Equivalence Among Generic AED
(EQUIGEN) Chronic Dose Trial/
D. Smith, M. Berg, N. Cohen,
N. Llewellyn, M. Lozano,
D. Schwieterman, J. Sieren, P. Bolger,
F. Diaz, B. Dworetzky, E. Elder,
B. Gidal, W. Jiang, R. Krebill,
N. McBee, A. Paige, J. Pollard,
M. Privitera, J. Szaflarski, T. Welty,
D. Ficker
2.287 Equivalence Among Generic
AEDs (EQUIGEN) – Single-Dose
Study/M. Berg, F. Diaz, P. Bolger,
B. Dworetzky, E. Elder, B. Gidal,
W. Jiang, R. Krebill, N. McBee,
A. Paige, J. Pollard, J. Szaflarski,
T. Welty, D. Ficker, M. Privitera
2.288 Aggression Adverse Events
With Concomitant Levetiracetam Use
In Perampanel Phase III Partial-Onset
Seizure Clinical Studies/R. Fain,
S. Chung, H. Yang, D. Xing,
B. Williams, A. Laurenza
2.289 Subgroup Analysis By Race In
Perampanel Phase III Clinical
Studies/A. Laurenza, H. Yang,
B. Williams, S. Huang, M. Sperling
2.290 Long-Term Safety And Efficacy
Of Eslicarbazepine Acetate
Monotherapy In Adults With
Refractory Partial-Onset Seizures:
A One-Year Open-Label Extension
Study/M. R. Sperling, J. Rogin,
J. H. Harvey, H. Cheng, D. Blum
2.291 Placebo-Adjusted Estimation
Of Treatment Effect Of Perampanel/
R. T. Wechsler, S. Mintzer, H. Yang,
B. Williams, D. Xing, A. Laurenza
58
Poster Session 2
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.292 Improvement In Seizure
Control During Conversion To
Eslicarbazepine Acetate Monotherapy:
A Pooled Analysis Of Two Trials In
Adults With Refractory Partial-Onset
Seizures/G. Krauss, V. Biton,
H. Cheng, D. Blum
2.293 Effect Of Adjunctive
Perampanel On Growth And
Development In Adolescents With
Inadequately Controlled Partial-Onset
Seizures/J. E. Pina-Garza, H. Yang,
B. Williams, D. Kumar, A. Laurenza
2.294 Adjunctive Perampanel In
Adolescents With Inadequately
Controlled Partial-Onset Seizures:
Efficacy And Safety Results From
Study 235/B. Renfroe, L. Lagae,
B. Williams, H. Yang, D. Kumar,
A. Laurenza
2.295 Pharmacokinetic,
Pharmacodynamic And Cognitive
Effects Of Adjunctive Perampanel In
Adolescents With Inadequately
Controlled Partial-Onset Seizures/
Z. Hussein, B. E. Gidal, H. Yang,
B. Williams, D. Kumar, A. Laurenza,
J. Ferry, K. J. Meador
Cohort Studies
2.296 Changes In Antiepileptic Drug
Prescribing Patterns In A Large,
Tertiary-Care Epilepsy Center (20002011)/J. Moeller, A. Legge,
K. Detyniecki, L. Hirsch,
R. Buchsbaum, H. Choi
2.297 Lacosamide Monotherapy
Treatment Pathways In Epilepsy
Patients In A U.S. Managed Care
Population/T. Durgin, R. Wade,
C. Chen, D. Hines, C. Makin
2.298 Analysis Of Real-World
Rufinamide Utilization In The
Treatment Of Epilepsy: Demographic
And Socioeconomic Factors/
R. L. Knoth, J. H. Lasley, S. A. Field,
J. Kerrick Walker, S. Mendes
2.299 Beyond Lennox-Gastaut
Syndrome: A Retrospective Study Of
Clobazam In Pediatric Refractory
Epilepsy/S. Reddy, C. Lopez,
M. Messinger, D. Elledge, A. Wilfong
2.300 Experience With Lacosamide In
Galicia, Spain (GALACO Study):
Results At 12 Months/X. Rodriguez
Osorio, F. López González, A. Pato,
M. Saavedra Piñeiro,
E. Rubio-Nazábal, I. Cabo López,
N. Raña Martínez, M. Sobrido,
M. Aguado Valcárcel
2.301 Efficacy Of Clobazam Add On
Treatment Of Refractory Focal
Epilepsy In Adults/P. Klein, A. Barber,
I. Tyrlikova, J. Janousek, A. Azarion,
L. Goldman, D. Gorelik
2.302 Lacosamide Effectiveness In
Pediatric Epilepsy: Effect Of
Concomitant NA Channel
Medications/E. Robbins, J. W. Cohen,
S. Kessler
2.303 Clinical Outcomes Of
Treatment With Oxtellar XR® Or
Immediate-Release Oxcarbazepine
(OXC-IR) In Typical Care Settings:
A Standardized Case Record
Review/W. O’Neal, E. E. Hur,
K. Stringer, T. Resnick
2.304 Long-Term Follow-Up Of
Lacosamide As Add-On Therapy In
Refractory Partial Onset Epilepsy In
Adults In Real Clinical Practice Of
University Hospital, Bratislava/
G. Timarova, S. Mehešová
2.305 Analysis Of Real-World
Rufinamide Utilization In The
Treatment Of Epilepsy: Dosing,
Titration, And Concomitant
Antiepileptic Drugs/S. Mendes,
S. A. Field, J. H. Lasley,
J. Kerrick Walker, R. L. Knoth
2.306 Valproate And Lamotrigine: Is
Clobazam More Effective Than Other
Drugs As Adjunctive Therapy?/
V. Moraes, S. Vincentiis, K. Valente
Drug Interaction
2.307 Interaction Study Between
Brivaracetam And Ethanol In Healthy
Subjects/A. Stockis, A. C. Kruithof,
J. M. van Gerven, M. L. de Kam,
S. Watanabe, P. A. Peeters
2.308 Pharmacokinetic Variability Of
Clobazam And Its Metabolite
Desmethylclobazam In Clinical
Practice – Impact Of Comedication/
M. Burns, S. Johannessen,
C. J. Landmark
2.309 The Effect Of Epidiolex
(Cannabidiol) On Serum Levels Of
Concomitant Anti-Epileptic Drugs In
Children And Young Adults With
Treatment-Resistant Epilepsy In An
Expanded Access Program/
D. Friedman, M. Cilio, N. Tilton,
J. Sullivan, J. Hedlund, E. Rosenberg,
J. Bluvstein, O. Devinsky
2.310 In Vitro Pharmacokinetic
Profile Of Brivaracetam Reveals Low
Risk Of Drug-Drug Interaction And
Unrestricted Brain Permeability/
H. Chanteux, S. Kervyn, B. Gerin,
M. Rosa, N. Latour, A. Stockis,
J. Nicolas
2.311 Seizure Control In Patients
Initiated On Clobazam Who Use
Frequent 1,4-Benzodiazepines/
G. Russo, T. Vollaro, R. Davis, N. Le
Drug Side Effects
2.312 Adverse Visual Side Effects Of
Antiepileptic Drugs In Adults With
Epilepsy/B. Chen, K. Detyniecki,
L. Hirsch, R. Buchsbaum, H. Choi
2.313 Antiepileptic Use And
Dyslipidemia: A Systematic Review/
M. Vyas, J. Costel, L. Escalaya,
J. G. Burneo
2.314 Anti-Epileptic Drugs And
Vitamin D Deficiency In Children With
Epilepsy/J. Yu, S. Lee, J. Koh
Sunday December 7, 2014
Other
2.325 Generic Antiepileptic Drugs,
Mood Disorders And
Pharmacovigilance: Case Analyses And
Literature Review/K. R. Kaufman,
A. M. Zimmerman, S. Wong,
N. D. Kaufman, P. J. Struck
2.326 Adherence Concerning
Antiepileptic Medication: The
Patients’ View/A. Villagran,
M. A. Mevåg, V. Kjærvik,
S. Johannessen, C. J. Landmark,
O. Henning
2.327 Effectiveness And Tolerance Of
Clobazam Used As Adjunctive To A
Sodium-Blocker Antiepileptic Drug In
Maximum Tolerated Doses In Focal
Seizures/E. A. Seraphim,
L. Rodrigues, J. T. Corso, P. Naves,
G. Bienes, E. Yacubian
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.328 An In Vitro Screen For
Antiepileptogenic Compounds Utilizing
Organotypic Hippocampal Slice
Cultures/Y. Saponjian, Y. Berdichevsky,
W. Swiercz, K. Staley
2.329 Topiramate (TPM) And Impaired
Verbal Fluency: Observations From
Three Formulations With Different
Input Rates/S. E. Marino,
S. T. Brittain, S. V. Pakhomov
2.330 Individual Pharmacokinetic
Profile Analysis From An Average
Bioequivalence Study Of Lamotrigine
In Generic-Brittle Patients: What Can
Be Learned About Patients With
Switchability Issues/T. Ting, W. Jiang,
X. Jiang, J. Polli
2.331 Use Of Computer Simulations
To Test The Concept Of Dose
Forgiveness In The Era Of ExtendedRelease (XR) Drugs/S. T. Brittain
2.332 Brivaracetam Achieves Brain
SV2A Occupancy Faster Than
Levetiracetam/J. Mercier, D. Holden,
A. K. Deo, K. Fowles, S. Kervyn,
N. Nabulsi, J. Nicolas, H. Klitgaard,
Y. Huang, J. D’Souza, R. E. Carson,
J. Hannestad
2.333 Evaluation Of Weight-Based
Dosing Of Fosphenytoin In Obese
Pediatric Patients/M. M. Messinger,
S. J. Bork, B. S. Moffett,
G. G. Burgess, A. Wilfong
Surgery
Adult
2.334 Neurological And Medical
Complications Of Epilepsy Surgery At
A Tertiary Level Hospital In A
Developing Country/M. Leon-Vazquez,
F. Chavez-Hassan, L. M. Espaillat
Solano, J. Villeda Hernandez,
M. Alonso-Vanegas, D. Crail Melendez,
A. Ruiz Chow, I. E. Martinez-Juarez
2.335 Preoperative Evaluation Of
Speech And Memory Dominance
Estimated By Intracarotid Propofol
Test/T. Kunieda, N. Mikuni, T. Kikuchi,
R. Inano, T. Inada, Y. Takahashi,
S. Nishida, T. Nakae, S. Shibata,
Y. Yamao, Y. Arakawa, R. Matsumoto,
A. Ikeda, S. Miyamoto
2.336 Failed Epilepsy Surgery
Deserves A Second Chance/
C. M. Reed, S. Dewar, D. Eliashiv
2.337 Stereotactic Laser Ablation:
How Much Hippocampal Atrophy
Optimizes Seizure Freedom?/G. Popli,
D. Couture, A. Laxton, R. Gross,
J. Willie, A. Sharan, M. Sperling,
D. Labiner, M. Weinand, R. Marsh,
G. Worrell, G. Cascino, J. J. Shih,
R. Wharen, W. Tatum, R. Patwardhan,
B. Fernald, A. Shetty
2.338 Outcomes After Temporal
Lobectomy After Invasive Monitoring
Versus No Monitoring/A. Romeo,
B. Agee, L. Ver Hoef, K. Riley
2.339 Stereotactic Laser AmygdaloHippocampotomy For Mesial Temporal
Lobe Epilepsy: Collective Experience
From Seven Single-Center,
Prospective, Investigator-Initiated
Studies Objectives/R. Gross, J. Willie,
S. Helmers, K. J. Meador, S. Laroche,
R. Faught, E. Gedzelman, A. Sharan,
M. Sperling, R. Marsh, G. Cascino,
G. Worrell, J. J. Shih, R. Wharen,
W. Tatum, G. Popli, A. Laxton,
D. Couture, M. Weinand, D. Labiner,
A. Mehta, C. Harden, D.
2.340 Robotic-Assisted
MRI-Compatible
Stereoelectroencephalography:
Technique And Complications/J. Hall
Pediatrics
2.341 WITHDRAWN
2.342 Pediatric Epilepsy Surgery
Strategy And Complications: InterCenter Worldwide Variability/
B. Rydenhag, A. Cukiert, W. Harkness,
I. Panel
2.343 Pediatric Epilepsy Surgery
Techniques General Issues: InterCenter Worldwide Variability/
A. Cukiert, B. Rydenhag,
W. Harkness, T. International
Pediatric Epilepsy Surgery Panel
2.344 Seizure Outcome After
Battery Depletion In Patients With
Secondary Generalized Epilepsy
Submitted To Vagus Nerve
Stimulation/A. M. Lima,
J. A. Burattini, C. M. Cukiert,
A. Cukiert
2.345 ‘Subtotal’ Hemispherectomy
In Children With Intractable Focal
Epilepsy/H. Chugani, E. Asano,
C. Juhasz, A. Kumar, W. Kupsky,
S. Sood
2.346 MR-Guided Laser Interstitial
Thermal Therapy For Drug-Resistant,
Lesional Epilepsy in Children/
E. C. Lewis, J. Ragheb, M. Duchowny,
I. Miller
2.347 Corpus Callosotomy With
Stereotactic Laser Ablation In A
Pediatric Patient/A. Dolce, D. Curry,
A. Wilfong
2.348 Usefulness Of Intraoperative
Insular Electrocorticography During
Modified Functional Hemispherectomy/
G. Kim, J. Seo, J. Baumgartner,
K. Lee
2.349 The Ultimate Case Of Curative
Focal Heterotopia Resection:
Resolution Of Lennox-Gastaut
Syndrome And Epileptic
Encephalopathy/J. R. Fesler,
S. Kanaan, T. B. Mapstone, Y. Ng
2.350 Surgical Outcome In
Adolescents With Mesial Temporal
Sclerosis (MTS): Is It Different Than
Adults?/P. Farooque, L. Hirsch,
S. Levy, F. Testa, R. Mattson,
H. Zaveri, J. Bonito, D. Spencer
2.351 Repeat Epilepsy Surgery For
Children With Refractory Seizures:
Profiles And Outcomes/J. Ziobro,
D. Depositario-Cabacar, K. Havens,
J. Conry, S. Weinstein, T. Zelleke,
A. Kao, T. Tsuchida, M. Kolodgie,
A. Yaun, C. Oluigbo, W. Gaillard
SUNDAY
2.315 Adverse Drug Reactions To
Antiepileptic Drugs In Children With
Epilepsy/J. Kim, H. Park, W. Kim,
H. Kim, J. Kang, S. Kim, J. Yu, Y. Kim
2.316 The Pediatric Epilepsy Side
Effects Questionnaire©: Establishing
Minimal Clinically Important Difference
Scores/K. Junger, D. Morita, A. Modi
2.317 Adverse Effects Of
Antiepileptic Drug Treatment: The
Patients’ View/V. K. Kjærvik,
M. A. Mevåg, A. Villagran,
S. Johannessen, O. Henning,
C. J. Landmark
2.318 Pigmentary Abnormalities
(Discoloration) Associated With
Ezogabine/Retigabine Treatment:
Clinical Aspects/S. Evans,
A. Alio Saenz, C. Harrington, D. Kelly,
N. Walsh, S. McDonald, W. Lee,
N. Brickel
2.319 Unusual Case Of Drug Rash
With Eosinophilia And Systemic
Symptoms (DRESS) With
Ethosuximide/S. Paudel, A. Patel,
P. Kandel, P. Rawal
2.320 Randomized Crossover Study
Comparing Neuropsychological Effects
Of Lacosamide Versus Carbamazepine
Immediate Release In Healthy
Subjects/K. J. Meador, D. W. Loring,
A. Boyd, W. Byrnes, D. Dilley,
E. Webster, S. Borghs, M. De Backer,
T. Story, P. Dedeken
2.321 An Interesting Case Of Sinus
Nodal Dysfunction Following Use Of
Lacosamide/M. Gurme, C. M. Reed,
D. Eliashiv
2.322 Beyond Efficacy: Focus On
Safety And Effectiveness Of
Antiepileptic Drugs (AEDs)/M. Wen,
V. Nguyen, Y. Bukovskaya,
S. Dergalust
2.323 Effect Of Long-Term
Administration Of Low Dose Of
Rapamycin On Development And
Immunity In Young Rats/L. Zeng
2.324 Pigmentary Abnormalities
(Discoloration) Associated With
Ezogabine/Retigabine Treatment:
Nonclinical Aspects/J. S. Prescott,
C. Evans, A. Alio Saenz
Poster Session 2
59
Sunday December 7, 2014
2.352 The Spectrum Of Sleep
Disorders In Children Undergoing PreSurgical Evaluation For Refractory
Epilepsy/S. Jain, P. Horn, H. Greiner
2.353 REM Sleep EEG Indicates
Epileptogenic Hemisphere For
Successful Epilepsy Surgery In
Children With Generalized Interictal
Epileptiform Discharges/K. Okanari,
S. Baba, H. Otsubo, E. Widjaja,
S. Sakuma, C. Go, K. Jones,
K. Nishioka, S. Oba, T. Matsui,
M. Ueno, S. Ukitsu, J. Rutka,
J. Drake, E. Donner, S. Weiss,
O. Snead, A. Ochi
2.354 Thermal Ablation For Patients
Who Failed Surgery Or Would Seldom
Be Considered As Surgical Candidate/
D. F. Clarke, J. B. Titus,
N. Nussbaum, F. F. Perkins,
K. C. Keough, M. R. Lee
2.355 Complete Resection Of Fast
Ripples Is A Superior Predictor Of
Seizure-Freedom After Epilepsy
Surgery In Comparison To
Conventional Intraoperative
Electrocorticography Findings/
S. A. Hussain, G. Mathern, R. Sankar,
J. Wu
All Ages
2.356 Predictive Power Of
Presurgical Studies For Temporal
Lobectomy Seizure Freedom/
O. I. Khan, D. M. Goldenholz, A. Jow,
W. Theodore
2.357 Frameless Image-Guided
Stereotactic Implantation Of Depth
Electrodes Via Craniotomy For
Presurgical Evaluation Of
Pharmacoresistant Epilepsy/H. Khoo,
H. Kishima, S. Oshino, N. Tani,
T. Maruo, T. Yanagisawa, K. Edagawa,
Y. Inoue, M. Hirata, T. Yoshimine
2.358 Surgical Removal Of High
Frequency Oscillations Correlates
With Postsurgical Outcome – A
Prospective Multi-Center Study/
J. Jacobs, J. Y. Wu, P. Perucca,
R. Zelmann, M. Mader, F. Dubeau,
A. Schulze-Bonhage, G. Mathern,
J. Gotman
2.359 Appropriating Surgical
Intervention In Mesial Temporal-Lobe
Epilepsy (MTLE) Patients: Comparison
Of Parameters Influencing Timing Of
Surgery In Patients With Epilepsies
With Different Evidence Levels For
Surgery/K. Iida, K. Kagawa,
M. Kartagiri, A. Hashizume, K. Kurisu
2.360 Laser Ablation Therapy For The
Management Of Medically-Resistant
Epilepsy After Age 50/F. Vale,
H. Waseem, M. Schoenberg, V. Kelley,
A. Bozorg, S. Benbadis, D. Cabello
60
Poster Session 2
8:00 a.m. – 6:00 p.m.
Convention Center – Hall 4B, Level 4
2.361 Temporal Lobe Epilepsy With
Bilateral Features: Prognostic
Factors And Outcomes/H. Waseem,
K. E. Eichstaedt, M. Schoenberg,
V. Kelley, A. Bozorg, S. Benbadis,
F. Vale
2.362 Electrical Stimulation Of The
Centromedian Nucleus Of The
Thalamus For The Treatment Of
Intractable Epilepsy/Y. Shon, S. Lim,
W. Kim
2.363 Acute Intraoperative Entropy
Rise During Hippocampal Deep Brain
Stimulation Surgery/A. Marin,
H. Carmona, N. Sinisterra,
A. Liscano, C. M. Cukiert, A. Cukiert
2.364 Safety And Efficacy Of
Complete Corpus Callosotomy As A
Localization Tool For Catastrophic
Unlocalizing Epilepsy/J. Seo, K. Lee,
J. Baumgartner, B. Pullum
2.365 Does Seizure Outcome
Influence Nonseizure Outcome, LongTerm Outcome After Surgery For
MTS/M. Tripathi, K. Garg, A. Garg,
A. Wadhawan, M. Goel, C. Bal,
C. Sarkar, V. Kumar, P. Madakasira,
S. Chandra
Health Services
2.366 Incidence And Prevalence Of
Epilepsy In Low-Income Children:
Preliminary Analysis/A. Chandran Pillai,
K. Kaiboriboon, S. Koroukian,
E. Pestana Knight
• AES 68TH ANNUAL MEETING
Seattle, WA •
MONDAY December 8, 2014
www.AESnet.org
7:00 a.m. – 8:30 a.m.
Special Interest Group Meetings
Location listed under each session
Ketogenic Diet: Does the Ketogenic Diet Offer a “Cure” for
Epilepsy?
Convention Center – Room 613, Level 6
Coordinators: Susan Masino, Ph.D., Christina A. Bergqvist, M.D.
Speakers: Detlev Boison, Ph.D., Sudha Kessler, M.D., Renee A. Shellhaas, M.D.,
Timothy A. Simeone, Ph.D.
We have an arsenal of treatments for epilepsy, but do we have any cures?
More specifically, could the time-honored treatment of a ketogenic diet also
be an anti-epileptogenic treatment and offer insight into a cure? What proof
do we have that this is, or is not, the case?
This year the discussion will be organized into a pro/con debate of clinical
evidence and basic science evidence — with ample time for rebuttal and
audience participation. Our invited speakers are expected to take a side as we
explore this hot topic. We hope to have fun and inspire the community to
share their thoughts, suggest experiments and put forth provocative ideas to
help move the field forward.
Neuropsychology: Can We Spare Memory with Newer
Surgical Approaches for Temporal Lobe Epilepsy? Emergent
Outcome Data from Laser Ablation, Multiple Hippocampal
Transection, and Fornix DBS
Convention Center – Room 609, Level 6
Emergent neuropsychological outcome data will be presented on three novel
surgical techniques and will be critically evaluated and discussed with the
audience. The topic (neuropsychology, surgery, temporal lobe) and the
neuropsychologist-neurosurgeon paired presentations are expected to draw a
diverse multidisciplinary audience.
NINDS and Non-Profit Research Resources
Convention Center – Room 620, Level 6
Coordinators: Brandy Fureman, Ph.D., Randall Stewart, Ph.D.,
William Benzing, Ph.D., Steve Roberds, Ph.D., Ilene Miller, J.D., Seth Wohlberg
Speakers: Abigail Hemani, Scott C. Baraban, Ph.D.
The purpose of this SIG is to generate focused two-way discussion between
government and non-profit funders and basic and clinical researchers
attending the AES annual meeting. This discussion will educate researchers
on how government and non-profits set their priorities and fund research or
make other resources available, and it will educate non-profit leaders on what
else they could do to support basic and clinical researchers in the epilepsies.
The ultimate goal of this group is to accelerate research on the epilepsies by
more effectively making valuable resources available to the research
community.
Nursing
Convention Center – Room 612, Level 6
Coordinators: Frank W. Drislane, M.D., Howard Goodkin, M.D., Ph.D.
Speakers: Peter Kaplan, M.B.B.S., Lawrence J. Hirsch, M.D.,
Howard Goodkin, M.D., Ph.D.
Neurologists agree readily that generalized convulsive Status Epilepticus (SE)
is a neurologic emergency and that it should be halted immediately and the
patient kept from having recurrence of seizures. There is no consensus,
however, that all forms of SE (particularly nonconvulsive SE) need be treated
so aggressively. Even after interruption of convulsive SE, there is
disagreement on how long seizures need be suppressed, and on which EEG
abnormalities signify seizures that require re-treatment. Prolongation of
medically-induced coma with highly sedating drugs keeps patients at risk of
prolonged ICU stays and of new medical complications.
Dr. Peter Kaplan, who has written on the risks of overtreatment (including a
paper this year on worsened outcome for aggressively treated SE patients)
will make the case that much of current treatment is excessive.
Dr. Larry Hirsch, who has studied the treatment of ICU patients with refractory
SE, as well as the deleterious consequences of SE itself, will speak in favor of
vigorous seizure suppression. Finally, Dr. Howard Goodkin, with both a clinical
and basic science perspective, will discuss what evidence from basic and
clinical research can guide us in determining how aggressively to treat NCSE.
8:45 a.m. – Noon
Merritt-Putnam Symposium: Stress,
Cannabinoids and Epilepsy: The Science
Behind the Buzz
(3.0 CME Credits)
Convention Center – Ballroom 6C, Level 6
Presentation: Hans O. Lüders, M.D., Ph.D., William G. Lennox Award
MONDAY
Coordinators: Philip S. Fastenau, Ph.D., Gail L. Risse, Ph.D.
Speakers: Daniel L. Drane, Ph.D., Robert Gross, M.D., Philip Fastenau, Ph.D.,
Jonathan P. Miller, M.D.
Status Epilepticus: Are We Over-Treating Status Epilepticus,
and Especially, Nonconvulsive Status Epilepticus?
Overview
The impact of stress on seizure control has long been recognized but the
neurobiology of stress impact on neurophysiology is not widely known.
Similarly, cannabinoids have been considered as potentially effective adjunctive
treatment for epilepsy as an alternative to traditional medications but here,
too, the neurobiology requires further elucidation. There is evidence of shared
mechanisms between stress impact on neurologic function and the
neurobiology of cannabinoids. These topics will be explored, providing
information necessary for improved management of patients with
pharmacoresistant epilepsy. Presentations on basic science related to stress
and to cannabinoids, and clinical data regarding both will be presented.
Research on how cannabinoid receptors alter the brain’s immune system will
be presented, as well as progress that has been made in identifying
cannabinoid agents devoid of drug of abuse properties that may provide
treatment for diverse neurological disorders.
Learning Objectives
Convention Center – Room 608, Level 6
u
Identify a patient for whom stress is contributing to difficulties in
management of seizures and develop treatment strategies to address
the role of stress
The Nurse Travel Award winners will present their poster topics in a
10-minute synopsis with audience discussion and question session. In
addition, we will hold a discussion on an epilepsy certificate program and
feasibility of epilepsy certification in nursing.
u
Query patients regarding use of cannabinoids and address the impact of
such use in developing treatment plans
u
Identify a patient who is using cannabinoids for treatment of epilepsy and
discuss the impact of the use of cannabinoids
Coordinators: Tara Myers, CPNP, Wendy Miller, Ph.D., RN, CCRN
Speakers: Nurse Travel Award Winners
61
MONDAY December 8, 2014
Assist clinicians in developing treatment plans that account for the impact
of cannabinoids and their interaction with traditional medications
u
Counsel patient regarding the need for stress management in treatment
of epilepsy
Location listed under each session
u
Counsel patients regarding the impact of stress on seizure control and
develop plans for managing stress
NEW – Epilepsy and Aging
u
Evaluate the possible adverse effects of cannabinoids on cognitive
function in patients using cannabinoids for seizure treatment.
Target Audience
Basic, Intermediate and Advanced (see page 120 for details)
Program
Chair: Amy Brooks-Kayal, M.D.
9:00 a.m.
Introduction
Amy Brooks-Kayal, M.D.
9:15 a.m.
The Neurobiology of Stress: How Stress and Epilepsy
Intersect at the Synapse
Tallie Z. Baram, M.D., Ph.D.
9:45 a.m.
Stress and Epilepsy: What Are the Clinical Data?
Sheryl Haut, M.D.
10:15 a.m. Stress and Cannabinoids: What Is the Link?
Jaideep Bains, Ph.D.
10:45 a.m. Cannabinoids and Epilepsy: What Are the Clinical Data?
Allen Hauser, M.D.
Special Interest Group Meetings
Convention Center – Room 620, Level 6
Coordinators: Bruce P. Hermann, Ph.D., Kimford J. Meador, M.D.,
Helen E. Scharfman, Ph.D.
Speakers: Carrie McDonald, Ph.D., David Loring, Ph.D., Ilo Leppik, M.D.,
R. Eugene Ramsay, M.D., Helen Scharfman, Ph.D., Manisha Patel, Ph.D.
This SIG will focus on neurological, neuropsychological, imaging and basic
science aspects of the relationship between epilepsy and aging. This includes
the complications of aging with chronic epilepsy and the issue of new onset
epilepsy with advancing chronological age. The initial meeting will include
brief invited presentations and discussants from clinical neurology,
neuropsychology, and basic science.
Surgery: Surgical Failure in Pediatric and Adult Epilepsy:
“The Slam Dunk Case That Wasn’t!”
Convention Center – Room 609, Level 6
Coordinators: Saadi Ghatan, M.D., Gerald Grant, M.D.
Speakers: TBA
We will solicit cases from pediatric and adult surgical epilepsy programs and
select 3-5 cases for presentation, reviewing cases in advance and sticking to
a strict timeline. Presenters are asked to provide a case that was predicted to
be an unequivocal success but resulted in a failure to adequately treat the
patient’s epilepsy or realize the goal of the operation. Audience participation is
then solicited to generate discussion and suggestions about approaches and
recommendations, with moderators polling the audience.
11:10 a.m. Cannabinoids in Treatment of Neurological and
Psychiatric Disorders: Is There a Potential Role in
Epilepsy?
Nephi Stella, Ph.D.
Tuberous Sclerosis: Thinking Outside the Tuber in TSC
11:40 a.m. Panel Discussion and Conclusions
Amy Brooks-Kayal, M.D.
This SIG will focus on the role of non-tuberal cortex and sub-cortical
structures in epilepsy and neurobehavioral disabilities in TSC.
Credit Designation
Convention Center – Room 612, Level 6
Coordinator: Peter E. Crino, M.D., Ph.D.
Speakers: Peter Crino M.D., Ph.D., Delia Talos Ph.D., Juurian Peters M.D.
The American Epilepsy Society designates this live activity for a maximum of
3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
2:15 p.m. – 3:00 p.m.
Nurses may claim up to 3.0 contact hours for this session.
Convention Center – Ballroom 6C, Level 6
Presentation: Karen Gale, Ph.D., Extraordinary Contributions Award
Nurse Practitioners may claim 3.0 hours of pharmacology for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 3.0 contact hours (0.3 CEUs). UAN 0077-9999-14-035-L01-P.
Initial Release Date: 12/8/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the
Merritt-Putnam Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Core Competencies: Professionalism, Medical Knowledge, Practice-based
Learning and Systems-based Practice
Acknowledgment
This program is supported in part by CURE.
62
9:00 a.m. – 10:30 a.m.
u
Lennox and Lombroso Lecture:
Priorities in Pediatric Epilepsy Research
Lecturer: Anne Berg, Ph.D.
The past several decades of clinical and epidemiological research have
provided a wealth of knowledge about the diversity within the pediatric
epilepsies and greatly clarified the sometimes reassuring but still too often
devastating prognosis of many of these disorders. The tremendous advances
in neuroimaging, molecular cell biology, and therapeutics hold the promise of
prevention, more effective targeted treatment, and even disease modification
for these epilepsies with the possibility of ameliorating what can otherwise be
moderate to severe lifelong disability. The challenge is to learn how -when
and in whom- to utilize these techniques and therapies in an optimal manner
to assure the best patient outcomes. Stakeholder identified and endorsed
priorities can help develop a series of research priorities for accomplishing
this goal.
MONDAY December 8, 2014
3:00 p.m. – 4:30 p.m.
Investigators’ Workshop
This workshop is an AES Research Grant funded study
Convention Center – Room 607, Level 6
Modeling Epilepsies with Patient-Derived Induced
Pluripotent Stem Cells
Moderator: Jack M. Parent, M.D.
Speakers: Kevin Ess, M.D., Ph.D., Jack Parent, M.D., Lori Isom, Ph.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Town Hall
FDA Update and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competency: Professionalism
3:00 p.m. – 5:00 p.m.
FDA Town Hall Update: SUDEP and
Clinical Trials
(2.0 CME Credits)
Convention Center – Room 612, Level 6
Overview
In 2011, a meta-analysis published in Lancet Neurology suggested that patients
randomized into placebo-controlled add-on studies of antiepileptic drugs had a
higher likelihood of having SUDEP if they were randomized to the placebo arm
compared to addition of an active drug. This analysis was recently repeated by
the FDA using data requested from the companies performing the trials. This
symposium will discuss the following issues: 1) How do the findings impact the
design of add-on studies of antiepileptic drugs? 2) What do these findings mean
for clinical practice? The session will include a long interactive audience
discussion session, as specifically requested by the FDA, to provide community
input to the regulatory process.
Learning Objectives
3:00 p.m. – 5:15 p.m.
Pediatric Epilepsy Highlights Session
Convention Center – Ballroom 6E, Level 6
Note: Number below refers to poster assignment
This session will showcase selected scientific abstracts focused on topics in
clinical care and research in pediatric epilepsy. Authors will present a six-minute
overview of their work. Presentations are chosen from all submitted abstracts.
Participants will be able to view posters and meet the authors at the end of the
program.
1.032 Diminished Antiepileptogenic Effects Of Neurosteroids In Mice
Lacking Delta-Subunit Extrasynaptic GABA-A Receptors/Bryan Clossen
1.052 Early-Life Clonazepam Exposure Leads To Persistent Alteration Of
Seizure Susceptibility/Hana Kubova
Define patient-specific risk/benefit ratios related to treatment
interventions vs absence of intervention in treatment resistant patients
1.097 Behavioral Co-Morbidities In Pediatric Epilepsy: What Is The Role Of
Cognition?/Soyong Eom
u
Counsel patients regarding risks and benefits related to treatment
interventions vs absence of intervention in treatment resistant patients
1.122 Temporal Lobe Epilepsy With Hippocampal Sclerosis: The Role Of
5HT1A and 5HT2A Receptos In Human Epileptogenesis/Kette Valente
u
Understand and counsel patients regarding risks and benefits related to
treatment interventions vs absence of intervention in treatment resistant
patients.
Target Audience
1.365 Surgical Versus Medical Treatment For Children With Epileptic
Encephalopathy In Infancy And Early Childhood – An Observational Cohort
Study By Far-East Asia Catastrophic Epilepsy (FACE) Study Group/
Taisuke Otsuki
Program
2.023 Psychiatric Comorbidity In Children With Recent-Onset Epilepsy:
A 2-Year Prospective Controlled Investigation/Jana Jones
Intermediate and Advanced (see page 120 for details)
Co-Chairs: Jacqueline A. French, M.D. and Billy Dunn, M.D.
3:00 p.m.
3:05 p.m.
Introduction
Billy Dunn, M.D.
Review of 2011 Analysis
Philippe Ryvlin, M.D., Ph.D.
3:20 p.m.
Presentation of FDA Analysis
Mary Doi, M.D., M.S.
3:40 p.m.
Potential Impact on Clinical Trial Design and Practice
Jacqueline A. French, M.D.
4:00 p.m.
Interactive Panel/Audience Discussion
Eric Bastings, M.D.
Norman Hershkowitz, M.D., Ph.D.
Mary Doi, M.D., M.S.
Alice Hughes, M.D.
Billy Dunn, M.D.
Sally Jo Yasuda, Pharm.D., M.S.
4:55 p.m.
Conclusions
Jacqueline A. French, M.D.
MONDAY
u
2.169 Familial Ring Chromosome 20 Syndrome – A Case Report/
Iris Unterberger
2.179 Left Temporal Lobe Epilepsy Presenting As Apparent Life-Threatening
Events In Infants/Richard Tang-Wai
3.013 Inflammatory Mechanisms Of Epileptogenesis In The Genetic
Epilepsy, Tuberous Sclerosis Complex/Bo Zhang
3.202 A Brain-Machine Interface For Burst Suppression Control in Pediatric
Status Epilepticus/Christos Papadelis
63
MONDAY December 8, 2014
3:00 p.m. – 5:15 p.m.
Platform Sessions: 3 Concurrent Sessions
See page 120 for locations
There will be three concurrent sessions consisting of selected key scientific
abstracts. Authors will present a 10-minute overview of their work followed
by a five-minute Q & A.
5:30 p.m. – 8:00 p.m.
Pediatric State of the Art Symposium:
Long-term Outcomes of Neonatal Seizures
(2.5 CME Credits)
Convention Center – Ballroom 6C, Level 6
Overview
Seizures occur in a significant number of neonates, yet many critical questions
remain regarding their diagnosis, treatment, and long-term prognosis. Modern
neurophysiological monitoring indicates that the scope of the neonatal seizure
problem may be more extensive than previously appreciated. Although
contemporary neuroprotective strategies have led to improved short-term
outcomes, the impact of both seizures and the medications used to treat
them are now being explored more rigorously in both animal models and
humans. There is a need for clinicians who treat infants, children,
adolescents, and even adults to become familiar with the long-term sequelae
of neonatal seizures. Importantly, these sequelae include not only seizures —
cognitive, neuropsychological and social outcomes are affected, as well. This
State of the Art Symposium will address the long-term outcomes of neonatal
seizures, with a focus on both epilepsy and non-epilepsy factors.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.5 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.5 contact hours (0.25 CEUs). UAN 0077-9999-14-036-L01-P.
Initial Release Date: 12/8/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Pediatric
State of the Art Symposium and has approved this program as part of a
comprehensive lifelong learning program, which is mandated by the ABMS as
a necessary component of maintenance of certification.
Core Competencies: Patient Care and Systems-based Practice
Acknowledgment
This program is supported in part by an educational grant from
Mallinckrodt Pharmaceuticals.
Learning Objectives
u
Recognize long-term sequelae of neonatal seizures from information
provided by outcome studies
u
Choose appropriate medications used to treat neonatal seizures based on
information from follow up studies regarding long-term sequelae
u
Utilizing information provided regarding long-term sequelae of neonatal
seizures and medications used to treat them, counsel families about
seizure- and development related outcomes after neonatal seizures.
Target Audience
Intermediate and Advanced (see page 120 for details)
Program
Co-Chairs: Adam Hartman, M.D. and Renée A. Shellhaas, M.D., M.S.
64
5:30 p.m.
Introduction and Case Presentation
Adam Hartman, M.D.
5:45 p.m.
Introduction to Neonatal Seizures
Geraldine Boylan, Ph.D.
6:10 p.m.
Clinical and EEG Predictors of Prognosis
Renée A. Shellhaas, M.D., M.S.
6:35 p.m.
Are Neonatal Seizures So Bad?
Rodney Scott, M.D.
7:00 p.m.
Are Seizure Medicines So Bad?
Timothy Benke, M.D., Ph.D.
7:25 p.m.
Neonatal Seizure Management 2014
Janet Soul, M.D.
7:50 p.m.
Conclusions
Renée A. Shellhaas, M.D., M.S.
Get Your Annual Meeting
CME / CE Credit Online
Go to www.AESnet.org
See page 120 for details
Monday December 8, 2014
A. Clinical
Platform Sessions
3:00 p.m. - 5:15 p.m.
B. Treatment / Imaging
C. Translational
Convention Center – Room 608, Level 6
Convention Center – Room 609, Level 6
Convention Center – Room 603, Level 6
Moderators: Amy Crepeau, M.D., Nicholas Abend, M.D.
Moderators: Jacquelyn Bainbridge, Pharm.D.,
Jeffrey Ojemann, M.D.
Moderators: Suzanne Bausch, Ph.D., Lori Isom, Ph.D.
B.01 Neural Mechanism Of Impaired Consciousness
In Typical Childhood Absence Seizures/J. Guo, R. Kim,
W. R. Xiao, E. Feeney, X. Bai, M. Negishi,
M. J. Crowley, L. C. Mayes, T. Constable,
H. Blumenfeld
C.01 Synaptic Impairment Of Frontal Cortical FastSpiking Basket Cells Induces Cognitive And Behavioural
Deficits In Mice With A Cacna1a Loss-Of-Function
Mutation./A. Lupien-Meilleur, I. Riebe, L. Damaj,
C. Vanasse, G. Louise, A. M. Van den Maagdenberg,
J. Lacaille, E. Rossignol
3:15 p.m. A.02 Factors Influencing Driving Impairment In
B.02 Safety And Pharmacokinetics Of IV Loading
Dose Of Lacosamide In The ICU/R. E. Ramsay,
V. Sabharwal, F. Khan, H. Dave
C.02 Dravet Syndrome Patient-Derived Induced
Pluripotent Stem Cell Cardiac Myocytes Have
Increased Sodium Current Density And Increased
Beating Rate/C. R. Frasier, H. Zhang, K. Collon,
J. Parent, L. L. Isom
3:30 p.m. A.03 Terminal Seizure Remission 45 Years After
B.03 Field Potential Imaging: A New Paradigm For
Focal Epilepsy/G. P. Kalamangalam, R. E. Gabr,
P. A. Narayana
C.03 Cerebellar Control Of Spontaneous Seizures In
A Mouse Model Of Temporal Lobe Epilepsy/
E. Krook-Magnuson, C. Armstrong, G. G. Szabo,
M. Oijala, I. Soltesz
3:45 p.m. A.04 Children With Epilepsy And Mild
B.04 Automated Detection Of Cortical Dysplasia In
MRI-Negative Epilepsy: Class II Diagnostic Evidence/
S. Hong, B. Bernhardt, D. Schrader, N. Bernasconi,
A. Bernasconi
C.04 (1-3)Insulin-Like Growth Factor 1 Suppresses
Seizures And Hypsarrhythmia In An Animal Model Of
Infantile Spasms./C. L. Lee, J. D. Frost, Jr., J. T. Le,
R. A. Hrachovy, J. W. Swann
4:00 p.m. A.05 Management Of Children With Refractory
B.05 Increased Cerebral Oxygenation Precedes
Generalized Tonic Clonic Seizures/B. D. Moseley,
J. Britton, E. So
C.05 Development Of Glutamatergic Transmission
Onto Transplanted MGE Interneurons/M. Howard,
S. Baraban
4:15 p.m. A.06 Pulmonary Edema Occurs In Nearly
B.06 Continuous Infusions In Refractory Convulsive
Status Epilepticus. Results From The Pediatric Status
Epilepticus Research Group (pSERG)./T. Loddenkemper,
I. Sánchez Fernández, N. Abend, R. Arya, R. Basu,
N. Brenton, J. Carpenter, K. Chapman, J. Condie,
N. Dean, W. Gaillard, T. Glauser, J. Goldstein,
H. Goodkin, A. J. Hani, M. Jackson, K. Kapur,
T. Kebede, J. Klehm, M. Mikati, K. Peariso, M. Sacco,
K. Schmidt, A. Topjian, D. Turner, A. Wilfong,
K. Williams, M. Wainwright, R. Tasker
C.06 A Novel Mouse Model Of Chromosome
Xq22.1 Deletion Syndrome Displays Epilepsy And
Cortical Circuit Dysfunction/E. M. Goldberg,
J. Zhou, C. Yue, P. Wang, D. Coulter
4:30 p.m. A.07 Temporal Lobe Epilepsy In Patients With
B.07 The Johns Hopkins Hospital Adult Epilepsy Diet
Center: Results And Experience In Four Years/
M. Cervenka, E. Kossoff, B. Henry, J. Barnett,
R. Fisher
C.07 Neuron Subset-Specific-PTEN Deletion Induces
Abnormal Skeletal Activity In Mice/J. Lugo,
M. Thompson, P. Huber, G. Smith, A. Holley, S. Bain,
E. Gardiner, R. Kwon
4:45 p.m. A.08 A Diagnostic Blood Test For Epilepsy:
B.08 Long-Term Memory And Language Outcomes
With Responsive Cortical Stimulation Do Not Differ By
Stimulation Localization/D. W. Loring, R. Kapur,
K. J. Meador, M. Morrell
C.08 Hippocampal DBS Affects Disease Development
In The KA Rat Model For TLE/B. Van Nieuwenhuyse,
R. Raedt, J. Delbeke, M. Sprengers, I. Dauwe,
S. Gadeyne, W. Wadman, P. Boon, K. Vonck
Epilepsies/A. Berg, K. Rychlik
Persons With Refractory Epilepsy/V. Punia,
P. Farooque, W. Chen, L. Hirsch, A. Berg,
H. Blumenfeld
selected for the Fritz Dreifuss Honor
Onset Of Absence Epilepsies/M. Holtkamp,
A. Kirschbaum, A. Kowski, D. Janz
Intellectual Disability Do Not Have A High Risk Of
Long-Term Resistant Epilepsy; However,
Moderate Or Severe/Profound Intellectual
Disability Is Ominous: A Population-Based Study
With >20 Years Of Follow-Up/P. Camfield,
C. Camfield
Epilepsy. A Decision Analysis Comparing Medical
Versus Surgical Treatment/I. Sánchez Fernández,
S. An, T. Loddenkemper
One-Third Of Monitored Patients With Convulsive
Seizures And Is Directly Associated With The
Duration Of The Preceding Seizure/J. Kennedy,
P. Parikh, K. Hardin, M. Seyal
Nonlesional MRI And Normal Memory: An SEEG
Study/J. Miller, J. Sweet, S. Suresh, P. Landazuri,
H. Lüders
A Soluble ICAM-5-Based Panel/J. R. Pollard,
P. B. Crino, G. P. Mueller, O. Eidelman, C. Dalgard,
E. Brand, C. T. Anderson, P. Cai, M. Wamil,
M. C. Strauman, E. Burakgazi-Dalkilic, K. A. Davis,
H. B. Pollard
5:00 p.m. A.09 Predictive Model For Early Posttraumatic
Seizures In The PICU/R. Rajaraman, J. Lerner,
D. Arndt, D. McArthur, J. Fischer, M. Zeiger,
M. Choe, C. Giza
MONDAY
3:00 p.m. A.01 The Not So Simple Course Of Childhood
selected for Goldberg Kaufman Honor
B.09 Structural Connectivity Of Limbic Brain Regions
In Patients With Psychogenic Non-Epileptic Seizures
(PNES)/K. Hernando, J. Allendorfer, S. Lee,
L. Ver Hoef, J. Szaflarski
C.09 Seizures And SUDEP In A Mouse Knock-In Model
Of SCN8A Related Epileptic Encephalopathy/J. Wagnon,
M. Korn, R. Parent, J. Jones, G. Murphy, J. Parent,
M. Meisler
The Fritz Dreifuss Honor is awarded to the highest ranking abstract in the outstanding patient care topic category and is sessioned as Platform A.02. The abstract honored is
selected by the Scientific Program Committee from all submitted abstracts.
The Rebecca Goldberg Kaufman Honor is awarded to the highest ranking abstract in the psychiatric topic category and is sessioned as Platform B.08. The abstract honored is
selected by the Scientific Program Committee from all submitted abstracts.
65
Monday December 8, 2014
Poster Session 3
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
 Authors Present: Noon – 2:00 p.m.
 Poster Walking Tours (see page 15 for details)
Translational Research
Mechanisms
3.001 Increase In Dendritic Spines
Correlates With Increased Synapses
In Hippocampal CA1 Following HypoxiaInduced Neonatal Seizures/
J. Lippman-Bell, S. Francomacaro,
F. Jensen
3.002 Using CRISPR In Utero
Electroporation To Study The Function
Of PCDH19/Y. Wang, F. Chen,
J. loturco, J. Parent
3.003 Targeting The JAK/STAT
Pathway For Disease Modification In
Epilepsy/A. J. Carrel,
H. L. Grabenstatter, J. Carlsen,
Y. Cruz Del Angel, S. Russek,
M. F. Wempe, A. Brooks-Kayal
3.004 Topology Of Network
Synchronization During Early
Epileptogenesis/K. Lillis, Z. Wang,
G. Q. Zhao, B. Bacskai, K. Staley
3.005 Retrograde Monosynaptic
Tracing Of Inputs To Neonatal- Vs.
Adult-Born Dentate Granule Cells In A
Rodent Temporal Lobe Epilepsy
Model/X. Du, A. L. Althaus, H. Zhang,
E. G. Wolf, J. Parent
3.006 Disabled 1-Deficient Mice
Exhibit Hippocampal Structural
Abnormalities And A Reduced Seizure
Threshold/M. J. Korn, J. Parent
3.007 Hippocampal Metaplasticity
Induced By Early Life Hypoxic Seizures
In Rats/H. Sun, F. E. Jensen
3.008 Extracellular And Intracellular
K+ Accumulation And Buffering
During Focal Cortical Epilepsy: A
Spatiotemporal Study In Vivo/
S. Dufour, P. Bazzigaluppi, O. Levi,
P. Carlen
3.009 Ceftriaxone Treatment In A
Rat Posttraumatic Epilepsy Model
Preserves Cortical Inhibitory
Interneuron Function And Parvalbumin
Expression/M. Q. Hameed, T. Hsieh,
J. Morales-Quezada, G. S. Goodrich,
A. Rotenberg
3.010 Mifepristone Treatment PostStatus Epilepticus Normalizes Basal
Corticosterone Levels, Increases
Calretinin Positive Cell Number In The
Dentate Gyrus And Reduces Hilar Cell
Proliferation In Mice/A. C. Wulsin,
J. P. Herman, S. Danzer
3.011 ProBDNF Levels Increase
Rapidly After Seizures In The Mouse/
A. X. Thomas, Y. Cruz Del Angel,
S. J. Russek, B. L. Hempstead,
A. R. Brooks-Kayal
3.012 Preventive Effect Of
Levetiracetam Against The
Pathological Changes In Hippocampus
Of Temporal Lobe Epilepsy Model
Mice/T. Higo, H. Sugano, M. Nakajima,
Y. Iimura, H. Arai
3.013 Inflammatory Mechanisms Of
Epileptogenesis In The Genetic
Epilepsy, Tuberous Sclerosis
Complex/B. Zhang, N. Rensing, J. Zou,
M. Yang, M. Wong
66
3.014 Functional Evaluation Of A De
Novo GRIN2A Mutation In A Patient
With CSWSS, Continuous Spike And
Waves During Slow-Wave Sleep
Syndrome/H. Yuan, A. Tankovic,
S. F. Traynelis
3.015 A Juvenile Myoclonic Epilepsy
GABAA Receptor Mutation Causes
The Developmentally-Dependent
Expression Of Seizures And Cortical
Disinhibition/M. Gallagher, F. Arain,
C. Zhou, L. Ding, S. Zaidi
3.016 Mechanisms Of Epilepsy And
Epileptic Encephalopathy Due To
KCNT1 Mutations/I. H. Quraishi,
G. E. Kim, J. K. Kronengold,
R. L. Couture, M. L. Schwartz,
G. Barcia, R. Nabbout, L. K. Kaczmarek
3.017 A KCNQ2/3 Mutation Causing
Severe Epilepsy Disrupts Channel
Targeting To The Axon Initial
Segment/B. Tran, M. Xu, E. C. Cooper
3.018 Prenatal Valproic Acid
Exposure Impairs Interneuron
Proliferation And Migration/
R. F. Martin, E. Powell
3.019 The Effects Of TRPV1 Ligands
On Blood Brain Barrier Permeability In
A Rodent Model Of Experimental
Febrile Seizures/L. Scott, K. B. Rivard,
K. Barrett, S. Nakanishi,
M. Scantlebury
3.020 5-HT6 Receptor Ligands
Modulate Seizure Thresholds And
Inhibitory Synaptic Transmission In
The Dentate Gyrus/G. J. Remigio,
G. W. Saunders, P. J. West
3.021 The Effect Of Vitamin D On The
Pentylenetetrazol-Kindling And The
Seizure-Induced Neuronal Damage In
The Mouse Hippocampus/S. Lim,
Y. Shon, W. Kim
3.022 Modulation Of NKCC1 And
KCC2 Co-Transporters For Control Of
Drug-Resistant Seizures/V. Dzhala,
Y. Saponjian, Y. De Koninck, K. Staley
3.023 Time Course Of The Neuronal
Sodium Concentration In
PosttTraumatic Epileptogenesis In
Vitro/T. Balena, K. Staley
3.024 A Novel Therapy For Status
Epilepticus Using Biodegradable
Immune-Modifying Nanoparticles/
D. Xu, S. Miller, S. Koh
3.025 Hypothalamus On The Horizon
Of The Seizure Control/T. Chachua,
C. Chern, I. Lilja, J. Veliskova,
L. Velisek
Models
3.026 Use Of Ethosuximide To
Improve Outcome In The Kainic Acid
Model Of Temporal Lobe Epilepsy/
S. S. Iyengar, J. J. LaFrancois,
H. E. Scharfman
3.027 Unravelling The EEG Footprints
That Develop Into Spontaneous
Recurrent Seizures (SRS) During
Epileptogenesis In C57BL6/J Mouse
Model Of Temporal Lobe Epilepsy
(TLE)/S. Puttachary, S. Sharma,
T. Thippeswamy
3.028 The Piriform Cortex In The
Intrahippocampal Kainic Acid Model:
Effects Of Lesions And Deep Brain
Stimulation On Spontaneous
Seizures/M. Sprengers, R. Raedt,
R. Siugzdaite, B. Descamps,
B. Van Nieuwenhuyse, I. Dauwe,
J. Delbeke, W. Wadman, P. Boon, K. Vonck
3.029 Effect Of A Conventional
Antiepileptic Strategy On Seizure
Activity And Neuroprotection In A Rat
Model Of Human Cortical Dysplasia:
Data From A Pilot Study/G. Battaglia,
P. Nobili, A. Finardi, F. Colciaghi
3.030 New Model Of Focal Cortical
Dysplasia Associated Epilepsy/
L. S. Hsieh, J. H. Wen, G. Buchanan,
K. Claycomb, H. Zhan, A. Bordey
3.031 Electrographic Spiking And
Frequency Power Analysis In Mouse
CCI Models Of TBI Compared With
Memory And Motor Deficits/J. Carlsen,
D. Raible, L. Frey, A. Brooks-Kayal
3.032 Oxidative Stress-Mediated
Mitochondrial Dysfunction And
Neuronal Loss Contribute To Cognitive
Deficits In Experimental Temporal Lobe
Epilepsy/J. Pearson, S. Rowley,
L. Liang, B. Day, M. Patel
3.033 Aberrant Diurnal And Circadian
Rhythms In Epileptic Mouse Model/
R. Maganti, E. Wallace, J. Williams
3.034 Microelectrode Array Neuronal
Recordings From Intact Larval Zebrafish/
M. Meyer, A. Poduri, A. Rotenberg
3.035 Enhancing KCC2 By Acute TrkB
Inhibition Rescues PhenobarbitalResistant Seizures In A Model Of
Neonatal Ischemia/S. Kadam, S. Kang,
M. Johnston
3.036 Cardiac Consequences Of
Repeated Brief Seizures In Chronic
Experimental Temporal Lobe Epilepsy/
J. Jefferys, A. Ashby-Lumsden,
T. Lovick, K. Qing, S. Lee, P. Irazoqui
3.037 Spike-Wave Discharges Before
And After The Induction Of Epilepsy In Rats/
J. LaFrancois, K. Bermudez-Hernandez,
H. E. Scharfman
3.038 Pattern Recognition And
Quantification Of Spike-And-Wave
Discharge In Normal And Brain-Injured
Sprague-Dawley Rats/D. Barth,
F. Dudek, K. Rodgers
3.039 Flupirtine Is More Efficacious
Than Phenobarbital In The Treatment
Of Hypoxia-Ischemia Induced Neonatal
Seizures In A Rodent Model/
D. Sampath, A. White, Y. Raol
3.040 EEG Analysis After Ketamine
Induction – Mechanistic Similarities To
Anti-NMDA Receptor Encephalitis/
C. N. Braun, L. UnCheol, S. Glynn,
M. George
3.041 Increased Neuroinflammation
In A Mouse Model Of Tuberous
Sclerosis/A. A. Coley, H. Sun,
S. S. Soldan, F. E. Jensen, D. M. Talos
Monday December 8, 2014
Human Studies
3.053 Does Valproate Increase Levels
Of Folate Receptor Autoantibodies In
Women?/C. Lau, C. Harden,
A. Palacios, R. Finnell
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.054 Characteristics Of Seizure
Termination In Focal And Generalized
Seizures/M. Borzello, A. Maheshwari,
C. Chu, M. Westover, M. Kramer,
S. Cash
3.055 Looking For Complexity In
Quantitative Semiology Of Frontal And
Temporal Lobe Seizures Using
Neuroethology And Graph Theory/
N. Garcia-Cairasco, P. Bertti,
J. Tejada, A. Pinheiro Martins,
M. Cleto Dal-Cól, V. Terra,
J. Cortes de Oliveira, T. Rodrigues Velasco,
A. Ceiki Sakamotob
3.056 Quantitative Proteomic
Profiling Reveals Repression Of
Epilepsy Risk Genes Due To Aberrant
MicroRNA Activity In Epileptogenic
TSC Tubers/A. A. Dombkowski,
D. Cukovic, N. J. Carruthers,
P. M. Stemmer, H. T. Chugani,
D. C. Chugani
3.057 The North American SUDEP
Registry/B. Kaufman, D. Hesdorffer,
E. Donner, G. Lapham, J. Buchhalter,
D. Friedman, O. Devinsky
3.058 Deep Brain Stimulation For
Focal Epilepsy – How Do Changes Of
Interictal Epileptic Discharges
Correspond To Outcome?/H. Lee,
C. Kluge, F. Marquardt, J. Voges,
L. Buentjen, S. Rampp, A. Kowski,
M. Holtkamp, H. Heinze, F. Schmitt
3.059 The Safety, Efficacy And
Dosing Of Barbiturate Coma In
Pediatric Sustained Refractory
Status Epilepticus/E. Payne,
C. Griffiths, H. Frndova, A. Trope,
C. Hahn
3.060 Whole Brain Networks Of
Visual Object Recognition/
C. Kadipasaoglu, C. Conner,
V. Baboyan, N. Tandon
3.061 Ventricular Repolarization
Instability In Children With Epilepsy/
W. Ali, B. Bubolz, A. Anderson, Y. Lai
3.062 Multiple Functions Of The PreCentral Frontal Eye Field/E. C. Brown,
O. Muzik, R. Rothermel, C. Juhasz,
A. Shah, D. Fuerst, S. Mittal,
S. Sood, E. Asano
Biomarkers
3.063 Tracking Inflammation In
Epileptogenic Brain Tissue In The Rat
By Nanoparticles/S. Eyal, E. Portnoy,
B. Polyak, D. Inbar, A. Mann, A. Rai,
A. Bishara, M. Shmuel, S. Magdassi,
T. Ben Hur, D. Ekstein
3.064 High Frequency Oscillations
Deviate From Neuronal Avalanche
Dynamics In The Ictal Onset Zone/
E. Gireesh, C. Jouny, N. Crone
3.065 The Role Of Physiologic
Biomarkers During A Taurine Trial For
Succinic Semialdehyde Dehydrogenase
Deficiency/J. Schreiber, P. Pearl,
I. Dustin, E. Wiggs, E. Barrios,
E. Wassermann, K. M. Gibson,
W. Theodore
3.066 Mass Spectrometry-Based
Metabolomics Approach For
Uncovering Epileptogenic Mechanisms
And Biomarker Discovery/
S. Heischmann, L. B. Gano, K. Quinn,
C. Cruickshank-Quinn, N. Reisdorph,
M. Patel
3.067 Generalized, Automated
Algorithm For Detecting HFOs And
The Extent Of The Seizure Onset
Zone/S. Gliske, W. Stacey
3.068 Occurence Of Ictal High
Frequency Oscillations Mirrows
Seizure Strength In Rats/N. Birk,
K. Somerlik-Fuchs, T. Stieglitz,
A. Schulze-Bonhage, J. Jacobs
3.069 How Reliable Are The HighFrequency Oscillations And Delayed
Responses As Epileptogenicity
Biomarkers? A Study Based On
Intracranial Stimulation/A. Barborica,
C. Donos, M. Maliia, J. Ciurea,
A. Rasina, I. Mindruta
3.070 Early Seizure Detection Using
Relative Gamma And Ripple Band
Phase Decoherence/Z. Nadasdy,
D. Benites, J. Shen, D. Briggs,
D. F. Clarke, R. Buchanan, M. Lee,
D. Nelson, P. Modur
3.071 High Frequency Oscillations In
Patients With Nonlesional Class I
Outcomes In Seizure Onset Channels
Versus Non Seizure Onset Channels
In Temporal And Neocortical
Structures/N. D. Child, J. Cimbalnik,
V. M. Vasoli, V. Svehlik,
B. H. Brinkmann, M. Stead, G. Worrell
3.072 Spectroscopic Imaging In Early
Post-Status Epilepticus In A Rodent
Model/P. S. Pearce, N. de Lanerolle,
A. Rapuano, T. Hitchens, J. W. Pan
3.073 Automated High-Frequency
Oscillation Detection From Tripolar
Concentric Ring Electrode Scalp
Recordings/M. Abtahi,
I. E. Martínez-Juárez, O. Makeyev,
A. Medvedev, J. Gaitanis, R. Fisher,
W. Besio
3.074 Modulating Epileptogenesis In
The Glutamine-Synthetase Deficient
Model Of MTLE/E. Perez, H. Zaveri,
R. Joshi, H. Wang, E. Damisah,
R. Dhaher, T. Eid
MONDAY
3.042 In Vivo Modulation Of Synaptic
Noise: A Novel Model Of Ictogenesis/
H. Luna-Munguia, P. Starski, W. Stacey
3.043 Lithium-Pilocarpine And DFPInduced Status Epilepticus In
Immature Rats: Behavioral,
Electrographic, And Neuropathological
Characteristics/E. A. Scholl,
N. Simon, M. Lehmkuhle, J. Ekstrand,
F. E. Dudek
3.044 Epilepsy In A Novel Tuberous
Sclerosis Mouse Model/S. C. Dhamne,
E. Chadwick, S. Lammers,
M. Q. Hameed, D. Kwiatkowski,
A. Rotenberg, M. Sahin
3.045 First In-Vivo Model For
Electrically Induced Seizures – An
Electroclinical Characterization/
A. Y. Kitay, M. Brosch, F. Marquardt,
L. Buentjen, C. Kluge, J. Mylius,
E. Selezneva, K. Kopitzki, J. Voges,
H. Heinze, H. Scheich, F. Schmitt
3.046 Identifying Gene Pathways
Activated After Audiogenic Atimulus
In Wistar Audiogenic Rats/A. Matos,
A. S. Schwambach Vieira, V. Pascoal,
C. S. Rocha, D. Nascimento,
S. Martins, C. Maurer Morelli,
A. Martins, A. Godard,
I. Lopes-Cendes
3.047 Comparison Of Spike-Wave
Discharges And Other Oscillatory
Activity In Normal Animals With
Spontaneous Recurrent Seizures
Across Several Animal Models Of
Acquired Epilepsy/F. Dudek,
K. M. Rodgers, W. A. Pouliot,
S. Kadam, E. H. Bertram, D. S. Barth
3.048 Rapamycin Normalizes Total
EEG Power In Neuron Subset-Specific
PTEN Knock-Out Mice/
A. Regnier-Golanov, L. Nguyen,
A. Brewster, V. Patil, A. Anderson
3.049 Early EKG Changes And
Cardiac Activation Of Intracellular
Signaling Cascades In A Model Of
Acquired Epilepsy/A. Brewster,
A. Anderson, Y. Lai
3.050 Late Inhibition Of mTOR
Suppresses Fully Established Epilepsy
And Associated Neuropathology In The
NS-Pten KO Mouse Model Of Cortical
Dysplasia/L. Nguyen, A. Brewster,
M. Clark, A. Regnier-Golanov,
C. Sunnen, V. Patil, A. Anderson
3.051 Neonatal Stroke And
Phenobarbital Treatment: Improved
T-Maze Function And Impact On PostStroke Hilar Neurogenesis/A. Comi,
M. Mateo, S. George, A. Garson,
K. Fisk, H. Miao
3.052 Gender Differences In
Cerebrospinal Fluid Levels Of
Monamine Metabolites In The
Baboon/M. Patel, J. Rogers, C. Szabo,
M. Leland, M. A. Javors
Poster Session 3
Behavior/Neuropsychology/
Language
Adult
3.075 Development And Field-Testing
Of An Epilepsy Self-Management
Instrument For Adults With
Epilepsy/C. Escoffery, Y. Bamps,
W. LaFrance, S. Stoll, R. Shegog,
J. Buelow, P. Shafer, N. Thompson
3.076 Distinct Domains Of Impulsivity
Are Impaired In Juvenile Myoclonic
Epilepsy, But Not In Temporal Lobe
Epilepsy/P. Rzezak, S. Moschetta,
E. Lima, C. X. Castro, A. Coan,
C. Guerreiro, G. Busatto, K. Valente
3.077 Stability And Variability Of
Cognitive Performance In Patients
With Epilepsy/M. T. Lutz, T. Mayer
67
Monday December 8, 2014
3.078 Depression And Isolation In
People With Epilepsy/N. Thompson,
Y. A. Bamps, L. Selwa, S. Stoll,
C. Begley, E. K. Johnson, R. Fraser
3.079 PHQ-9 And GAD-7 As Reliable
Screening Tools For Mood Disorders
In People With Epilepsy (PWE)/
I. Ahmed, S. Nair, A. Riaz, I. Ali
3.080 The Impact Of Disease
Variables And Standard Cognitive
Measures On Social Cognition In
Epilepsy/K. Bujarski, L. Flashman,
R. M. Roth
3.081 Felt Stigma In Families
Containing Multiple Individuals With
Epilepsy/M. Sabatello, S. T. Sorge,
J. O. Okeke, V. Tangel, S. Shostak,
J. C. Phelan, J. Goldsmith,
M. Winawer, D. Hesdorffer,
W. K. Chung, R. Ottman
3.082 Depression And Seizure
Frequency Predicts Worse Social
Functioning In Patients With Juvenile
Myoclonic Epilepsy (JME)/
S. C. Moschetta, C. A. Guerreiro,
C. Lima Castro, A. Coan, P. Rzezak,
K. Valente
3.083 Unique Characteristics Of
Patients With Comorbid Epileptic And
Psychogenic Nonepileptic Seizures/
J. J. Konikkara, J. Pacheco,
P. Van Ness, M. Agostini, R. Hays,
L. Howe-Martin, C. B. Culver,
J. Munoz, K. Ding, P. Modur, P. Gupta
3.084 Preoperative Hippocampal
Volume And Neuropsychological
Outcomes/S. C. Germeyan, E. Wiggs,
L. Sepeta, E. Emery, I. Dustin,
K. zaghloul, S. Inati, W. Theodore
3.085 Comparison Of Common Data
Elements From The Managing Epilepsy
Well (MEW) Integrated Database And
A Well Characterized Sample With
Nonepileptic Seizures/W. LaFrance,
Jr, Y. Bamps, S. Stoll, S. S. Sahoo,
E. Welter, J. Sams, C. Tatsuoka,
M. Sajatovic
Genetics
Human Studies
3.086 Screen For Somatic Mosaic
Mutations In Unexplained Dravet
Syndrome Patients/C. Myers,
J. McMahon, I. Scheffer, H. Mefford
3.087 The Phenotypic Spectrum Of
SCN2A Encephalopathy: A Diagnosis
With Treatment Implications/
K. Howell, J. McMahon, G. L. Carvill,
A. Poduri, M. T. Mackay,
M. V. Rodriguez Casero, R. Webster,
D. Clark, J. L. Freeman, S. Calvert,
S. Mandelstam, H. Mefford,
A. S. Harvey, I. Scheffer
3.088 Are Mutations Of The
Respiratory Control Gene PHOX2B
Associated With Sudden Unexpected
Death In Epilepsy (SUDEP)?/
B. M. Regan, R. D. Bagnall,
D. E. Crompton, C. Cutmore,
S. Berkovic, I. E. Scheffer,
C. Semsarian
68
Poster Session 3
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.089 Whole-Exome Sequencing In 84
Cases Of Unsolved Progressive
Myoclonus Epilepsy/M. Muona,
S. Berkovic, L. M. Dibbens,
K. L. Oliver, S. Maljevic, T. Joensuu,
M. A. Bayly, S. Petrou, H. Lerche,
A. Palotie, A. Lehesjoki
3.090 Familial Adult Myoclonic
Epilepsy: A New Family Consistent
With Linkage To Chromosome 2/
K. Klein, M. Pendziwiat,
R. Straussberg, I. Blatt, C. E. Kim,
P. S. Reif, S. von Spiczak, A. Korczyn,
H. Muhle, F. Rosenow, H. Hakonarson,
G. Kuhlenbäumer, H. Goldberg-Stern,
U. Stephani, Z. Afawi, I. Helbig
3.091 Genetic Determinants Of
Common Epilepsies: A Meta-Analysis
Of Genome-Wide Association
Studies/G. Na
3.092 CHD2 Myoclonic
Encephalopathy: Self-Induced
Seizures, Photosensitivity And
Variable Cognitive Outcome/
R. Thomas, L. Zhang, G. L. Carvill,
J. Archer, S. Mandelstam, D. Craiu,
S. Berkovic, D. Gill, H. Mefford,
I. Scheffer
3.093 Whole-Exome Sequencing And
Targeted Re-Sequencing In Pediatric
Epileptic Encephalopathies/
J. L. Michaud, M. Lachance,
F. F. Hamdan, S. Dobrzeniecka,
H. Mefford, R. G. Lafrenière,
B. Minassian, P. Cossette,
E. Rossignol
3.094 CACNA1A-Related Hemiplegic
Migraine Mimicking Psychogenic
Non-Epileptic Seizures (PNES)/
M. Chadehumbe, M. Mintz, R. Boles
3.095 Epilepsy Genetics Initiative
(EGI)/D. Goldstein, E. Heinzen,
D. Lowenstein, S. Berkovic,
T. Dixon-Salazar, J. Milder, H. White,
O. Devinsky, D. Dlugos, W. Gallentine,
M. Mikati, A. Poduri, I. Scheffer,
J. Sullivan
3.096 Copy Number Variants Are An
Important Cause Of Unexplained
Epilepsy Plus Other Neurological
Abnormalities/S. E. Buerki, E. Sade,
P. Eydoux, M. Connolly, M. Demos
3.097 Severe Multi-Organ
Involvement Including Pancreatic
Neuroendocrine Tumor In A 51-YearOld Female With Tuberous Sclerosis
Complex/F. Andermann, D. Amrom,
M. Heshmati Moghaddam, P. Zanelli,
E. Andermann
3.098 Regional Variation Of SLC7A11
Expression In Glioblastoma
Associated Seizures/J. Lee, J. Snyder,
T. Mikkelsen, P. Wen
3.099 Uncovering New Genetic Loci
For Infantile Spasms Syndrome/
E. D. Marsh, J. Glessner, X. Bozarth,
W. Dobyns, H. Hakonarson, I. Helbig
3.100 Utilizing Brain Expression
Networks To Prioritize Candidate
Epileptic Encephalopathy Genes/
K. L. Oliver, V. Lukic, N. P. Thorne,
S. F. Berkovic, I. E. Scheffer, M. Bahlo
3.101 Association Between
Polymorphisms In Genes Involved In
P-Glycoprotein Regulation And
Pharmacoresistance In ChildhoodOnset Epilepsy/J. Montalvo,
M. Rios-Motta, S. Gonzalez-Crespo,
L. Gonzalez-Sepulveda, K. Acevedo,
M. Vazquez, I. Pita
3.102 Whole Exome Sequencing In
Intractable Paediatric Epilepsy
Patients In Calgary/L. Bello-Espinosa
3.103 Copy Number Variants In
Children With Epilepsy/
S. J. Mackenzie, Y. Eksioglu
3.104 Natural History Of Seizures In
Rett Syndrome And MECP2-Related
Disorders/D. Tarquinio, J. B. Lane,
W. Hou, W. Kaufmann, S. A. Skinner,
K. J. Motil, J. L. Neul, D. Glaze,
A. K. Percy
Animal Studies
3.105 Superimposing Status
Epilepticus On NS-PTEN
Haploinsufficient And Wild Type Mice
Results In Long-Term Changes In
Behavior/G. Smith, J. White,
J. Nicoletti, A. Pandian, J. Lugo
3.106 Selective Targeting Of Scn8a
Expression Confers Seizure
Resistance In Two Mouse Models Of
Refractory Epilepsy/J. Wong,
C. Makinson, H. Zafar, A. Escayg
3.107 Scn2a-null Heterozygosity
Improves Survival And Modifies
Neurocardiac Interaction In The
Kcna1-Null Mouse Model Of SUDEP/
E. Glasscock, N. Gautier, B. Karumuri,
R. Liu, I. Vlachos, L. Iasemidis
Neuropathology of Epilepsy
Human Studies
3.108 Oligodenderoglia-Like Cells In
White Matter Recruiting The
Extensive Epileptogenic Zones In
Pediatric Intractable Focal Epilepsy/
S. Sakuma, W. Halliday, K. Okanari,
S. Baba, M. Nakajima, Y. Sato,
A. Ochi, H. Otsubo
3.109 Hippocampal Changes In
Refractory Status Epilepticus:
Autopsy Findings/K. M. Ikeda, L. Ang,
G. Young
3.110 Neuroinflammatory Processes,
Acute Neuronal Injury And Blood Brain
Barrier In SUDEP/Z. Michalak,
D. Obari, M. Thom, S. Sisodiya
3.111 Cerebral Glucose
Hypometabolism Is Associated With
Mitochondrial Dysfunction In Patients
With Intractable Epilepsy And Cortical
Dysplasia/J. Tenney, L. Rozhkov,
P. Horn, L. Miles, M. Miles
3.112 The Serum Levels Of Sodium
And Uric Acid In Children With Benign
Convulsion With Mild Gastroenteritis/
S. Kim, J. Kang, H. Bang, T. Kim,
H. Kim, J. Kang, J. Kim, Y. Kim
Monday December 8, 2014
3.113 Gene Expression Profiling In
Dentate Granule Cells Of Mesial
Temporal Lobe Epilepsy Patients With
And Without Hippocampal Sclerosis/
N. G. Griffin, Y. Wang, L. Hong,
C. Hulette, M. Haglund, R. Radtke,
P. Skene, S. Sinha, E. Heinzen
3.114 A Case Of Glioneuronal Tumor
With Focal Cortical Dysplasia Type
IIb/T. Saito, S. Sukigara, S. Hanai,
A. Takahashi, M. Sasaki, T. Otsuki,
M. Itoh
In Vitro Studies
3.125 Laser Scanning
Photostimulation Reveals Altered
Astrocyte Maturation In A Model Of
Developmental Cortical Malformation/
M. Armbruster, C. Dulla
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.126 Real-World Assessment Of The
Burden Of Epilepsy In Tuberous
Sclerosis Complex (TSC) Patients In
The United Kingdom (UK)/P. Crawford,
C. Shepherd, D. Demuth, P. Nasuti,
L. Lucchese, Z. Haider, E. Gray,
M. Magestro
3.127 Managing Information Well:
Towards An Ontology-Driven
Informatics Platform For Data
Sharing And Secondary Use In
Epilepsy Self-Management Research
Centers/S. D. Lhatoo, S. S. Sahoo,
G. Zhang, Y. Bamps, R. Fraser,
S. Stoll, C. Tatsuoka, E. Welter,
M. Sajatovic
3.128 Sudden Unexpected Death In
Epilepsy. A Population-Based Study/
A. Einarsdottir, O. Sveinsson,
E. Olafsson
3.129 Using Routine Data To
Investigate Secular Trends In Hospital
Admission Amongst Children With
Epilepsy: A Nationwide Study/
O. Ajetunmobi, C. Weir, R. Wood,
R. Chin
3.130 A Study Of Epilepsy Prevalence
And Incidence In The U.S. Using
Administrative Claims Data/
S. Helmers, D. Thurman, T. Durgin,
A. Kalsanka Pai, A. Patel, E. Faught
3.131 Epidemiology Study Of
Association Between Onset Of
Chronic Headache And Epilepsy/
T. Chen
3.132 Long QT Mutations And QT
Prolongation Are Linked With An
Increased Risk Of Seizures/
D. S. Auerbach, M. Ruwald,
M. Andrews, A. Moss
3.133 Retrospective Review Of
Seizures Associated With Posterior
Reversible Encephalopathy Syndrome
(PRES)/N. Dike, S. Rana
3.134 Trajectories Of Emotional
Well-Being In Children With Newly
Diagnosed Epilepsy/S. W. Goodwin,
P. Wilk, M. Campbell, K. N. Speechley
3.135 Fertility In Epilepsy: Effects Of
Estimated Offspring Risk And Genetic
Attribution/V. Tangel, S. T. Sorge,
J. O. Okeke, S. Shostak, J. C. Phelan,
J. Goldsmith, M. Winawer,
D. Hesdorffer, W. K. Chung,
R. Ottman
3.136 Defining The Prevalence And
Characteristics Of Seizure Clusters/
T. Choezom, S. Zhang,
S. Radhakrishna, J. Bonito, H. Zaveri,
R. Joshi, L. Hirsch, K. Detyniecki
3.137 Sudden Unexpected Death In
Dravet Syndrome: A Case-Control
Study/E. Donner, D. Friedman,
B. Kaufman, D. Hesdorffer,
G. Lapham, J. Buchhalter, J. Thaler,
S. Rai, A. Thaler, O. Devinsky
3.138 Predictors Of Seizure
Clusters/B. Chen, H. Choi, L. Hirsch,
R. Buchsbaum, K. Kato, A. Legge,
K. Detyniecki
3.139 The Clinical And Social Impact
Of The Post-Ictal State/C. Josephson,
N. Jette, Y. Aghakhani, P. Federico,
A. Hanson, W. Murphy, N. Pillay,
S. Wiebe
3.140 The Elixhauser Index In Incident
Epilepsy And First Unprovoked
Seizure: Means And Reliability Of
Patient Or Parent Report And
Hospital Medical Record/E. Leaffer,
A. Hauser, A. Pack, E. Baldin,
C. I. Akman, D. Hesdorffer
3.141 How Do Caregivers Determine
Seizure Severity In Their Child With
Epilepsy?/S. Shih, M. Ardini,
B. Kroner, W. Gaillard,
S. Cushner-Weinstein, J. Salpekar,
K. Havens, A. Kao, T. Zelleke,
D. Depositario-Cabacar
3.142 Patterns Of Comorbidity In
Pregnant Women with Epilepsy/
A. M. Malek, D. A. Wilson,
B. Wannamaker, R. B. Newman,
J. E. Vena, A. Selassie
3.143 Tuberous Sclerosis – Does
Regional Differences In Clinical
Features Exist?/E. V. Caetano,
P. B. Cerqueira, M. G. Manreza,
U. C. Reed, L. B. Sampaio,
E. C. Miotto, F. A. Costa,
P. S. Mendes, B. J. Correa
3.144 Parental Worry About
Nocturnal Seizures And Utilization Of
Methods For Monitoring/B. Kroner,
S. Shih, M. A. Ardini, W. Gaillard
3.145 Etiologies And Yield Of
Investigations For Infantile Spasms:
Results Of A U.S. Multicenter,
Prospective Study/E. Wirrell, C. Joshi,
R. Shellhaas, C. Keator, S. Kumar,
W. Mitchell
Neurophysiology
Other Clinical EEG
3.146 Pharmacologically Induced
Burst Suppression In Pediatric And
Adult Patients – Varying But
Predictable Pattern?/L. M. Sorin,
B. Jabo, T. Losey
3.147 Completely Lateralized Vertex
Waves Of Sleep Are A Normal
Phenomenon: A Retrospective,
Blinded, Case Control Study/
J. N. Brenton, J. R. Mytinger
3.148 Posterior Rhythmic Delta
Activity In Patients With Absence
Epilepsy/R. Fabris, L. Wong-Kisiel,
K. Nickels
3.149 Multifocal Electrographic
Seizures Recorded By 128 Channel
Dense Array High-Resolution EEG In
Outpatient EEG LAB/H. Hasegawa
3.150 EEG Focal Interictal
Epileptiform Transients (FIET) & Their
Correlation With Clinical Diagnosis/
F. Matsuo
3.151 How Much Does Sleep
Deprivation EEG Useful For Detecting
Epileptiform Abnormalities?/D. Ozbek,
I. Midi, K. Agan
MONDAY
Animal Studies
3.115 NMDA Receptor Activation
Contributes To Benzodiazepine
Refractoriness By Enhancing Ampa
Receptor Mediated Transmission
During Status Epilepticus/S. Joshi,
K. Rajasekaran, J. Williamson,
J. Kapur
3.116 Circulating Ccr2+ Monocytes
Display Delayed Brain Infiltration After
Chemoconvulsant-Induced Status
Epilepticus/N. Varvel, J. J. Neher,
R. J. Miller, M. Jucker, R. Dingledine
3.117 Deletion Of Micro-RNA-146a
Leads To Fewer Animals Developing
Acute Behavioral Seizures Following
Viral Encephalitis/M. F. Cusick,
J. E. Libbey, R. M. O’Connell,
R. S. Fujinami
3.118 Effects Of Neuronal Nitric
Oxide Synthase Inhibition In A
Neonatal Mouse Model Of Acute
Hypoxic Seizures/S. A. Zanelli,
P. Wagley, J. Kapur
3.119 Regulation Of Hippocampal
Glutamate Transporter-1 (GLT1)
Expression In The Intrahippocampal
Kainic Acid Model Of Epileptogenesis/
J. A. Hubbard, J. Szu, D. Binder
3.120 Impact Of Targeted Ablation Of
Developing Dentate Granule Cells On
Temporal Lobe Epileptogenesis/
B. Hosford, J. Liska, S. Danzer
3.121 Do Ripples Change After
Pilocarpine-Induced Status
Epilepticus?/C. Behr, M. Lévesque,
C. Pack, J. Gotman, M. Avoli
3.122 Sex- And Brain Region-Specific
Regulation Of Brd2 In GABAergic
Neurons In A Juvenile Myoclonic
Epilepsy Mouse Model/J. A. Miller,
F. Mohammad, D. S. Chandler,
J. Veliskova, L. Velisek,
D. A. Greenberg
3.123 Evaluation Of The Inflammatory
Process In Focal Cortical Dysplasia
Model By Freeze Lesion/A. Donatti,
A. Fernandes, N. Garcia-Cairasco
3.124 Effects Of Postnatal
Inflammation On Brain Excitability In A
Mouse Model Of Autism Spectrum
Disorder/M. L. Lewis, L. Qulu,
S. A. Candy, J. M. Rho, Q. J. Pittman
Epidemiology
Poster Session 3
69
Monday December 8, 2014
3.152 Generalized Onset Seizures
With Focal Evolution Should Be
Recognized As A Seizure Type/
A. Linane, B. Abou-Khalil, A. Lagrange
3.153 Preictal Failure Of Post-Spike
Slow Waves To Control Spike-Related
High-Frequency Oscillations Is
Associated With Seizure Initiation In
Focal Cortical Dysplasia Type II/
Y. Sato, S. M. Doesburg, S. M. Wong,
A. Ochi, H. Otsubo
3.154 Correlation Between
Bispectral Index And
Electrocorticography During Epilepsy
Surgery/D. San Juan Orta,
M. Gómez Ramírez,
L. R. Rodríguez Arias,
A. Osorio Santiago, A. López Pizano,
R. Llerenas Zamora,
R. Vázquez Gregorio,
A. Espinoza López,
C. Trenado, A. Hernandez Ruiz,
J. Delgado-delaMora,
M. Alonso-Vanegas, D. Anschel
3.155 Diagnostic Utility And Yield Of
Routine Electroencephalogram Study
In Patients Referred By
Epileptologists And Carrying A
Diagnosis Of Epilepsy/A. Gudlavalleti,
B. B. Allen, N. K. Sethi, G. Solomon
3.156 Diagnosis Of Electrical Status
Epilepticus In Sleep Made By A
Clinician Versus Computerized Spike
Detection Software: A Comparison/
T. Bryant, M. Guess, L. Wenzel,
D. Tadlock, C. Joshi
3.157 Validation Of The M-Score, An
EEG Grading Scale For Infantile
Spasms/J. R. Mytinger, S. A. Hussain,
J. J. Millichap, N. Ryan, G. L. Heyer
3.158 30 Minute Versus Extended
Outpatient Eeg For The Detection Of
Epileptiform Abnormalities In New
Referrals/D. Burkholder, J. Britton,
V. Rajasekaran, R. Fabris,
J. C. Perumpillichira, K. Kelly, E. So,
K. Nickels, L. Wong-Kisiel,
T. Lagerlund, G. Cascino, G. Worrell,
E. Wirrell
3.159 High-Rate REM Sleep High
Frequency Oscillations (HFOs) Are
Specific To Epileptogenicity/
R. Sakuraba, M. Iwasaki, E. Okumura,
K. Jin, Y. Kakisaka, K. Kato,
T. Tominaga, N. Nakasato
3.160 The Dynamic Changes Of Ictal
High Frequency Oscillations During
Temporal Lobe Seizures Recorded By
Stereo-Electroencephalography/
S. Wu, J. Tao, S. Rose, S. Lhatoo,
H. Lüders
3.161 Detectability Of Fast Ripples
On The Scalp EEG: A Preliminary
Study With Subdermal Electrodes/
F. Pizzo, B. Frauscher,
T. Ferrari-Marinho, F. Dubeau,
J. Gotman
3.162 Fixation-Off Sensitivity (FOS)Like Phenomenon After Embolic
Strokes Of The Parietal And Occipital
Regions/F. Tirol, A. Foroughi,
P. Foreman
70
Poster Session 3
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.163 The Intracerebral EEG Pattern
Of Focal Cortical Dysplasia Changes
During The Different Stages Of
Sleep/I. Menezes Cordeiro,
N. von Ellenrieder, F. Dubeau,
J. Gotman, B. Frauscher
3.164 Changes In Scalp EEG Spectral
Content During Deep Temporal Lobe
Seizures Lacking A Scalp Ictal
Correlate/A. D. Lam, S. S. Cash
3.165 Quantitative Analysis Of
Interictal Discharges In Mesial
Temporal Lobe Epilepsy/L. A. Oliveira,
A. D. Borges, S. Yamashita,
L. Betting
3.166 The Epileptiform Abnormalities
In Pediatric Autoimmune
Neuropsychiatric Disorders
Associated With Streptococcus
(PANDAS) Patients/X. Zhou,
A. Buckley, S. Swedo, S. Inati
3.167 How High Is High Enough? Do
Faster EEG Sampling Rates Lead To
Improved Seizure Onset Localization?/
S. P. DeVries, K. A. Davis,
J. B. Wagenaar, W. C. Stacey
3.168 Changes In Intracranial
Electroencephalography (iEEG) In Five
Patients During WADA/S. Le,
K. J. Meador
3.169 Increased Left Hemisphere
Interictal Epileptiform Discharges Are
Associated With Language Based
Knowledge And Learning In Benign
Rolandic Epilepsy/M. Takeoka,
J. Girard, C. Harini, C. Vega, K. Boyer
3.170 EEG Photic Driving: Clinical
Significance Of Asymmetric
Responses/M. T. Kendirli, H. Tekeli,
E. Togrol, F. Ozdag
3.171 The Utility Of Ambulatory
Electroencephalography (aEEG)/
K. AbdeleRahman, R. Mahajan,
M. Grigg-Damberger
3.172 Prevalence Of Epileptiform
Activity In Children Less Than 1 Year
Of Age Referred For Polysomnography/
A. W. Ho, A. Adeleye, A. Nettel-Aguirre,
V. Kirk, J. Buchhalter
3.173 Differences In The Yield Of
Routine EEG Studies In Patients 60
Years Or Older As Compared To
Patients Less Than 60-Years-Old
Presenting With Transient Loss Of
Consciousness/N. Gupta,
C. Christodoulou, J. Miller-Horn
3.174 Broadband Intracranial Ictal
EEG Analysis In Lesional And NonLesional Pharmacoresistant
Epilepsy/M. Dhakar, A. Shah
3.175 Characteristic Electrographic
Findings In Fraternal Twins With
Sialidosis/A. Sheikh, J. Menon,
V. Ramsey-Williams, D. Cameron, H. Li
3.176 Fun Finding Artifacts This Is
An Interactive Poster Showing Some
Common And Uncommon Artifacts.
The Goal Is To Challenge All Levels Of
EEG Knowledge. See The Artifact And
You Guess What You Think That It Is,
Once You Have An Idea You Can Check
Your Answer/C. L. Riley
3.177 Intracranial Recording: A
Glimpse On White – Grey Matter
Differences/M. Mercier, S. Bickel,
P. Megevand, D. Groppe, A. Mehta,
F. Lado
3.178 Visual-Evoked Responses As A
Biomarker For Neural HyperExcitability In Childhood Absence
Epilepsy/R. Holt, F. Pei, B. Porter,
J. Tsai, A. Norcia
3.179 Eletroencephalographic Profile
Of Outpatients Presenting Seizures
During Routine EEG on a Tertiary
Teaching Hospital/R. Alessi,
C. N. Alencar, P. B. Lima,
M. R. Silveira, J. Q. Andrade,
E. Garzon
3.180 Photic Stimulation: Get More
Information From An Old Test; Can We
Do Better? Utility Of Change In SPR
As A Marker Of Chronc Efficacy/
P. Timmings
Computational Analysis & Modeling
Of EEG
3.181 Accuracy Of EEG
Interpretation Without A Reference
Standard/J. Slater, A. C. Grant,
A. Omurtag
3.182 On Seizure Dynamics And
Propagation/C. Bernard, V. Jirsa,
W. Stacey, F. Bartolomei, T. Proix
3.183 Spectral Analysis Of
Intracranial Interictal Bursts May
Localize Seizure Onset/H. Ung,
K. Davis, D. Wulsin, B. Litt
3.184 Epileptic Spikes And High
Frequency Oscillations Are More
Frequent During Generalized Slow
Oscillations Than During The Rest Of
NREM Sleep/B. Frauscher,
N. von Ellenrieder, T. Ferrari-Marinho,
F. Dubeau, M. Avoli, J. Gotman
3.185 Ripple (80-250Hz)
Characterization In Nonepileptic
Brain Regions/N. von Ellenrieder,
B. Frauscher, T. Ferrari-Marinho,
F. Dubeau, J. Gotman
3.186 Interictal Localization Of The
Seizure Onset Zone Using High
Frequency Oscillations And Visibility
Graphs/A. M. Spring, R. A. Bessemer,
D. J. Pittman, Y. Aghakhani, P. Federico
3.187 Interictal Phase Clustering Of
High Frequency Oscillations Derived
From 256-Channel Scalp EEG
Correlates With The Epileptogenic
Zone/M. D. Holmes, C. Ramon
3.188 MRI And Electrical Source
Analysis In Patients With Temporal
Lobe Encephaloceles: Localization And
Clinical Correlation/M. Quach
3.189 Index Of HFO Cross-Frequency
Coupling For Assessing The Seizure
Onset Zone/C. Jouny, U. Malinowska,
M. Cervenka, G. Bergey
3.190 Investigation Of HFO In Human
Intracranial EEG With A Semi-Supervised
X-means Clustering/S. Liu, N. Ince,
A. Abosch, T. Henry, Z. Sha
Monday December 8, 2014
3.191 Co-Occurrence Of High
Frequency Oscillations For
Identification Of The Seizure Onset
Zone/U. Malinowska, G. Bergey,
M. Cervenka, C. Jouny
3.192 Integrating 3D Source
Localization And Connectivity Maps
For Guiding Pre-Surgical Subdural
Grid Placement/A. Pinzon-Ardila,
M. Cabrerizo, N. Rojas, P. Jayakar,
G. Sergio, M. Adjouadi
3.193 Validating Individual Head
Models In Electrical Source Imaging
Of Spikes And Seizures/K. Jenson,
D. Tucker, P. Luu, M. D. Holmes
3.194 Source Localization Techniques
Are Essential In More Accurate
Determination Of Target Tuber
Conglomerates For MRI-Guided LaserInduced Thermal Ablation For
Treatment Of Intractable Epilepsy And
Neurocognitive Comorbidities In
Pediatric Tuberous Sclerosis/
Y. Eksioglu, Z. Tovar-Spinoza, F. Duffy
3.195 Frequency-Frequency Coupling
Of Brain Oscillations In Studying Ictal
EEG Activity/Y. Hsin
Clinical Epilepsy
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.202 A Brain-Machine Interface For
Burst Suppression Control In
Pediatric Status Epilepticus/
C. Papadelis, C. Doshi,
S. Thome-Souza, E. Grant, R. Tasker,
T. Loddenkemper
3.203 New-Onset Refractory Status
Epilepticus: Etiology And Outcome In
A Retrospective Series Of 121
Cases/N. Gaspard, B. Foreman,
V. Alvarez, C. M. Cabrera Kang,
J. Probasco, A. Jongeling, E. Meyers,
K. Haas, A. Espinera, S. Schmitt,
E. Gerard, T. Gofton, P. Kaplan,
J. Lee, B. Legros, J. Szaflarski,
M. Westover, S. Laroche, L. Hirsch
3.204 Clinical Correlates And
Outcome Of Cyclic Seizures In
Critically Ill Patients: A Case-Control
Study/L. F. Pinto, E. Gilmore,
O. Petroff, N. Rampal, L. Hirsch,
N. Gaspard
3.205 Eyewitnesses Of Seizures Are
More Accurate Historians Than The
Patients/M. Spitz, S. Moreland,
K. Horiuchi, K. Lervik, P. Korb,
C. Drees, R. DeBello, L. Strom,
L. Frey, A. Shrestha, C. O’Brien
3.206 Automated EMG Based
Seizure Detection And Quantification
For The Home And The EMU, A
Prospective Multicenter Study/
J. Cavazos, M. Girouard, L. Whitmire
3.207 Jeavons Syndrome: Seizing The
Light – A Compulsive Epilepsy
Disorder?/A. Yadav, I. Tuxhorn
3.208 The Proportion Of Time Spent
In The Tonic Phase Of A Convulsive
Seizure Predicts Postictal
Hypopnea/E. Acton, A. Thaler,
A. Krause, C. Anderson,
A. Esfahanizadeh, J. Pollard
3.209 Associated Cardiac Findings In
Children With Down Syndrome And
Infantile Spasms/D. Daniels, K. Knupp,
T. Benke, F. Hickey,
K. Wolter-Warmerdam, D. L. Cohen
3.210 KCNQ2-Deficiency: Clinical
Spectrum Of Epilepsy,
Encephalopathy, And Response To
Ezogabine/K. Park, J. Millichap,
E. C. Cooper
3.211 Temporal IEDs In
Extratemporal Lobe Epilepsy Are
Associated With Temporal
Hypometabolism On PET Imaging/
E. Hartl, J. Rémi, A. Loesch,
C. Vollmar, S. Noachtar
3.212 Co-Oscillation Of Spikes,
Spindles And K Complexes: A Useful
Biomarker Of Epileptogenicity And
Outcome In Children With Epilepsy?/
A. Zrik, I. Tuxhorn, A. Yadav, P. Rai
3.213 Clinical And Intracranial EEG
Features After Secondarily
Generalized Seizures/L. M. Bateman,
C. Schevon
3.214 Characteristics Of Other
Seizure Types Associated With
Infantile Spasms/J. Millichap,
L. Wong-Kisiel, E. Yozawitz, J. Sullivan
3.215 Electrographic And
Hemodynamic Changes In Patients With
Focal Seizures/K. Hecox, J. Zemblis,
C. Sauer, H. Whalen, P. Monrad
3.216 Clinical Course of Seizures In
Ring Chromosome 20 Syndrome/
H. Ikeda, H. Ikeda, T. Hiyoshi,
E. Yamazaki, K. Yoshimura, Y. Inoue
Clinical Treatments
3.217 The Application Of An
Explanatory Model Of Treatment
Decision- Making In A Patient With
Medically Refractory Focal Epilepsy/
S. Dewar, H. Pieters
3.218 Protective Effects Of Vagus
Nerve Stimulation On Cardiac
Electrical Instability In Patients With
Drug-Resistant Epilepsy/A. Schomer,
B. D. Nearing, S. Schachter,
E. Bachman, P. Shafer, D. Sundstrom,
R. L. Verrier
3.219 Pyridoxine Deficiency In Adult
Status Epilepticus Patients/H. Dave,
R. Ramsay, F. Khan, V. Sabharwal,
I. Iwuchukwu
3.220 Outpatient Initiation Of The
Ketogenic Diet: The BC Children’s
Hospital Experience/A. Michoulas,
M. Connolly, K. Selby, E. Anghelina,
A. Ferguson, C. Simonson, F. Zanotto,
K. Farrell
3.221 Electrical Stimulation Of The
Hippocampus For Medically Refractory
Mesial Temporal Lobe Epilepsy: A
Long-Term Follow-Up Study/S. N. Lim,
C. Y. Lee, S. T. Lee, P. H. Tu,
B. L. Chang, C. H. Lee, C. W. Chang,
W. E. Tseng, T. Wu
3.222 A Lack Of Clinically Significant
Vision Loss Among Vigabatrin-Treated
Patients With Infantile Spasms: The
UCLA Experience/M. Schwarz, M. Li,
J. Tsao, R. Zhou, Y. W. Wu,
S. A. Hussain
3.223 The National Infantile Spasms
Consortium (NISC): Moving Towards
Standardization Of Care And Improved
Treatment And Outcomes In Infantile
Spasms/N. Ryan, J. Coryell,
J. R. Mytinger, K. Nickels, K. Knupp
3.224 Improving Efficiency In
Management Of Status Epilepticus
Using A Specific EMR Order Set/
J. Boggs, R. Bolen, L. Bishop,
M. Bailey, M. Bennett
3.225 Management Of Super
Refractory Status Epilepticus With
Ketamine And/Or Propofol/V.
Sabharwal, H. Dave, R. Lancaster,
M. Almualim, F. Khan, H. McGrade,
E. Ramsay
3.226 New-Onset Refractory Status
Epilepticus: Immune Modulatory
Therapy And Outcome/C. M. Cabrera
Kang, S. M. Laroche, B. Foreman,
V. Alvarez, J. Probasco, A. Jongeling,
E. Meyers, K. Haas, S. E. Schmitt,
E. Gerard, T. Gofton, P. W. Kaplan,
J. Lee, B. Legros, J. P. Szaflarski,
M. Westover, L. J. Hirsch, N. Gaspard
MONDAY
Clinical Diagnosis
3.196 Clinical Manifestations Of The
Patients With Caspr2 Encephalitis/
J. Sunwoo, J. Byun, J. Moon, J. Shin,
J. Jun, S. Lee, K. Jung, K. Jung,
K. Chu, S. Lee
3.197 Asystole In The Epilepsy
Unit/A. Honig, S. Chen, F. Benninger,
R. Bar Yossef, R. Eichel,
S. Kipervasser, I. Blatt, M. Neufeld,
D. Ekstein
3.198 Electroclinical Features Of
Ring Chromosome 20 Syndrome In
Children/H. Ikeda, H. Ikeda, K. Imai,
Y. Takahashi, Y. Inoue
3.199 Referral Delay For Epilepsy
Surgery Centers In Patients With
Temporal Lobe Epilepsy And
Hippocampal Sclerosis: Why We
Should Educate Neurologists In First
And Secondary Care Centers/
S. de Vincentiis, K. Rodrigues
Ximenes Goldberg,
S. E. de Melo-Souza, F. J. Arruda,
P. C. Ragazzo, H. van der Linden J.r.,
K. Dualibi Ramos Valente
3.200 Increased Cerebrovascular
Reactivity In The Epileptogenic
Temporal Lobe In Mesial Temporal Lobe
Epilepsy Patients/K. Alhadid,
O. Sobczyk, G. Montandon,
J. Poublanc, L. Venkatraghavan,
A. Crawley, J. Fisher, D. Mikulis,
T. Valiante
3.201 Ictal EEG Yield In NewlyTreated Focal Epilepsy: Interim
Findings From The Human Epilepsy
Project (HEP)/R. Singh, M. Hegde,
V. Mays, D. Dlugos, on behalf of the
HEP EEG Core and HEP Investigators
Poster Session 3
71
Monday December 8, 2014
3.227 Lightning Strike Induced Vagus
Nerve Stimulator Malfunction/P. Shah,
G. Ghearing
3.228 Ketamine In Refractory Status
Epilepticus – A Two Year
Retrospective Study On 26
Patients/J. Höfler, A. Zerbs,
J. Dobesberger, G. Pilz, M. Leitinger,
H. Novak, E. Trinka
3.229 Frequency And Predictors Of
Rescue Medication Use In Children
Admitted To The Epilepsy Monitoring
Unit/L. AHMADI, K. Nickels,
L. Wong-Kisiel, E. Wirrell
3.230 Use Of Clobazam In Pediatric
Epilepsy At A Tertiary Care Center/
N. McNamara, S. Joshi
3.231 Clinical Characterization Of The
Pre-Ictal State In The Pediatric
Population: A Caretaker’s Perspective
On Seizure Prediction/P. Patel,
R. Jehle, D. Gold, S. Haut
3.232 Spectrum Of Autoimmune
Epilepsy With Glutamic Acid
Decarboxylase Antibody/A. Shah,
M. Dhakar
3.233 Early Complications Of
Subdural Electrode Placement In
Pediatric Epilepsy Surgery/
P. Pojomovsky, A. Mandel, D. McBrian,
M. Giordano, L. Goldenstein,
N. Feldstein, G. McKhann, C. Akman
3.234 Efficacy Of Ketogenic Diet: An
Experience Of King Fahd Specialist
Hospital-Dammam (KFSH-D)/
R. S. Al-Baradie
Prognosis
3.235 Electrodermal Sleep Storm
Activity As A Biomarker In Epilepsy
Patient/K. Kapur, S. Thome-Souza,
J. Klehm, R. Sarkis, E. Nagarajan,
M. Jackson, R. Picard, C. Doshi,
C. Papadelis, B. Dworetzky,
C. Reinsberger, T. Loddenkemper
3.236 Mortality In Children Evaluated
For Epileptic Spasms At A Tertiary
Care Center/C. Harini, E. Nagarajan,
A. Bergin, K. Kapur, C. Marti,
M. Takeoka, T. Loddenkemper,
M. Libenson
3.237 Predictors Of Refractory
Status Epilepticus/M. Gonzalez,
E. Santamarina, M. Toledo, S. Sarria,
M. Sueiras, L. Guzman, J. Salas Puig
3.238 Ictal Vital Signs In Epilepsy/
W. O. Tatum, M. L. Langston,
E. Acton, K. H. Yelvington,
C. Bowman, J. J. Shih, W. Cheshire
3.239 EEG Prior To Weaning
Antiepileptic Therapy In Seizure-Free
Children: A Cost-Effectiveness
Analysis/B. McCoy, E. Donner
3.240 Correlation Of EEG Findings
And Prognosis In Patients On
Therapeutic Hypothermia After
Cardiac Arrest/Y. Krutoshinskaya,
S. Manganaro, R. Krel, L. Bello
3.241 Outcome Of Early Successful
Seizure Control Or Aggressive
Seizure Management In Presumed
Childhood Encephalitis/N. Rismanchi,
J. Gold, S. Sattar, C. Glaser,
H. Sheriff, A. Mower, J. Crawford,
M. Nespeca, S. Wang
72
Poster Session 3
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.242 Clinical Phenotypes Within
Patients With Non-Lesional Temporal
Lobe Epilepsy Based On Response To
Antiepileptic Drugs/J. Kim
3.243 Epilepsy With Onset Within 3
Years Of Age: Electro-Clinical
Characterization And Long-Term
Outcome/A. Vignoli, G. F. Scornavacca,
F. La Briola, K. Turner, V. Chiesa,
E. Zambrelli, V. Fergnani, M. Canevini
3.244 Adaptive Function In Dravet
Syndrome/S. Kim, D. Nordli, L. Laux
3.245 Diagnosis, Treatment, And
Outcomes Of Infantile Spasms In The
Trisomy 21 Population/C. Beatty,
J. Wrede, H. Blume
3.246 Clinical And
Electroencephalographic
Characteristics Of Neonates Who
Underwent Continuous
Electroencephalographic Monitoring/
A. J. Sansevere, I. Sánchez
Fernández, J. Klehm, E. Nagarajan,
L. St. Louis, P. Pearl, J. Neil,
T. Loddenkemper
3.247 Long-Term Seizure Outcome In
Response To Carbamazepine In
Children With Newly Diagnosed Partial
Onset Epilepsy/G. Aungaroon,
S. Standridge, K. Holland
3.248 Sudden Unexpected Death In
Epilepsy, Peri-ictal Physiology And The
SUDEP-7 Inventory/N. Odom
3.249 Interictal Background Is
Associated With Survival And
Neurodevelopmental Outcome In Term
Infants Undergoing Hypothermia For
Hypoxic-Ischemic Encephalopathy/
L. Rao, J. Wu, T. Chanlaw, H. Wang,
M. Garg
3.250 EEG Monitoring In Patients
With Hypothermia Post Cardiac
Arrest – A Comparison Of ‘Evolving’
Patterns And Outcomes/K. Suchdev,
S. Rao, L. Avedian, S. Thadur,
D. Zutshi
3.251 Praxis Induction In Juvenile
Myoclonic Epilepsy. Significance In
Prognosis/C. P. Uchida, K. Carvalho,
M. B. Guaranha, L. M. Guilhoto,
E. Yacubian
3.252 Sudden Unexpected Death In
Epilepsy (SUDEP) – Vanderbilt
University Experience/
S. Bandyopadhyay, N. Azar, A. Arain
3.253 Seizure Outcomes After
Glioma Resection/A. C. Jongeling,
P. D. Canoll, C. Schevon, S. Srinivasan
Neuroimaging
Structural Imaging
3.254 Relationship Between Cortical
Thickness And Sulcal Depth In
Pediatric Focal Epilepsy/S. Gurbani,
P. Siddarth, D. Tosun, J. Levitt,
R. Caplan
3.255 MRI Characterization Of
Cerebellar Tubers In Tuberous
Sclerosis Complex: Longitudinal Follow
Up And Associations With Clinical
Manifestations/A. Yogi, Y. Hirata,
J. Wu, P. Pan, G. Mathern,
N. Salamon
3.256 Brain Morphometry On MultiModal Imaging For The Detection Of
Epileptogenic Cortical Dysplasias/
L. Kini, S. Das, K. Davis, B. Litt
3.257 Transient Focal Lesion In
Corpus Callosum After First Episode
Of Generalized Seizure: A Case
Report/R. Vakili, M. M. Donohue,
T. Emch
3.258 Are There Neuroanatomical
Differences In New Onset Focal
Epilepsy? Preliminary Results From
The Human Epilepsy Project/
H. R. Pardoe, R. Kuzniecky,
A. HEP MRI Core
3.259 Disrupted Modular
Architecture Of Brain Structural
Network In Temporal Lobe Epilepsy/
Z. Chen, C. Yasuda, G. C. Beltramini,
T. M. Lopes, M. Morita, A. Coan,
F. Bergo, F. Cendes, C. Beaulieu,
D. Gross
3.260 Disrupted Brain Volumetric
Network In Temporal Lobe Epilepsy/
C. Yasuda, C. Zhang, G. C. Beltramini,
M. Morita, A. Coan, P. Araujo,
F. Bergo, C. Beaulieu, F. Cendes,
D. Gross
3.261 Contralateral Hippocampal
Atrophy Following Temporal Lobe
Surgery For Temporal Lobe Epilepsy/
C. A. Elliott, C. Yasuda, L. Concha,
M. Liu, D. Gross, T. Sankar,
M. Wheatley, C. Beaulieu
3.262 Correlation Between
Brainstem Rotation After
Hemispherectomy And The
Occurrence Of Clinical Symptoms In
Hemimegalencephaly Patients/A. Yogi,
Y. Hirata, J. Wu, P. Pan, G. Mathern,
N. Salamon
3.263 Volumetric And Shape
Analyses Of Hippocampal Subfields In
Temporal Lobe Epilepsy With
Hippocampal Sclerosis/J. Kim
3.264 Reduced Right Hippocampal
Volume In Patients With Left
Hippocampal Atrophy Is Associated
With Anxiety And Depression/
T. Stoub, C. L. Grote, A. Kanner
3.265 Biometric Correlations With
Diffusion Tensor Data Of Temporal
Lobe Epilepsy Mcd Patients At
3.0T/S. Nikolova, R. Nikolov,
R. Bartha, J. G. Burneo
3.266 Reversible Brain MRI Changes
Associated With Periodic Lateralized
Epileptiform Discharges (PLEDs)/
A. B. Memon, A. Shah, M. Basha
3.267 Cortical Thickness And
Cognition In Children With ECTS: A
Longitudinal Study/D. Jackson,
C. Garcia-Ramos, K. Dabbs, J. Jones,
D. Hsu, C. Stafstrom, L. Zawadzki,
M. Koehn, M. Seidenberg, B. Hermann
3.268 Hippocampal Subregion
Analysis In Adults With Mesial
Temporal Lobe Epilepsy/L. Sepeta,
S. C. Germeyan, M. Berl, J. Ostuni,
W. Gaillard, W. Theodore
Monday December 8, 2014
3.269 Magnetic Resonance Imaging
Abnormalities Associated With
Status Epilepticus: A Case Report
And Literature Review/A. M. Feyissa,
L. Ponce Mejia, T. Masel
3.270 Disrupted Brain Network
Topology In New-Onset Pediatric
Epilepsy: A Controlled Prospective
Study/J. Lin, R. Rajyaguru, J. Riley,
G. Gulsen, K. Dabbs, J. Jones,
D. Jackson, D. Hsu, C. Stafstrom,
M. Seidenberg, L. Bonilha,
B. Hermann
3.271 To Evaluate Original Diffusion
Properties Of Neural Pathways Of
Patients With Partial Seizures And
Secondary Generalization By Individual
Anatomic Reference Atlases/S. Peng,
T. Harnod, C. Huang, Y. Hsin
3.272 Increased Fractional
Anisotropy In Children With
Epilepsy/M. Berl, V. Terwilliger,
L. Sepeta, W. Gaillard
3.273 Quantitative Analysis Of Fiber
Density From Diffusion Tensor Imaging
Identifies Structural Changes In
Cryptogenic Focal Epilepsy/J. Joc,
N. Khalilieh, E. Hartl, S. Noachtar,
C. Vollmar
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.281 Identification Of A Pre-Spike
Network In Mesial Temporal Lobe
Epilepsy/N. L. Faizo, H. Burianová,
M. Gray, J. Hocking, G. Galloway,
D. Reutens
3.282 FMRI Mesial Temporal
Activation Paradigm For Children With
Epilepsy/H. Shurtleff, J. Nixon,
M. Warner, A. V. Poliakov, D. W. Shaw,
E. Novotny, J. Ojemann
3.283 Altered Functional Connectome
For Fearful Face Processing In
Temporal Lobe Epilepsy/J. Riley,
R. Rajyaguru, G. Gulsen, J. Lin
3.284 Resting State fMRI Lateralizes
Seizure Onset But Fails To Predict
Cognitive Change After Anterior
Temporal Lobectomy In Temporal Lobe
Epilepsy/M. Gelfand, K. Davis
3.285 Altered Resting-State
Networks In Psychogenic
Nonepileptic Seizures And Idiopathic
Generalized Epilepsy/D. An, C. Luo,
S. Chen, B. Yan, D. yao, D. Zhou
3.286 Ictal Perfusion Pattern With
And Without Secondarily Generalized
Tonic-Clonic Seizure: A Voxel-Based
ECD-SPECT Analysis In Temporal Lobe
Epilepsy/X. Chen, C. H. Wong,
R. McCredie, M. L. Bartley,
D. C. Farlow, Z. Zhao, E. Somerville,
A. Bleasel
3.287 Abnormal Functional
Organisation Of Default-Mode And
Task-Positive Networks In LennoxGastaut Syndrome/A. Warren,
J. Archer, D. Abbott, G. Jackson
Antiepileptic Drugs
Clinical Trials
3.288 FDA OGD’s Post-Marketing
Studies To Ensure Therapeutic
Equivalence Of Generic Antiepileptic
Drugs In Epilepsy Patients/X. Jiang,
N. Zheng, T. Ting, J. Polli,
M. Privitera, M. Berg, W. Jiang
3.289 Open Label Trial Of Add-On
Lacosamide Versus High Dose
Monotherapy In Patients With
Breakthrough Seizures/J. Alam,
N. Llewellyn, B. Dworetzky, R. Sarkis,
P. Pennell, E. Bubrick, J. Lee
3.290 Immediate Steady State
Concentrations In Plasma After Oral
Or Intravenous Lacosamide Loading
Dose/W. Cawello, J. Andreas,
C. Schaefer
3.291 Focal Seizure Frequency By
Study Phase And Seizure Type In
Conversion To Lacosamide
Monotherapy Study: A Post-Hoc
Analysis/J. Stern, M. Sperling,
S. S. Chung, P. Ryvlin, R. Wechsler,
S. Dimova, M. De Backer, T. Story,
M. Brock, C. McShea, K. J. Werhahn
3.292 Conversion To Lacosamide
Monotherapy: Post-Hoc Analysis On
Responder And Seizure Freedom
Rates/P. Ryvlin, M. Sperling,
S. S. Chung, J. Stern, R. Wechsler,
S. Dimova, M. De Backer, T. Story,
M. Brock, C. McShea, K. J. Werhahn
3.293 Lacosamide Added To A
Baseline Monotherapy In Patients
With Partial-Onset Seizures (POS):
Efficacy And Safety Across Center
Types In The VITOBA Study/C. Brandt,
M. Noack-Rink, T. Mayer, U. Runge, F.
Ramirez, T. Lauterbach, P. Dedeken
3.294 Safety And Tolerability Of
Lacosamide Monotherapy In Elderly: A
Subgroup Analysis From Lacosamide
Trials In Diabetic Neuropathic Pain/
J. Sirven, E. Faught, M. De Backer,
K. Eckhardt, F. Tennigkeit, S. Bongardt,
D. Rudd, D. Sen, K. Werhahn
3.295 Efficacy and Safety Of
Lacosamide As Adjunctive Treatment
For Partial-Onset Seizures In
Hispanic/Latino Patients From Mexico:
Post Hoc Analysis Of An Open-Label
Trial/H. Ceja Moreno, P. Tzvetanov,
W. Waldman Zadeh, A. Escartin,
I. Wild, W. Byrnes, F. Tennigkeit,
S. Borghs, C. McShea, P. Dedeken,
M. De Backer
3.296 WITHDRAWN
3.297 Lacosamide Added To An
Existing Monotherapy In Epilepsy
Patients With Partial-Onset Seizures:
A Subgroup Analysis Of The Elderly
Population In The VITOBA Study
(VImpat Added To One Baseline
AED)/U. Runge, T. Mayer,
M. Noack - Rink, F. Ramirez,
M. De Backer, F. Tennigkeit,
K. Werhahn
3.298 An Open-Label Trial Evaluating
The Efficacy And Safety Of
Lacosamide As First Add-On
Treatment Of Partial-Onset
Seizures/P. Tzvetanov, W. Waldman,
A. Escartin, W. Byrnes, F. Tennigkeit,
P. Dedeken, M. De Backer, S. Borghs,
T. Li
3.299 Tolerability Of Lacosamide 200
Mg/Day Starting Dose: Post-Hoc
Analysis Of Conversion To Lacosamide
Monotherapy Study/K. J. Werhahn,
S. Dimova, C. McShea, M. Brock,
W. Byrnes, M. De Backer, E. Faught
3.300 Reduction Of TreatmentLimiting Non-Psychotic Behavioral
Adverse Events Associated With
Levetiracetam: An Open-Label,
Prospective Study Of Patients With
Epilepsy Switching From
Levetiracetam To Brivaracetam
Treatment/S. Yates, T. Fakhoury,
W. Liang, K. Eckhardt, J. D’Souza
3.301 Impact Of Adding Perampanel
To Existing Anti-Epileptic Drug (AED)
Therapy On Health-Related Quality Of
Life (HRQL) As Measured By The
Quality Of Life In Epilepsy Inventory
(QOLIE-31-P) In A Pooled Population
Of Patients With Partial-Onset
Seizures (POS) f/W. Tsong,
S. Hudgens, A. Forsythe, R. Muniz
3.302 Vigabatrin For Treatment Of
Complex Partial-Onset Seizures In
Patients With Tuberous Sclerosis:
Prospective Trial And Retrospective
Case Series/B. Oommen, E. Brand,
A. Volpe, A. Krause, P. Crino,
J. Pollard
MONDAY
Functional Imaging
3.274 EEG-fMRI Study Of OperculoInsular Epilepsy/P. Pouliot, T. Tran,
M. robert, A. Bouthillier, D. Nguyen
3.275 Decreased Functional
Interactivity In Patients With Temporal
Lobe Epilepsy And Normal MRI/
A. Coan, B. M. Campos, F. Cendes
3.276 Additive Potential Of Real-Time
Functional Mapping (RTFM) To
Electrical Stimulation Mapping (ESM)
Results For Epilepsy Surgery
Candidates/M. Elsayed,
M. Korostenskaja, E. Castillo, P. Chen,
A. Schaal, B. Edmonds, C. M. Salinas,
M. Westerveld, J. Seo, G. Schalk,
P. Brunner, J. Baumgartner, K. Lee
3.277 7T Mrs In Medically Refractory
Temporal Lobe Epilepsy Patients With
Normal 1.5T/M. jones, S. Nikolova,
J. G. Burneo, R. Bartha
3.278 Language fMRI And PostOperative Language Decline/E. Emery,
S. C. Germeyan, L. Sepeta, E. Wiggs,
M. Berl, I. Dustin, D. Goldenholz,
W. Gaillard, W. Theodore
3.279 Significance Of FDG-PET
Hypermetabolism In Focal Cortical
Dysplasia (FCD)/P. Laoprasert,
R. W. Dudley, S. Koh, M. Handler,
N. Stence, D. Mirsky, A. White
3.280 Voxel-Mirrored Homotopic
Connectivity Analysis Of Pediatric
Epilepsy Patients With Mesial
Temporal Sclerosis/A. V. Poliakov,
E. J. Novotny, S. L. Poliachik,
S. D. Friedman, G. E. Ishak,
J. N. Nixon, D. W. Shaw,
J. G. Ojemann
Poster Session 3
73
Monday December 8, 2014
3.303 Efficacy And Safety Of
Epidiolex (Cannabidiol) In Children And
Young Adults With TreatmentResistant Epilepsy: Initial Data From
An Expanded Access Program/
O. Devinsky, J. Sullivan, D. Friedman,
E. Thiele, E. Marsh, L. Laux,
J. Hedlund, N. Tilton, J. Bluvstein,
M. Cilio
3.304 Retrospective Study Of
Lacosamide In The Elderly (> 60 years
Of Age)/J. Bainbridge, P. Wong,
M. Spitz, L. Frey, C. Drees,
C. O’Brien, L. Strom, A. Shrestha,
J. Sirven, S. Benbadis, E. Maa,
S. S. Chung, B. Phillips
3.305 The Initial Results Of
Adjunctive Lacosamide For
Uncontrolled Partial-Onset Seizures in
Eskisehir, Turkey/O. O. Erdinc,
G. Akdag, G. Uzuner, D. Ilhan Algin
3.306 Vigabatrin In The First Line
Treatment Of Infantile Spasms/
K. Jones, J. Boyd, C. Go, A. Ochi,
B. McCoy, K. Puka, O. Snead
3.307 Prospective, Controlled Trial Of
Cannabadiol In A Case Of FIRES/
C. Lopez, A. Wilfong, T. P. Ngo,
M. R. Jenner
3.308 Initial Therapy Outcomes In
Absence Epilepsy : Ethosuximide,
Valproic Acid, Lamotrigine And The
Combination Of Valproic Acid And
Lamotrigine/B. Eun
Other
3.309 Efficacy And Tolerability Of
Lacosamide As An Adjunctive
Treatment In Vascular Epilepsy: 3
Months Study/F. L. Gonzalez,
X. Rodriguez Osorio, M. Toledo,
M. Saavedra Piñeiro, E. Santamarina,
I. Lopez Dequit, A. Pato,
D. Campos Blance, P. Bellas,
J. Salas Puig, J. Poza Aldea
3.310 Classification Of Phenytoin As
A Narrow Therapeutic Index Drug/
N. Zheng, L. Fang, W. Jiang
3.311 A Preliminary Analysis Of The
Effect Of Lacosamide On Seizure
Control And Neuropsychological
Performance: Anxiety, Depression And
Quality Of Life/M. Romero Acebal,
C. Sánchez Ortiz, F. Villalobos Chávez,
G. Rubio Esteban, L. Redondo Verge,
J. Romero-Godoy, E. Calzado Rivas,
P. Quiroga Subirana, R. Hervas
Navidad, P. Martínez Agredano,
C. Pedraza Benitez
3.312 Efficacy And Tolerability Of
Lacosamide In The Treatment Of
Children With Refractory Generalized
Epilepsy/C. Miskin, D. Khurana,
I. Valencia, A. Legido, D. Hasbani,
K. Carvalho
3.313 Therapeutic Use Of
Lacosamide Does Not Alter Its
Distribution Between Serum And
Cerebrospinal Fluid/A. Shah,
S. Michelhaugh, S. Mittal
74
Poster Session 3
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.314 VPA Retains Suppressive Ppr
Effect At Steady-State With Less
Variability Than CBZ: Retrospective
Analysis Of 239 Photosensitive Clinic
Patients/D. G. Kasteleijn-Nolst
Trenite’, R. Reed
3.315 Efficacy Of Clobazam On
Patients With Failed Resective
Surgery Aparna Sarma DO,
Carolina Restrepo, Janice Jordan,
C. Akos Szabo M.D./A. Sarma,
C. Restrepo, J. Jordan, C. Szabo
3.316 Resistance To Rectal Diazepam
In Dravet’s Syndrome/P. McGoldrick,
S. Wolf
3.317 Commonly Prescribed
Antiepilepsy Drugs In Nursing Home
Residents/A. Birnbaum, S. Bathena,
I. Leppik
Non-AED / Non-Surgical
Treatments (Hormonal,
Ketogenic, Alternative, Etc.)
Adult
3.318 An Evaluation Of Catamenial
Seizure Patterns And The Relationship
Between The Menstrual Cycle,
Seizures, And Ketosis In Women On
The Modified Atkins Diet For
Treatment For Epilepsy/E. Felton,
E. Kossoff, B. Henry, M. Cervenka
3.319 Auricular Acupuncture For The
Treatment Of Nonepileptic Seizures:
NADA4NES Pilot Study/E. Maa
3.320 LORETA z-Score Neurofeedback
Training In Patients With DrugRefractory Epilepsy/L. Frey, C. O’Brien
3.321 The Impact Of An Art Therapy
Program On Self-Esteem And Quality
Of Life In People With Epilepsy/
J. M. Buelow, L. R. Vitko,
J. M. Gattone, J. R. Kakacek
Pediatrics
3.322 Predictors Of Ketogenic Diet
Efficacy In Children Based On The
Electroencephalogram/I. M. Walker,
R. Said
3.323 Intravenous
Methylprednisolone For Intractable
Childhood Epilepsy/M. M. Jan
3.324 Therapeutic Plasma Exchange
(TPE) In Children With AntibodyMediated Neurologic Disease/
M. Oldham, M. Sweeney, P. Horn,
L. Peglar, E. Rompies,
K. Wesselkamper, B. Hallinan,
S. Goldstein
3.325 Preliminary Overview Of Social
Stressors And Social Work Support
Of Patients And Caregivers In The
Ketogenic Diet Program At Boston
Children’s Hospital/C. Ryan, F. Chris,
K. Costas, S. Tarrant, P. Lora,
P. Pearl, A. Bergin
3.326 Ketogenic Diet Initiation: Step
By Step For Sweet Success/L. Pixley,
S. Tarrant, K. Costas, K. Kapur,
A. Bergin
3.327 Blood Beta-Hydroxybutyrate
Levels Correlate With Seizure
Frequency In Epileptic Patients
Treated With The Ketogenic Diet/
J. Buchhalter, J. D. Smith,
S. D’Alfonso, R. Singer, M. Connolly,
A. Michoulas, E. Fung, D. Sinasac,
J. M. Rho
3.328 Evaluation Of Patients’ Right
And Left Ventricular Functions Who
Treated With Ketogenic Diet/
O. Dokgoz, K. celegen, O. Guzel,
U. Yilmaz, R. Isgüder, M. Celegen,
T. Mese
3.329 A Chef Educator’s Role In The
Ketogenic Diet Program At Children’s
Mercy Hospital/R. Finn
3.330 Lack Of Efficacy Of The
Ketogenic Diet In The Treatment Of
Highly Refractory Infantile Spasms/
J. Shin, K. Murata, J. Matsumoto,
S. A. Hussain
3.331 Complications Of Vagus Nerve
Stimulation For Epilepsy In Children:
How Can We Do Better?/B. Sitwat,
S. Williams, C. Patterson, S. Gedela,
E. Tyler-Kabara, M. Tamber, Y. Sogawa
3.332 New Onset Super-Refractory
Tonic Status Epilepticus In Child With
Down Syndrome: Successful
Treatment With Ketogenic Diet/
L. P. Sampaio, C. L. Moreira,
L. Caboclo
3.333 Clinical Characteristics Of
Children Less Than 3 Years Of Age
Who Elected Vns As An Adjunctive
Therapy For Medically Intractable
Epilepsy/L. D. Fernandez, S. Gedela,
Y. Sogawa
3.334 Pentobarbital, Propylene
Glycol, And Ketosis In Refractory
Status Epilepticus/K. Costas,
R. Tasker, J. Soul, N. Lamb, L. Li,
A. Bergin
3.335 Use Of The Ketogenic Diet In
The Neonatal Intensive Care Unit –
Safety and Tolerability/A. Hall,
M. Gustafson, L. Thompson
All Ages
3.336 Benefits Of Exercise in
Patients With Epilepsy: A Literature
Review/F. Gilliam, R. Hogan, G. Gilmet
3.337 Safety And Tolerability Of 1 Hz
Deep Repetitive Transcranial Magnetic
Stimulation (rTMS) For Treatment Of
Temporal Lobe Epilepsy/L. Oberman,
R. Gersner, A. Zangen, A. Rotenberg
Animal
3.338 Antidepressants Have
Different Effects On The Vesicular
Glutamate Transporter 1 And EEG
Spectrum In The Rat Hippocampus/
D. Shin, H. Song
3.339 Non-Invasive Low Frequency
Sensory Stimulation Suppresses
Seizures In Two Rodent Models Of
Epilepsy/N. Couturier
Monday December 8, 2014
3.340 Beta-hydroxybutyrate And
Docosahexaenic Acid Suppress
Seizures And Hippocampal Network
Hyperexcitability In A Mouse Model Of
Dravet Syndrome/Y. Abdulkadir,
T. Scheuer, W. Catterall, F. Kalume
3.341 Regulation Of Brain PPARγ
Mediates Ketogenic Diet Anti-Seizure
Efficacy/T. A. Simeone,
S. A. Matthews, K. K. Samson,
K. Simeone
3.342 A 35% Triheptanoin Diet
Reduces Spontaneous Electrographic
Seizures in Pilocarpine-Induced
Epileptic Mice/A. Fernandez, J. Stoll
Surgery
Pediatrics
3.350 Pediatric Epilepsy Surgery
Techniques Specific Issues: InterCenter Worldwide Variability/
W. Harkness, B. Rydenhag, A.
Cukiert, I. Panel
3.351 Epilepsy Related
Characteristics Of Children Less Than
Five Years Of Age Who Underwent
Epilepsy Surgery/E. Thompson,
J. Walker, W. Chlon, S. LeSure,
D. F. Clarke
8:00 a.m. – 3:00 p.m.
Convention Center – Hall 4B, Level 4
3.352 Surgical Treatment Of Patients
With Rasmussen Encephalitis
(34 Cases)/Y. Guan, G. Luan
3.353 SEEG-Based Tailored Laser
Ablation For Lesional Epilepsy/
T. P. Ngo, C. Lopez, D. Curry,
A. Wilfong
3.354 Review Of Extended Multi-lobar
Epilepsy Surgery In Pediatric
Patients/R. Yu, H. Kang, J. Lee,
D. Kim, H. Kim
3.355 Follow Up EEG, MRI And
Frequency Of Relapse In Children
Status Post Resection Of Focal
Cortical Dysplasia/K. Havens,
C. Oluigbo, S. Magge, W. Gaillard,
G. Vezina, D. Depositario-Cabacar
3.356 Special Needs Of Autistic
Patients Undergoing Epilepsy Surgery:
Review Of Inpatient Management In
57 Cases/S. Ghatan, M. Kokoszka,
P. McGoldrick, M. La Vega-Talbott,
H. Raynes, R. Prince, J. Kim, H. Kang,
S. Wolf
3.357 Acute, Mid-And Long-Term
Outcomes Of Medically Refractory
Epilepsy And Neurocognitive
Difficulties Following Staged MRIGuided Thermal Laser Ablation In
Pediatric Patients With Tuberous
Sclerosis Complex/Y. Eksioglu,
Z. Tovar-Spinoza
3.358 Outcomes Of Stereotactic
Laser Ablation For TreatmentResistant Epilepsy In The Pediatric
Population With 1-Year Follow-Up/
D. Curry, A. Shetty, A. Wilfong
3.359 MEG In Pediatric Presurgical
Evaluation: Comparative Study With
Intracranial EEG Recordings In
Children With Focal Cortical
Dysplasia/U. Thome, N. Agarwal,
Z. I. Wang, H. Murakami, B. Krishnan,
R. Burgess, A. Alexopoulos, A. Gupta
3.360 Acute Intralesional Recording
In Hypothalamic Hamartoma:
Description Of 4 Cases/N. Specchio,
M. Rizzi, M. Trivisano, L. Fusco,
E. Rebessi, S. Cappelletti, F. Villani,
A. Savioli, A. De Benedictis,
C. Marras, O. Delalande, F. Vigevano
3.361 PET And SPECT Concordance
With EEG And MRI In Pre-Surgical
Evaluation For Pediatric Epilepsy/
C. Moufawad El Achkar, M. Takeoka
3.362 Surgical Management Of
Patients With CSWS: The Detroit
Experience/R. Agarwal, A. Kumar,
E. Asano, R. Rothermel, S. Sood,
H. Chugani
3.363 MRI-Guided Laser-Induced
Thermal Ablation: A Promising Tool
With Favorable Acute, Mid And LongTerm Outcomes For Intractable
Seizures And Neurocognitive
Comorbidities In Cortical Dysplasias/
Y. Eksioglu, K. Ogden, S. Huckins,
Z. Tovar-Spinoza
3.364 Deep Focal Cortical Dysplasia
And Surgical Outcomes In Children/
D. Depositario-Cabacar, K. Havens,
C. Oluigbo, S. Magge, G. Vezina,
W. Gaillard
All Ages
3.365 VNS (Vagus Nerve Stimulation)
Is A Useful Tool To Promote The
Epilepsy Surgery/I. Takumi, T. Nozaki,
Y. Kishi, A. Morita
3.366 Epilepsy Surgery In Or Close To
Eloquent Cortex – New Methods Open
For Surgery In More Patients/A. Egge,
M. Stanisic, P. Larsson
3.367 Spontaneous Improvement In
Seizure Control After Intracranial
Electrode Implantation/C. Morris,
J. Boggs, V. Woodard, C. O’Donovan,
G. Popli
3.368 Radiographic Changes
Following Laser Interstitial Thermal
Therapy For Medically Intractable
Epilepsy/R. Buckley, J. Ojemann
3.369 Temporopolar Grey/White
Matter Abnormalities In Temporal
Lobe Epilepsy With Hippocampal
Sclerosis And Long-Term Prognosis
After Epilepsy Surgery/P. V. Naves,
L. Caboclo, H. Carrete. Jr.,
R. Centeno, B. V. Kelmann, E. Yacubian
3.370 Magnetoencephalography
Localization Can Guide Reoperation
After Unsuccessful Neocortical
Epilepsy Surgery/I. Mohamed,
A. Pooladian, Y. T. Tran, M. Robert,
A. Bouthillier, D. Nguyen
3.371 Stereotactic Laser Ablation
For Epilepsy: An Analysis Of The
Safety Profile From Peer-Reviewed
Reports/A. Wilfong, A. Shetty,
D. Curry
3.372 Seizure Outcome After
Battery Depletion In Patients
Submitted To Deep Brain Stimulation
For Epilepsy./J. A. Burattini,
A. M. Lima, C. M. Cukiert, A. Cukiert
3.373 Epilepsy Surgical Outcomes
2004-2013: The USC Experience
With Standard Temporal Lobectomy
And Selective Amygdalohippocampectomy/
Y. Marquez, M. N. Zubair, B. Lee,
D. Millett, L. Kalayjian, D. Ko,
S. Shaw, C. Heck, C. Liu
3.374 Results Of A Drug Withdrawal
Protocol After Temporal Lobe Epilepsy
Surgery/R. S. Centeno,
M. D. Guimaraes, L. Caboclo
3.375 Speed And Precision Of
Robotic Depth Electrode Placement
For Stereotactic EEG/N. Tandon,
G. Kalamangalam, B. Seignot
MONDAY
Adult
3.343 Super-Selective
Amygdalohippocampotomy Using RealTime Magnetic Resonance Guided
Laser Ablation In Patients With
Mesial Temporal Lobe Epilepsy/
J. W. Yoon, W. Tatum, J. J. Shih,
V. Gupta, P. Vibhute, R. Wharen
3.344 Cognitive Outcome Of Patients
Undergoing Stereotactic Laser
Ablation Of Cavernous Malformations
To Control Chronic Seizures/
D. L. Drane, J. Willie, D. W. Loring,
N. Voets, A. M. Saindane,
M. Ivanisevic, R. Brewster, R. Jayakar,
R. Faught, K. J. Meador, R. Gross
3.345 A Case Report Of A Patient
With Refractory Temporal Lobe
Epilepsy Suffered Ischemic Stroke
After The Wada Test Had Good
Outcome/H. Gong, M. Kim-Tenser,
D. Ko
3.346 Modulating Cortico-Cortical
Evoked Potentials And Their
Connectivity Maps With Differing
Stimulation Parameters/S. Bickel,
M. Mercier, P. Megevand, D. Groppe,
A. Mehta, F. Lado
3.347 Frontal Topectomy May Be
Palliative In Difficult To Localize
Intractable And Disabling Frontal
Epilepsy/J. Oster
3.348 Assessment Of Driving
Outcomes After Epilepsy Surgery/
R. Dawkins, N. Omar, B. Agee,
B. Walters, K. Riley
3.349 Stimulation Of Ncl. Accumbens
In Intractable Partial Epilepsy –
Possible Candidates/F. C. Schmitt,
A. Kowski, L. Buentjen, H. Stefan,
H. B. Straub, T. Mayer, T. Zaehle,
F. Oltmanns, H. Heinze, M. Holtkamp,
J. Voges
Poster Session 3
75
THE EPILEPSY RESEARCH BENCHMARKS
2014 NINDS Benchmarks for Epilepsy Research
Beginning in 2000, the National Institute of Neurological Disorders and Stroke (NINDS) has hosted a series of Curing the
Epilepsies conferences in partnership with epilepsy advocacy and professional organizations to assess progress in epilepsy
research and help set an agenda for future years. As an outcome, these conferences have led to the development of
Benchmarks for Epilepsy Research, which reflect shared priorities across the epilepsy community. The current 2014
Benchmarks are:
I.
Understand the causes of the epilepsies and epilepsy-related neurologic, psychiatric, and somatic
conditions
A. Identify new genes and pathways associated with epilepsies and epilepsy-related conditions.
B. Identify new infectious, immune, age-related, environmental, or other causes and risk factors associated with the
epilepsies and epilepsy-related conditions.
C. Determine whether factors related to age, gender, race / ethnicity, socioeconomic status, and other features of
specific populations affect risk and mechanisms of epilepsy and epilepsy-related conditions.
D. Determine whether the bi-directional relationships that exist between the epilepsies and several co-occurring
conditions (e.g., neuropsychiatric or neurodevelopmental disorders) result from the same underlying causal
mechanisms, interacting mechanisms, or are a consequence of the first presenting condition.
II. Prevent epilepsy and its progression
A. Understand epileptogenic processes involved in epilepsies with neurodevelopmental origins, including those due to
genetic or presumed genetic causes.
B. Understand epileptogenic processes involved in the development of epilepsy following traumatic brain injury, stroke,
brain tumor, infections, neurodegeneration, or other insults to the brain.
C. Identify biomarkers that will aid in identifying, predicting, and monitoring epileptogenesis and disease progression,
including markers early after injury / insult that identify those people at risk for epilepsy.
D. Develop or refine models aligned with the etiologies of human epilepsies to enable improved understanding of
epileptogenesis and rigorous preclinical therapy development for epilepsy prevention or disease modification.
E. Identify new targets and develop interventions to prevent or modify epileptogenesis and the progression of epilepsy
and epilepsy-related conditions.
III. Improve treatment options for controlling seizures and epilepsy-related conditions without side effects
A. Understand the initiation, propagation, and termination of seizures at the network level in different forms of epilepsy.
B. Identify biomarkers for assessing or predicting treatment response, including markers that may identify specific
populations that are likely to have good outcomes or develop adverse responses.
C. Develop or refine models that are aligned with etiologies and clinical features of human epilepsies, especially
treatment resistant forms, to enable improved understanding of ictogenesis and preclinical development to improve
seizure control with fewer side effects. Establish the sensitivity and specificity of these models with regard to current
therapies.
D. Identify, develop, and improve interventions to detect, predict, prevent, or terminate seizures, including approaches
suitable for use in the home and other non-medical settings.
E. Identify, develop, and improve anti-seizure therapies that target (either alone, or in combination) novel or multiple
seizure mechanisms.
F. Develop, improve, and implement interventions for effective self-management, including treatment adherence.
G.Develop and validate objective patient-centered outcome metrics for clinical studies.
IV. Limit or prevent adverse consequences of seizures and their treatment across the lifespan
A. Understand and limit adverse impacts of seizures on quality of life, including effects on neurodevelopment, mental
health, intellectual abilities, and other neurological and non-neurological functions.
B. Understand and limit adverse impacts of anti-seizure treatments (medical, surgical, or other interventions) on quality
of life, including effects on neurodevelopment, mental health, intellectual abilities, and other neurological and
non-neurological functions.
C. Understand risk factors and mechanisms involved in non-epileptic seizures (NES). Develop effective approaches for
earlier and accurate diagnosis and treatment.
D. Identify causes, risk factors, and potential preventive strategies for sudden unexpected death in epilepsy (SUDEP) and
other epilepsy-related mortality (for example, suicide) in people with epilepsy.
E. Identify the impact of pharmacological treatment of the epilepsies on fetal and neonatal development. Develop
strategies to control seizures in pregnancy without causing harm to either the mother or child.
Walter Koroshetz, M.D.
Acting Director, NINDS
Daniel H. Lowenstein, M.D.
Chair, Benchmarks Stewards
University of California,
San Francisco
Raymond J. Dingledine, Ph.D.
Vice-Chair, Benchmarks Stewards
Emory University
Brandy Fureman, Ph.D.
Co-Chair, Benchmark Stewards
NINDS
For more information about the Benchmarks and to view Steward’s previous reports, please visit:
http://www.ninds.nih.gov/research/epilepsyweb/2014benchmarks.htm
76
• AES 68TH ANNUAL MEETING
Seattle, WA •
TUESDAY December 9, 2014
www.AESnet.org
7:00 a.m. – 8:30 a.m.
Special Interest Group Meetings
Location listed under each session
Critical Care (ICU EEG Monitoring) – Controversies in ICU
EEG Interpretation and Management
Convention Center – Room 612, Level 6
Coordinators: Suzette M. LaRoche, M.D., Cecil Hahn, M.D.
Speakers: Tammy Tsuchida, M.D., Ph.D., Courtney Wusthoff, M.D.,
William Gallentine, D.O., Eric Payne, M.D., M.P.H., FRCPC, Sarah Schmitt, M.D.,
Lawrence J. Hirsch, M.D.
We will present three controversial cases (one neonatal, one pediatric, one adult)
that demonstrate controversial EEG patterns and approach to management.
Speakers will utilize a pro / con format, debating the merits of aggressive vs.
non-aggressive treatment.
Genetics: Personalized Epilepsy Diagnosis and Treatment
Convention Center – Room 613, Level 6
Coordinators: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D.
Speakers: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D.,
Stephen Traynelis, Ph.D., Elizabeth K. Ruzzo, Ph.D.
This SIG will discuss the use of genome sequencing for individual diagnosis
and its implication for treatment. The speakers will review exome application
on an individual level, present cases that highlight the possibilities and
limitations of personalized genetic medicine, and then discuss how to apply
genetic data for individualized therapeutics.
NEW – Global Health in Epilepsy: How Can You Get Involved?
Convention Center – Room 603, Level 6
Coordinator: Sheryl Haut, M.D.
Speakers: Jose Cavazos., M.D., Ph.D., Lionel Carmant, M.D.
Practice Management
Convention Center – Room 618, Level 6
Coordinator: Gregory Barkley, M.D.
Annual update on ICD and CPT coding plus an open forum to discuss
Electronic Health Record (EHR) issues, tips, and tricks. Participants are
encouraged to submit suggestions of problems or tips from their own
practices ahead of time. Submit to [email protected].
Sleep and Epilepsy: Sleep Polygraphy Monitoring in the
EMU: Are We Missing a Diagnostic / Therapeutic
Opportunity?
Temporal Lobe Club: The Thalamus in Epilepsy – Player or
Bystander?
Convention Center – Room 620, Level 6
Coordinators: John Huguenard, Ph.D., Robert S. Fisher, M.D., Ph.D.
Speakers: Robert S. Fisher, M.D., Ph.D., John Huguenard, Ph.D.,
Hal Blumenfeld, M.D., Ph.D.
The thalamus has been called “the gateway to the cortex.” Do seizures travel
through the gate, and if so, in which direction? The role of the thalamus in
seizures has been debated for decades. In this temporal lobe club session, we
will consider whether the thalamus is a player or bystander in epilepsy. Time
is set aside for a lively group discussion.
Tumor Induced Epilepsy – Meningiomas
Convention Center – Room 604, Level 6
Coordinators: Jeffrey Politsky, M.D., FRCP(C), Theodore Schwartz, M.D., FACS
Speakers: Sandeep Mittal, M.D., Jeffrey Politsky, M.D., FRCP(C),
Jeffrey G. Ojemann, M.D.
The focus of the 2014 Tumor-Related Epilepsy SIG will be meningiomas.
Dr. Sandeep Mittal and Dr. Jeffrey Politsky will be present clinical data. There
will be a third presenter to discuss pathologic basis of meningioma-related
epilepsy. We will also invite members to submit cases in advance and will
reserve the final 20-30 minutes of the SIG for an open forum discussion.
Women’s Issues: Controversies in Caring for Women with
Epilepsy
Convention Center – Room 615, Level 6
Coordinators: Danielle Andrade, M.D., M.Sc., Mona Sazgar, M.D.
Speakers: Samuel F. Berkovic, M.D., Terence J. O'Brien, M.D., FRACP,
Andrew G. Herzog, M.D., M.Sc., Sanjeev V. Thomas, M.D., D.M.
Caring for women with epilepsy poses significant challenges to healthcare
professionals. Despite a growing wealth of knowledge, many issues remain
controversial and we lack evidence-based guidelines and consensus for many
difficult management issues in this field. This SIG targets four major
controversial issues in counseling and caring for women with epilepsy and
intends to bring together expert opinion and best available evidence in
addressing these difficult areas.
1. Controversies about inheritance of epilepsy
2. Controversies about teratogenicity of new AEDs and prenatal counseling
3. Controversies regarding contraception and epilepsy
4. Controversies in hormonal and non-hormonal treatment of catamenial
epilepsy.
TUESDAY
Participation in epilepsy-related global health projects is exciting, productive
and important! Many people are still unaware of the possible avenues to
pursue global health. This SIG will focus on opportunities for international
collaborations, professorships and partnerships around the world, both in
person and via telemedicine. The speakers will discuss challenges across
different regions, successes and lessons learned. Areas to be highlighted as
examples include ILAE supported activities such as the PECA (Partnering
Epilepsy Centers in the Americas) program of the North American
Commission of the ILAE and visiting professorship programs in Africa, and the
ILAE/WFN supported epilepsy demonstration project in Haiti.
diagnosing and treating sleep comorbidities in epilepsy patients.
Approximately 15-40% of patients with refractory epilepsy have comorbid
sleep apnea, and treatment of sleep apnea in epilepsy patients may improve
seizure burden, in addition to improving alertness and well-being and
modifying future health risk. However, identification of sleep apnea remains
challenging, and most epilepsy centers have separate clinical infrastructures
for the evaluation of epilepsy and sleep disorders, despite obvious intuitive,
practical, and logistical advantages of employing sleep polygraphy techniques
directly in the epilepsy monitoring setting. This year’s Sleep and Epilepsy SIG
will feature three expert epileptologists addressing the timely issue of utilizing
polysomnography in the differential diagnosis of epilepsy and spells, and the
importance of identifying sleep apnea in epilepsy monitoring inpatients.
Convention Center – Room 606, Level 6
Coordinators: Mark S. Quigg, M.D., Erik K. St. Louis, M.D.
Speakers: Milena Pavlova, Terence J. O’Brien, M.D., FRACP,
Erik K. St. Louis, M.D.
Comorbid sleep disturbances such as obstructive sleep apnea, insomnia, and
restless legs syndrome are frequent in persons with epilepsy, and
epileptologists are increasingly recognizing the importance and value of
77
TUESDAY December 9, 2014
8:45 a.m. – 10:45 a.m.
Hot Topics Symposium: Epilepsy Updates
(2.0 CME Credits)
Convention Center – Ballroom 6C, Level 6
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Hot Topics
Symposium and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competency: Medical Knowledge
Overview
The Hot Topics symposium will present information about newly developed
approaches to epilepsy diagnosis and management. Faculty will discuss how
MRI can be used to facilitate understanding the pathophysiology of epilepsy
and interictal functional disturbances through study of the default mode
network. In addition, new MRI analyses evaluate disease progression with
important implications for both diagnosis and treatment. How generic drug
use impacts seizure control will be discussed, presenting data from a new
study. Lastly, a new less invasive surgical treatment for epilepsy, thermal
ablation, will be discussed. This potpourri of topics covers the most recent
advances in epilepsy, and should be valuable to both clinicians and basic
scientists.
Learning Objectives
u
Recognize when to use generic anticonvulsant drugs when appropriate,
based on the potential impact on treatment efficacy and tolerability and
assists patients in understanding the pros and cons of utilizing generic
medications
u
Utilizing current understanding of the pathophysiology of epilepsy,
including progression of disease, learner utilizes new diagnostic and
treatment approaches
u
Educate patients on how new diagnostic and treatment approaches can
be used to manage refractory epilepsy.
8:45 a.m. – 10:45 a.m.
Scientific Symposium: The Epidemiology,
Pathophysiology & Prevention of SUDEP
(2.0 CME Credits)
Convention Center – Ballroom 6E, Level 6
Overview
This symposium will review the basic and clinical science of Sudden
Unexpected Death in Epilepsy (SUDEP). Specific areas that will be addressed
include epidemiology, clinical risk factors, potential role of preventive strategies,
gaps in how physicians educate patients and families, current biomarkers of
SUDEP and the evidence for the role of devices in seizure detection and their
potential role in preventing SUDEP. In addition, two leading models used to
understand the mechanisms underlying SUDEP in animals and humans will be
discussed: the role of the serotonergic system and respiration and insights into
human SUDEP from a mouse model of Dravet syndrome.
Learning Objectives
u
Apply understanding of the clinical risk factors, epidemiology, educational
gaps, and basic mechanisms of SUDEP, to developing treatment plans
focused on potential role of preventive strategies
u
Counsel patients and families regarding utility of devices to detect
seizures
u
Counsel patients / families regarding clinical risk factors, epidemiology,
educational gaps, and potential role of preventive strategies underlying
SUDEP
u
Understand and advice practitioners and patients / families regarding
issues of medication adherence and therapeutic levels as prevention
strategy for SUDEP prevention
Assist patients / families to develop cognitive skills and strategies to
improve medication adherence that could be life saving for some patients.
Target Audience
Intermediate (see page 120 for details)
Program
Co-Chairs: R. Edward Hogan, M.D. and Michael R. Sperling, M.D.
8:45 – 8:50 a.m.
Introduction
Michael R. Sperling, M.D.
8:50 – 9:15 a.m.
The Default Mode and Networks in Epilepsy
Jean Gotman, Ph.D.
9:15 – 9:40 a.m.
Progression of Disease in Epilepsy
Andrea Bernasconi, M.D.
u
9:40 – 10:05 a.m.
Generic Drug Update
Michael D. Privitera, M.D.
Target Audience
10:05 – 10:30 a.m.
Thermal Ablation
Robert Gross, M.D., Ph.D.
Program
10:30 – 10:45 a.m.
Conclusions
R. Edward Hogan, M.D.
8:45 a.m.
Introduction
Orrin Devinsky, M.D.
8:55 a.m.
The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Risk Factors and Prevention of SUDEP
Dale C. Hesdorffer, Ph.D.
9:15 a.m.
Serotonin, Adeonsine and Respiration
George B. Richerson, M.D., Ph.D.
Nurses may claim up to 2.0 contact hours for this session.
9:35 a.m.
Insights from Dravet Syndrome
William A. Catterall, Ph.D.
9:55 a.m.
Biomarkers of SUDEP and the Role of Devices
Daniel Friedman, M.D.
Credit Designation
Basic, Intermediate, and Advanced (see page 120 for details)
Chair: Orrin Devinsky, M.D.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-14-038-L01-P.
Initial Release Date: 12/9/2014.
78
TUESDAY December 9, 2014
10:15 a.m. Pediatric SUDEP and Patient / Family Education
Elizabeth J. Donner, M.D.
10:35 a.m. Conclusions
Orrin Devinsky, M.D.
Credit Designation
The American Epilepsy Society designates this live activity for a maximum of
2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses may claim up to 2.0 contact hours for this session.
Pharmacy Credit
AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based
activity for 2.0 contact hours (0.2 CEUs). UAN 0077-9999-14-037-L01-P.
Initial Release Date: 12/9/2014.
ABPN Core Competencies
The American Board of Psychiatry and Neurology has reviewed the Scientific
Symposium and has approved this program as part of a comprehensive
lifelong learning program, which is mandated by the ABMS as a necessary
component of maintenance of certification.
Core Competencies: Patient Care, Practice-based Learning, Interpersonal and
Communication Skills
Seven on-demand audio webinars introducing the core
Audio Webinars include:
l
Basics of Epilepsy
l
Recognition and Care of Seizures and Emergencies: Parts 1-2
l
Overview of Treatment Options: Parts 1-2
l
Patient and Family Education and Self-Management Approaches
TUESDAY
elements of seizures, epilepsy, and epilepsy care. This program
will assist nurses and other health care professionals to provide
appropriate care and support to patients and families in any
health care setting.
https://www.AESnet.org/epilepsy_101
79
See you in
Philadelphia!
2015 ANNUAL
MEETING
December 4 - 8
PHILADELPHIA, PA
Pennsylvania Convention Center
•
•
•
•
•
FUTURE ANNUAL
MEETING DATES
2016
2018
2017
2019
Houston, TX
George R. Brown Convention Center
December 2 - 6
Washington, D.C.
Washington Convention Center
December 1 - 5
80
CME Symposia and Lectures
Platform Sessions
Informative Exhibitors
Special Interest Group Meetings
Skills Workshops
New Orleans, LA
Ernest N. Morial Convention Center
November 30 - December 4
Baltimore, MD
Baltimore Convention Center
December 6 - 10
SOUTH GALLERIA
Coat
Check
ESCALATOR
DOWN TO
LEVEL 3
PE
1
ESCALATOR
UP TO
LEVEL 6
PE
2
Elevators
CYBER CAFE
6
7
PE PE
Poster
Session
Entrance
When
Exhibits
are
Closed
WF
Poster Information Table*
OFFICE
#2
OFFICE
#1
216
220
316
205
217
219
223
PAVILION
C
400
305
606
501 600
505
511 610
513 612
519
PAVILION
D
724
726
605
617
625
FOOD &
BEVERAGE
SOUTH LOBBY - LEVEL 4
REGISTRATION
BAG DISTRIBUTION
MAIN
ENTRANCE
405
EPILEPSY
RESOURCE
CENTER
333
233 332
337
339
335
336
101 200 202 201 300 301
105
117
119
AES
125
133 232
237
135 234
PAVILION
B
235 334
239
137 236
PAVILION
A
MEDIA WALL
Elevators
Exhibit
Manager
Office
POSTER BOARDS
816
818
805
811
817
823
932
905
909
911
913
915
917
919
921
925
927
FOOD &
BEVERAGE
EXIT
EXIT
800 801 900 902 901
WF
705
713
717
721 820
723 822
725
824
833
733 832
727
835
837 936
735 834
737 836
EXHIBITOR FLOOR PLAN
EXHIBITOR
LOUNGE
GES
*Poster Walking Tours begin at the Poster Information Table
Exhibit Hall Hours:
Saturday, December 6 ..................................................Noon - 6:00 p.m.
Sunday, December 7 ........................................10:00 a.m. - 6:00 p.m.
Monday, December 8 ......................................10:00 a.m. - 3:00 p.m.
81
EXHIBITOR LOCATIONS
Booth
ABRET Neurodiagnostic Credentialing & Accreditation* .....3
Ad-Tech Medical Instrument Corp.................................505
AED Pregnancy Registry .............................................733
Ambry Genetics .........................................................233
Ambu Inc. ..................................................................911
American Board of Clinical Neurophysiology, Inc. (ABCN)* ..2
American Board of Psychiatry and Neurology ................837
American Clinical Magnetoencephalography Society*
(ACMEGS) ...................................................................5
American Clinical Neurophysiology Society (ACNS)* ...........4
American Epilepsy Society ..........................................125
Angel Wings Foundation* ..............................................16
Anita Kaufmann Foundation, The* ...................................1
ANT North America ....................................................236
Ark Diagnostics, Inc. ..................................................820
ASET – The Neurodiagnostic Society* ............................15
Athena Diagnostics, Inc. .............................................612
Aurora Health Care ....................................................235
B. Braun CeGat, LLC ..................................................915
BIOPAC Systems, Inc..................................................836
Blackrock NeuroMed...................................................817
Brain Vision LLC.........................................................835
Cadwell Laboratories, Inc. ...........................................811
captureproof..............................................................919
Charlie Foundation, The and Ice Epilepsy* ......................19
Child Neurology Foundation .........................................832
Clever Sys, Inc. ..........................................................927
Compumedics Limited .................................................805
Courtagen Diagnostics Lab .........................................936
CorTechs Lab, Inc .......................................................334
CURE (Citizens United for Research in Epilepsy)*..............6
Cyberonics, Inc. .........................................................223
Department of Veterans Affairs, Epilepsy Centers of
Excellence*..................................................................9
DigiTrace EEG Services ...............................................727
Dravet Syndrome Foundation* .......................................11
Eisai Inc. ...................................................................305
Electrical Geodesics, Inc.....................................717, 816
ELEKTA......................................................................519
Elsevier, Inc. ..............................................................901
Emfit Corp. ................................................................909
emka TECHNOLOGIES Inc............................................701
Emory Genetics Laboratory.........................................202
Epilepsy Foundation*...............................................8, 513
GeneDx .....................................................................822
GlaxoSmithKline .........................................................336
GW Pharmaceuticals ..................................................133
IEEG.org* ....................................................................17
International Epilepsy Congress...................................234
INSYS Therapeutics....................................................200
Jack Pribaz Foundation, The .......................................332
John Libbey EUROTEXT ...............................................301
82
Booth
LGS (Lennox-Gastaut Syndrome) Foundation*.................10
Lifelines Neurodiagnostic Systems, Inc. .......................921
Lundbeck ...........................................................405, 511
Mallinckrodt Pharmaceuticals..............................217, 316
Medical Neurogenetics, LLC........................................216
MediKidz....................................................................232
Medtech Surgical .......................................................800
Medtronic..................................................................932
Moberg Research.......................................................239
Monteris Medical .......................................................905
Multi Channel Systems ...............................................300
National Association of Epilepsy Centers......................723
National Institute of Neurological Disorders &
Stroke (NINDS)........................................................725
Natus Neurology Incorporated.....................................705
Neuralynx, Inc ............................................................713
Neurology Reviews .....................................................101
NeuroPace, Inc...........................................................824
NeuroQuest LLC ........................................................834
Neurotech .................................................................610
Nexstim ....................................................................119
Nihon Kohden America, Inc. .........................................617
Novartis Pharmaceuticals ...........................................137
Optima Neuroscience, Inc. ..........................................833
Oxford University Press ..............................................219
PCDH19 Alliance*...........................................................7
Persyst Development Corporation ...............................925
Physicians Insurance ..................................................220
Pinnacle Technology, Inc...............................................737
PMT Corporation ........................................................606
PreventionGenetics ....................................................902
Rhythmlink International, LLC ......................................721
Ring14 USA Outreach*.................................................12
Ripple LLC .................................................................724
Rogue Research Inc....................................................900
RosmanSearch, Inc. ...................................................726
SeizureTracker.com* .....................................................21
Smart Monitor Corp. ..................................................917
SUDEP Aware* ............................................................20
Sunovion Pharmaceuticals Inc. ....................................105
Supernus Pharmaceuticals, Inc. ..................................605
Texas Children’s Hospital.............................................201
Transgenomic, Inc.......................................................801
Triangle BioSystems, Inc. ............................................735
Tuberous Sclerosis Alliance* ..........................................22
UCB, Inc............................................................135, 205
UCSF Medical Center .................................................913
Upsher-Smith Laboratories, Inc ..........................625, 823
Vitaflo USA ................................................................117
Wiley .........................................................................818
Wolters Kluwer Health................................................400
*Please see Epilepsy Resource Center Participants on page 83
Stop by the EPILEPSY RESOURCE CENTER
at the Entrance of the Exhibit Hall
2014 Epilepsy Resource Center
— Participants —
Table # ERC Participants:
Presentation Area
ENTRANCE
ENTRANCE
ENTRANCE
ENTRANCE
1 The Anita Kaufmann Foundation
2 American Board of Clinical Neurophysiology,
Inc. (ABCN)
3 The American Board of Registration of EEG
and EP Technologies (ABRET)
4 American Clinical Neurophysiology Society
(ACNS)
5 American Clinical MEG Society (ACMEGS)
6 CURE (Citizen’s United for Research in
Epilepsy)
7 PCDH19 Alliance
8 Epilepsy Foundation
9 Epilepsy Centers of Excellence, Department of
Veterans Affairs
10 LGS Foundation
11 Dravet Syndrome Foundation
12 Ring14 USA Outreach
14 North American SUDEP Registry
15 ASET – The Neurodiagnostic Society
16 Angel Wings Foundation
17 IEEG.org
18 British Paediatric Neurology Association
19 The Charlie Foundation and ICE Epilepsy
20 SUDEP Aware
21 SeizureTracker.com
22 Tuberous Sclerosis Alliance
Many of the ERC participants will be offering mini-workshops dedicated to the education, awareness
and research for people with epilepsy worldwide. All participants of AES, including exhibitors, are invited to
attend the mini-workshops. The schedule will be posted daily outside the ERC.
The Epilepsy Resource Center is a comprehensive one-stop resource for patients, researchers and clinicians
specializing in the area of epilepsy.
83
EXHIBITORS
as of October 21, 2014
Exhibit Schedule
Saturday, December 6: Noon-6:00 p.m.
Lunch: Noon-1:00 p.m.
Symposia Break: 5:00 p.m.-6:00 p.m.
Prize Drawing: 5:30 p.m.
ABRET Neurodiagnostic Credentialing &
Accreditation
Booth #3
2908 Greenbriar Dr - Ste A
Springfield IL 62704
Phone: 217-726-7980
Fax: 217-726-7989
Email: [email protected]
Website: www.abret.org
Contact: Ms. Janice Walbert
ABRET Neurodiagnostic Credentialing &
Accreditation offers five credentials (R. EEG
T.®, R. EP T.®, CNIM®, CLTM, CAP) and
manages three laboratory accreditation
programs, LAB-EEG, LAB-NIOM, and LABLTM. Learn more about laboratory
accreditation, view resources for
technologists and receive assistance in
recruiting neurodiagnostic technologists.
Ad-Tech Medical Instrument Corp.
Booth #505
1901 William St
Racine WI 53404
Phone: 262-634-1555
Fax: 262-634-5668
Email: [email protected]
Website: www.adtechmedical.com
Contact: Ms. Angie Bouwma
Sunday, December 7:10:00 a.m.-6:00 p.m.
Lunch: Noon-1:00 p.m.
Suds for Science: 5:00 p.m.-6:00 p.m.
Prize Drawing: 5:30 p.m.
Ambry Genetics
Booth #233
15 Argonaught
Aliso Viejo CA 92656
Website: www.ambrygen.com
Contact: Colleen Garcia
Ambry Genetics is a College of American
Pathologists (CAP)-accredited and Clinical
Laboratory Improvement Amendments (CLIA)certified commercial clinical laboratory with
headquarters in Orange County, California.
Ambry is a leader in providing genetic
services focused on clinical diagnostics and
genomic services, and has established a
reputation for unparalleled customer
satisfaction.
Ambu Inc.
Booth #911
6740 Baymeadow Dr
Glen Burnie MD 21060
Phone: 800-262-8462
Email: [email protected]
Website: www.ambuusa.com
Contact: Megan Hasson
Ambu is dedicated to the development of
innovative products that help save lives and
simplify workflow of the anesthetists to the
benefit of the patients.Within the field of
anesthesia Ambu offers a wide range of
products from resuscitators, face masks and
laryngeal masks to the highly innovative
single use flexible intubation scope.
Monday, December 8: 10:00 a.m.-3:00 p.m.
Lunch: Noon-1:00 p.m.
Prize Drawing & Grand Prize Drawing:
2:30 p.m.
American Board of Psychiatry and Neurology
Booth #837
2150 E Lake Cook Rd - #900
Buffalo Grove IL 60089
Phone: 847-229-6500
Fax: 847-229-6600
Email: [email protected]
Website: www.abpn.com
Contact: Ms. Karen Back
The American Board of Psychiatry and
Neurology serves the public interest and the
professions of psychiatry and neurology by
promoting excellence in practice through its
certification and maintenance of certification
processes. ABPN also oversees the
certification process for physicians seeking
certification in child and adolescent psychiatry.
American Clinical Magnetoencephalography
Society (ACMEGS)
Booth #5
555 E. Wells Street Ste 1100
Milwaukee WI 53202
Phone: 414-918-9804
Email: [email protected]
Website: www.acmegs.org
Contact: Ms. Megan Kelley
ACMEGS is a non-profit association whose
membership includes clinical MEG facilities in
For over 25 years, Epilepsy Centers have
the U.S. Founded by physicians committed to
made Ad-Tech their choice for invasive
high-quality care of patients with epilepsy,
electrodes for brain mapping and epilepsy
ACMEGS now advocates for patients with
monitoring. We offer a large variety of
neurological conditions who may benefit from
electrodes and accessories to meet you and
MEG by educating policymakers about
your patient’s needs. Visit our Booth to
American Board of Clinical Neurophysiology, recommended standards of care,
discover why Ad-Tech is your best choice.
reimbursement, and provider regulations.
Inc. (ABCN)
Booth #2
AED Pregnancy Registry
American Clinical Neurophysiology Society
2908 Greenbriar Dr Ste A
Booth #733
(ACNS)
Springfield IL 62704
121 Innerbelt Rd - Ste 220
Booth #4
Phone: 217-726-7980
Massachusetts General Hospital
555 E. Wells Street Ste 1100
Fax: 217-726-7989
Somerville MA 02143
Milwaukee WI 53202
Email: [email protected]
Phone: 888-233-2334
Phone: 414-918-9803
Website: www.abcn.org
Fax: 617-724-8307
Fax: 414-276-3349
Contact: Ms. Janice Walbert
Email: [email protected]
Email: [email protected]
The ABCN has a 65 year history of promoting Website: www.acns.org
Website: www.aedpregnancyregistry.org
excellence in Clinical Neurophysiology and
Contact: Ms. Caitlin Smith
Contact: Ms. Megan Kelley
offers examinations with added competency
The North American AED Pregnancy Registry in Epilepsy Monitoring or Neurophysiologic
The American Clinical Neurophysiology Society
is dedicated to determine the safety of
Intraoperative Monitoring. A General Clinical (ACNS) is a professional association dedicated
anticonvulsant medications that can be taken Neurophysiology Track is also available. A
to fostering excellence in clinical
by women during pregnancy. The primary goal Critical Care EEG Track will be offered in fall
neurophysiology and furthering the
is to determine the frequency of major
understanding of central and peripheral
2015. International testing is available.
malformations in the infants exposed during
nervous system function in health and disease
pregnancy to anticonvulsant drugs. Please
through education, research, and the provision
visit our booth to learn more about our
of a forum for discussion and interaction.
findings, and to obtain materials for use in
your office.
84
EXHIBITORS
American Epilepsy Society
Booth #125
342 N Main St
West Hartford CT 06117-2507
Phone: 860-586-7505
Fax: 860-586-7550
Email: [email protected]
Website: www.AESnet.org
Contact: Ms. Cheryl-Ann Tubby
Ark Diagnostics, Inc.
Booth #820
48089 Fremont Blvd
Fremont CA 94538
Phone: 510-270-6270
Fax: 510-270-6298
Email: [email protected]
Website: www.ark-tdm.com
Contact: Mr. Ryan Olandria
Visit the AES booth for information on
membership, publications, and research
funding opportunities. Stop by to watch
interviews being taped with member experts
on some of the hottest topics at the meeting.
Recognize a mentor or colleague by
purchasing a Community of Caring pin, and
support AES research and awareness
programs. Get a personal tour of AES online
resources including the Epilepsy Learning
Institute, EMU Caring, and the AES website.
AES logo scarves, ties and bowties will also
be available for purchase.
Ark Diagnostics Inc. designs, manufactures,
and distributes in vitro diagnostic products.
ARK’s proprietary assays accurately measure
drug levels in biological fluids. Clinicians use
these measurements to guide dosing
decisions for safe, effective, and personalized
drug therapy. Anti-epileptic drug assays (FDA
510k Cleared): Levetiracetam, Lamotrigine,
Topiramate, Gabapentin, and Zonisamide.
Angel Wings Foundation
Booth #16
2134 Baldwin Ct
Hanover Park IL 60133
Phone: 630-550-1049
Email: [email protected]
Website: www.angelwingsfoundation.net
Contact: Ms. Debbie Flader
Angel Wings Foundation is dedicated to
enhancing the lives of adults with epilepsy,
allowing them to reach their full potential
through independent living in the community.
Angel Wings will create home where adults
with epilepsy can lead person-centered lives,
with supports in place. Angel Wings will offer
recreational, vocational and educational
opportunities for adults with epilepsy.
Anita Kaufmann Foundation, The
Booth #1
PO Box 751
Livingston NJ 07039
Phone: 201-655-0420
Email: [email protected]
Website: www.akfus.org
Contact: Ms. Debra Josephs
ANT North America
Booth #236
437 S. Yellowstone Dr #216
Madison WI 53719
Phone: 608-204-0878
Email: [email protected]
Website: www.ant-neuro.com
Contact: Moshe Yuchtman
ASET – The Neurodiagnostic Society
represents more than 4,500 allied health
professionals who perform neurodiagnostic
procedures. ASET provides education and
advocacy, creates greater awareness of the
profession, and establishes standards and
best practices to ensure quality patient care.
Stop by the ASET booth to see our newest
publications and educational offerings.
Athena Diagnostics, Inc.
Booth #612
Ms. Lorri Harrell
200 Forest Street 2nd Floor
Marlborough MA 01752
Phone: 800-394-4493
Email: [email protected]
Website: www.athenadiagnostics.com
Athena Diagnostics is a leader in diagnostics
testing for neurological diseases. Our
comprehensive test menu includes over 400
tests for epilepsy, muscular dystrophy,
peripheral neuropathy, stroke, and other
neuromuscular and developmental disorders.
Aurora Health Care
Booth #235
3305 West Forest Home Ave
Milwaukee WI 53215
Phone: 414-389-2696
Email: [email protected]
Website: www.aurora.org/doctor
Contact: Christine McCarrier
Aurora Health Care is the largest healthcare
system in eastern Wisconsin and extends into
northern Illinois. Our integrated delivery model
helps us coordinate and simplify quality care,
minimize costs and improve our patients’
overall health care experience. Our 15
hospitals and 90+ clinics support
neurologists who believe that better health
care leads to stronger communities.
B. Braun CeGaT is a genetic diagnostic
laboratory that offers an extensive menu
of single-gene sequencing tests and over
150 multi-gene diagnostic panels for a
wide variety of genetic diseases, including
19 panels that analyze 400+ genes
associated with epilepsies, migraines, and
related disorders.
BIOPAC Systems, Inc.
Booth #836
42 Aero Camino
Goleta CA 93117
Phone: 805-685-0066
Fax: 805-685-0067
Email: [email protected]
Website: www.biopac.com
Human and animal wireless EEG systems
with AcqKnowledge analysis automation &
scoring: small animal seizure detection,
EPOCH 2-ch long-term wireless
EEG/neural signals, B-Alert X10 wireless
EEG & Cognitive State Metrics, Mobita
32-ch wireless EEG system with water
electrodes, BioNomadix Wireless
Physiology amplifiers, Stellar telemetry
interface for multiple animals, Developer
Scripting, and more!
Blackrock NeuroMed
Booth #817
630 Komas Dr - Ste 200
Salt Lake City UT 84108
Phone: 801-994-5661
Fax: 801-582-1509
Email: [email protected]
Website: www.blackrockneuromed.com
Contact: Ms. Shanna Ryan
Blackrock NeuroMed’s Cervello® EEG/LTM
systems provide physicians and clinicians
an advanced EEG monitoring system with
up to 256 channels, remote monitoring
capabilities, Bluetooth wireless
connectivity and a full HD 1080 PTZ video
camera. All systems include
comprehensive service and support with
start to finish integration and IT
consultation.
Brain Vision LLC
Booth #835
2500 Gateway Centre Blvd Ste 100
Morrisville NC 27560
Phone: 919-460-2510
Fax: 214-224-0829
Email: [email protected]
Website: www.brainvision.com
Brain Vision LLC offers full service
solutions for customized
neurophysiological related research
including epilepsy related on infants and
adults that include EEG/ERP as well as
fNIRS software and hardware, fMRI
85
EXHIBITORS
AKF, global sponsor of Purple Day®, is a
501(c)(3) public charity with a grassroots
mission to educate the public not to fear
people with epilepsy. Visit
purpledayeveryday.org and akfus.org to learn
about our Heads Up For Vets and Lace Up For
Epilepsy Programs, or to register for our
Purple Day Mall of America Walk for Epilepsy in
conjunction with the CNF Brain Carnival on
3/21/15.
ASET – The Neurodiagnostic Society
Booth #15
402 E Bannister Rd Ste A
Kansas City MO 64131-3019
Phone: 816-931-1120
Fax: 816-931-1145
Email: [email protected]
Website: www.aset.org
Contact: Ms. Sarah Ecker
B. Braun CeGat, LLC
Booth #915
824 Twelfth Ave
Bethlehem PA 18018
Phone: 844-692-3428
Email: [email protected]
Website: www.bbrauncegat.com
Contact: Mitch Nemcek
EXHIBITORS
compatible equipment, stimulation devices
(TMS, tDCS, tACS), wireless system
applications for passive, active, dry
electrodes and accessories.
Cadwell Laboratories, Inc.
Booth #811
909 N Kellogg St
Kennewick WA 99336
Phone: 509-735-6481
Fax: 509-783-6503
Email: [email protected]
Website: www.cadwell.com
Contact: Ms. Lori Kaufman
Cadwell introduces a new concept in
Ambulatory and Clinical EEG. Come byBooth
811 to see the new ARC Alterna EEG
system. Completely new software designed
with the EEG specialist in mind, you will
appreciate the clean, simple look and feel of
this new system. The addition of an all new
Photic Stimulator allows for clinical EEGs
with the Ambulatory hardware while still
providing Ambulatory EEGs.
captureproof
Booth #919
190 7th St. Ste 4
San Francisco CA 94103
Phone: 415-770-2020
Email: [email protected]
Website: www.captureproof.com
Do your patients send you videos?
CaptureProof is the HIPAA secure photo and
video solution that organizes events
chronologically. Videos are uploaded by the
patient and shown at the next appointment
or shared online. You can also share images
with peers for consults. See-and-know what
your patients are talking about. Sign-up free
at captureproof.com using invite code:
AES2014.
Charlie Foundation, The and Ice Epilepsy
Booth #19
1325 Victoria Circle S
Elm Grove WI 53122
Phone: 262-271-3479
Fax: 262-754-1369
Email: [email protected]
Website: www.charliefoundation.org
Contact: Ms. Beth Zupec-Kania
The Charlie Foundation advocates ketogenic
diet therapies through education programs
and offers KetoCalculator, a web-based diet
tool designed to manage ketogenic therapies.
ICE Alliance provides drug information,
advocacy support for appropriate medical
treatment and education, a patient registry
and funding of research for intractable
childhood epilepsies:ice-epilepsy.org
Child Neurology Foundation
Booth #832
201 Chicago Ave - Ste 200
Minneapolis MN 55431
Phone: 612-928-6326
Fax: 612-454-2744
Email: [email protected]
Website: www.childneurologyfoundation.org
Contact: Ms. Amy Brin Miller
86
CNF improves lives of families battling one or
more of the 450+ childhood neurologic
disorders through our web resources, by
supporting affiliate organizations, public
policy initiatives, and the hope derived from
our annual scholarships and awards.
Clever Sys, Inc.
Booth #927
11425 Isaac Newton Sq - Ste 202
Reston VA 20190
Phone: 703-787-6946
Fax: 703-757-7467
Email: [email protected]
Website: www.cleversysinc.com
Contact: Ms. Naili Zhang
Headquartered in the metropolitan D.C. area,
Clever Sys. Inc. sells products and services for
lab animal behavior analysis including rodents,
drosophila, zebra fish, primates, etc.. Our
products utilize information of animal full body
as well as animal body parts, providing
measurements of novel behavioral paradigms
and new parameters, which are more revealing
of the intrinsic of animal behaviors.
Compumedics Limited
Booth #805
6605 W WT Harris Blvd - Ste F
Charlotte NC 28269
Phone: 704-749-3200
Fax: 704-749-3299
Email: [email protected]
Website: www.compumedics.com.au
Contact: Ms. Marjie Cummings
Compumedics provides solutions for Epilepsy
monitoring. NEUVO LTM and Grael EEG
Systems with CURRY 7 Neuroimaging Suite
meet requirements for routine and
ambulatory recordings as well as LTM /
Neuro-ICU monitoring. Compumedics
addresses ultra-high density recordings,
source localization and source imaging. See
more and do more with Compumedics.
CorTechs Labs, Inc.
Booth # 334
4690 Executive Dr - Ste 250
San Diego CA 92121
Phone: 858-459-9700
Fax: 858-459-9705
Email: [email protected]
Website: www.cortechslabs.com
Contact: Ms. Shelly Adams
Courtagen Diagnostics Lab
Booth #936
12 Gill St - Ste 3700
Woburn MA 01801
Phone: 617-999-4122
Fax: 617-892-7191
Email: [email protected]
Website: www.courtagen.com
Contact: Mr. John Geanacopoulos
Courtagen is a diagnostic sequencing and
molecular information company that converts
NGS sequencing data into actionable clinical
information for neurological and metabolic
disorders such as mitochondrial disorders
(mtSEEK® and nucSEEK®), epilepsy
(epiSEEK®), and intellectual disability,
including autism spectrum disorders
(devACT™ and devSEEK™).
CURE (Citizens United for Research
in Epilepsy)
Booth #6
430 W Erie Ste 210
Chicago IL 60654
Phone: 312-255-1801
Fax: 312-255-1809
Email: [email protected]
Website: www.cureepilepsy.org
Contact: Ms. Tracy Dixon-Salazar
CURE (Citizens United for Research in
Epilepsy) is a nonprofit organization
dedicated to finding a cure for epilepsy by
raising funds for research and by increasing
awareness of the prevalence and devastation
of the disease. Since its inception in 1998,
CURE has raised over $28 million to fund
epilepsy research and other initiatives that
will lead the way to a cure.
Cyberonics, Inc.
Booth #223
100 Cyberonics Blvd
Houston TX 77058
Phone: 281-228-7200
Fax: 281-218-9332
Email: [email protected]
Website: www.vnstherapy.com
Contact: Ms. Renee Adams
Cyberonics, Inc. is the leader in device
solutions for epilepsy and is committed to
consistently delivering innovative and
effective solutions for physicians, caregivers
and people with epilepsy. Cyberonics’ VNS
Therapy® is available in more than 70
countries for the treatment of drugresistant epilepsy, with more than 80,000
patients implanted worldwide.
Department of Veterans Affairs, Epilepsy
Centers of Excellence
Booth #9
4150 Clement St (127E)
San Francisco CA 94121
Phone: 415-221-4810
Fax: 415-379-5666
Email: [email protected]
Website: www.epilepsy.va.gov
Contact: Mr. Ryan Rieger
The Department of Veterans Affairs, Epilepsy
Centers of Excellence's mission is to improve
the health and well-being of Veteran patients
with epilepsy and other seizure disorders
through the integration of clinical care,
outreach, research, and education.
EXHIBITORS
DigiTrace EEG Services
Booth #727
200 Corporate Pl - Ste 5B
Peabody MA 01960
Phone: 978-536-7400
Fax: 978-535-9778
Email: [email protected]
Website: www.sleepmed.md
Contact: Mr. Dan Martin
ELEKTA
Booth #519
400 Perimeter Center Terrace
Suite 50
Atlanta GA 30346
Phone: 770-670-2592
Fax: 770-448-6338
Email: [email protected]
Contact: Doris AuBuchon
DigiTrace EEG products and services are used
by dozens of comprehensive epilepsy centers
throughout the U.S. In addition, there are
over 40 SleepMed Service Centers around the
country where physicians can refer their
patients for ambulatory EEG testing. We are
noted for unique capabilities including our
lightweight head-mounted preamplifier that
minimizes motion artifact.
Elekta is the global leader in advanced
magnetoencephalography (MEG)
instrumentation. MEG is a highly sensitive and
completely non-invasive technology increasingly
used for localizing the epileptogenic zone(s)
and adjacent eloquent cortex in pre-surgical
evaluation of epileptic patients.
Dravet Syndrome Foundation
Booth #11
PO Box 16536
West Haven CT 06516
Phone: 203-392-1950
Fax: 203-907-1940
Email: [email protected]
Website: www.dravetfoundation.org
Contact: Ms. Mary Anne Meskis
The mission of Dravet Syndrome Foundation
(DSF) is to aggressively raise research funds
for Dravet syndrome and related epilepsies;
to increase awareness of these catastrophic
conditions; and to provide support to affected
individuals and families.
Eisai Inc.
Booth #305
100 Tice Blvd
Woodcliff Lake NJ 07677
Phone: 201-692-1100
Fax: 201-692-1804
Email: [email protected]
Website: www.eisai.com/US
Contact: Ms. Shirley Hunt
As the U.S. pharmaceutical subsidiary of
Tokyo-based Eisai Co., Ltd., we are a fully
integrated pharmaceutical business with
discovery, clinical, manufacturing and
marketing capabilities. Our key areas of
commercial focus include oncology and
specialty care (Alzheimer’s disease, epilepsy
and metabolic disorders).
EGI brings next-generation clinical EEG
systems, tools, and workflows to hospitals
and clinics worldwide. EEG Systems feature
EGI’s Geodesic Sensor Net for rapid
application and unprecedented comfort.
Your choice of routine EEG systems or dense
array systems for source estimation. Visit
EGI’s booth to see this in action!
Elsevier is a world-leading provider of
information solutions that enhance the
performance of science, health, and
technology professionals, empowering them
to make better decisions, deliver better care,
and sometimes make groundbreaking
discoveries, that advance the boundaries of
knowledge and human progress. Visit our
booth to find out about our Neurology
journals.
Emfit Corp.
Booth #909
PO Box 342394
Austin TX 78734
Phone: 512-266-6950
Fax: 512-266-7203
Email: [email protected]
Website: www.emfit.com
Contact: Ms. Christine Ocean
Emfit is a pioneer and world-leading
manufacturer of movement activity and
discreet vitals monitoring systems. We will be
demonstrating the Emfit Movement Monitor
for monitoring and detecting abnormal,
nighttime movements, along with the newly
released Emfit QS Sleep Monitor
for tracking and recording essential sleep
statistics, including heart rate, respiration
rate, and movement activity.
emka TECHNOLOGIES Inc.
Booth #701
307 Annandale Rd - Ste 203
Falls Church VA 22042
Phone: 703-237-9001
Fax: 703-237-9006
Email: [email protected]
Website: www.emkatech.com
Contact: Ms. Virginie Brechet
Stop by booth#701 to discover the all new
non-invasive and tether-less monitoring
system: rodentPACK v2. An affordable, head-
Emory Genetics Laboratory
Booth #202
2165 N Decatur Rd
Decatur GA 30033
Phone: 404-778-8500
Fax: 404-778-8559
Email: [email protected]
Website: www.genetics.emory.edu
Contact: Mr. Derek Stevens
Emory Genetics Laboratory (EGL) features
fully integrated molecular genetics,
cytogenetics, and biochemical genetics
laboratories, making it a "one-stop shop"
for genetic testing. EGL benefits from its
affiliation with Emory University, but EGL
is not the typical, highly specialized
academic laboratory. EGL offers a full
range of test options, with more than
900 tests available.
Epilepsy Foundation
Booths #8, 513
8301 Professional Pl
Ardmore MD 20785
Phone: 301-918-3739
Email: [email protected]
Website: www.epilepsy.com
Contact: Ms. Temi Aregbesola
The Epilepsy Foundation is a communitybased, family-led organization dedicated
to improving the lives of people impacted
by seizures. We provide programs,
services, support, and encourage
innovation in accelerating new treatments
and therapies.We educate about proper
seizure awareness, recognition and first
aid.We advocate for improved rights and
regulations involving people living with
epilepsy.
GeneDx
Booth #822
481 Edward H Ross Dr
Elmwood Park NJ 07407
Phone: 301-519-2100
Fax: 301-519-2892
Email: [email protected]
Website: www.genedx.com
Contact: Ms. Marianne Sansing
GeneDx is highly respected laboratory,
specializing in genetic testing for rare
Mendelian disorders. GeneDx offers
sequencing and deletion/duplication
testing for inherited cardiac disorders,
mitochondrial disorders, neurological
disorders, inherited cancer disorders,
prenatal disorders and other rare genetic
disorders. GeneDx also offers whole
exome sequencing, next-generation and
microarray-based testing.
87
EXHIBITORS
Electrical Geodesics, Inc.
Booth #717, 816
500 East 4th Ave Ste 200
Eugene OR 97401
Phone: 541-687-7962
Fax: 541-687-7963
Email: [email protected]
Website: www.egi.com
Contact: Ms. Diana Aguilar
Elsevier, Inc.
Booth #901
1600 JKF Blvd - Ste 1800
Philadelphia PA 19103
Phone: 215-239-3491
Fax: 215-239-3494
Email: [email protected]
Website: www.elsevierhealth.com
Contact: Mr. Jeffrey Francis
mounted, radio-telemetry device for
recording EEG, EMG, ECG, temperature,
and/or activity from up to 32 subjects
simultaneously! Weighs only 4.5g with
batteries, 5 meters transmission range,
150 hours continuous recording, no
refurbishment, just replace batteries.
EXHIBITORS
GlaxoSmithKline
Booth #336
Ms. Laura Byrne
Five Moore Dr
Research Triangle Park NC 27709
Phone: 800-366-8900
Email: [email protected]
Website: www.gsk.com
GlaxoSmithKline is a leading research-based
pharmaceutical company with a powerful
combination of skills to discover and deliver
innovative medicines. We offer a number of
program resources to support effective
health management strategies and improve
patient care. Please visit our exhibit to learn
more about our products and resources.
GW Pharmaceuticals
Booth #133
1 Cavendish Pl
London W1G 0QF
United Kingdom
Phone: 917-280-2424
Email: [email protected]
Website: www.gwpharm.com
Contact: Kelly Simontacchi
With 15 years of cannabinoid research
experience, GW is the world leader in
development of novel cannabinoid prescription
medicines to address unmet patient needs
across a range of therapeutic areas. Our
portfolio includes the world’s first plantderived cannabinoid prescription drug,
Sativex®, as well as Epidiolex®, currently in
development for treatment of Dravet and
Lennox-Gastaut syndromes.
IEEG.org
Booth #17
Room 301 Hayden Hall, 240 S. 33rd St
Philadelphia PA 19104
Phone: 215-746-4850
Email: [email protected]
Website: eeg.org
Contact: Carolyn Wilkinson
IEEG.org: A Scientific Platform for
collaborative science. The International
Epilepsy Electrophysiology Portal is a
collaborative initiative funded by the
NIH/NINDS. This initiative seeks to advance
research towards the understanding of
epilepsy by providing a platform for sharing
data, tools and expertise between
researchers. ( NIH Grant #1 U24
NS063930-01)
International Epilepsy Congress
Booth #234
7 Priory Office Park, Stillorgan Rd
Co. Dublin 18
Ireland
Phone: 353-1-2056720
Fax: 353-1-2123576
Website: www.epilepsycongress.org
Contact: Mr. Fergus Egan
The ILAE is the world's preeminent
association of physicians and other health
professionals working towards a world where
no person’s life is limited by epilepsy. The IBE
88
exists to improve the quality of life of people
with epilepsy and their families and carers
through national epilepsy organizations
around the world.
INSYS Therapeutics
Booth #200
1333 S Spectrum #100
Chandler AZ 85286
Phone: 602-910-2617
Email: [email protected]
Website: www.insysrx.com
Contact: Anna Marzahl
INSYS Therapeutics is a specialty
pharmaceutical company that develops and
commercializes innovative drugs and novel
drug delivery systems of therapeutic
molecules, including its proprietary sublingual
spray technology, to help improve patient
quality of life. Focused on pharmaceutical
cannabinoids development, the company is
evaluating its pharmaceutical cannabidiol
(CBD) for epilepsy treatment.
Jack Pribaz Foundation, The
Booth #332
PO Box 813
Wheaton IL 60187
Phone: 630-485-9986
Email: [email protected]
Website: www.jacksarmy.org
Contact: Angela Cherry
The Jack Pribaz Foundation is a 501(c)(3)
charity established in Illinois in 2011. Named
for a boy diagnosed with one of the first
known cases of KCNQ2 epileptic
encephalopathy in North America, its mission
is to support research for this condition by
raising funds and awareness. To learn more
visit www.kcnq2.org and.
John Libbey EUROTEXT
Booth #301
127 Avenue de la Republique
92120 Montrouge
France
Phone: 330-146-7306-79
Fax: 330-140-8409-99
Email: [email protected]
Website: www.jle.com
Contact: Mr. Gilles Cahn
For decades, JOHN LIBBEY EUROTEXT
has been THE Publisher of both worldrenowned specialists and new authors
in Epilepsy. Through Epileptic Disorders,
the Educational Journal of the ILAE, and
moreover through our huge book series,
we provide first-class knowledge in the field
of Epilepsy. Visit www.epilepticdisorders.com,
The Real Forum for The Worldwide Epilepsy
Community.
LGS (Lennox-Gastaut Syndrome) Foundation
Booth #10
192 Lexington Ave Ste 216
New York NY 10150
Phone: 718-374-3800
Email: [email protected]
Website: www.lgsfoundation.org
Contact: Ms. Christina San Inocencio
The LGS Foundation is a non-profit
organization dedicated to providing
information about Lennox-Gastaut Syndrome
while raising funds for research, programs
and services for individuals living with LGS,
and their families.
Lifelines Neurodiagnostic Systems, Inc.
Booth #921
411 Edwardsville Rd Ste A
Troy IL 62294
Phone: 618-667-6445
Fax: 618-667-1982
Email: [email protected]
Website: www.lifelinesneuro.com
Cloud-based technology is the next step in
the evolution of EEG, and LifeLines
Neurodiagnostic Systems is leading the
industry with innovative, new products. iEEG
Cloud is a complete, home video solution.
Record and upload the EEG/video data to the
Cloud for review over the Internet in nearreal time. We maintain servers with our
hosted solution. Stop by booth #921 to see
how EEG is evolving!
Lundbeck
Booth #405, 511
Four Parkway North
Deerfield IL 60015
Phone: 847-282-1000
Fax: 847-282-1001
Email: [email protected]
Website: www.lundbeck.com/us
Contact: Ms. Lisa Berry
Headquartered in Deerfield, Illinois, with a
portfolio specialty central nervous system
(CNS) therapies and a robust pipeline of
promising CNS compounds, Lundbeck is
committed to providing innovative therapies
that fulfill unmet medical needs of people
with CNS disorders, including rare diseases,
for which few, if any, effective treatments
are available.
Mallinckrodt Pharmaceuticals
Booth #217, 316
26118 Research Rd
Hayward CA 94545
Phone: 510-400-0721
Fax: 510-400-0710
Email: [email protected]
Website: www.mallinckrodt.com/ard
Contact: J.T. Thomas
Mallinckrodt is a global specialty
pharmaceutical and medical imaging business
that develops, manufactures, markets and
distributes specialty pharmaceutical
products and medical imaging agents. The
company's Specialty Pharmaceuticals
segment includes branded and specialty
generic drugs and active pharmaceutical
ingredients, and a Global Medical Imaging
segment.
EXHIBITORS
Medical Neurogenetics, LLC
Booth #216
5424 Glenridge Dr NE
Atlanta GA 30342
Phone: 678-225-0222
Fax: 678-225-0212
Website: www.mnglab.com
Contact: Juliann Kowalski
soft tissue, including for use in neurosurgical
procedures. More than 45 U.S. centers have
performed more than 900 neurosurgical
cases.
National Institute of Neurological
Disorders & Stroke (NINDS)
Booth #725
31 Center Dr - Bldg 31 - Rm 8A07
Bethesda MD 20892-2540
Phone: 301-496-5751
Fax: 301-402-2186
Email: [email protected]
Website: www.ninds.nih.gov
Contact: Ms. Natalie Frazin
The National Institute of Neurological
Disorders and Stroke (NINDS) supports
basic, translational, and patient-oriented
research on epilepsy prevention, diagnosis
and treatment, including mechanisms
underlying seizures and epileptogenesis,
gene discovery and targeted therapeutics,
epidemiology, psychosocial and behavioral
consequences, and development of new
therapies. Free patient information.
Natus Neurology Incorporated
Booth #705
3150 Pleasant View Road
Middleton WI 53562
Phone: 608-829-8500
Fax: 847-949-8615
Email: [email protected]
Website: www.natus.com
Neuralynx, Inc
Booth #713
105 Commercial Dr
Bozeman MT 59715
Phone: 406-585-4542
Fax: 406-585-9034
Email: [email protected]
Website: www.neuralynx.com
Contact: Ms. Kathy Walsh
Neuralynx ATLAS systems record the entire
range of human electrophysiology from
surface EEG to single units via micro-wires.
Features include DC capability, flexible
referencing, and 40 KHz acquisition across
all channels. ATLAS provides complete
integration with Nihon Kohden EEG systems
for a seamless clinical workflow. This
functionality makes ATLAS the logical choice
for clinical research.
Neurology Reviews
Booth #101
7 Century Dr - Ste 302
Parsippany NJ 07054
Phone: 973-290-8228
Fax: 973-206-9178
Email: [email protected]
Website: www.frontlinemedcom.com
Contact: Ms. Lynne Kalish
EXHIBITORS
Moberg Research
Booth #239
224 S Maple Way
Ambler PA 19002
MNG provides expert diagnostics through
Phone: 215-283-0860
clinical services, biochemical testing and Next
Fax: 215-283-0859
Generation Sequencing. Our panels are the
Email: [email protected]
most cost effective and comprehensive
Website: www.moberg.com
available, particularly for cellular energetics,
Contact: Ms. Kathleen Fitzgerald
muscular dystrophies, and epilepsy. A major
focus is to provide rapid sequencing
The Moberg CNS Monitor continuously
/metabolic diagnostics. Now available is an
records EEG and processed EEG trends,
Anticonvulsant-Resistant Epilepsy Rapid
time-synchronized with other physiology.
Evaluation Kit.
Multimodal monitoring with integrated video,
EEG trends and physiology helps you evaluate
MediKidz
patients' neurological statuses. View
Booth #232
correlations between EEG and parameters
21 West 46th St
from other devices including vital signs, ICP,
New York City NY 10036
brain oxygen, cerebral blood flow, and more.
Phone: 718-808-5144
Email: [email protected]
Monteris Medical
Website: www.medikidz.com
Booth #905
Contact: Ryan Mulcock
16305 36th Ave N - Ste 200
Plymouth MN 55446
Medikidz is an exciting initiative in children’s
Phone: 719-487-9558
health education, which aims to provide
Fax: 763-746-0084
accurate and relevant medical information for
Email: [email protected]
young people. Medikidz believes that every
Website: www.monteris.com
child deserves access to medical information
Contact: Ms. Lisa Bichsel
they can understand. We are creating a
global community of young people that are
Monteris Medical manufactures minimallyinformed, empowered and health-aware.
invasive devices for MR-guided neurosurgery
including: The NeuroBlate System for precise
Medtech Surgical
controlled laser ablation therapy of epilepsy
Booth #800
and brain lesion targets; AxiiiS Stereotactic
211 Warren St - Ste 306
Miniframe skull-mounted platform for imageNewark NJ 07103
guided trajectory alignment; AtamA System,
Phone: 612-251-6698
an MR-compatible transport and head
Fax: 855-329-7672
stabilization system.
Email: [email protected]
Website: www.medtechsurgical.com
Multi Channel Systems
Contact: Mr. Eric Caille
Booth #300
60 Marine St
ROSA™ is a FDA approved Neurosurgery
Farmingdale NY 11763
robot to offer a touchless Laser Registration
Phone: 631-393-6401
that has been in use for several years in
Fax: 631-393-6407
leading Epilepsy programs in North America
Email: [email protected]
and abroad. With over 1600 procedures to
Website: www.multichannelsystems.com
date ROSA™ is on the forefront of SEEG
Contact: Ms. Margaret Badon
Invasive monitoring. We offer a complete
program including training, case observations, Multi Channel Systems develop precision
consultation and innovative webinars and
scientific measuring instrumentation &
referral programs.
equipment for research groups at universities
& the pharmaceutical industry, in the field of
Medtronic
electrophysiology. We provide solutions for
Booth #932
extracellular recordings with microelectrode
8058 El Rio St
arrays in vitro & in vivo with the MEA-System
Houston TX 77054
& the ME-System as well as for electrical
Phone: 713-275-2063
stimulation with the STG series.
Fax: 713-741-0122
Email: [email protected]
National Association of Epilepsy Centers
Website: www.visualaseinc.com
Booth #723
Contact: Mr. Andre Marquette
600 Maryland Ave SW - Ste 835W
Washington DC 20024
The Visualase Thermal Therapy System is an
Phone: 202-524-6767
MRI-guided, minimally invasive laser ablation
Email: [email protected]
system which allows for continuous
Website: www.naec-epilepsy.org
monitoring of an ablation in real-time. The
Contact: Ms. Johanna Gray
system is FDA-cleared for the ablation of
The National Association of Epilepsy Centers
is a non-profit 501(c)(6) trade association
with a membership of more than 210
specialized epilepsy centers in the United
States. With the goal of no seizures and no
side effects, NAEC strives to make high
quality healthcare available to and affordable
for epilepsy patients across the country.
89
EXHIBITORS
NEUROLOGY REVIEWS is a clinical news
publication with articles and timely
department features that keep neurologists,
primary care physicians, and other healthcare
professionals informed of the latest news
affecting their practice. NEUROLOGY
REVIEWS covers major medical conferences
and monitors the peer review literature to
report the latest research findings.
NeuroPace, Inc.
Booth #824
455 N. Bernardo Ave
Mountain View CA 94043
Phone: 650-237-2700
Fax: 650-237-2701
Email: [email protected]
Website: www.neuropace.com
Contact: Ms. Kathy Miller
NeuroPace, Inc. develops and produces
medical device solutions for the treatment of
neurological disorders. NeuroPace, Inc. has
FDA approval for the RNS® System, the
world’s first and only neurostimulator that
provides targeted, responsive therapy for
patients with medically refractory epilepsy.
NeuroQuest LLC
Booth #834
S75 W17317 Janesville Rd
Muskego WI 53150
Phone: 262-679-7100
Fax: 855-777-8378
Email: [email protected]
Website: www.neuroquestllc.com
Contact: Ms. Mindy Gersonde
There's no place like home to have your
EEG(SM), especially since we make house
calls. NeuroQuest LLC is the premiere
provider of extended ambulatory video EEGs.
Our technologists travel into your patient's
home, a clinic, office or institution to meet
the goal of providing the highest quality, most
convenient, cost-effective EEGs.
Nexstim
Booth #119
1360 Union Hill Rd Ste 5B
Alpharetta GA 30004
Phone: 770-664-1000
Website: www.nexstim.com
Contact: Sydney Bridger
Nexstim’s Navigated Brain Stimulation (NBS)
System integrates TMS, EMG, & MRI guided
navigation to noninvasively map the motor
cortex with the accuracy of DCS. Nexstim
holds FDA clearances for (NBS) PreProcedural Planning and (NexSpeech) for
Mapping Language Function. Future FDA
applications: Stroke Rehabilitation*,
Depression, and TBI. *currently in clinical
trials.
PCDH19 Alliance
Booth #7
6 Wisteria Ct
Novato CA 94945
Phone: 415-892-5794
Email: [email protected]
Website: www.pcdh19info.org
Contact: Ms. Julie Walters
Nihon Kohden America, Inc.
Booth #617
15353 Barranca Pkwy
Irvine CA 92618
Phone: 949-580-1555
Fax: 949-580-1550
Email: [email protected]
Website: www.nkusa.com
Contact: Ms. Jeannie Callahan
The PCDH19 Alliance focuses on raising and
directing funds to scientific research with the
goal of finding better, more effective
treatments and, ultimately, a cure; providing
information and support to affected families;
and assisting the efforts of the medical
community, so that no family suffers without
a diagnosis and the most appropriate medical
treatment.
For over 60 years Nihon Kohden has been
the trusted Neurology solution for Epilepsy
Monitoring, Electroencephalography, EEG &
PSG Wireless & Ambulatory Recording,
Polysomnography, Out of Center Sleep
Testing/PSG, Electromyography, Evoked
Potentials, Intra-operative and cEEG ICU
monitoring. Serving the Best Minds in
Neurology for Over Sixty Years.
Persyst Development Corporation
Booth #925
12625 High Bluff Dr - Ste 213
San Diego CA 92130
Phone: 858-461-4542
Fax: 858-461-4531
Email: [email protected]
Website: www.persyst.com
Novartis Pharmaceuticals
Booth #137
One Health Plaza
East Hanover NJ 07936
Phone: 862-778-2159
Website: www.novartisoncology.com
Contact: Marianne LaRosa
Neurotech
Booth #610
15285 Watertown Plank Rd Ste 2
Elm Grove WI 53122
Phone: 262-754-0895
Email: [email protected]
Website: www.neurotecheeg.com
Contact: Vickie Wolfe
Novartis Oncology has emerged as a global
leader in oncology through targeted research
and open partnership in the pursuit of new
therapies capable of transforming outcomes
for people with cancer. Our research is driven
by a distinctive scientific and clinical strategy,
focusing on unmet medical needs and disease
pathways.
Neurotech EEG Telemedicine – In Home Tests,
24/7 Remote Monitoring – Neurotech
provides 24+ hour EEG tests to diagnose
seizures. With prompt scheduling,
technologists hookup patients in their homes.
R EEG T remotely monitors patients
continuously, any problems resolved by
technologist returning to patient if
necessary; ensuring quality test results.
Physicians have live online access to data.
Optima Neuroscience, Inc.
Booth #833
11930 Research Circle
Alachua FL 32615
Phone: 386-462-9622
Fax: 386-462-5365
Email: [email protected]
Website: www.optimaneuro.com
90
Oxford University Press
Booth #219
198 Madison Ave
New York NY 10016
Phone: 212-726-6000
Fax: 212-726-6494
Email: [email protected]
Website: www.oup.com/us
Contact: Ms. Meagan Burnett
Optima Neuroscience is a medical device
company developing innovative technologies
for the diagnosis and treatment of
neurological disorders. Optima's initial
product lines feature neurological status
monitoring technologies designed to directly
address these needs.
For more than twenty years Persyst has
produced the most trusted and innovative
EEG analysis products. Today, Persyst is the
world’s leading supplier of artifact reduction,
seizure detection, spike detection, and
quantitative analysis software to every
leading EEG manufacturer for continuous EEG
monitoring, LTM and ambulatory EEG.
Physicians Insurance
Booth #220
1301 Second Ave Ste 2700
Seattle WA 98101
Phone: 206-343-7300
Fax: 206-343-7100
Email: [email protected]
Website: www.phyins.com
Contact: Catherine Kunkel
Physicians Insurance A Mutual Company is
the largest medical professional liability
insurance company in the Northwest, with
7,000 members in Oregon, Washington,
Idaho, and Wyoming. Owned and operated by
its insured physicians and clinics, Physicians
Insurance offers broad protection at a
reasonable cost, focusing on patient safety
and claims management.
EXHIBITORS
Pinnacle Technology, Inc.
Booth #737
2721 Oregon St
Lawrence KS 66046
Phone: 785-832-8866
Fax: 785-749-9214
Email: [email protected]
Website: www.pinnaclet.com
Contact: Ms. Linda Lane
Pinnacle provides preclinical research tools.
New this year is optogenetics technology
integrated into our seizure monitoring
systems. Biosensors can be added to the
core EEG/EMG units to measure
neurotransmitters along with seizure activity.
Our analysis software finds, identifies, marks
and analyzes seizure events. Synchronized
video and precision timing can be added to
any system.
PMT Corporation
Booth #606
1500 Park Rd
Chanhassen MN 55317
Phone: 952-470-0866
Fax: 952-470-0865
Email: [email protected]
Website: www.pmtcorp.com
Contact: Ms. Amanda Bammert
Rhythmlink offers an array of monitoring
devices including the first and only FDA
cleared disposable MR Conditional EEG
products on the market.
Ring14 USA Outreach
Booth #12
4313 Wood Dr.
Midland TX 79707
Phone: 765-491-6910
Email: [email protected]
Website: www.ring14usa.org
Contact: Yssa DeWoody
Ripple LLC
Booth #724
2015 S 1100 E
Salt Lake City UT 84106
Phone: 801-413-0139
Fax: 801-413-2874
Email: [email protected]
Website: www.rppl.com
Contact: Mr. Mitch Frankel
Ripple provides high performance
electrophysiology data acquisition systems
for neuromuscular recording and stimulation.
Our systems are compact, portable, and
heavily optimized for real-time, closed-loop
control applications with up to 512 channels
of EMG, EEG and microelectrode data. Our
PMT Corporation is the premier supplier of an software is cross platform, and can be run
extensive line of neurosurgical products,
on Windows, Mac OS X, and Linux.
offering Cortac, cortical surface electrodes,
Depthalon, depth electrodes and sEEG depth Rogue Research Inc.
electrodes for epilepsy monitoring and
Booth #900
microsurgical instruments. PMT also offers
4398 St-Laurent Ste 206
high-end neck braces, including halo systems Montreal QC H2W 1Z5 Canada
and orthotic vests for cervical, thoracic and
Phone: 514-284-3888
lumbar spinal immobilization.
Fax: 514-284-6750
PreventionGenetics
Booth #902
3800 South Business Park Ave
Marshfield WI 54449
Phone: 715-387-0484
Email: [email protected]
Website: www.preventiongenetics.com
Contact: Danielle Krohn
Rhythmlink International, LLC
Booth #721
1140 First St S
Columbia SC 29202
Phone: 816-429-5931
Fax: 803-252-1111
Email: [email protected]
Website: www.rhythmlink.com
Contact: Mr. Garrett Butler
Rhythmlink International is a medical device
manufacturing company specializing in devices
that help connect patients to machines to
record or elicit physiologic information.
Seizure Tracker provides free tools to help
patients and doctors better understand
seizure activity and surrounding treatments.
The site provides patients with resources to
log their seizures along with medication, diet,
VNS settings and much more. Reports
generated on SeizureTracker.com include
graphs that illustrate trending in treatment
efficacy and can be easily shared with care
providers.
Smart Monitor Corp.
Booth #917
6203 San Ignacio Ave #112
San Jose CA 95119
Phone: 408-505-1976
Fax: 408-351-0154
Email: [email protected]
Website: www.smart-monitor.com
Contact: Ms. Sheri Becker
Smart Monitor provides monitoring solutions
for people with chronic health conditions.
Founded in 2009 and headquartered in San
Jose, CA, Smart Monitor fuses together
sensor, mobile and cloud technologies with
big-data analytics in a seamless environment.
Our patent protected solutions foster
autonomy and enhance safety,while offering
significant peace-of mind to their families and
care providers.
SUDEP Aware
Booth #20
Rogue Research develops the Brainsight®
283 Danforth Ave Ste 350
Toronto ON M4K 1N2 Canada
family of neuronavigation products, including
Phone: 416-556-8770
Brainsight TMS, the first and most popular
Email: [email protected]
neuronavigation system designed specifically
Website: www.sudepaware.org
for TMS. Brainsight NIRS is a unique fNIRS
system designed specifically for multimodality Contact: Ms. Tamzin Jeffs
applications, allowing fNIRS acquisition during
TMS and simultaneous fNIRS acquisition along SUDEP Aware is a not-for-profit organization
that has worked since 2007 to bring more
with EEG, fMRI or MEG.
awareness and better understanding to
Sudden Unexpected Death in EPilepsy
RosmanSearch, Inc.
(SUDEP). It provides support to families and
Booth #726
researchers through its co-founder
30799 Pinetree Rd Ste 250
partnership between Dr Elizabeth Donner
Pepper Pike OH 44124
(Pediatric Neurologist at Sick Kids Hospital,
Phone: 216-287-2302
Toronto) & Tamzin Jeffs (who has epilepsy
Fax: 216-803-6672
and lost her sister to SUDEP).
Email: [email protected]
Website: www.rosmansearch.com
Contact: Mrs. Beth Dery
RosmanSearch is a dual-specialty, truly
expert, high integrity neurosurgical and
neurology recruiting service you can trust.
We specialize exclusively in neurosciences
permanent placement, and our recruitment
methodology is data driven and unique in the
industry.
Sunovion Pharmaceuticals Inc.
Booth #105
84 Waterford Dr
Marlborough MA 01752
Phone: 508-481-6700
Fax: 508-357-7490
Email: [email protected]
Website: www.sunovion.com
Contact: Ms. Susan Mahoney
EXHIBITORS
PreventionGenetics is a leader in providing
comprehensive clinical DNA testing offering
NextGen Sequencing, Sanger sequencing and
deletion/duplication testing via array CGH for
over 1000 genes. Our highly experienced
team of geneticists provide fast turnaround
times, outstanding personalized service, and
the highest quality testing at the lowest
prices possible. We are CLIA/CAP accredited.
Email: [email protected]
Website: www.rogue-research.com
Contact: Mrs. Diane Gariepy
SeizureTracker.com
Booth #21
PO Box 10738
Alexandria VA 22310
Phone: 703-339-8448
Fax: 703-339-8430
Email: [email protected]
Website: www.seizuretracker.com
Contact: Mr. Robert Moss
91
EXHIBITORS
Sunovion is a leading pharmaceutical company
dedicated to discovering, developing and
commercializing therapeutic products that
advance the science of medicine in the
Psychiatry, Neurology and Respiratory
disease areas and improve the lives of
patients and their families. Sunovion is a
subsidiary of Sumitomo Dianippon Pharma
Co., Ltd.
Triangle BioSystems, Inc.
Booth #735
2224 Page Rd Ste 108
Durham NC 27703
Phone: 919-361-2663
Fax: 919-544-3061
Email: [email protected]
Website: www.trianglebiosystems.com
Contact: Mr. James Morizio
Upsher-Smith Laboratories, Inc
Booth #625, 823
6701 Evenstad Dr
Maple Grove MN 55369
Phone: 763-315-2000
Fax: 763-315-2244
Email: [email protected]
Website: www.upsher-smith.com
Contact: Ms. Becky Bouley
Supernus Pharmaceuticals, Inc.
Booth #605
1550 E Gude Dr
Rockville MD 20850
Phone: 301-838-2500
Email: [email protected]
Website: www.supernuspharma.com
Contact: Mr. Tilton Conner
Miniaturized stimulation and recording
solutions for rodent and other animal models.
Wireless Stim headstage (2-16ch). Recording
headstages for single unit, EEG and other
signals: tethered, multiplexed or signature
wireless headstages (5–128Ch). Software:
Neuroware™ acquisition, Optimap™ video
tracking, StimWare™. Custom
electrophysiology engineering solutions.
Upsher-Smith Laboratories, Inc., founded in
1919, is a growing pharmaceutical company
dedicated to its mission of Advancing
Pharmacotherapy. Improving Life™. With
capabilities ranging from early-stage research
to delivering on-market products, UpsherSmith is committed to developing quality
products that enable people to live life to its
greatest potential.
Tuberous Sclerosis Alliance
Booth #22
801 Roeder Rd Ste 750
Silver Spring MD 20910-4467
Phone: 301-562-9890
Fax: 301-562-9870
Email: [email protected]
Website: www.tsalliance.org
Contact: Ms. Katie Smith
Vitaflo USA
Booth #117
316 Montgomery St
Alexandria VA 22314
Phone: 631-897-6939
Email: [email protected]
Website: www.vitaflousa.com
Contact: Ms. Katrina Bellan
Supernus Pharmaceuticals, Inc. is a specialty
pharmaceutical company focused on
developing and commercializing products for
the treatment of CNS diseases. The company
has two marketed products for epilepsy,
Oxtellar XR® (oxcarbazepine) extendedrelease tablets and Trokendi XR® (topiramate)
extended-release capsules.
Texas Children’s Hospital
Booth #201
1919 S Braeswood Ste 6226
Houston TX 77030
Phone: 832-824-2143
Fax: 832-825-2624
Email: [email protected]
Website: www.texaschildrens.org
Contact: Ms. Karen Wilkinson
The Neuroscience Center at Texas Children’s
Hospital, located in Houston, Texas is
committed to creating a healthier future for
children and women by leading in patient
care, education and research. Utilizing
Neurology, Neurosurgery and the Jan and Dan
Duncan Neurological Research Institute, we
are able to identify, monitor and surgically
correct the full continuum of neurological
conditions.
Transgenomic, Inc.
Booth #801
12325 Emmet St
Omaha NE 68164
Phone: 402-452-5400
Fax: 402-452-5401
Email: [email protected]
Website: www.transgenomic.com
Contact: Mr. Scott Stremick
Transgenomic, Inc. specializes in genetic
testing for cardiology (FAMILION), neurology,
mitochondrial disorders and oncology.
Transgenomic develops assays and offers
testing with the goal to overall improve
medical diagnosis and outcomes for patients.
Founded in 1974, the TS Alliance is the only
national voluntary health agency dedicated to
finding a cure for TSC, while improving the
lives of those affected. TSC is a genetic
disorder characterized by seizures and tumor
growth in vital organs such as the brain,
heart, kidneys, lungs and skin.
UCB, Inc.
Booth #135, 205
1950 Lake Park Dr
Smyrna GA 30080
Phone: 770-970-7500
Fax: 770-970-8917
Email: [email protected]
Website: www.ucb-group.com
Contact: Mr. Dave Tappan
Wiley
Booth #818
111 River Street
Hoboken NJ 07030
Phone: 201-748-6000
Fax: 201-748-6617
Email: [email protected]
Website: www.wiley.com
At UCB, we have a passionate, long-term
commitment to discovering and developing
innovative medicines that transform the lives
of people living with severe immunological
diseases and central nervous system
disorders. With 8,500 employees in 40
countries, we invest more than 25% of
revenue in cutting-edge scientific research
to meet unmet patient needs.
Wiley is the leading society publisher. We
publish on behalf of more societies and
membership associations than anybody else,
and offer libraries and individuals 1,250 online
journals, thousands of books and e-books,
reviews, reference works, databases, and
more. For more information, or our online
resource: onlinelibrary.wiley.com.
UCSF Medical Center
Booth #913
3360 Geary Blvd Ste 301
San Francisco CA 94118
Phone: 415-353-7703
Email: [email protected]
Website: jobs.ucsfmedicalcenter.org
Contact: Cheryl Hardin
Wolters Kluwer Health
Booth #400
Two Commerce Sq 2001 Market St
Philadelphia PA 19103
Phone: 215-521-8300
Fax: 215-521-8493
Email: [email protected]
Website: www.lww.com
Contact: Ms. Joey-Rose Jester
If you are looking to take your career in the
END field to the next level then UCSF Medical
Center Neurodiagnostics Program is for you!
UCSF has one of the largest, most
comprehensive epilepsy surgery programs
in the western United States.
92
Vitaflo® is at the forefront of developing
innovative specialized medical foods for
Metabolic Disorders, Nutrition Support and
other areas of disease specific nutrition. Our
aim is to create nutritional products that
combine the best of cutting edge research
with the lifestyle demands of modern living,
ensuring the most acceptable products are
available for the patient.
Wolters Kluwer Health is a leading global
provider of information, business intelligence
and point-of-care solutions for the healthcare
industry. Clinicians rely on Wolters Kluwer
Health’s market leading information-enabled
tools and software solutions throughout their
professional careers from training to
research to practice.
ABSTRACT AUTHOR INDEX
A
Alegre, M. 2.153
Alencar, C.N. 3.179
Alessi, R. 2.259, 2.260, 3.179
Alexandre, F.P. 1.086
Alexandre, V. 2.226
Alexopoulos, A. 1.040, 1.144, 1.149,
1.240, 2.249, 3.359
Alhadid, K. 3.200
Alhashem, A. 1.104
Alhusaini, S. 1.248
Ali, A. 2.095
Ali, I. 1.321, 3.079
Ali, N. 1.239, 2.106
Ali, W. 3.061
Alio Saenz, A. 2.318, 2.324
Alkawadri, R. 1.156
Allard, L. 2.239
Allen, A. 2.095
Allen, B.B. 3.155
Allen, V. 1.267
Allendorfer, J. 1.236, 1.257, B.09
Almane, D. 2.023
Almualim, M. 3.225
Almutairi, F. 1.104
Alonso-Vanegas, M. 2.186, 2.334,
3.154
Alqadi, K. 2.172
Alsaadi, T. 2.086
Alshafai, L. 1.189
Althaus, A.L. 3.005
Altura, C. 1.285
Alvarez, V. 3.203, 3.226
Aly, R. 2.066
Amador, A. 2.222
Amaro, P. 2.153
Amina, S. 2.126
Amiri, M. 1.171
Amrom, D. 1.121, 3.097
An, D. 3.285
An, S. 2.035, A.05
Anastassopoulos, K.P. 1.273, 1.287
Andermann, E. 1.121, 1.317, 1.319,
3.097
Andermann, F. 1.121, 3.097
Anders, B. 1.307, 1.308, 2.280,
2.281, 2.284
Anderson, A. 1.139, 3.048, 3.049,
3.050, 3.061
Anderson, C. 3.208
Anderson, C.T. A.08
Anderson, M. 1.290
Anderson, W. 1.045, 1.061, 2.025
Anderson, W.S. 1.064
Ando, N. 1.224, 1.243
Ando, T. 1.079
Andrade, D. 1.112, 2.095
Andrade, E. 2.261
Andrade, J.Q. 3.179
Andreas, J. 2.283, 3.290
Andrews, J. 1.164
Andrews, M. 3.132
Andriola, M. 1.132, 1.142, 2.162
Ang, L. 3.109
Anghelina, E. 3.220
Anschel, D. 3.154
Antony, A. 1.073
Aoki, M. 2.149
Appavu, B. 2.127
Appleton, R. 1.109
Aracri, P. 1.108
Arai, H. 1.116, 1.363, 1.370, 2.132,
3.012
Arain, A. 1.327, 2.117, 3.252
Arain, F. 3.015
Arakawa, Y. 1.350, 2.335
Araujo, P. 3.260
Archer, J. 3.092, 3.287
Ardini, M. 3.141, 3.144
Arican, N. 1.053
Arita, K. 1.265, 2.002
Arkilo, D. 1.123
Armbruster, M. 3.125
Armstrong, C. C.03
Arndt, D. 1.182, A.09
Arnedo, V. 1.085
Arnett, A. 1.090, 1.091
Arnold, S.T. 2.088
Arrigoni, E. 1.162
Arruda, F.J. 2.274, 3.199
Arya, R. 1.353, B.06
Arzimanoglou, A. 2.263, 2.277
Asadi-Pooya, A. 1.311
Asano, E. 1.251, 2.345, 3.062, 3.362
Ashby-Lumsden, A. 3.036
Asratyan, S. 2.076
Assaad, B. 1.151, 2.215
Ates, N. 1.053
Atherton, D. 2.070
Athing, U. 2.121
Atsumi, S. 2.202
Auerbach, D.S. 3.132
Auguste, K.I. 1.369
Aung, T. 2.109, 2.140
Aungaroon, G. 3.247
Auvin, S. 1.055, 1.056, 2.263
Avallone, J. 1.133
Avedian, L. 3.250
Avoli, M. 1.301, 3.121, 3.184
Ayasoufi, K. 1.008
Azar, N. 1.187, 1.327, 2.160, 3.252
Azarion, A. 2.301
Azuma, J. 1.116
Azuma, Y. 1.224, 1.235, 1.243
Azzam, R. 1.280, 2.117
B
Baba, H. 1.359, 1.361, 1.365
Baba, K. 1.365
Baba, S. 1.127, 1.145, 2.353, 3.108
Babiarz, K. 2.085
Baboyan, V. 3.060
Babtain, F. 1.223
Bachman, E. 1.188, 3.218
Backofen-Wehrhahn, B. 1.069
Bacskai, B. 1.021, 3.004
Badesch, B. 1.267
Bagliella, E. 2.233
Bagnall, R.D. 3.088
Bahlo, M. 3.100
Bai, X. B.01
Bailey, L. 2.022, 2.250
Bailey, M. 3.224
Bain, S. C.07
Bainbridge, J. 3.304
Bakaki, P. 2.052, 2.090
Baker, D. 1.140
Baker, E. 1.184
Baker, M. 1.327
Baker, S. 1.043
Bakken, I. 2.072
Bal, C. 2.365
Balabanov, A. 2.037, 2.205
Balaguera, P. 2.241
Baldeweg, T. 1.190
Baldin, E. 3.140
Balena, T. 1.021, 3.023
Balestri, M. 2.146
Ball, T. 1.167
Ballaban-Gil, K. 2.061
Bamps, Y. 3.075, 3.078, 3.085, 3.127
Bandt, S. 1.376
Bandyopadhyay, S. 3.252
Bang, H. 3.112
Banks, G. 1.057
Bar Yossef, R. 2.175, 3.197
Baraban, S. C.05
Baram, T. 1.009,
Barba, C. 1.348
Barber, A. 2.301
Barber, J. 2.039
Barborica, A. 1.191, 3.069
Barbosa-Nunez, C. 1.294
Barcia, G. 3.016
Barisic, N. 1.107, 1.118
Barker-Haliski, M. 1.050
Barkley, G.L. 1.151, 2.212, 2.215
Barnard, M.E. 1.154
Barnes, D. 2.058
Barnett, J. B.07
Barnett, P. 1.255, 2.237
Barrett, K. 1.025, 3.019
Barrios, E. 3.065
Barritt, S.E. 1.278
Barth, D. 3.038, 3.047
Bartha, R. 3.265, 3.277
Bartley, M.L. 3.286
Bartolomei, F. 1.377, 2.226, 3.182
Basha, M. 2.214, 3.266
Baslet, G. 2.236
Bastar, J. 1.161
Basu, I. 1.064
Basu, R. B.06
Bateman, L. 1.057, 3.213
Bates, J. 2.059
Bathena, S. 3.317
Battaglia, G. 3.029
Baudry, M. 1.039
Bauer, G. 2.068
Baulac, M. 3.296
Baumer, F. 2.124
Baumgartner, J. 1.179, 2.014, 2.248,
2.253, 2.255, 2.348, 2.364, 3.276
Bautista, J. 2.273
Baxter, R. 1.194
Baykan, B. 1.128, 2.183
Baykan, B. 2.224
Baykara, Y. 1.076
Bayly, M.A. 3.089
Baysal Kirac, L. 1.128
Bazil, C. 2.209, 2.212
ABSTRACT AUTHOR INDEX
Aaberg, K. 2.072
Abbott, D. 3.287
Abdel-Latief, O. 1.066
AbdeleRahman, K. 3.171
Abdulkadir, Y. 3.340
Abel, T.J. 1.079
Abela, E. 2.244
Abend, N. 1.136, 1.182, B.06
Abibullaev, B. 1.130
Abisogun, A. 2.246
Abosch, A. 3.190
Abou-Khalil, B. 1.186, 1.280, 1.321,
1.327, 1.338, 2.117, 2.242, 3.152
Abramovici, S. 2.157
Abramson, E.L. 2.043
Abtahi, M. 3.073
Abu Abthan, M. 1.223
Abubakr, A. 1.183
Acevedo, K. 3.101
Aceves, J. 1.341
Ackley, M. 1.296, 1.303
Acton, E. 3.208, 3.238
Adams, E. 1.094, 2.021, 2.270
Adeleye, A. 3.172
Adhami, S. 2.196
Adjouadi, M. 3.192
Adkins, A. 1.066
Afawi, Z. 3.090
Afra, P. 1.068
Agadi, S. 1.215, 1.341
Agan, K. 3.151
Agarwal, M. 1.275
Agarwal, N. 1.144, 3.359
Agarwal, R. 3.362
Agee, B. 2.338, 3.348
Agha, C. 2.066
Agha-Khani, Y. 2.198
Aghakhani, Y. 1.264, 2.067, 2.150,
3.139, 3.186
Agostini, M. 2.038, 2.189, 2.193,
3.083
Agostini, S. 2.166
Agrawal, S. 2.041
Aguado Valcárcel, M. 2.300
Ahishali, B. 1.053
Ahmadi, L. 3.229
Ahmed, I. 3.079
Ahmed, O.J. 1.018
Ajetunmobi, O. 3.129
Akasaka, N. 1.116
Akdag, G. 3.305
Akiyama, M. 1.172
Akiyama, T. 1.172
Akman, C. 3.233
Akman, C.I. 3.140
Al Ghamdi, S. 1.223
Al Jarrah, S.A. 2.001
Al Matrooshi, N.O. 2.086
Al matrooshi, N.O. 2.106
Al-Baradie, R.S. 3.234
Alagapan, S. 1.159
Alam, J. 3.289
Alareddy, A. 1.062
Albert, J. 2.052
Alberts, G. 2.016
Aldenkamp, A. 2.018
93
ABSTRACT AUTHOR INDEX
Bazzigaluppi, P. 1.016, 3.008
Beal, J.C. 2.061
Beatty, C. 3.245
Beaulieu, C. 3.259, 3.260, 3.261
Bebek, N. 1.128, 2.183, 2.224
Becchetti, A. 1.108
Bechstedt, S. 1.121
Becker, D. 2.007
Beers, C. 1.264
Begley, C. 2.009, 2.047, 3.078
Behr, C. 1.301, 3.121
Beimer, N.J. 2.030
Belfort, G. 1.296, 1.303
Bell, A.J. 2.144
Bellas, P. 3.309
Bello, L. 1.132, 1.142, 3.240
Bello-Espinosa, L. 1.360, 3.102
Belousova, E. 2.187
Beltramini, G.C. 3.259, 3.260
Ben Hur, T. 2.175, 3.063
Ben Salem, Z. 1.051
Ben-Menachem, E. 2.278
Benbadis, S. 1.101, 1.315, 1.317,
1.322, 1.340, 2.360, 2.361, 3.304
Bendrups, N. 1.279
Benedik, M. 2.187
Beniczky, S. 1.118
Benifla, M. 2.175
Benites, D. 3.070
Benke, T. 3.209
Bennett, M. 3.224
Bennett, O. 2.175
Benninger, F. 3.197
Bensalem-Owen, M. 1.323, 2.136
Bentz, J. 2.277
Berberi, N. 2.170
Berdichevsky, Y. 2.328
Berg, A. 1.097, 1.206, 2.035, A.01,
A.02
Berg, K. 2.021, 2.270
Berg, M. 1.324, 2.285, 2.286, 2.287,
3.288
Berg, R. 1.182
Bergey, G. 1.174, 1.216, 2.209,
3.189, 3.191
Bergin, A. 3.236, 3.325, 3.326, 3.334
Bergo, F. 3.259, 3.260
Berkeley, J. 2.200
Berkovic, S. 1.120, 3.088, 3.089,
3.092, 3.095, 3.100
Berl, M. 2.019, 3.268, 3.272, 3.278
Bermudez-Hernandez, K. 3.037
Bernard, C. 3.182
Bernardo,, D. 1.159
Bernasconi, A. 1.237, 1.244, B.04
Bernasconi, N. 1.237, 1.244, B.04
Bernhardt, B. 1.237, 1.244, B.04
Berquin, P. 2.263, 2.277
Berrios-Siervo, G. 2.012
Bertram, E.H. 3.047
Bertti, P. 3.055
Besag, F. 2.018
Besio, W. 3.073
Bessemer, R.A. 3.186
Betting, L. 3.165
Betts, K. 1.342
Bevot, A. 1.118
Bhatia, H. 1.223
94
Bhatia, P. 2.092
Bickel, S. 1.157, 2.246, 3.177, 3.346
Bienes, G. 2.327
Bilir, E. 1.207
Binder, D. 2.238, 3.119
Bingaman, W. 1.058, 1.093, 1.099,
1.240, 1.347, 1.362, 1.377
Biraben, A. 1.317, 2.226
Birk, N. 3.068
Birnbaum, A. 1.272, 3.317
Birney, K.A. 2.042
Bishara, A. 3.063
Bishop, L. 3.224
Biton, V. 2.278, 2.292
Blatt, I. 1.307, 1.308, 2.280, 2.281,
3.090, 3.197
Bleasel, A. 3.286
Blezin, F. 2.064
Block, S.C. 1.186
Blum, D. 1.273, 1.287, 1.312, 1.314,
1.315, 1.316, 1.317, 1.318, 1.319,
1.320, 1.321, 1.322, 1.323, 1.342,
2.278, 2.290, 2.292
Blumberg, J. 2.180
Blumcke, I. 1.346
Blume, H. 3.245
Blumenfeld, H. 1.044, 1.062, 1.076,
1.164, A.02, B.01,
Blumenfeld, J. 1.076
Blumenthal, H. 2.022
Bluvstein, J. 2.309, 3.303
Boada, R. 2.012
Boals, A. 2.022
Boelman, C. 1.145, 1.172
Bogaarts, G. 1.138
Boggs, J. 3.224, 3.367
Bolen, R. 3.224
Boles, R. 3.094
Bolger, P. 1.324, 2.285, 2.286, 2.287
Bollu, V. 1.342, 2.044
Bolton, J. 2.143
Bonanni, P. 2.122
Bond, T.C. 1.273, 1.287
Bonfert, M. 2.204
Bongardt, S. 3.294
Bonilha, L. 1.352, 2.004, 3.270
Bonito, J. 2.350, 3.136
Bonno, D.M. 1.125
Boon, P. 1.017, 1.067, 3.028, C.08
Bordey, A. 3.030
Borges, A.D. 3.165
Borggraefe, I. 2.204
Borghs, S. 2.219, 2.320, 3.295,
3.298
Bork, S.J. 2.333
Borlot, F. 1.112, 2.095
Borzello, M. 3.054
Bosler Walton, C. 2.006
Boudreau, E. 2.177, 2.269
Bouthillier, A. 2.123, 3.274, 3.370
Bowden, S.C. 1.279
Bower, M. 2.156
Bower Baca, C. 1.357
Bowman, C. 3.238
Bowyer, S. 1.151, 2.252
Boychuk, J. 1.027
Boyd, A. 2.320
Boyd, J. 3.306
Boyer, K. 2.017, 3.169
Boyle, M. 1.100
Bozarth, X. 3.099
Bozorg, A. 2.360, 2.361
Braesch, C.T. 1.278
Bragin, A. 1.177
Bramhall, M. 2.115
Brand, E. 3.302, A.08
Brandt, C. 2.059, 3.293
Braun, C.N. 3.040
Brazdil, M. 2.003
Brennan, G.P. 1.009
Brenton, J.N. 3.147
Brenton, N. B.06
Brewster, A. 3.048, 3.049, 3.050
Brewster, R. 3.344
Brickel, N. 2.318
Briggs, D. 2.131, 3.070
Brima, T. 1.305
Brinkmann, B. 1.175, 2.156, 3.071
Brittain, S.T. 1.337, 1.343, 2.329,
2.331
Britton, J. 1.374, 3.158, B.05
Brock, M. 3.291, 3.292, 3.299
Brodie, M. 1.331, 1.334, 1.335,
1.336
Brodtkorb, E. 2.282
Brooks, B. 2.271
Brooks-Kayal, A. 1.003, 3.003, 3.011,
3.031
Brosch, M. 3.045
Brouhard, G. 1.121
Brown, E.C. 3.062
Brown, M. 1.266
Brown, S. 1.209, 2.054
Brunner, P. 2.248, 2.255, 3.276
Brusco, S. 1.108
Bryant, T. 3.156
Bubolz, B. 3.061
Bubrick, E. 3.289
Buchanan, G. 1.049, 1.164, 3.030,
Buchanan, R. 3.070
Buchfelder, M. 1.146, 1.346
Buchhalter, J. 1.276, 3.057, 3.137,
3.172, 3.327
Buchsbaum, R. 2.296, 2.312, 3.138
Buchtel, H. 2.030
Buckley, A. 3.166
Buckley, R. 3.368
Buckley, S. 1.228
Buckmaster, P. 1.014
Budech, C.B. 1.241
Buelow, J. 3.075, 3.321
Buentjen, L. 3.045, 3.058, 3.349
Buerki, S.E. 3.096
Bui, E. 2.232
Bujarski, K. 1.246, 1.286, 2.042,
3.080
Bukovskaya, Y. 2.322
Bulacio, J. 1.063, 2.249
Bulloch, A.G. 1.285, 2.071
Bunker, M.T. 1.375
Bunnenberg, A. 1.263
Burakgazi-Dalkilic, E. A.08
Burattini, J.A. 2.344, 3.372
Burch, E.A. 2.088
Burdette, D. 1.151
Burgess, G.G. 2.333
Burgess, R. 1.063, 1.144, 1.149,
1.240, 2.073, 3.359
Burgos, J. 1.333
Burianová, H. 3.281
Burkholder, D. 1.374, 3.158
Burn, S. 1.109
Burneo, J.G. 1.185, 2.032, 2.054,
2.313, 3.265, 3.277
Burns, M. 2.308
Burns, S. 1.061
Buroker, J. 1.353
Busatto, G. 3.076
Busch, R.M. 1.093, 1.099, 1.347
Butler, C. 1.027
Byars, A.W. 1.353
Byerman, B. 1.066
Byrne, R.W. 2.241
Byrnes, W. 2.320, 3.295, 3.296,
3.298, 3.299
Byun, J. 2.168, 3.196
Bzymek, K. 1.017
C
Cabello, D. 2.360
Cabo López, I. 2.300
Caboclo, L. 3.332, 3.369, 3.374
Cabrera Kang, C.M. 3.203, 3.226
Cabrerizo, M. 3.192
Caetano, E.V. 2.119, 3.143
Cai, P. A.08
Cakmak, M. 2.129
Caller, T. 1.086, 1.286, 2.042
Calvert, S. 3.087
Calzado Rivas, E. 3.311
Cameron, D. 3.175
Cameron, J. 1.073
Camfield, C. 1.203, 2.223, A.04
Camfield, P. 1.203, A.04
Campbell, M. 3.134
Campos, B.M. 3.275
Campos Blance, D. 1.332, 3.309
Cances, C. 2.263
Candy, S.A. 3.124
Canevini, M. 2.184, 3.243
Canoll, P.D. 3.253
Caplan, R. 1.097, 1.252, 1.254,
2.018, 3.254
Cappelletti, S. 3.360
Cara, L. 1.168
Carbone, L. 1.096
Carlen, P. 1.010, 1.016, 3.008
Carlsen, J. 3.003, 3.031
Carlson, C. 2.148
Carlson, G. 1.075, 2.195
Carlson, H. 1.360
Carmona, H. 2.363
Carpenter, J. 1.182, B.06
Carrel, A.J. 3.003
Carrete Jr., H. 3.369
Carreño, M. 1.322, 2.278
CarrilloCarrillo, R. 2.186
Carruthers, N.J. 3.056
Carson, R.E. 2.332
Carvalho, K. 3.251
Carvalho, K. 3.312
Carver, C. 1.033
Carvill, G.L. 1.103, 3.087, 3.092
Cascino, G. 2.256, 2.337, 2.339,
3.158
ABSTRACT AUTHOR INDEX
Chen, H. 1.013
Chen, J.J. 1.286, 2.042
Chen, P. 1.179, 2.014, 2.248, 2.253,
2.255, 3.276
Chen, S. 1.242, 2.135, 3.197, 3.285
Chen, T. 3.131
Chen, W. 1.062, 1.076, 1.164, A.02
Chen, X. 3.286
Chen, Y. 1.009
Chen, Z. 3.259
Cheng, H. 1.318, 1.322, 2.290, 2.292
Cheng, J. 2.216
Chern, C. 3.025
Cheshire, W. 3.238
Chevalier-Riffard, C. 1.190
Chez, M. 1.368
Chiang, S. 2.240, 2.247
Chiba, Y. 1.300
Chiesa, V. 2.184, 3.243
Chikako, O. 1.235
Child, N.D. 3.071
Chin, M. 2.080
Chin, R. 2.015, 2.072, 2.223, 3.129
Chin, R.F. 1.092
Chiti, L. 1.108
Chiyonobu, T. 1.116
Chlon, W. 3.351
Cho, K. 1.230
Cho, S. 1.087
Cho, Y. 1.202, 1.218, 1.230
Choe, M. A.09
Choezom, T. 3.136
Choi, H. 2.296, 2.312, 3.138
Choi, J. 1.195
Choi, S. 1.117
Choi, Y. 1.219
Chow, E. 1.066
Chrastina, J. 2.003
Chris, F. 3.325
Christensen, J. 2.266
Christian, E. 1.303
Christodoulou, C. 3.173
Christodoulou, J. 1.154
Chu, C. 3.054,
Chu, J. 1.232
Chu, K. 2.168, 3.196
Chuang, S. 1.172
Chugani, D.C. 3.056
Chugani, H. 1.251, 2.167, 2.345,
3.056, 3.362
Chung, H. 1.234
Chung, J. 1.126, 2.227
Chung, J.M. 2.181
Chung, S. 1.111, 1.316, 1.319, 2.288
Chung, S.S. 1.198, 1.199, 1.200,
1.201, 1.307, 1.308, 1.334, 1.335,
1.336, 2.211, 2.280, 2.281, 3.291,
3.292, 3.304
Chung, W.K. 2.275, 3.081, 3.135
Ciechanowski, P. 2.039
Cieza, S. 2.153
Cilio, M. 2.146, 2.309, 3.303
Cimbalnik, J. 1.175, 2.156, 3.071
Cinar, N. 2.129
Ciricillo, S. 1.368
Ciurea, J. 1.191, 3.069
Clark, A.M. 1.307, 1.308, 2.280,
2.281, 2.284
Clark, C. 2.033, 2.047
Clark, D. 3.087
Clark, M. 3.050
Clark, S. 2.050
Clarke, D.F. 2.354, 3.070, 3.351
Claus, R. 1.315, 1.316, 1.317, 1.323,
2.278
Claycomb, K. 1.049, 3.030
Cleto Dal-Cól, M. 3.055
Clossen, B. 1.032
Coan, A. 3.076, 3.082, 3.259, 3.260,
3.275
Cobia, M. 2.115
Cohen, D.L. 2.012, 3.209
Cohen, G. 2.031
Cohen, J. 2.138
Cohen, J.W. 2.302
Cohen, M.S. 1.278
Cohen, N. 1.257, 2.286
Colciaghi, F. 3.029
Cole, A.J. 1.314
Coleman, M. 1.085
Coley, A.A. 3.041
Collon, K. C.02
Colón-Zimmermann, K. 1.084
Coman, D. 1.041
Comi, A. 3.051
Concha, L. 3.261
Condie, J. B.06
Congedo, B.A. 1.284
Conner, C. 3.060
Connolly, M. 2.040, 3.096, 3.220,
3.327
Connors, R. 1.057
Conry, J. 2.351
Constable, T. B.01
Constantinou, J. 1.151, 2.215
Conti, V. 1.108
Cook, M. 1.227, 1.232
Cooper, E.C. 3.017, 3.210
Corallo, K. 1.082
Cordeiro, M. 1.137
Cornett, K. 2.194
Correa, B.J. 2.119, 3.143
Corso, J.T. 2.327
Cortes de Oliveira, J. 3.055
Coryell, J. 3.223
Cossette, P. 3.093,
Cossu, M. 2.184
Costa, F.A. 2.119, 3.143
Costas, K. 3.325, 3.326, 3.334
Costel, J. 2.313
Cothros, N. 2.054
Cotten, J. 1.023
Coulter, D. C.06
Couture, D. 2.256, 2.337, 2.339
Couture, R.L. 3.016
Couturier, N. 3.339
Covington, T.M. 2.074
Craddock, R.C. 2.246
Crail Melendez, D. 2.334
Craiu, D. 3.092
Cramer, J.A. 1.273, 1.287
Crawford, J. 3.241
Crawford, P. 3.126
Crawley, A. 3.200
Crespel, A. 2.226
Crino, P. 3.302,
Crino, P.B. A.08
Cristofaro, S. 2.173
Crocker, C. 2.171
Crompton, D.E. 1.120, 3.088
Crone, N. 1.174, 1.353, 2.025, 3.064
Cross, J. 1.190
Crowder Skarpaas, T. 1.216, 2.212
Crowley, M.J. B.01
Cruickshank-Quinn, C. 3.066
Cruz, E. 1.132, 1.142, 2.162
Cruz Del Angel, Y. 1.003, 3.003, 3.011
Cukier, Y. 2.011, 2.029
Cukiert, A. 2.342, 2.343, 2.344,
2.363, 3.350, 3.372
Cukiert, C.M. 2.344, 2.363, 3.372
Cukovic, D. 3.056
Culver, C.B. 2.038, 3.083
Cummins, T.R. 1.294
Cunningham, C. 1.076
Cunningham, C.E. 1.100
Curatolo, P. 2.187
Curry, D. 2.347, 3.353, 3.358, 3.371
Cushner-Weinstein, S. 3.141
Cusick, M.F. 3.117
Cutmore, C. 3.088
Cutter, G. 2.161, 2.163
Czech, T. 1.137
D
D’Alfonso, S. 1.276, 3.327
D’Ambrosio, R. 1.372
D’Souza, J. 2.219, 2.332, 3.300
D’Souza, W. 1.227, 1.232, 1.279
Da Rold, M. 2.122
Dabbs, K. 1.169, 3.267, 3.270
Dabscheck, G. 2.143
Dagam, J. 1.333
Dahlin, M. 2.187
Dalgard, C. A.08
Dalvi, N. 2.101, 2.120
Damaj, L. C.01
Damera, S. 2.010
Damiano, J.A. 1.120
Damisah, E. 3.074
Daniels, D. 3.209
Danny, L. 1.231
Danzer, S. 3.010, 3.120
Danzer, S.C. 1.048
Das, N. 2.221
Das, S. 3.256
Dauwe, I. 3.028, C.08
Dave, H. 2.107, 3.219, 3.225, B.02
Davis, A. 2.233, 2.234
Davis, A.M. 1.100
Davis, E.C. 1.278
Davis, G.G. 2.070
Davis, K. 1.242, 2.135, 3.183, 3.256,
3.284
Davis, K.A. 1.266, 3.167, A.08
Davis, R. 2.057, 2.311
Dawe, R. 1.074
Dawkins, R. 3.348
ABSTRACT AUTHOR INDEX
Cash, S. 3.054
Cash, S.S. 1.018, 3.164
Castelnau, P. 2.263
Castillo, A. 1.332
Castillo, E. 1.179, 2.014, 2.248,
2.253, 2.255, 3.276
Castillo, R. 1.341
Castro, C. 1.295
Castro, C.X. 3.076
Catterall, W. 3.340
Cavalleri, G. 1.248
Cavaretta, J. 1.234
Cavazos, J. 3.206
Cavitt, J. 2.228
Cawello, W. 2.283, 3.290
Caylor, L. 2.039
Ceiki Sakamotob, A. 3.055
Ceja Moreno, H. 3.295
Celegen, K. 3.328
Celegen, M. 3.328
Cendejas, L. 1.074, 2.085
Cendes, F. 1.319, 1.377, 3.259,
3.260, 3.275
Centeno, R. 3.369, 3.374
Cerqueira, P.B. 2.119, 3.143
Cerven, S. 1.198, 1.199, 1.200,
1.201
Cervenka, M. 1.174, 3.189, 3.191,
3.318, B.07
Cha, B. 2.083
Chabardes, S. 1.191, 1.348
Chabrol, T. 1.039
Chachua, T. 3.025
Chadehumbe, M. 2.016, 3.094
Chadwick, E. 3.044
Chae, J. 1.119, 1.195
Chagin, K. 1.377
Chan, S. 1.190
Chan, V. 1.208
Chandler, D.S. 3.122
Chandra, S. 2.365
Chang, B.L. 3.221
Chang, B.S. 1.154
Chang, C.W. 3.221
Chang, E. 1.369
Chang, T. 1.136, 1.137
Chanlaw, T. 3.249
Chansard, M. 1.030
Chanteux, H. 2.310
Chapa Davila, J. 2.126
Chapman, B. 2.112
Chapman, K. 1.098, 1.182, 1.326,
1.345, B.06
Charpier, S. 1.039
Chassoux, F. 2.226
Chauvel, P. 1.377
Chavez, G. 1.155
Chavez-Hassan, F. 2.334
Chaytor, N. 2.039
Chea, K. 2.262
Chekhovtsov, I. 1.075
Chemali, Z. 2.008
Chen, B. 1.262, 2.312, 3.138
Chen, C. 2.297
Chen, D.K. 1.089
Chen, E. 1.076
Chen, F. 3.002
95
ABSTRACT AUTHOR INDEX
Day, B. 3.032
Dayyoub, T. 2.215
Dazzo, E. 1.113
De, G. 1.342
De Backer, M. 2.320, 3.291, 3.292,
3.294, 3.295, 3.296, 3.297, 3.298,
3.299
De Benedictis, A. 3.360
de Grauw, A. 2.185
de Grauw, X. 2.185
De Jonghe, P. 1.115
de Kam, M.L. 2.307
De Koninck, Y. 3.022
de la Pena, C.B. 2.230
de Lanerolle, N. 3.072
de Melo-Souza, S.E. 2.274, 3.199
de Paula, V.D. 1.122
De Toffol, B. 2.226
de Vincentiis, S. 2.274, 3.199
de Vries, P. 2.187
Dean, N. B.06
DeBello, R. 2.053, 3.205
DeCoster, C. 2.051
Dedeken, P. 2.320, 3.293, 3.295,
3.296, 3.298
del Prete, A. 1.020
Delalande, O. 3.360
Delanty, N. 1.248
Delazer, M. 2.245
Delbeke, J. 3.028, C.08
Deleo, F. 2.184
Delgado-delaMora, J. 3.154
DeLorenzo, R. 1.026
Demos, M. 3.096
Demuth, D. 3.126
Denny, D. 1.198, 1.199, 1.200, 1.201
Deo, A.K. 2.332
Depaulis, A. 1.039
Depienne, C. 1.118
Depondt, C. 1.141
Depositario-Cabacar, D. 1.354, 2.351,
3.141, 3.355, 3.364
Derambure, P. 2.226
Dergalust, S. 2.322
Derry, R. 1.096
Descamps, B. 3.028
Deshpande, L. 1.026
Desnous, B. 1.055, 1.056
Desrochers, J.A. 2.160
DeStefino, V. 1.073
Detyniecki, K. 2.176, 2.296, 2.312,
3.136, 3.138,
Devinsky, O. 1.123, 1.133, 1.262,
2.007, 2.033, 2.170, 2.309, 3.057,
3.095, 3.137, 3.303,
DeVries, S.P. 3.167
Dewar, S. 2.336, 3.217
Dhaher, R. 1.041, 3.074
Dhakar, M. 3.174, 3.232
Dhamne, S.C. 3.044
Diaz, F. 1.324, 2.285, 2.286, 2.287
Diaz, M. 2.222
Diaz-Medina, G. 1.139
Dibbens, L.M. 3.089
DiCaccio, B. 2.155
Dickens, D. 2.235
Dickerson, B. 2.008
Dickstein, L. 1.002
96
Didato, G. 2.184
Diehl, B. 1.057
Dike, N. 3.133
Dilley, C. 2.033, 2.047
Dilley, D. 2.320
Dimova, S. 3.291, 3.292, 3.299
Ding, K. 2.038, 2.189, 2.193, 3.083
Ding, L. 3.015
Ding, Y.S. 1.262
Dingledine, R. 3.116
Dionisio, A. 1.058, 1.153
Divino, V. 2.044
Dixon-Salazar, T. 3.095
Dlugos, D. 1.182, 3.095, 3.201,
Dobesberger, J. 3.228
Dobrinsky, C. 2.276, 2.279
Dobrzeniecka, S. 3.093
Dobyns, W. 1.043, 3.099
Doesburg, S. 1.145
Doesburg, S.M. 3.153
Doescher, J. 2.235
Doggett, K. 3.296
Doherty, C. 1.248
Doherty, J. 1.296, 1.303
Dokgoz, O. 1.229, 3.328
Dolce, A. 2.347
Dombkowski, A.A. 3.056
Donahue, D. 2.250
Donatti, A. 3.123
Donner, E. 2.353, 3.057, 3.137, 3.239
Donner, E.J. 1.208
Donohue, K.D. 1.071
Donohue, M.M. 3.257
Donos, C. 3.069
Dorland, N. 2.148
Doshi, C. 2.213, 3.202, 3.235
Doss, J. 1.094, 2.021
Doss, R. 1.080, 2.026, 2.046
Doucet, G. 1.255, 2.237
Dove, C. 1.185
Drake, J. 1.172, 2.353
Drane, D. 1.352, 3.344
Drazkowski, J. 2.139, 2.166
Drees, C. 2.053, 3.205, 3.304
Drouin, N. 2.239
Du, X. 3.005
du Plessis, D. 1.109
Dualibi Ramos Valente, K. 2.274, 3.199
Dubeau, F. 1.121, 1.259, 2.358,
3.161, 3.163, 3.184, 3.185
Dubey, D. 2.189
Dubroff, J.G. 1.266
Duchowny, M. 2.346
Duckrow, R. 1.062, 1.156, 1.216,
2.151, 2.212
Dudek, F. 1.161, 1.166, 3.038, 3.043,
3.047
Dudley, R.W. 1.267, 3.279
Duempelmann, M. 1.129, 1.167
Duffy, F. 3.194
Dufour, S. 1.016, 3.008
Dulla, C. 3.125,
Dumpelmann, M. 2.180
Duncan, R. 1.109
Dunn, D. 2.018
Dunn, M. 2.235
Dupuis, N. 1.055, 1.056
Durand, D. 1.019,
Durgin, T. 2.058, 2.297, 3.130
Dustin, I. 1.002, 3.065, 3.084, 3.278
Duveau, V. 1.039
Duwell, E. 2.192
Dworetzky, B. 1.281, 1.324, 2.213,
2.236, 2.285, 2.286, 2.287, 3.235,
3.289
Dykstra, H. 2.074
Dzhala, V. 1.021, 3.022
E
Eb, A. 1.275
Eberle, M. 2.238
Eberly, L.E. 1.272
Ebril, M. 1.188
Eckhardt, K. 3.294, 3.300
Edagawa, K. 2.357
Edakawa, K. 1.060
Edmonds, B. 2.248, 2.255, 3.276
Egawa, K. 1.021, 2.174
Egge, A. 3.366
Eichel, R. 3.197
Eichstaedt, K.E. 2.361
Eid, T. 1.041, 3.074
Eidelman, O. A.08
Einarsdottir, A. 3.128
Eisenschenk, S. 2.212
Eksioglu, Y. 2.268, 3.103, 3.194,
3.357, 3.363
Ekstein, D. 1.302, 2.175, 3.063,
3.197
Ekstrand, J. 3.043
Ekstrom, A. 1.078
El Tahry, R. 1.067
El-Hagrassy, M. 2.268
Elder, E. 1.324, 2.285, 2.286, 2.287
Elger, C. 1.067, 1.316, 1.320
Eliashiv, D. 2.227, 2.321, 2.336
Eliassen, J.C. 1.257
Elledge, D. 2.299
Ellingson, B. 1.238, 1.245, 1.261
Elliott, C.A. 3.261
Elmenshawi, I. 2.272
Elmoufti, S. 2.219
Elsayed, M. 2.255, 3.276
Emch, T. 3.257
Emerson, R. 1.057,
Emery, E. 3.084, 3.278
Enatsu, R. 1.063
Endres, J. 2.085
Engel, J. 1.278
Engel, M. 2.221
Englot, D.J. 1.369
Enoki, H. 1.371
Entz, L. 1.157
Eom, S. 1.097
Eom, T. 2.220
Epi4K/EPGP, C. 1.114
Epstein, J. 2.236
Erdinc, O.O. 3.305
Escalaya, L. 2.313
Escartin, A. 3.295, 3.298
Escayg, A. 1.046, 3.106
Escoffery, C. 3.075
Esfahanizadeh, A. 3.208
Eskandar, E.N. 1.018
Eslamy, H. 1.250
Espaillat Solano, L.M. 2.186
Espaillat Solano, L.M. 2.334
Espinera, A. 3.203
Espinoza López, D.A. 3.154
Ess, K.
Ettinger, A.B. 2.276
Eun, B. 3.308
Euroepinomics-Res, C. 1.114
Evans, C. 2.324
Evans, J. 1.255
Evans, S. 2.318
Evrard, C. 2.269
Eyal, S. 3.063
Eydoux, P. 3.096
F
Faber, A. 2.040
Fabo, D. 1.157
Fabris, R. 3.148, 3.158
Fain, R. 2.276, 2.288
Faingold, C. 1.023, 1.034,
Faizo, N.L. 3.281
Fakhoury, T. 1.312, 3.300
Fallil, Z. 1.157, 2.246
Fang, L. 3.310
Fant, R.V. 2.279
Farah, J. 1.109
Faria, L. 1.299
Farlow, D.C. 3.286
Farmen, A. 2.231
Farooque, P. 2.350, A.02
Farrell, K. 3.220
Farwell Gonzalez, K.D. 1.194
Fasano, A. 1.112
Faught, E. 2.047, 2.219, 3.130,
3.294, 3.299
Faught, R. 2.339, 3.344
Faulkner, M. 2.041
Fauth, C. 2.169
Fayed, N. 1.100
Federico, P. 1.264, 2.067, 3.139,
3.186
Feeney, E. B.01
Fehr, K. 2.270
Feldstein, N. 3.233
Felton, E. 3.318
Feng, H. 1.023
Feoli, E. 1.131
Ferastraoaru, V. 2.180
Fergnani, V. 3.243
Ferguson, A. 3.220
Ferguson, L. 1.093, 1.099, 1.347
Ferguson, R.J. 1.086
Fernald, B. 2.256, 2.337
Fernandes, A. 3.123
Fernandez, A. 1.062, 3.342
Fernandez, G. 1.106
Fernandez, L.D. 3.333
Ferrari-Marinho, T. 3.161, 3.184,
3.185
Ferrazzano, P. 1.169
Ferreira, J. 1.101, 2.187
Ferro, M. 2.223
Ferrrari, L. 1.162
Ferry, J. 2.295
Fertig, E. 1.131, 1.140, 2.230
Fesler, J.R. 2.349
Fessler, A. 1.125
ABSTRACT AUTHOR INDEX
Frost, Jr., J.D. C.04
Fu, A. 1.198, 1.199, 1.200, 1.201
Fuerst, D. 3.062
Fujikawa, M. 2.060, 2.132, 2.149
Fujimoto, A. 1.371
Fujinami, R.S. 3.117
Fujita, K. 1.220
Fujita, M. 1.002
Fujita, S. 1.014
Fujiwara, H. 1.152, 1.353
Fukasawa, T. 1.243
Fukumizu, M. 2.202
Fuller, P.M. 1.162
Funck, V. 1.295
Fung, E. 3.327
Fung, S.H. 2.254
Furman, M. 1.164
Fusco, L. 3.360
G
Gabelia, D. 2.262
Gabr, R.E. B.03
Gabrieli, J.D. 1.154
Gaddam, A. 2.208
Gaddam, S. 2.215
Gadeyne, S. C.08
Gadhoumi, K. 1.178
Gaik-Siew, C. 1.105
Gaillard, W. 1.354, 2.142, 2.351,
3.141, 3.144, 3.268, 3.272, 3.278,
3.355, 3.364, B.06
Gaitanis, J. 3.073
Galanopoulou, A.S. 1.304, 1.305,
Galimberti, C. 1.316
Gallagher, M. 3.015
Gallentine, W. 1.182, 2.194, 3.095
Galloway, G. 3.281
Gama, H. 1.315, 1.316, 1.317, 1.323,
2.278
Gandomi, S. 1.194
Gangisetty, O. 1.033
Gano, L.B. 3.066
Gao, J. 1.155
Garces, M. 1.332
Garcia, P. 1.369
Garcia, R. 1.295
Garcia Gracia, C. 2.073
Garcia-Cairasco, N. 3.055, 3.123
Garcia-Ramos, C. 3.267
Gardella, E. 1.118
Gardiner, E. C.07
Garg, A. 2.032, 2.365
Garg, K. 2.365
Garg, M. 3.249
Garrido, E. 1.295
Garrity, L. 2.229
Garson, A. 3.051
Garzon, E. 3.179
Gaspard, N. 1.135, 2.151, 3.203,
3.204, 3.226
Gaston, T. 1.236
Gaston, T.E. 1.247, 1.249
Gattaz, W.F. 1.122
Gattone, J.M. 3.321
Gautier, N. 3.107
Gavrilovici, C. 1.030
Gaxiola Valdez, I. 1.264
Gebre, R. 1.076
Gedela, S. 2.159, 3.331, 3.333
Gedzelman, E. 2.339
Gelfand, M. 3.284
Geller, E. 2.212
Geng, B. 1.062
Genov, R. 1.010
George, M. 3.040
George, S. 3.051
Gerard, E. 3.203, 3.226
Gerin, B. 2.310
Germeyan, S.C. 3.084, 3.268, 3.278
Gernert, M. 1.069, 1.070
Gerrard, J. 1.156, 2.151
Gersner, R. 1.158, 1.302, 3.337
Gerstl, L. 2.204
Gey, L. 1.070
Ghani, A. 1.255, 2.237
Ghassemi, A. 1.368
Ghatan, S. 3.356
Ghearing, G. 2.147, 2.157, 3.227
Gholipour, T. 2.113
Giarratano, M. 1.340
Gibson, K.M. 3.065
Gibson, M. 1.225
Gidal, B. 1.324, 2.284, 2.285, 2.286,
2.287
Gidal, B.E. 2.295
Gilbert, T. 1.263
Gilby, K. 1.047
Gill, D. 3.092
Gilliam, F. 3.336
Gilmet, G. 3.336
Gilmore, E. 1.135, 3.204
Giordano, M. 3.233
Girard, J. 2.017, 3.169
Gireesh, E. 3.064
Girouard, M. 3.206
Giza, C. 1.182, A.09
Gizewski, E. 2.245
Glaser, C. 3.241
Glass, H.C. 1.136
Glasscock, E. 3.107
Glauser, T. 2.024, B.06
Glaze, D. 3.104
Glessner, J. 3.099
Glielmi, C. 1.262
Gliske, S. 3.067
Glykys, J. 1.021
Glynn, S. 2.030, 3.040
Go, C. 1.127, 1.172, 1.189, 2.353,
3.306
Gobbi, G. 2.018
Godard, A. 3.046
Goel, M. 2.365
Gofton, T. 3.203, 3.226
Gokyigit, A. 1.128, 2.183, 2.224
Golby, A. 2.025
Gold, D. 3.231
Gold, J. 2.104, 3.241
Goldberg, E.M. C.06
Goldberg-Stern, H. 3.090
Goldenholz, D. 1.065, 3.278
Goldenholz, D.M. 2.356
Goldenstein, L. 3.233
Goldie, J. 1.158
Goldman, A. 2.222
Goldman, L. 2.301
Goldschmidt, Y. 2.033
Goldsmith, J. 2.275, 3.081, 3.135
Goldstein, D. 3.095
Goldstein, J. 1.182, B.06
Goldstein, S. 3.324
Gómez Ramírez, M. 3.154
Gommer, E. 1.138
Goncharova, I. 2.151
Gong, H. 3.345
Gonsalves, C. 2.110
Gonzales, E. 1.274, 1.356
Gonzalez, F.L. 3.309
Gonzalez, M. 3.237
Gonzalez-Crespo, S. 3.101
Gonzalez-Martinez, J. 1.058, 1.063,
1.153, 1.240, 1.347, 1.362, 1.377,
2.249
Gonzalez-Sepulveda, L. 3.101
González de la Aleja, J. 1.332
Good, L. 1.054
Goodkin, H. 1.028, B.06
Goodrich, G.S. 3.009
Goodwin, S.W. 3.134
Gordon, C.M. 1.375
Gorelik, D. 2.301
Gospe, S.M. 1.241
Goswami, S. 2.041, 2.098
Gotman, J. 1.171, 1.178, 1.259,
2.358, 3.121, 3.161, 3.163, 3.184,
3.185,
Gowda, A. 2.256
Goy, E. 2.269
Goyal, A. 1.022
Gozzo, F. 2.184
Grabenstatter, H.L. 1.003, 3.003
Graf, S. 2.102
Graham, A. 2.058
Granbichler, C. 2.068
Grant, A.C. 1.085, 3.181
Grant, E. 3.202
Gray, E. 3.126
Gray, M. 3.281
Greenberg, D.A. 3.122
Grefe, A. 2.210
Greiner, H. 1.152, 1.353, 2.352
Griffin, N.G. 3.113
Griffiths, C. 3.059
Grigg-Damberger, M. 3.171
Grinspan, Z. 2.043, 2.055, 2.221
Groomes, L. 2.025
Groppe, D. 1.157, 2.246, 3.177,
3.346
Gross, D. 3.259, 3.260, 3.261
Gross, D.W. 1.253
Gross, R. 1.349, 2.212, 2.256, 2.337,
2.339, 3.344
Grote, C.L. 3.264
Grouiller, F. 2.244
Grova, C. 2.239,
Gu, B. 1.006
Gu, F. 1.299
Guan, Y. 3.352
Guaranha, M.B. 3.251
Gubernale, M. 2.122
Gudbranson, E. 1.062, 1.076
Gudlavalleti, A. 3.155
ABSTRACT AUTHOR INDEX
Feucht, M. 2.187
Feyissa, A.M. 3.269
Ficker, D. 2.285, 2.286, 2.287
Fiedler-Kelly, J. 1.312, 1.314, 1.319,
1.320, 1.321
Field, S.A. 2.298, 2.305
Fiest, K. 2.071
Fiest, K.M. 1.285
Filippi, C. 1.057
Finardi, A. 3.029
Fine, A. 2.203
Finger, L. 2.107
Finn, C. 1.286
Finn, R. 3.329
Finnell, R. 3.053
Fiol, M. 2.206
Fischer, J. A.09
Fisher, E. 2.019
Fisher, J. 3.200
Fisher, R. 1.068, 3.073, B.07
Fishman, J. 2.031
Fisk, K. 3.051
Fitzsimons, M. 1.248
Flanagan, P. 1.153
Flashman, L. 3.080
Fleming, M. 2.092, 2.230
Fletcher, L. 2.050
Fleury, A. 2.186
Flores, J. 1.332
Fonseca, N. 1.122
Ford, L. 1.309
Foreman, B. 3.203, 3.226
Foreman, P. 2.200, 3.162
Foreman, P.J. 2.257
Forgacs, P.B. 2.105
Forman, S. 1.023
Forman, S.D. 1.284
Foroughi, A. 2.200, 3.162
Forsythe, A. 3.301
Fountain, N. 1.209, 2.081
Fowles, K. 2.332
Franaszczuk, P. 1.174
Francois, D. 2.268
Francomacaro, S. 3.001
François, C. 1.334, 1.335, 1.336
Fraser, R. 3.078, 3.127
Fraser, R.T. 2.039
Frasier, C.R. C.02
Frauscher, B. 2.121, 2.262, 3.161,
3.163, 3.184, 3.185
Freedman, D. 2.250
Freeman, J.L. 3.087
French, C. 1.231
French, J. 1.318, 2.007, 2.176, 2.233
Frey, L. 2.053, 3.031, 3.205, 3.304,
3.320
Freyer, C. 2.173
Fried, I. 1.177
Friedman, D. 2.007, 2.142, 2.170,
2.309, 3.057, 3.137, 3.303
Friedman, K. 1.262
Friedman, S.D. 1.241, 3.280
Frigerio, F. 1.020
Fritz, P. 2.033, 2.047
Frndova, H. 3.059
Frohlich, F. 1.159
Frost, M. 2.235, 2.270
97
ABSTRACT AUTHOR INDEX
Guekht, A. 2.076
Guenot, M. 1.348
Guerreiro, C. 3.076, 3.082
Guerrini, R. 1.108
Guess, M. 3.156
Gugler, K. 2.133, 2.137
Guilfoyle, S. 1.090, 1.091
Guilhoto, L.M. 3.251
Guimaraes, M.D. 3.374
Guiraud-Diawara, A. 1.334, 1.335,
1.336
Gulsen, G. 3.270, 3.283
Gulyaeva, N. 2.076
Gummadavelli, A. 1.044, 1.164
Gunasekara, R.C. 2.268
Guo, A. 1.213
Guo, D. 1.024
Guo, J. B.01
Gupta, A. 1.144, 1.362, 3.359
Gupta, N. 3.173
Gupta, P. 2.038, 2.189, 2.193, 3.083
Gupta, R.K. 2.125
Gupta, V. 3.343
Gupta, Y.K. 1.022
Gurbani, S. 1.252, 1.254, 3.254
Gurkoff, G. 1.078
Gurme, M. 2.321
Gurses, C. 1.053, 1.128, 2.183,
2.224
Gusev, E. 2.076
Gustafson, M. 2.133, 2.137, 3.335
Guttuso, T. 2.125
Guzel, O. 3.328
Guzman, L. 3.237
Gwinn, R. 2.212
H
Haas, K. 1.327, 2.160, 3.203, 3.226
Hader, W. 1.360, 2.082
Haginoya, K. 1.367
Haglund, M. 3.113
Hahn, C. 1.182, 3.059
Haider, Z. 3.126
Hajek, M.A. 1.049
Hakami, T. 1.231
Hakimi, A. 2.034
Hakonarson, H. 3.090, 3.099
Halford, J.J. 2.160
Hall, A. 3.335
Hall, J. 2.239, 2.340
Halliday, W. 3.108
Hallinan, B. 3.324
Halvorsen, M.B. 1.307, 1.308
Hamano, S. 1.365
Hamberger, M.J. 2.027
Hamdan, F.F. 3.093
Hameed, M.Q. 3.009, 3.044
Hamer, H. 1.146, 1.346
Hamid, H. 2.059
Hammond, N. 2.111
Hammond, R. 1.296, 1.303
Han, H. 1.218
Han, J. 1.313
Han, R. 1.372
Han, S. 1.218
98
Hanai, S. 3.114
Hanaya, R. 1.265, 2.002
Handler, M. 1.267, 2.103, 3.279
Handreck, A. 1.069
Haneef, Z. 2.240, 2.247
Hani, A.J. 2.194, B.06
Hannestad, J. 2.332
Hanson, A. 2.067, 3.139
Hanson, M. 1.333
Hanson, R. 2.085
Hanusa, B.H. 1.284
Hanáková, H. 1.051
Haque, O. 1.355
Hara, K. 2.091, 2.093, 2.097
Hara, M. 2.091, 2.093, 2.097
Harada, Y. 1.370
Harden, C. 1.157, 2.011, 2.029,
2.092, 2.233, 2.246, 2.256, 2.339,
3.053
Hardin, K. A.06
Haridas, B. 2.055
Harini, C. 1.098, 2.196, 3.169, 3.236
Harkness, W. 2.342, 2.343, 3.350
Harnod, T. 3.271
Harrell, E. 2.131
Harrington, C. 2.318
Harrington, J. 1.086, 2.033, 2.042
Harris, D. 2.124
Harris, K. 1.137
Harris, R. 1.238, 1.261
Hart, S. 1.306
Hartl, E. 2.165, 3.211, 3.273
Hartman, A.
Harvey, A.S. 3.087
Harvey, D.W. 2.152
Harvey, J. 1.068, 1.312, 1.319, 2.290
Harward, S.C. 1.269
Hasbani, D. 3.312
Hasegawa, H. 3.149
Hashizume, A. 1.265, 2.359
Hastings, W. 1.341
Hauser, A. 2.076, 3.140
Haut, J. 1.093, 1.099
Haut, S. 2.176, 3.231
Haut, S.R. 2.180
Havens, K. 2.351, 3.141, 3.355,
3.364
Hawasli, A.H. 1.376
Hawkins, C. 1.189
Hays, R. 2.038, 2.189, 2.193, 3.083
He, B. 1.268
Heath, J. 2.124
Heck, C. 1.216, 2.212, 3.373
Hecox, K. 1.173, 3.215
Hedlund, J. 2.309, 3.303
Hedrick, N.G. 1.269
Heers, M. 1.167
Hegde, M. 3.201
Heier, L.A. 2.221
Heinen, F. 2.204
Heinze, H. 3.045, 3.058, 3.349
Heinzen, E. 3.095, 3.113
Heischmann, S. 3.066
Heiss, J. 1.150
Helbig, I. 1.115, 3.090, 3.099
Helmers, S. 2.047, 2.339, 3.130
Helmstaedter, C. 1.283
Hempstead, B.L. 3.011
Hemza, J. 2.003
Henegan, P.L. 1.086
Hennessy, R. 2.176
Henning, O. 2.317, 2.326
Henry, B. 3.318, B.07
Henry, T. 3.190
Heo, K. 1.218, 1.230
HEP Investigators 2.173, 2.176, 3.201
HEP MRI Core 3.258
Herbillon, V. 2.263
Herekar, A. 1.216, 2.209
Herman, J.P. 3.010
Herman, S. 1.205
Hermann, B. 1.169, 2.004, 2.023,
2.218, 3.267, 3.270
Hernandez, A. 2.250
Hernandez Ronquillo, L. 1.228
Hernandez Ruiz, A. 3.154
Hernando, K. 1.236, B.09
Hertzberg, C. 2.187
Hervas Navidad, R. 3.311
Hesdorffer, D. 2.070, 2.275, 3.057,
3.081, 3.135, 3.137, 3.140
Heshmati Moghaddam, M. 3.097
Hevner, R. 1.250
Heyer, G.L. 3.157
Heyse, H. 1.257
Hibbard, K. 2.024
Hickey, F. 3.209
Higdon, L. 2.147
Higo, T. 1.363, 1.370, 3.012
Hildebrand, M.S. 1.120
Hilkman, D. 1.138
Hill, C. 2.135,
Hines, D. 2.297
Hinn, A. 2.057
Hino-Fukuyo, N. 1.367
Hira, J. 2.246
Hirai, S. 1.116
Hirata, M. 1.060, 2.357
Hirata, Y. 1.238, 1.245, 1.261, 3.255,
3.262
Hirose, S. 1.365
Hirose, Y. 2.093
Hirsch, E. 2.226
Hirsch, L. 1.062, 1.135, 1.156, 2.151,
2.296, 2.312, 2.350, 3.136, 3.138,
3.203, 3.204, 3.226, A.02
Hirvonen, J. 1.002
Hitchens, T. 3.072
Hixson, J. 2.058, 2.176
Hiyoshi, T. 3.216
Hjalgrim, H. 1.118
Ho, A.W. 3.172
Hoang, K. 2.034
Hoch, D. 2.045
Hochberg, L.R. 1.018
Hocking, J. 3.281
Hoegl, B. 2.262
Hoerth, M. 1.082
Hofer, M. 2.262
Höfler, J. 3.228
Hoffmann, D. 1.191, 1.348
Hogan, R. 1.307, 1.308, 1.376,
2.280, 2.281, 3.336
Holden, D. 2.332
Holland, K. 1.353, 3.247
Hollen, C. 2.034
Holley, A. 1.292, C.07
Holmes, M.D. 1.180, 3.187, 3.193
Holt, R. 3.178
Holtkamp, M. 3.058, 3.349, A.03
Homa, K.A. 1.286
Honda, R. 1.147, 1.359, 1.361,
2.225, 2.341
Hong, J. 1.002
Hong, L. 3.113
Hong, S. 1.087
Hong, S. 1.130, 1.365, 2.207, B.04
Honig, A. 3.197
Hope, C. 1.111
Hope, O. 2.037
Hori, J.M. 1.278
Horiuchi, K. 3.205
Horn, P. 2.352, 3.111, 3.324
Hosain, S.A. 1.134
Hosford, B. 3.120
Hosny, H. 2.217
Hosoyama, H. 2.002
Hou, W. 3.104
Howard, M. 1.079, C.05
Howard, T. 2.215
Howe-Martin, L. 2.038, 3.083
Howell, K. 3.087
Hrachovy, R.A. C.04
Hsieh, C. 2.094
Hsieh, L.S. 3.030
Hsieh, T. 3.009
Hsin, Y. 3.195, 3.271
Hsu, D. 1.169, 2.023, 3.267, 3.270
Hsu, M. 1.169, 2.238
Hsu, S. 1.351
Huang, C. 2.094, 3.271
Huang, S. 2.289
Huang, Y. 1.006, 1.041, 1.253, 2.332
Hubbard, J.A. 3.119
Huber, P. C.07
Huckins, S. 3.363
Hudgens, S. 3.301
Huiskamp, F. 2.145
Hulette, C. 3.113
Hummelova, Z. 2.003
Hunt, M. 2.206
Hunter, M. 1.092, 2.015
Hur, E.E. 2.303
Husain, A. 2.036, 2.048, 2.077
Hussain, S.A. 2.108, 2.355, 3.157,
3.222, 3.330
Hussein, Z. 2.295
Huynh, J. 2.233
Hwang, D. 2.029
Hwang, E.S. 1.278
Hwang, H. 1.119, 1.195, 1.212
Hwang, K. 1.087, 2.207
Hwang, S. 1.157, 2.011, 2.246
Hwang, Y. 1.119, 1.195, 1.212
Hyder, F. 1.041
ABSTRACT AUTHOR INDEX
I
J
Jabo, B. 3.146
Jack, S.M. 2.065
Jackson, D. 1.169, 2.023, 3.267,
3.270
Jackson, G. 2.243, 3.287
Jackson, G.D. 1.120
Jackson, M. 1.329, 2.213, 3.235,
B.06
Jacobs, J. 1.129, 1.167, 2.358, 3.068
Jacobson, M. 1.318
Jaffe, D.B. 1.165
Jähn, J. 1.115
Jain, M. 2.085, 2.241
Jain, S. 2.352
Jaisani, Z. 1.240
Jalota, A. 2.241
Jan, M.M. 3.323
Jang, S. 1.163
Janio, E.A. 1.278
Janke, K. 2.011, 2.029
Janousek, J. 2.301
Jansen, A. 2.187
Janz, D. A.03
Jasinski, T. 2.197
Javors, M.A. 3.052
Jayabal, V. 1.148
Jayakar, P. 3.192
Jayakar, R. 3.344
Jefferys, J. 3.036
Jehi, L. 1.226, 1.347, 1.362, 1.377,
2.073
Jehle, R. 3.231
Jenko, K. 1.002
Jenner, M.R. 3.307
Jensen, F. 3.001, 3.007, 3.041
Jensen, J. 1.352
Jenson, K. 1.180, 3.193
Jeon, J. 1.202
Jeong, J. 1.251
Jepsen, B. 1.118
Jetté, N. 1.285, 2.051, 2.067, 2.071,
2.082, 3.139
Ji, K. 1.218
Jiang, W. 1.324, 2.285, 2.286, 2.287,
2.330, 3.288, 3.310
Jiang, X. 2.330, 3.288
Jiang, Y. 1.030
Jih, J. 1.306
Jimenez, X.F. 2.273
Jin, K. 1.367, 2.132, 2.149, 2.154,
3.159
Jin, X. 1.155
Jirsa, V. 3.182
Joachim, K.C. 2.056
Joaquim, H.P. 1.122
Job, A. 1.191
Jobst, B. 1.086, 1.209, 1.286, 2.042,
2.212
Joc, J. 3.273
Joensuu, T. 3.089
Johannessen, S. 2.282, 2.308, 2.317,
2.326
Johnson, E.K. 2.039, 3.078
Johnson, J.K. 1.337, 1.343
Johnson, M. 1.076
Johnston, L.A. 1.047
Johnston, M. 3.035
Jokeit, H. 2.245
Jones, A. 1.066
Jones, D. 1.334, 1.335, 1.336
Jones, J. 1.169, 2.023, 3.267, 3.270,
C.09
Jones, K. 2.353, 3.306
Jones, M. 3.277
Jones, S.E. 1.240, 2.249
Jongeling, A. 3.226
Jongeling, A.C. 3.253
Jongeling, A. 3.203
Joo, E. 1.087, 1.130, 1.218, 2.207
Jordan, J. 3.315
Jordan, S. 2.050
Jorgensen, A. 1.109
Josan, V. 1.109
Josephson, C. 2.067, 3.139
Joshi, C. 1.206, 2.035, 3.145, 3.156
Joshi, R. 2.151, 3.074, 3.136
Joshi, S. 1.037, 2.050, 3.115, 3.230
Jouny, C. 1.174, 3.064, 3.189, 3.191
Jow, A. 2.356
Jozwiak, S. 2.187
Jucker, M. 3.116
Juhasz, C. 1.251, 2.345, 3.062
Jun, J. 2.168, 3.196
Jung, D. 1.222
Jung, H. 2.043
Jung, K. 2.168, 3.196
Jung, S. 1.170
Junger, K. 1.090, 1.091, 2.229, 2.316
Junna, M. 2.192
Jurasek, L. 2.089
Jurd, R. 2.007
K
Kaczmarek, L.K. 3.016
Kadam, S. 3.035, 3.047
Kadipasaoglu, C. 3.060
Kadish, N.E. 1.329
Kadiwala, H. 2.254
Kagawa, K. 1.265, 2.359
Kahane, P. 1.191, 1.348, 2.226,
Kahle, K.T. 1.021
Kaiboriboon, K. 2.052, 2.090
Kaido, T. 1.147, 1.365, 2.225, 2.341
Kaimovsky, I. 2.076
Kakacek, J.R. 3.321
Kakisaka, Y. 2.132, 2.149, 2.154,
3.159
Kalamangalam, G. 1.160, 1.168,
3.375, B.03
Kalayjian, L. 3.373
Kalsanka Pai, A. 3.130
Kalume, F. 1.043, 3.340
Kameyama, S. 1.365
Kaminski, R. 1.020
Kamson, D. 1.251
Kanaan, S. 2.349
Kandel, P. 2.319
Kaneko, Y. 1.147, 2.225, 2.341
Kang, H. 1.211, 3.354, 3.356
Kang, J. 2.315, 3.112
Kang, K. 1.219
Kang, S. 3.035
Kankirawatana, P. 1.268
Kanner, A. 2.191, 2.264, 2.265, 3.264
Kao, A. 2.351, 3.141
Kaplan, L.R. 1.106
Kaplan, P. 3.203
Kaplan, P.W. 3.226
Kapoor, S. 2.258
Kapur, J. 1.037, 3.115, 3.118
Kapur, K. 2.213, 3.235, 3.236, 3.326,
B.06
Kapur, R. 2.209, 2.212, B.08
Karaarslan, U. 1.229
Karavaeva, E. 1.245, 1.261
Karkar, K. 2.028
Karkare, S. 2.101, 2.120, 2.128
Karsidag, S. 2.129
Kartagiri, M. 1.265, 2.359
Karumuri, B. 3.107
Kashambwa, R. 2.233
Kashida, Y. 2.002
Kassab, A. 1.072
Kassai, B. 2.263
Kassiri, J. 2.178, 2.179
Kasteleijn-Nolst Trenite’, D.G. 3.314
Kato, K. 2.132, 2.149, 2.154, 3.138,
3.159
Kato, M. 1.105, 1.116
Kattan, M. 1.377
Katus, L. 1.271
Kaufman, B. 2.233, 3.057, 3.137
Kaufman, K.R. 2.325
Kaufman, N.D. 2.325
Kaufmann, W. 3.104
Kaushal, R. 2.043
Kavak, K. 1.214
Kawasaki, H. 1.079
Kaya, M. 1.053
Kayani, S. 1.054
Keating, J. 2.016
Keating, R. 1.354
Keator, C. 2.250, 3.145
Kebede, T. B.06
Keller, C. 1.157
Kellermann, T. 2.004
Kelley, V. 2.360, 2.361
Kellogg, M.A. 2.118
Kelly, D. 1.054, 2.318
Kelly, K. 1.331, 3.158
Kelly, K.M. 2.160
Kelly, P. 2.036, 2.048, 2.077
Kelmann, B.V. 3.369
Kelten, B. 2.129
Kemmotsu, N. 2.005, 2.251
Kempapura, M. 1.341
Kendirli, M.T. 3.170
Kennedy, J. A.06
Keough, K.C. 2.354
Kern, L.M. 2.043
Kern, R.T. 2.160
Kerr, M.S. 2.010
Kerr, W.T. 1.278
Kerrick Walker, J. 2.298, 2.305
Kervyn, S. 2.310, 2.332
Kessler, S. 2.302
Khaddam, O. 2.086
Khalid, E. 2.188
Khalilieh, N. 3.273
Khan, F. 2.107, 3.219, 3.225, B.02
Khan, I. 1.181
Khan, O. 1.341
Khan, O.I. 2.356
Khawaja, A.M. 2.161, 2.163
Khaytin, I. 2.210
Khoo, H. 1.060, 2.357
Khurana, D. 3.312
Khusiwilai, K. 1.137
Kidokoro, H. 1.224, 1.235, 1.243,
2.158
Kikuchi, T. 1.350, 2.335
Kim, B. 1.218
ABSTRACT AUTHOR INDEX
Iannotti, G. 2.244
Iasemidis, L. 3.107
Iida, K. 1.265, 2.002, 2.359
Iijima, K. 1.220
Iimura, Y. 1.363, 1.370, 3.012
Ikeda, A. 1.110, 1.350, 2.335
Ikeda, H. 3.198, 3.216
Ikeda, K.M. 3.109
Ikeda, T. 1.116
Ikegaya, N. 2.341
Ilhan Algin, D. 3.305
Imai, K. 3.198
Inaba, Y. 1.116
Inada, T. 2.335
Inaji, M. 2.091, 2.093, 2.097
Inano, R. 1.350, 2.335
Inati, S. 1.002, 1.150, 3.084, 3.166
Inati, S.K. 2.010
Inbar, D. 3.063
Ince, N. 3.190
Innis, R. 1.002
Inoue, N. 1.233
Inoue, Y. 1.060, 1.365, 2.357, 3.198,
3.216
International Pediatric Epilepsy Surgery
Panel, T. 2.343
Iragui-Madoz, V. 2.251
Irazoqui, P. 3.036
Iriarte, J. 2.153
Isaacs Lebeau, K. 1.083
Iseki, H. 1.373
Isgüder, R. 3.328
Ishak, G. 1.250
Ishak, G.E. 1.241, 3.280
Ishihara, N. 1.224, 1.235, 1.243
Ishihara, Y. 1.300
Isnard, H. 2.263
Isnard, J. 1.348
Isojarvi, J. 1.334, 1.335, 1.336
Isom, L.L. C.02,
Ito, T. 2.174
Ito, Y. 1.224, 1.235, 1.243
Itoh, K. 1.300
Itoh, M. 3.114
Ivanisevic, M. 3.344
Iwaki, T. 1.357
Iwasaki, K. 1.373
Iwasaki, M. 1.367, 2.132, 2.149,
2.154, 3.159
Iwasaki, T. 1.116
Iwuchukwu, I. 3.219
Iyengar, S.S. 3.026
Iyer, S. 1.133
Izadi, A. 1.078
99
ABSTRACT AUTHOR INDEX
Kim, C.E. 3.090
Kim, D. 1.130, 1.204, 1.218, 3.354
Kim, E. 1.313, 1.328
Kim, G. 1.218, 2.348
Kim, G.E. 3.016
Kim, H. 1.119, 1.195, 1.211, 1.212,
1.244, 1.365, 2.164, 2.185, 2.315,
3.112, 3.354
Kim, J. 1.087
Kim, J. 1.211, 1.218, 2.164, 2.207,
2.315, 3.112, 3.242, 3.263, 3.356
Kim, K. 1.093, 1.119, 1.195, 1.212,
1.218
Kim, M. 1.117, 1.218, 1.219
Kim, R. B.01
Kim, S. 1.081, 1.218, 1.221, 2.164,
2.220, 2.315, 3.112, 3.244
Kim, T. 3.112
Kim, W. 1.218, 2.164, 2.315, 2.362,
3.021
Kim, Y. 1.117, 2.164, 2.315, 3.112
Kim-Tenser, M. 3.345
Kimura, S. 1.116
King, J. 2.034
King-Stephens, D. 1.216, 2.209
King-Stevens, D. 2.212
Kini, L. 3.256
Kinoshita, M. 1.110, 2.080
Kipervasser, S. 3.197
Kirk, V. 3.172
Kirkpatrick, M. 1.118
Kirmani, B. 1.341
Kirschbaum, A. A.03
Kishi, Y. 3.365
Kishima, H. 1.060, 2.357
Kitay, A.Y. 3.045
Kiura, Y. 1.265
Kjærvik, V. 2.317, 2.326
Klaas, P. 1.093, 1.099
Kleen, J. 1.086
Klehm, J. 1.098, 1.197, 1.329, 1.345,
2.213, 3.235, 3.246, B.06
Klein, K. 3.090
Klein, P. 1.315, 2.230, 2.301
Kleineschay, T. 2.253
Kleinfeld, K. 1.187
Klitgaard, H. 1.298, 2.332
Klooster, D. 1.154
Kloosterman, F. 1.017
Kluge, C. 3.045, 3.058
Kluger, D. 1.076
Klus, C. 1.129
Knopf, L. 1.188
Knoth, R.L. 2.298, 2.305
Knowlton, R.C. 1.236, 1.369
Knupp, K. 1.326, 2.035, 3.209, 3.223
Ko, D. 3.345, 3.373
Ko, T. 1.036, 1.328
Kobau, R. 2.074
Kobayashi, A. 1.233
Kobayashi, E. 2.239
Kobayashi, J. 1.208
Kobayashi, K. 1.172, 1.365
Kobayashi, M. 1.060
Kobylarz, E. 1.286, 2.042
Koehn, M. 3.267
Kogure, S. 1.233
100
Koh, E. 1.218
Koh, J. 2.314
Koh, S. 1.218, 1.222, 1.267, 3.024,
3.279
Kohler, C. 2.135
Kohli, S. 1.214
Kokoszka, M. 3.356
Kolls, B.J. 2.160
Kolodgie, M. 2.351
Komaki, H. 2.225
Kommajosyula, S.P. 1.034
Kondo, T. 1.110
Konikkara, J.J. 2.038, 3.083
Kopitzki, K. 3.045
Koppelstaetter, F. 2.245
Korb, P. 2.053, 3.205
Korczyn, A. 3.090
Korgaonkar, A.A. 1.007
Korn, M. 3.006, C.09
Koroma, M. 1.126
Korostenskaja, M. 1.179, 2.014,
2.248, 2.253, 2.255, 3.276
Koroukian, S. 2.052, 2.090
Korzeniewska, A. 1.174
Koscik, R. 2.218
Kossoff, E. 3.318, B.07
Kotagal, P. 2.172
Kothare, S. 2.170
Kotloski, R. 1.038
Kotzot, D. 2.169
Kowacs, P. 1.315
Kowski, A. 3.058, 3.349, A.03
Kozupsky, J. 2.265
Kraemer, D.L. 2.144
Kraemer, G. 2.099
Kramer, M. 3.054
Krause, A. 3.208, 3.302
Krauss, G. 1.316, 1.320, 2.292
Krebill, R. 1.324, 2.285, 2.286, 2.287
Kreiman, G. 2.025
Kreisl, W. 1.002
Krel, R. 3.240
Krishnan, B. 1.040, 1.144, 1.240,
3.359
Krishnan, V. 1.290
Kronengold, J.K. 3.016
Kroner, B. 3.141, 3.144
Krook-Magnuson, E. C.03
Krueger, A. 1.270
Krug, K. 2.241
Kruithof, A.C. 2.307
Krutoshinskaya, Y. 3.240
Krylov, V. 1.059, 2.076
Kuba, R. 2.003
Kubikova, R. 2.003
Kubota, M. 1.116
Kubota, T. 1.224, 1.243
Kubota, Y. 1.063
Kubova, H. 1.052
Kucewicz, M.T. 1.175, 2.156
Kuchibhotla, K. 1.021
Kuchukhidze, G. 2.068, 2.245
Kucuk, M. 1.053
Kucukboyaci, N. 2.005, 2.251
Kudela, P. 1.045
Kuhlenbäumer, G. 3.090
Kumada, S. 1.116
Kumada, T. 1.116
Kumar, A. 2.345, 3.362
Kumar, D. 2.293, 2.294, 2.295
Kumar, R. 1.022
Kumar, S. 3.145
Kumar, U. 1.289
Kumar, V. 2.365
Kunieda, T. 1.350, 2.335
Kunnakkat, S.D. 1.085
Kuo, C. 1.180
Kupsky, W. 2.345
Kuratani, J. 1.250
Kurisu, K. 1.265, 2.359
Kurlemann, G. 1.115
Kuruba, R. 1.029, 1.031
Kutluay, E.E. 2.160
Kuzniecky, R. 1.352, 3.258
Kwan, P. 1.231
Kwiatkowski, D. 3.044
Kwon, C. 2.082
Kwon, H. 1.130
Kwon, O. 1.081, 1.170
Kwon, R. C.07
L
La Briola, F. 3.243
La Vega-Talbott, M. 3.356
Laban-Grant, O. 1.131, 2.230
Labiner, D. 1.349, 2.256, 2.337,
2.339
Lacaille, J. C.01
Lach, L. 1.100
Lachance, M. 3.093
Lachhwani, D. 1.093, 1.099, 1.192
Lackner, P. 2.121
Lacuey Lecumberri, N. 2.126
Ladino, L.D. 1.228
Lado, F. 3.177, 3.346
LaFrance, W. 3.075, 3.085
LaFrancois, J. 3.026, 3.037
Lafrenière, R.G. 3.093
Lagae, L. 2.294
Lagerlund, T. 3.158
Lagrange, A. 3.152
Lai, Y. 1.139, 3.049, 3.061
Lam, A.D. 3.164
Lamanna, I. 1.141
Lamar, T. 1.046
Lamartine Sabido Monteiro, M. 1.141
Lamb, N. 3.334
Lambrakis, C. 1.131
Lammers, S. 3.044
Lancaster, R. 3.225
Lancman, M. 1.083, 1.131, 2.020,
2.230
Lancman, M.E. 1.083, 2.020, 2.230
Landazuri, P. A.07
Landmark, C.J. 2.282, 2.308, 2.317,
2.326
Lane, J.B. 3.104
Lang, A.E. 1.112
Lang, N. 2.199
Langer, J. 2.267
Langston, M.L. 3.238
Lantz, G. 1.263
Lanyon, R. 1.082
Laoprasert, P. 1.267, 2.012, 2.103,
3.279
LaPalme-Remis, S. 1.225
Lapham, G. 3.057, 3.137
Lapointe, V. 1.017
Laroche, S. 2.339, 3.203
LaRoche, S.M. 2.160, 3.226
Larsen, J. 1.118
Larsson, P. 3.366
LaSarge, C.L. 1.048
Lashley, S. 2.039
Lasley, J.H. 2.298, 2.305
Latour, N. 2.310
Lau, C. 2.233, 3.053
Laura, W. 1.139
Laurenza, A. 1.325, 2.276, 2.279,
2.288, 2.289, 2.291, 2.293, 2.294,
2.295
Laureta, M. 2.128
Lauterbach, T. 3.293
Laux, L. 3.244, 3.303
Lavingia, J. 2.148
Lawson, J. 2.187
Laxton, A. 2.337, 2.339
Le, J.M. 1.278
Le, J.T. C.04
Le, N. 2.311
Le, S. 3.168
Leaffer, E. 3.140
Leanage, G. 1.035
Lebedeva, A. 2.076
Leclercq, K. 1.020
Lee, B. 1.230, 3.373
Lee, C. 2.210
Lee, C.H. 3.221
Lee, C.L. C.04
Lee, C.Y. 3.221
Lee, D. 1.078, 2.005
Lee, E. 1.211, 1.218
Lee, H. 3.058
Lee, I. 1.313, 2.220
Lee, J. 1.211, 1.218, 3.098, 3.203,
3.226, 3.289, 3.354
Lee, K. 1.179, 1.196, 1.234, 2.014,
2.110, 2.248, 2.253, 2.255, 2.348,
2.364, 3.276
Lee, M. 1.036, 3.070
Lee, M.R. 2.354
Lee, S. 1.218, 1.219, 1.236, 2.168,
2.314, 3.036, 3.196, B.09
Lee, S.T. 3.221
Lee, V. 2.159
Lee, W. 2.318
Lee, Y. 1.130, 1.230, 1.328
Lega, B. 1.058, 1.153
Legatt, A.D. 2.180
Legendre, A. 1.039
Legg, K. 2.171
Legge, A. 2.296, 3.138
Legido, A. 3.312
Legros, B. 1.141, 3.203, 3.226
Lehesjoki, A. 3.089
Lehmkuhle, M. 3.043
Leijten, F. 2.145
Leitinger, M. 3.228
Leland, M. 3.052
Lemesiou, A. 1.057
Lenz, F. 2.025
Leon, Y.C. 1.101
Leon-Vazquez, M. 2.186, 2.334
Leonard, S. 2.032
ABSTRACT AUTHOR INDEX
Liu, R. 1.030, 3.107
Liu, S. 3.190
Liu, Y.C. 1.208
Liu, Z. 2.261
Llerenas Zamora, R. 3.154
Llewellyn, N. 2.233, 2.286, 3.289
Locke, D. 1.082
Loddenkemper, T. 1.098, 1.182, 1.197,
1.329, 1.345, 2.035, 2.213, 3.202,
3.235, 3.236, 3.246, A.05, B.06
Loeb, J. 1.004
Loesch, A. 2.165, 3.211
Loi, R.Q. 2.005
Long, X. 1.023
Longo, D. 2.146
Longo, F.M. 1.299
Lopes, T.M. 3.259
Lopes-Cendes, I. 3.046
Lopez, C. 2.299, 3.307, 3.353
Lopez, M. 2.191
Lopez Dequit, I. 3.309
López-Gomáriz, E. 1.332
López González, F. 1.332, 2.300
López Pizano, A. 3.154
Lopez-Trigo Picho, F. 1.332
Lora, P. 3.325
Loring, D.W. 2.320, 3.344, B.08
Lösch, C. 2.277
Loscher, W. 1.070
Losey, T. 3.146
Losher, C. 2.165
Lossius, M. 2.072, 2.231
Loturco, J. 3.002
Loughman, A. 1.279
Louise, G. C.01
Love, T.E. 1.347
Lovell, K. 2.131
Lovick, T. 3.036
Lowden, A. 1.210
Lowe, H. 1.208
Lowen, K. 1.338
Lowenstein, D. 3.095
Lozano, M. 2.286
Lu, Y. 1.268
Luan, G. 1.005, 1.365, 3.352
Lucchese, L. 3.126
Luczak, A. 1.017
Lüders, H. 2.126, 3.160, A.07
Ludmir, E.B. 1.006
Ludwig, E. 1.312, 1.314, 1.319,
1.320, 1.321
Luef, G. 2.121, 2.245, 2.262
Lugo, J. 1.292, 3.105, C.07
Lukic, V. 3.100
Luna-Munguia, H. 3.042
Lundstrom, B. 1.176
Luo, C. 3.285
Lupien-Meilleur, A. C.01
Lushbough, C. 1.085
Lutz, M.T. 3.077
Luu, P. 1.180, 1.263, 3.193
Ly, C. 1.009
Lyons, R. 1.288, 2.026
M
Ma, Y. 1.299
Maa, E. 3.304, 3.319
Macaulay, D. 1.213
Macaya, A. 2.187
Machado, A. 2.239
Maciag, C. 1.303
Mackay, M.T. 3.087
Mackenzie, S.J. 3.103
Mackie, E.J. 1.291
Macrodimitris, S. 1.285, 2.071
Madakasira, P. 2.365
Mader, E. 2.114
Mader, M. 1.129, 2.358
Madhavan, D. 2.197
Madhavan, R. 2.025
Madsen, J. 2.025
Madsen, J.R. 1.366
Maehara, T. 2.091, 2.093, 2.097
Maertens, P. 2.115
Maganti, R. 3.033
Magdassi, S. 3.063
Magestro, M. 3.126
Magge, S. 1.354, 3.355, 3.364
Mah, S. 2.051
Mahajan, R. 3.171
Maher, D. 2.227
Maheshwari, A. 3.054
Mahmood, N. 2.215
Mai, R. 2.184
Maideniuc, C. 2.214
Maillard, L. 2.226
Mailo, J.A. 2.130
Majmudar, S. 1.089
Makeyev, O. 3.073
Makin, C. 2.044, 2.297
Makinson, C. 3.106
Malek, A.M. 3.142
Maliia, M. 3.069
Malik, A. 2.206
Malik, M. 2.230
Malik, S. 2.250
Malinowska, U. 3.189, 3.191
Maljevic, S. 3.089
Mall, E.M. 1.069
Maloney, T. 2.024
Malykhin, N.V. 1.253
Mamelak, A. 1.126, 2.181
Mandadi, S. 1.025
Mandel, A. 3.233
Mandelstam, S. 3.087, 3.092
Mandrekar, J. 1.374
Manganaro, S. 1.132, 1.142, 2.063,
2.162, 3.240
Manganas, L. 1.132, 1.135, 2.162
Mangano, F. 1.353
Manitpisitkul, P. 1.309
Mann, A. 3.063
Mann, K. 1.090
Manreza, M.G. 2.119, 3.143
Mapstone, T.B. 2.349
Marchal, C. 2.226
Marcotegui, I. 2.153
Mares, P. 1.051, 1.052
Mari, F. 1.108
Marin, A. 2.363
Marini, C. 1.108, 1.115
Marino, S.E. 2.329
Mariyappa, N. 1.143
Marquardt, F. 3.045, 3.058
Marquez, Y. 3.373
Marras, C. 3.360
Marsh, E. 3.303
Marsh, E.D. 3.099
Marsh, R. 1.175, 1.374, 2.156,
2.256, 2.337, 2.339
Marsh, S. 2.211
Marsh, S.T. 1.042
Marson, A. 1.109
Marti, C. 3.236
Martin, R.F. 3.018
Martinez, G. 1.296
Martinez, J. 1.295
Martinez, R.C. 2.114
Martinez-Juarez, I.E. 2.186, 2.334
Martinez-Perez, A. 2.186
Martins, A. 3.046
Martins, S. 3.046
Martz, G.U. 2.160
Martínez Agredano, P. 3.311
Martínez-Juárez, I.E. 3.073
Maruo, T. 1.060, 2.357
Maruyama, A. 1.220
Masel, T. 3.269
Mason, K. 1.151, 2.252
Mason, S. 1.288
Massaro, A. 1.137
Massey, S. 2.170
Massot-Tarrús, A. 1.185
Matagne, A. 1.298
Mateo, M. 3.051
Mathern, G. 1.245, 1.357, 2.355,
2.358, 3.255, 3.262
Matkovic, Z. 1.231
Matos, A. 3.046
Matosevic, B. 2.121
Matsui, T. 2.353
Matsumoto, H. 1.116
Matsumoto, J. 1.175, 1.182, 2.156,
3.330
Matsumoto, N. 1.105, 1.116
Matsumoto, R. 1.350, 2.335
Matsuo, F. 3.150
Matsuo, T. 1.177
Matsuura, M. 2.091, 2.093, 2.097
Matthews, S.A. 3.341
Mattson, R. 2.350
Matur, Z. 2.224
Maturu, S. 2.215
Maurer Morelli, C. 3.046
Mauri, J. 1.332
Mavroudakis, N. 1.141
Maxwell, C. 1.285
Mayer, T. 3.077, 3.293, 3.297, 3.349
Mayes, L.C. B.01
Mays, V. 2.173, 3.201
Maytal, J. 2.128
Mazarati, A. 1.055, 1.056, 1.289
Mbelwa, S. 2.089
McArthur, D. A.09
McAuley, J. 1.306
McBee, N. 1.324, 2.285, 2.286,
2.287
McBrian, D. 3.233
McCarthy, A. 1.203
McCarthy, D. 1.184
McCoy, B. 1.189, 3.239, 3.306
McCredie, R. 3.286
McDonald, C. 2.005, 2.251
ABSTRACT AUTHOR INDEX
Leppik, I. 1.272, 1.325, 3.317
Lerche, H. 3.089
Lerner, J. 1.182, A.09
Lervik, K. 3.205
Lesage, F. 1.072, 1.260
LeSure, S. 3.351
Leung, L. 2.236
Leuthardt, E. 1.376
Leventer, R.J. 1.120
Lévesque, M. 1.301, 3.121
Levi, O. 3.008
Levin, H. 2.240, 2.247
Levin, S. 2.223
Levitt, J. 1.252, 1.254, 3.254
Levy, S. 2.350
Lewis, E. 1.225
Lewis, E.C. 2.141, 2.346
Lewis, M.L. 3.124
Leyden, K. 2.005, 2.251
Leymon-Porter, B. 2.031
Lhatoo, S. 2.090, 2.126, 3.127, 3.160
Li, B. 2.051
Li, H. 3.175
Li, L. 3.334
Li, M. 3.222
Li, N. 1.076
Li, P. 1.214, 2.125
Li, S. 1.231
Li, T. 1.005, 3.298
Li, W. 1.164
Li, Y. 1.007
Liang, L. 3.032
Liang, W. 3.300
Libbey, J.E. 3.117
Libenson, M. 3.236
Lie, O. 2.028
Liebenthal, J. 2.102
Ligot, N. 1.141
Lilja, I. 3.025
Lillis, K. 1.011, 3.004
Lim, B. 1.119, 1.195, 1.212
Lim, S. 2.362, 3.021
Lim, S.N. 3.221
Lima, A.M. 2.344, 3.372
Lima, E. 3.076
Lima, P.B. 3.179
Lima Castro, C. 3.082
Lin, C. 1.351
Lin, J. 1.352, 2.004, 2.013, 3.270,
3.283
Lina, J. 1.178, 2.239
Linane, A. 1.280, 3.152
Lindsay, K. 1.109
Lineweaver, T. 1.093, 1.099
Liow, J. 1.002
Lippman-Bell, J. 3.001
Lipski, W.J. 1.073
Lipton, R.B. 2.180
Liscano, A. 2.363
Lisicki, D. 1.101
Liska, J. 3.120
Lispi, M. 2.146
Litt, B. 3.183, 3.256
Liu, C. 3.373
Liu, G. 1.038
Liu, K. 2.032
Liu, M. 1.237, 2.081, 3.261
101
ABSTRACT AUTHOR INDEX
McDonald, S. 2.318
McDonough, T. 2.221
McGoldrick, P. 3.316, 3.356
McGrade, H. 3.225
McGuire, R. 1.067
McIntosh, A. 1.231
McKee, H.R. 1.280
McKhann, II, G.M. 2.027, 3.233
McLachlan, R. 1.185
McLellan, A. 1.092, 2.015
McMahon, J. 1.103, 3.086, 3.087
McNamara, J. 1.006, 1.038, 1.269
McNamara, N. 3.230
McNaughton, B.L. 1.017
McPhillips, M. 1.092
McShea, C. 3.291, 3.292, 3.295,
3.299
Meador, K.J. 2.295, 2.320, 2.339,
3.168, 3.344, B.08,
Mealey, R. 2.135
Mecchella, J.N. 1.286
Medvedev, A. 3.073
Mefford, H. 1.103, 3.086, 3.087,
3.092, 3.093
Megevand, P. 1.157, 3.177, 3.346
Mégevand, P. 2.246
Mehešová, S. 2.304
Mehrizi, M. 2.152
Mehrotra, K. 2.268
Mehta, A. 1.157, 2.011, 2.246,
2.256, 2.339, 3.177, 3.346
Mehta, D. 2.029
Meisler, M. C.09
Melaiki, B. 1.104
Melanson, D. 1.121
Memon, A.B. 3.266
Mendes, P.S. 2.119, 3.143
Mendes, S. 2.298, 2.305
Mendez, D. 2.045
Mendoza, L. 1.257, 1.310
Mendoza, M. 2.176
Menezes Cordeiro, I. 3.163
Menon, J. 3.175
Menon, U. 2.066
Mercan, M. 1.207
Mercedes, B. 2.226
Mercier, J. 2.332
Mercier, M. 3.177, 3.346
Mesad, S. 1.131
Mese, T. 1.229, 3.328
Messinger, M. 2.299, 2.333
Metcalfe, A. 2.082
Mevåg, M.A. 2.317, 2.326
Meyer, F. 1.175, 1.374, 2.156
Meyer, K. 1.344
Meyer, M. 3.034
Meyers, E. 3.203, 3.226
Miao, H. 3.051
Michalak, Z. 3.110
Michaud, J.L. 3.093
Michel, C. 2.244
Michelhaugh, S. 3.313
Michelucci, R. 1.113
Michoulas, A. 3.220, 3.327
Midi, I. 3.151
Midura, M. 1.062
Mikati, M. 3.095, B.06
Mikkelsen, T. 3.098
102
Mikulis, D. 3.200
Mikuni, N. 2.335
Milder, J. 3.095
Miles, L. 3.111
Miles, M. 3.111
Milh, M. 2.263
Milham, M. 2.246
Millan, C.M. 2.241
Millen, K.J. 1.043
Miller, I. 2.346
Miller, J. 1.372, 2.039, 2.126, A.07
Miller, J.A. 3.122
Miller, R.J. 3.116
Miller, S. 3.024
Miller-Horn, J. 3.173
Millett, D. 3.373
Millichap, J. 3.210, 3.157, 3.214
Milligan, C.J. 1.291
Minassian, B. 3.093
Mindruta, I. 1.191, 3.069
Minotti, L. 1.191, 1.348
Mintz, M. 2.016, 3.094
Mintzer, S. 2.291
Miotto, E.C. 2.119, 3.143
Miozzo, M. 2.027
Mirchandani, N. 1.181
Mirro, E. 1.209
Mirsattari, S. 1.185
Mirsky, D. 1.267, 3.279
Mirza, N. 1.109
Misajon, J. 1.133
Miskin, C. 3.312
Misra, S.N. 1.215
Mitchell, W. 3.145
Mittal, M. 2.111
Mittal, S. 3.062, 3.313
Miura, K. 1.224, 1.235, 1.243
Miyama, S. 1.116
Miyamoto, S. 1.350, 2.335
Mizrahi, E. 2.212
Modi, A. 1.090, 1.091, 2.316
Modur, P. 1.077, 2.038, 2.131, 2.193,
3.070, 3.083
Moeller, J. 2.296
Moffett, B.S. 2.333
Mohamadpour, M. 2.016
Mohamed, I. 2.123, 3.370
Mohamed, M.A. 2.272
Mohammad, F. 3.122
Mohammadi, M. 1.127
Mohan, C. 2.268
Mohanarangan, K. 2.208
Mohanraj, R. 1.109
Moheet, A. 2.227
Molins, A. 1.332
Møller, R.S. 1.115, 1.118
Monica, N. 2.085
Monrad, P. 3.215
Montalvo, J. 3.101
Montandon, G. 1.010, 3.200
Montoya, J. 1.332
Moon, C. 1.196
Moon, H. 1.202
Moon, J. 2.168, 3.196
Moore, J.L. 2.006
Moorley, N. 1.198, 1.199, 1.200,
1.201
Moraes, V. 2.306
Morales-Quezada, J. 3.009
Moran, J. 1.151
Morawo, A. 1.076
Moreira, C.L. 3.332
Moreland, S. 3.205
Morgan, L. 2.028
Morgan, V. 2.117
Morgan, V.L. 2.242
Morisada, N. 1.220
Morita, A. 3.365
Morita, D. 1.090, 2.024, 2.316
Morita, M. 1.377, 3.259, 3.260
Morrell, M. 1.216, 2.209, 2.212, B.08
Morris, C. 3.367
Morris, G. 1.333
Morse, C. 1.002
Moschetta, S. 3.076
Moschetta, S.C. 3.082
Moseley, B.D. 2.228, B.05
Moseley, M. 1.006
Mosher, J. 1.063, 1.149, 2.249
Moshé, S. 1.305
Moss, A. 3.132
Moss, R. 1.065
Motamedi, G. 1.202
Motelow, J. 1.044, 1.164
Motika, P. 1.277
Motil, K.J. 3.104
Moufawad El Achkar, C. 3.361
Moura, L.V. 2.045
Moussa, N.A. 2.001
Mower, A. 3.241
Mowrey, W. 1.304, 1.305
Mrelashvili, A. 1.364
Mucci, G. 2.013
Mudugal, D. 2.197
mueller, A. 2.195
Mueller, G.P. A.08
Mueller, M. 2.271
Muhle, H. 1.115, 3.090
Muhonen, M. 2.013
Mullatti, N. 1.067
Mullins, J.G. 1.111
Muma, E. 2.215
Muniz, R. 3.301
Munoz, J. 1.210, 3.083
Muona, M. 3.089
Murakami, H. 1.149, 3.359
Murata, K. 3.330
Murphy, G. C.09
Murphy, M. 1.232
Murphy, W. 2.067, 3.139
Murro, A.M. 2.212
Muzik, O. 3.062
Myers, C. 3.086
Myers, L. 1.083, 1.088
Mylius, J. 3.045
Myseros, J. 1.354
Mytinger, J.R. 3.147, 3.157, 3.223
N
N Guyen The Tich, S. 2.263
Na, G. 3.091
Nabatame, S. 1.105
Nabbout, R. 2.187, 2.263, 3.016
Nabors, L.B. 1.330
Nabulsi, N. 2.332
Nachbauer, W. 2.121
Nadasdy, Z. 3.070
Naduvil Valappil, A. 1.149, 1.192,
1.362
Naeije, G. 1.141
Nagarajan, E. 1.197, 2.035, 2.213,
3.235, 3.236, 3.246
Nagasawa, T. 2.202
Nagase, H. 1.220
Naik, M. 2.159
Naik, P. 2.092
Nair, D. 1.063, 1.153, 1.216, 2.212,
2.249
Nair, S. 3.079
Najimipour, B. 1.068
Najm, I. 1.008, 1.012, 1.040, 1.058,
1.063, 1.240, 1.362, 1.377, 2.073,
2.249
Nakae, T. 1.350, 2.335
Nakagawa, E. 1.116, 1.147, 2.225,
2.341
Nakagawa, T. 1.220
Nakajima, M. 1.145, 1.363, 1.370,
2.174, 3.012, 3.108
Nakamura, K. 1.116
Nakane, S. 2.174
Nakanishi, S. 3.019
Nakano, H. 1.110
Nakasato, N. 1.367, 2.132, 2.149,
2.154, 3.159
Nakashima, M. 1.105, 1.116
Nakayama, T. 1.367
Nakhutina, L. 1.085
Nakken, K. 2.231
Nam, H. 1.218
Namihisa, Y. 2.060
Nampoothiri, S. 2.182
Napuri, S. 2.263
Narayana, P.A. B.03
Narayanan, M. 1.148
Narugami, M. 2.174
Nascimento, D. 3.046
Nash, K. 1.182
Nassar, M. 2.175
Nasuti, P. 3.126
Natsume, J. 1.224, 1.235, 1.243,
2.158
Navarro, V. 2.226
Naves, P. 2.327, 3.369
Navratilova, Z. 1.017
Ndayisaba, J. 2.068
Neal, J. 2.082
Nearing, B.D. 3.218
Negishi, M. B.01
Negoro, T. 1.224, 1.235, 1.243
Negrin, S. 2.122
Neher, J.J. 3.116
Neil, J. 2.059, 3.246
Neimat, J. 2.117
Nelson, D. 2.131, 3.070
Nelson, E.B. 1.257
Nelson, G.R. 2.134
Nemes, A. 1.008, 1.012, 1.040
Nemoto, M. 1.233
Neppe, V.M. 2.062
Nespeca, M. 2.104, 3.241
Nettel-Aguirre, A. 3.172
Neubauer, B. 1.115, 2.204
ABSTRACT AUTHOR INDEX
O
O’Brien, C. 2.053, 3.205, 3.304,
3.320
O’Brien, T. 1.231
O’Brien, T.J. 1.047, 1.291
O’Callaghan, F. 2.187
O’Connell, R.M. 3.117
O’Day, K. 1.344
O’Donovan, C. 3.367
O’Hara, B.F. 1.071
O’Neal, W. 2.303
O’Neill, B. 1.267
Oba, S. 2.353
Obari, D. 3.110
Obata, K. 2.080
Obeid, R. 2.159
Oberaigner, W. 2.068
Oberman, L. 3.337
Ochi, A. 1.127, 1.145, 1.172, 1.189,
2.353, 3.108, 3.153, 3.306
Odom, N. 2.057, 3.248
Ogawa, C. 1.243
Ogden, K. 3.363
Oguni, H. 1.365
Oh, A. 2.185
Oh, M. 1.221
Ohshima, M. 2.060
Ohta, K. 2.091, 2.093, 2.097
Oijala, M. C.03
Ojemann, J. 1.250, 3.280, 3.282,
3.368,
Okanari, K. 1.127, 1.145, 2.353,
3.108
Okanishi, T. 1.127, 1.172, 1.371
Okeke, J.O. 2.275, 3.081, 3.135
Okoshi, Y. 2.202
Oktem, O. 2.224
Okumura, A. 1.224
Okumura, E. 3.159
Olafsson, E. 3.128
Oldham, M. 3.324
Oliveira, L.A. 3.165
Oliver, K.L. 3.089, 3.100
Olney, N. 2.108
Olson, A. 2.046
Olson, L. 1.339
Oltmanns, F. 3.349
Oluigbo, C. 1.354, 2.351, 3.355,
3.364
Omar, N. 3.348
Omurtag, A. 3.181
Ono, T. 1.359, 1.361
Onomura, A. 1.373
Oommen, B. 2.135, 3.302
Opperman, C. 2.021
Orhan, N. 1.053
Orii, K. 1.116
Orozco-Suarez, S. 1.001
Orton, K. 2.134
Osaka, H. 1.116
Osako, M. 2.060
Osawa, S. 1.367
Osborn, M. 1.338
Oshino, S. 1.060, 2.357
Osorio Santiago, A. 3.154
Oster, J. 3.347
Ostuni, J. 3.268
Otsubo, H. 1.127, 1.145, 1.172,
1.189, 2.353, 3.108, 3.153
Otsubo, T. 2.002
Otsuka, K. 2.174
Otsuki, T. 1.147, 1.365, 2.225, 2.341,
3.114
Ottman, R. 2.275, 3.081, 3.135
Otáhal, J. 1.051
Oya, H. 1.079
Ozbek, D. 3.151
Ozdag, F. 3.170
P
Pacheco, J. 3.083
Pacheco, L. 1.295
Pacheco-Phillips, J. 2.049
Pack, A. 2.234, 3.140
Pack, C. 3.121
Paige, A. 1.324, 2.285, 2.286, 2.287
Painter, M. 2.159
Pakhomov, S.V. 2.329
Palacios, A. 3.053
Palao-Duarte, S. 2.078
Palat Chirakkara, S. 1.239
Palestrant, D. 2.227
Palmquist, M. 1.094
Palotie, A. 3.089
Pan, H. 2.236
Pan, J.W. 3.072
Pan, P. 3.255, 3.262
Pan, Y. 2.040
Pandey, R. 1.275
Pandian, A. 3.105
Panduranga, A. 2.177
Panel, I. 2.342, 3.350
Pang, T. 1.188, 1.205
Panigrahy, A. 2.159
Paolicchi, J. 2.221
Papadelis, C. 2.213, 3.202, 3.235
Papale, L. 1.046
Parada, I. 1.299
Pardoe, H.R. 3.258
Paredes Saenz, C.F. 1.158
Parent, J. 3.002, 3.005, 3.006, C.02,
C.09,
Parent, R. C.09
Parikh, P. A.06
Park, B. 2.238
Park, C. 1.130
Park, E. 1.366
Park, H. 2.315
Park, J.T. 2.167
Park, K. 1.110, 1.218, 3.210
Park, S. 1.030, 1.081, 1.218, 1.282,
1.313
Parker, P. 1.331
Parko, K. 2.058
Parra, M. 1.194
Parsons, K. 1.030
Parsons, T. 2.022
Parthasarathy, S. 1.148
Pascoal, V. 3.046
Pascual, F.T. 2.034
Pascual, J. 1.054
Pascual-Leone, A. 1.154, 1.205
Passarell, J. 1.312, 1.314, 1.319,
1.320
Passe, T. 2.235
Passen, N. 1.306
Passmore, C. 1.037
Patel, A. 2.055, 2.319, 3.130
Patel, A.B. 1.278
Patel, M. 3.032, 3.052, 3.066
Patel, P. 1.341, 3.231
Patel, R. 1.294
Pathmanathan, J. 1.184
Patil, V. 3.048, 3.050
Pato, A. 2.300, 3.309
Patten, S. 2.071
Patten, S.B. 1.285
Patterson, C. 3.331
Patterson, E. 1.372
Patterson, K.P. 1.009
Patwardhan, R. 2.256, 2.337, 2.339
Paudel, S. 2.319
Pavlova, M. 2.151
Payne, E. 1.182, 3.059
Pazarci, N. 2.183
Pazdera, L. 1.318
Pearce, P.S. 3.072
Peariso, K. B.06
Pearl, P. 1.197, 1.225, 3.065, 3.246,
3.325
Pearson, J. 3.032
Pedersen, M. 2.243
Pedersen, N.P. 1.162
Pedraza Benitez, C. 3.311
Peeters, P.A. 2.307
Peglar, L. 3.324
Pei, F. 3.178
Peinhof, S. 2.040
Pelayo, M. 2.126
Pella, R. 2.028
Pellegrino, G. 2.239
Pelliccia, V. 2.184
Peltier, A. 1.187
Pendziwiat, M. 1.115, 3.090
Peng, K. 1.260
Peng, S. 3.271
Pennell, P. 2.233, 3.289,
Penovich, P. 1.288, 1.320, 2.046
Perchyonok, Y. 1.120
Percy, A.K. 3.104
Perez, D.L. 2.236
Perez, E. 3.074
Perez Velazquez, J. 1.010
Perez-Ruiz, J. 2.186
Perkins, F.F. 2.354
Perlman, J.M. 2.221
Pernot, F. 1.039
Perry, L. 1.247, 1.249
Perry, M. 2.022, 2.250
Perucca, P. 2.358
Perumpillichira, J.C. 3.158
Perven, G. 1.226
Perzynski, A.T. 1.084
Peters, J. 1.098
Peters, P.A. 1.175
Petersen, B. 1.069
Petersen, C. 2.266
Petit, J. 2.226
Petroff, O. 1.135, 3.204
Petrou, S. 1.291, 3.089
Petty, S.J. 1.291
Phelan, J.C. 2.275, 3.081, 3.135
Phillips, B. 3.304
Phillips, K. 1.026
Picard, R. 2.213, 3.235
Pickrell, W.O. 1.111
Pieters, H. 1.357, 3.217
Pike, V. 1.002
Pillai, A. 2.366
Pillay, N. 2.067, 2.150, 2.198, 3.139
Pilli, V. 1.251
Pilz, G. 3.228
Pina-Garza, J.E. 2.293
Ping, X. 1.155
ABSTRACT AUTHOR INDEX
Neufeld, M. 3.197
Neul, J.L. 3.104
Neumann, A. 1.017
Neveux, M. 1.020
Newman, R.B. 3.142
Ng, E. 2.128
Ng, M. 2.113
Ng, Y. 2.201, 2.349
Ngo, T.P. 3.307, 3.353
Nguyen, D. 1.072, 3.274, 3.370
Nguyen, D.K. 1.260, 2.123
Nguyen, D.V. 2.123
Nguyen, L. 3.048, 3.050
Nguyen, M. 1.030, 2.123
Nguyen, V. 2.322
Ni, J. 1.043
Nick, S. 1.267
Nickels, K. 1.193, 1.355, 1.364,
2.079, 2.203, 3.148, 3.158, 3.223,
3.229
Nicolas, J. 2.310, 2.332
Nicoletti, J. 3.105
Niemann, H. 1.069
Nikanorova, M. 1.118
Nikolov, R. 3.265
Nikolova, S. 3.265, 3.277
Nishida, S. 1.350, 2.335
Nishioka, K. 2.353
Nishiyama, M. 1.220
Nita, D.A. 1.172
Nixon, J. 3.280, 3.282
Noachtar, S. 1.124, 2.165, 3.211,
3.273
Noack - Rink, M. 3.293, 3.297
Nobile, C. 1.113
Nobili, P. 3.029
Noe, K. 2.166
Noebels, J.
Noh, G. 2.083
Nonoda, Y. 1.116
Norcia, A. 3.178
Nordli, D. 1.222, 3.244
Norman, J.L. 2.110
Nourski, K.V. 1.079
Novak, H. 3.228
Novak, Z. 2.003
Noviawaty, I. 1.192
Novotny, E. 1.250, 3.280, 3.282
Nowell, M. 1.057
Nozaki, T. 3.365
Nuno, M. 2.227
Nussbaum, N. 2.354
103
ABSTRACT AUTHOR INDEX
Pinheiro Martins, A. 3.055
Pinto, L.F. 3.204
Pinzon-Ardila, A. 3.192
Pirmohamed, M. 1.109
Pirotte, B.D. 2.166
Pita, I. 3.101
Pittau, F. 2.244
Pittman, D.J. 1.264, 3.186
Pittman, Q.J. 3.124
Pixley, L. 3.326
Pizzo, F. 3.161
Plank, G. 2.136
Platel, J. 1.039
Plegue, M. 1.096
Plummer, C. 2.147
Poddar, K. 2.201
Poduri, A. 3.034, 3.087, 3.095
Pohlmann-Eden, B. 2.171
Pojomovsky, P. 3.233
Polack, P. 1.039
Poliachik, S. 1.241, 1.250, 3.280
Poliakov, A.V. 1.241, 1.250, 3.280,
3.282
Politsky, J. 1.131, 1.140
Pollard, H.B. A.08
Pollard, J. 1.324, 2.135, 2.285,
2.286, 2.287, 3.208, 3.302
Pollard, J.R. A.08
Polli, J. 2.330, 3.288
Polster, T. 1.115
Polyak, B. 3.063
Ponce Mejia, L. 3.269
Ponticello, L. 2.064
Pooladian, A. 3.370
Popli, G. 2.210, 2.256, 2.337, 2.339,
3.367
Porter, B. 3.178
Portnoy, E. 3.063
Poublanc, J. 3.200
Pouliot, P. 1.260, 3.274
Pouliot, W.A. 3.047
Powell, E. 3.018
Powell, K.L. 1.047
Poza Aldea, J. 1.332, 3.309
Prayson, R. 1.144, 1.240
Prescott, J.S. 2.324
Press, C. 1.326
Prieschl, M. 2.121, 2.262
Prince, D.A. 1.299
Prince, R. 3.356
Privitera, M. 1.324, 2.228, 2.285,
2.286, 2.287, 3.288,
Pro, S. 2.146
Probasco, J. 3.226, 3.203
Probst, L. 2.268
Proix, T. 3.182
Prusa, C. 1.306
Pugh, M. 2.059, 2.257
Puka, K. 1.095, 3.306
Pullum, B. 2.110, 2.364
Punia, V. A.02
Pushchinska, G. 1.181
Pustina, D. 1.255, 2.237
Puthenveettil, V. 2.182
Puttachary, S. 3.027
Pylypyuk, V. 2.241
104
Q
Qiang, J. 2.232
Qing, K. 3.036
Quach, M. 3.188
Que, G.T. 2.066
Quelen, C. 1.334, 1.335, 1.336
Quigg, M. 1.209
Quinn, H. 2.064
Quinn, K. 3.066
Quiroga Subirana, P. 3.311
Qulu, L. 3.124
Quraishi, I. 1.062
Quraishi, I.H. 3.016
Qureshi, M. 2.206
R
Rabinovitz, B. 2.029
Rabinowicz, A.L. 1.213
Radhakrishna, S. 3.136
Radtke, R. 3.113
Raedt, R. 1.017, 3.028, C.08
Ragazzo, P.C. 2.274, 3.199
Raghavan, M. 2.148
Ragheb, J. 2.346
Rai, A. 3.063
Rai, P. 3.212
Rai, S. 3.137
Raible, D. 3.031
Rajaraman, R. 2.108, A.09
Rajasekaran, K. 1.054, 3.115
Rajasekaran, V. 1.374, 3.158
Rajyaguru, R. 3.270, 3.283
Rama Madhava, A. 2.065
RamachandranNair, R. 2.065
Raman, K.R. 1.278
Ramey, P. 1.338
Ramirez, C. 1.101
Ramirez, F. 3.293, 3.297
Ramon, C. 3.187
Rampal, N. 1.135, 3.204
Rampp, S. 1.146, 1.346, 3.058
Ramsay, E. 2.107, 3.225
Ramsay, R. 3.219
Ramsay, R.E. B.02
Ramsey, R.K. 1.084
Ramsey-Williams, V. 3.175
Rana, S. 3.133
Randall, M. 1.034
Rankin, S. 1.043
Ransom, C. 1.015
Rao, L. 3.249
Rao, S. 3.250
Raol, Y. 3.039
Rappoport, D.A. 1.049
Rapuano, A. 3.072
Rasina, A. 3.069
Rau, S. 1.096
Rawal, P. 1.281, 2.319
Rayer, K. 1.169
Raygor, K. 1.369
Raynes, H. 3.356
Raña Martínez, N. 2.300
Rebessi, E. 3.360
Reck-Peterson, S. 1.121
Reddy, D. 1.029, 1.031, 1.032, 1.033
Reddy, J. 1.239
Reddy, S. 2.299
Redondo Verge, L. 3.311
Reed, C.M. 2.181, 2.321, 2.336
Reed, R. 3.314
Reed, U.C. 2.119, 3.143
Rees, M.I. 1.111
Reese Jr, J. 2.142
Regan, B.M. 3.088
Regnier-Golanov, A. 3.048, 3.050
Rehman, R. 2.048, 2.077
Reid, C.
Reif, P.S. 3.090
Reimers, A. 2.282
Reinsberger, C. 2.213, 3.235
Reisdorph, N. 3.066
Rektor, I. 2.003
Remi, J. 1.124, 2.165
Rémi, J. 3.211
Remigio, G.J. 3.020
Rener Primec, Z. 1.105
Renfroe, B. 2.294
Rensing, N. 1.024, 3.013
Resnick, T. 2.303
Restrepo, C. 3.315
Reutens, D. 1.035, 3.281
Rheims, S. 1.348, 2.226, 2.263
Rho, J.M. 1.030, 3.124, 3.327
Rhone, A.E. 1.079
Riaz, A. 3.079
Ribot, R. 2.063, 2.264
Richards, S. 2.040
Richardson, J. 2.064
Richardson, M. 1.073, 2.147
Richardson, Z. 1.281
Richeh, W. 2.114
Richerson, G. 1.164
Riebe, I. C.01
Riley, C.L. 3.176
Riley, J. 2.013, 3.270, 3.283
Riley, K. 2.338, 3.348
Rios-Motta, M. 2.096, 3.101
Rios-Motta, R. 2.096
Rismanchi, N. 3.241
Risse, G. 1.080, 2.026
Ritacco, D.G. 1.222
Ritchie, H. 2.057
Ritter, F. 2.021, 2.235
Rivard, K.B. 1.217, 3.019
Rizzi, M. 3.360
Robbins, E. 2.302
Robert, M. 3.274, 3.370
Roberts, H. 1.213
Roberts, J. 1.284
Robichaud, A. 1.303
Robichaud, A.J. 1.296
Robinson, L. 2.237
Robinson, S. 1.150
Rocha, C.S. 3.046
Rocha, F. 1.273, 1.287, 1.315, 1.316,
1.319, 1.320, 1.322, 2.278
Rocha, L. 1.001
Rodan, L. 2.124
Rodgers, K. 3.038
Rodgers, K.M. 3.047
Rodgers, P. 1.140
Rodrigues, L. 2.327
Rodrigues Velasco, T. 3.055
Rodrigues Ximenes Goldberg, K. 2.274,
3.199
Rodriguez, C. 2.238
Rodriguez, J. 1.295
Rodriguez Casero, M.V. 3.087
Rodriguez Osorio, X. 2.300, 3.309
Rodriguez Uranga, J. 1.332
Rodriguez-Osorio, X. 1.332
Rodríguez Arias, L.R. 3.154
Roehl, K. 2.205
Roers, E. 1.337
Roessler, K. 1.146, 1.346
Rogawski, M.A. 2.279
Rogers, B.P. 2.242
Rogers, J. 3.052
Rogin, J. 1.314, 2.290
Rojas, N. 3.192
Romain, J. 2.013
Romatoski, K. 1.154, 1.188
Romeo, A. 2.338
Romero Acebal, M. 3.311
Romero-Godoy, J. 3.311
Romigi, A. 1.108
Rompies, E. 3.324
Ronen, G. 1.100
Rosa, M. 2.310
Rose, D. 1.152, 1.353
Rose, K. 1.075, 2.195
Rose, S. 2.102, 3.160
Rosenbaum, P.L. 1.100
Rosenberg, E. 2.309
Rosenfeld, W. 1.315
Rosenow, F. 3.090
Rossi, M.A. 1.074, 2.085, 2.241
Rossignol, E. 3.093, C.01
Rotenberg, A. 1.158, 1.302, 3.009,
3.034, 3.044, 3.337
Roth, R.M. 1.086, 3.080
Rothermel, R. 3.062, 3.362
Rothman, S. 1.372
Roucard, C. 1.039
Rowley, S. 3.032
Roy, A. 1.043
Roy, A.G. 2.182
Rozen-Zvi, M. 2.033
Rozhkov, L. 3.111
Rubio Esteban, G. 3.311
Rubio-Nazábal, E. 2.300
Rudd, D. 3.294
Rudoinov, R. 1.057
Rueda, C.H. 1.050
Ruiz Chow, A. 2.334
Runge, U. 3.293, 3.297
Russek, S. 3.003, 3.011
Russo, G. 2.311
Rutecki, P. 2.209
Rutishauser, U. 1.126, 2.181
Rutka, J. 1.172, 1.189, 2.353
Ruttle-Soon, L. 1.360
Ruvalcaba, N. 1.295
Ruwald, M. 3.132
Ryan, B. 2.056
Ryan, C. 3.325
Ryan, E. 2.057
Ryan, N. 3.157, 3.223
Rychlik, K. A.01
Rydenhag, B. 2.342, 2.343, 3.350
Ryu, H. 1.195
ABSTRACT AUTHOR INDEX
Ryvlin, P. 1.348, 2.226, 3.291, 3.292
Rzezak, P. 2.259, 3.076, 3.082
S
1.167, 2.180, 2.358, 3.068
Schwabe, M.J. 1.173
Schwalb, J. 2.208
Schwambach Vieira, A.S. 3.046
Schwartz, M.L. 3.016
Schwarz, M. 3.222
Schwieterman, D. 2.286
Schönherr, M. 1.146
Scornavacca, G.F. 3.243
Scott, J. 1.150
Scott, L. 1.025, 3.019
Scullion, K. 1.217
Secore, K. 2.042
Secore, K.L. 1.086
Seeck, M. 2.244
Seidenberg, M. 2.023, 3.267, 3.270
Seidl, S. 1.078
Seif Eddeine, H. 2.127
Seignot, B. 3.375
Selassie, A. 2.087, 3.142
Selby, K. 3.220
Selezneva, E. 3.045
Selwa, L. 3.078
Semah, F. 2.219
Semsarian, C. 3.088
Sen, D. 3.294
Sencer, S. 2.224
Seneviratne, U. 1.227
Seo, D. 1.130, 2.207
Seo, J. 1.130, 1.179, 2.014, 2.110,
2.253, 2.255, 2.348, 2.364, 3.276
Sepeta, L. 2.019, 3.084, 3.268,
3.272, 3.278
Seppi, K. 2.068
Serafini, A. 2.122
Serafini, R. 1.004
Seraphim, E.A. 2.327
Sergio, G. 3.192
Serioli, E. 1.113
Serout, F. 1.164
Sethi, N.K. 1.271, 3.155
Seyal, M. A.06
Sha, Z. 3.190
Shafer, P. 3.075, 3.218
Shafi, M. 1.154, 1.205
Shah, A. 1.317, 1.321, 3.062, 3.174,
3.232, 3.266, 3.313
Shah, P. 3.227
Shahlaie, K. 1.078
Shallcross, A. 2.007
Shandra, O. 1.304
Shapiro, J.S. 2.043
Shapiro, M.J. 2.065
Shapiro, M.S. 1.165
Sharan, A. 1.255, 1.349, 2.256,
2.337, 2.339
Shariff, S. 2.032
Sharma, A. 2.228
Sharma, B. 1.270
Sharma, P. 1.047
Sharma, R. 2.201
Sharma, S. 3.027
Shatila, A. 2.086
Shaw, D.W. 1.241, 3.280, 3.282
Shaw, E.C. 2.074
Shaw, S. 3.373
Shea, K. 2.073
Shegog, R. 2.009, 3.075
Sheikh, A. 3.175
Shellhaas, R. 1.096, 1.136, 3.145,
Shen, A. 1.066
Shen, J. 2.131, 3.070
Shen, S.C. 1.208
Shen, V. 1.334, 1.335, 1.336
Shepherd, C. 3.126
Sheriff, H. 3.241
Sherman, E. 1.360
Shetty, A. 2.256, 2.337, 3.358, 3.371
Shetty, J. 1.092, 2.015
Shi, Y. 1.309
Shiau, D. 2.160
Shibata, S. 1.350, 2.335
Shields, D. 1.216
Shih, J.J. 1.349, 2.256, 2.337, 2.339,
3.238, 3.343
Shih, S. 3.141, 3.144
Shih, Y. 1.351
Shimoda, Y. 1.367
Shimono, M. 1.116
Shin, D. 1.218, 1.289, 3.338
Shin, H. 1.159, 2.057
Shin, J. 3.330, 2.168, 3.196
Shin, W. 1.218
Shindo, K. 2.080
Shinpoo, M. 1.116
Shiraishi, H. 2.174
Shmuel, M. 3.063
Shmuts, R. 2.135
Shneker, B. 1.306, 2.278
Shon, Y. 2.362, 3.021
Shostak, S. 2.275, 3.081, 3.135
Shrestha, A. 2.053, 3.205, 3.304
Shults, J. 1.182
Shurtleff, H. 3.282
Shutter, L.A. 1.310
Si, Y. 1.062, 1.076
Siddarth, P. 1.252, 1.254, 3.254
Siddiqui, K. 2.001, 2.188
Siddiqui, R.S. 2.188
Sidovar, M. 1.213
Siebert, R. 1.115
Siedentopf, C. 2.245
Sieren, J. 2.286
Silbersweig, D.A. 2.236
Sillanpaa, M. 2.018
Sills, G. 1.109
Silveira, M.R. 3.179
Silvia, M. 2.210
Simeone, K. 1.293, 3.341
Simeone, T. 1.293
Simeone, T.A. 3.341
Simon, N. 3.043
Simonson, C. 3.220
Sinasac, D. 3.327
Sinclair, D. 2.178
Singer, R. 3.327
Singh, A. 2.007
Singh, K. 2.196
Singh, M. 1.275
Singh, P. 2.117
Singh, R. 3.201
Singh, S. 2.150, 2.198
Singh, S.P. 2.041, 2.098
ABSTRACT AUTHOR INDEX
Saadatmand, H. 2.234
Saavedra Piñeiro, M. 2.300, 3.309
Sabatello, M. 3.081
Sabau, D. 2.152
Sabesan, S. 1.075, 2.195
Sabharwal, V. 2.107, 3.219, 3.225,
B.02
Sabri, J. 1.131
Sacco, M. B.06
Sackellares, J.C. 2.160
Sade, E. 3.096
Saenz, J. 1.281
Safi, D. 1.072
Sager, M. 2.218
Sahin, D. 1.053
Sahin, M. 3.044
Sahin, S. 2.129
Sahoo, S.S. 3.085, 3.127
Said, R. 1.210, 3.322
Said, R.R. 2.088
Saindane, A.M. 3.344
Sainju, R. 1.062, 1.135
Saito, T. 2.225, 3.114
Saito, Y. 1.147
Saitsu, H. 1.105, 1.116
Saiz-Diaz, R. 1.332
Sajatovic, M. 1.084, 3.085, 3.127
Sakaguchi, Y. 1.235, 1.243
Sakata, M. 2.060
Sakuma, S. 1.127, 1.145, 2.353,
3.108
Sakuraba, R. 3.159
Salam, M. 2.084
Salam, T. 1.010
Salamon, N. 1.238, 1.245, 1.261,
1.278, 3.255, 3.262
Salanova, V. 2.212
Salas Puig, J. 1.332, 3.237, 3.309
Salinas, C.M. 2.014, 2.248, 2.253,
2.255, 3.276
Salinsky, M. 2.177, 2.269
Salituro, F. 1.296
Salpekar, J. 3.141
Sampaio, L.B. 2.119, 3.143
Sampaio, L.P. 3.332
Sampath, D. 3.039
Sams, J. 3.085
Samson, K.K. 3.341
San Juan Orta, D. 3.154
Sanchez Barrera, W.S. 2.190
Sánchez Fernández, I. 1.098, 1.182,
1.197, 1.329, 2.035, 3.246, A.05,
B.06
Sánchez Ortiz, C. 3.311
Sanchez-Ortiz, L. 2.096
Sander, T. 1.115
Sander, V. 2.187
Sandy, S. 2.150, 2.198
Saneto, R. 1.250
Sankar, R. 1.289, 2.108, 2.195, 2.355
Sankar, T. 3.261
Sankaraneni, R.R. 2.172
Sansevere, A. 1.197
Sansevere, A.J. 3.246
Santamarina, E. 3.237, 3.309
Santana-Gomez, C. 1.001
Santaniello, S. 1.061
Santhakumar, V. 1.007
Santos, V.R. 1.048
Saper, C.B. 1.162
Saponjian, Y. 1.021, 2.328, 3.022
Saposnik, G. 2.032
Sarkar, C. 2.365
Sarkis, R. 2.008, 2.213, 3.235, 3.289
Sarma, A. 3.315
Sarma, S.V. 1.061, 2.010
Sarode, A. 1.341
Sarria, S. 3.237
Sasaki, M. 1.147, 2.225, 2.341,
3.114
Satishchandra, P. 1.143
Sato, K. 2.080
Sato, S. 1.150
Sato, Y. 1.145, 3.108, 3.153
Sattar, S. 2.104, 3.241
Sauer, C. 3.215
Saunders, G.W. 3.020
Sauro, K. 2.051
Savioli, A. 3.360
Sawan, M. 1.072, 1.260
Sawchuk, T. 1.276
Sawer Jr, R. 2.125
Scantlebury, M. 1.025, 1.030, 1.217,
3.019
Schaal, A. 2.248, 2.255, 3.276
Schachter, S. 1.232, 1.302, 3.218
Schaefer, C. 2.283, 3.290
Schaffer, D. 2.029
Schaffer, S. 2.011
Schalk, G. 2.248, 2.255, 3.276
Scharfman, H.E. 3.026, 3.037
Scheffer, I. 1.103, 1.115, 1.120,
3.086, 3.087, 3.088, 3.092, 3.095,
3.100
Scheich, H. 3.045
Scheuer, T. 3.340
Schevon, C. 1.057, 3.213, 3.253,
Schiemann, J. 2.219
Schiff, N. 1.044, 2.105
Schildt, C. 1.071
Schiltz, N. 2.090
Schmid, E. 2.245
Schmidt, K. B.06
Schmidt, M. 2.171
Schmidt, S. 1.159
Schmiedel, G. 1.118
Schmitt, F. 3.045, 3.058
Schmitt, F.C. 3.349
Schmitt, S. 1.242, 3.203
Schmitt, S.E. 3.226
Schneider, S. 2.128
Schober, H. 2.169
Schoedel, K.A. 1.323
Schoenberg, M. 2.360, 2.361
Scholl, E.A. 3.043
Schomer, A. 3.218
Schooley, D.E. 1.042
Schrader, D. B.04
Schreiber, J. 3.065
Schultz, L. 2.208, 2.215
Schulze-Bonhage, A. 1.067, 1.129,
105
ABSTRACT AUTHOR INDEX
106
Sinha, S. 1.143, 1.148, 1.239, 2.106,
2.188, 3.113
Sinha, S.R. 2.160
Sinisterra, N. 2.363
Sirsi, D. 2.088
Sirven, J. 3.294, 3.304
Sisodiya, S. 3.110
Sitwat, B. 3.331
Siugzdaite, R. 3.028
Sivaraju, A. 1.062
Skene, P. 3.113
Skibo, J. 1.043
Skidmore, C. 1.216, 1.255
Skinner, S.A. 3.104
Slansky, A. 2.063, 2.162
Slater, J. 1.160, 3.181
Slick, D. 1.360
Smith, B. 1.027, 2.194
Smith, D. 2.286
Smith, E. 1.057
Smith, G. 2.271, 3.105, C.07
Smith, J.D. 1.276, 3.327
Smith, M. 1.095, 2.212
Smith, N. 1.044
Smith, P.E. 1.111
Smyth, M. 1.372
Snead, C. 1.172
Snead, O. 1.189, 2.353, 3.306
Snead III, O.C. 1.127, 2.095
Snyder, J. 2.215, 3.098
So, E. 3.158, B.05
Sobczyk, O. 3.200
Sobrido, M. 2.300
Soderblom, E.J. 1.006
Sofat, P. 2.125
Sogawa, Y. 2.159, 3.331, 3.333
Sohn, Y. 1.218
Sohrabpour, A. 1.268
Soldan, S.S. 3.041
Solomon, G. 3.155
Solt, K. 1.023
Soltesz, I. C.03
Somerlik-Fuchs, K. 3.068
Somerville, E. 3.286
Sommer, B. 1.346
Song, H. 3.338
Soni, N. 1.085
Sonmezturk, H. 1.186, 1.327
Sood, S. 1.251, 2.345, 3.062, 3.362
Soraas, C. 2.072
Sorge, S.T. 2.275, 3.081, 3.135
Sorin, L.M. 3.146
Soucy, A. 1.270
Soul, J. 2.124, 3.334
Sousa, R. 1.273, 1.287, 1.317, 1.319,
1.320, 1.322, 1.323
Sozzani, S. 1.020
Spain, W. 1.015
Spampanato, J. 1.161, 1.166
Spanaki, M. 2.208, 2.215, 2.252
Specchio, L. 1.315
Specchio, N. 3.360
Speechley, K. 2.056, 2.069, 2.223,
3.134
Spencer, D. 1.156, 1.209, 1.216,
2.151, 2.350
Sperling, M. 1.255, 1.318, 1.320,
1.323, 1.349, 2.290, 2.256, 2.289,
2.337, 2.339, 3.291, 3.292,
Spiciarich, M.C. 2.061
Spitz, A. 1.106
Spitz, M. 2.053, 3.205, 3.304
Spreafico, R. 2.184
Sprengers, M. 1.017, 3.028, C.08
Spring, A.M. 3.186
Spritzer, S.D. 2.166
Spruill, T. 2.007
Squillacote, D. 1.213
Srikanth Mysore, C. 2.197
Srinivasan, S. 3.253
St. Louis, E. 2.192
St. Louis, L. 1.197, 3.246
Staba, R. 1.177
Stacey, W. 3.042, 3.067, 3.167,
3.182
Stafstrom, C. 1.169, 2.023, 3.267,
3.270
Staley, K. 1.011, 1.021, 2.328, 3.004,
3.022, 3.023
Stamatoyannopoulos, J. 1.103
Stamboulian-Platel, S. 1.039
Standridge, S. 2.229, 3.247
Stanisic, M. 3.366
Stanslaski, S. 1.073
Stanton, P. 1.295
Starski, P. 3.042
Stead, M. 1.175, 2.156, 3.071
Steenland, H. 1.017
Stefan, H. 1.346, 3.349, 1.146
Steger, H. 2.165
Stemmer, P.M. 3.056
Stence, N. 2.103, 3.279
Stephani, U. 1.115, 2.199, 3.090
Stephen, L. 1.331
Stern, E. 2.236
Stern, J. 1.278, 3.291, 3.292
Steve, T.A. 1.253
Steven, D. 2.054
Stieglitz, T. 3.068
Stino, A. 2.214
Stockis, A. 2.307, 2.310
Stocks, J.D. 1.337, 1.343
Stoll, J. 3.342
Stoll, S. 3.075, 3.078, 3.085, 3.127
Stoltenberg, C. 2.072
Storrs, J.M. 1.257
Story, T. 2.320, 3.291, 3.292
Storzbach, D. 2.269
Stoub, T. 3.264
Straub, H.B. 3.349
Strauman, M.C. A.08
Straussberg, R. 3.090
Streiner, D.L. 1.100
Striano, P. 1.113, 1.115
Striano, S. 1.113, 1.320, 1.322
Stribling, J. 2.064
Stringer, K. 2.303
Strode, D. 1.003
Strom, L. 1.314, 2.053, 3.205, 3.304
Struck, P.J. 2.325
Stufflebeam, S. 1.256, 1.258
Suchdev, K. 3.250
Sudo, A. 1.116
Sueiras, M. 3.237
Sugai, K. 1.147, 1.365, 2.225, 2.341
Sugano, H. 1.358, 1.363, 1.370,
3.012
Sukigara, S. 3.114
Sulc, V. 2.156
Sullivan, J. 1.136, 2.309, 3.095,
3.214, 3.303
Suls, A. 1.115
Sumi, Y. 2.091, 2.093, 2.097
Sumpter, R. 2.015
Sun, F. 1.209, 2.209
Sun, H. 1.028, 3.007, 3.041
Sun, P.Y. 1.193
Sunderam, S. 1.071, 1.077
Sundstrom, D. 3.218
Sunkaraneni, S. 1.312, 1.314, 1.319,
1.320, 1.321
Sunnen, C. 3.050
Sunwoo, J. 2.168, 3.196
Suren, P. 2.072
Suresh, S. A.07
Sutton, S. 2.057
Suwanpakdee, P. 1.240, 1.362
Suzuki, H. 2.132
Suzuki, N. 1.256, 1.258, 2.154
Svehlik, V. 1.175, 3.071
Sveinsson, O. 3.128
Svendsen, K.H. 1.272
Svendsen, T. 2.282
Svenson, L. 2.051
Swaminathan, A. 2.258
Swann, J. 1.013, C.04
Swearingen, R. 2.034
Swedo, S. 3.166
Sweeney, M. 3.324
Sweet, J. A.07
Swenson, A. 2.100
Swiercz, W. 1.011, 2.328
Sylvester, C. 1.080
Szabo, C. 2.028, 3.052, 3.315
Szabo, G.G. C.03
Szaflarski, B.A. 1.257
Szaflarski, J. 1.236, 1.257, 1.281,
1.310, 1.324, 1.330, 2.024, 2.161,
2.163, 2.285, 2.286, 2.287, 3.203,
3.226, B.09
Szaflarski, M. 1.281, 1.310
Szklarski, L. 2.016
Szu, J. 2.238, 3.119
Sætre, E. 2.282
T
Tabata, A. 2.091, 2.097
Taccone, F. 1.141
Tadlock, D. 3.156
Tailby, C. 2.243
Takada, S. 1.220
Takagi, Y. 1.350
Takahashi, A. 1.147, 1.365, 2.225,
2.341, 3.114
Takahashi, K. 2.174
Takahashi, R. 1.110, 1.350
Takahashi, Y. 2.335, 3.198
Takami, Y. 1.116
Takeoka, M. 1.098, 2.017, 3.169,
3.236, 3.361
Takeshita, S. 1.116
Takeuchi, T. 1.235, 1.243
Takumi, I. 3.365
Talib, L.L. 1.122
Talos, D.M. 3.041
Talypov, A. 1.059, 2.076
Tamber, M. 3.331
Tampieri, D. 1.121
Tan, M. 1.231
Tanaka, N. 1.256, 1.258
Tanaka, S. 2.091, 2.093, 2.097
Tanaka, T. 1.220
Tandon, N. 3.060, 3.375
Tang, H. 2.025
Tang-Wai, R. 2.179
Tangel, V. 2.275, 3.135, 3.081
Tani, N. 2.357
Tankovic, A. 3.014
Tanuma, N. 2.202
Tao, J. 2.102, 3.160
Tao, W. 1.015
Tapia, M. 2.037
Taplinger, D. 2.267
Tarquinio, D. 3.104
Tarrant, S. 3.325, 3.326
Tasker, R. 1.197, 3.202, 3.334, B.06
Tassi, L. 1.377, 2.184
Tatsuoka, C. 3.085, 3.127
Tatum, W. 1.349, 2.155, 2.256,
2.337, 2.339, 3.343
Tatum, W.O. 3.238
Tayah, T. 1.260
Taylor, C.T. 1.165
Taylor, D. 1.295
Tecoma, E. 2.005, 2.251
Tejada, J. 3.055
Tekeli, H. 3.170
Telecka, S. 2.003
Telesco, R. 2.159
Tellez-Zenteno, J. 1.228, 2.082, 2.095
Temkin, N. 2.039
Tenney, J. 1.152, 2.024, 3.111
Tennigkeit, F. 3.294, 3.295, 3.297,
3.298
Terashima, H. 1.116
Terhaerdt, J. 2.069
Terra, V. 3.055
Terrill, M. 1.263
Terry, D. 2.049
Terwilliger, V. 2.019, 3.272
Teskey, G. 1.030, 1.217,
Testa, F. 2.350
Teter, B. 1.214
Tezer-Filik, F. 1.124
Thadani, V. 1.286, 2.042
Thadur, S. 3.250
Thaker, A.A. 1.266
Thakur, D.S. 1.286
Thaler, A. 3.137, 3.208
Thaler, J. 3.137
Thamattoor, A. 1.014
Theodore, W. 1.002, 1.065, 1.150,
1.225, 2.356, 3.065, 3.084, 3.268,
3.278
Thibert, R. 1.123
Thiele, E. 3.303
Thippeswamy, T. 3.027
Thom, M. 3.110
Thomas, A.X. 3.011
ABSTRACT AUTHOR INDEX
Tripathi, M. 2.365
Trivisano, M. 3.360
Trobliger, R. 2.020
Troncoso, L. 1.118
Troncoso, M. 1.118
Trope, A. 3.059
Tropea, T. 1.271
Tsai, J. 3.178
Tsao, J. 3.222
Tseng, P. 2.081
Tseng, W.E. 3.221
Tsenov, G. 1.052
Tshionyi, M. 2.085
Tsimerinov, E. 2.227
Tsong, W. 3.301
Tsuchida, T. 1.136, 1.137, 2.351
Tsuchiya, K. 1.233
Tsuji, T. 1.224
Tu, P.H. 3.221
Tucker, D. 1.180, 1.263, 3.193
Turco, L. 2.041
Turnbull, J. 2.126
Turner, D. B.06
Turner, K. 3.243
Turner, M. 2.229
Tuxhorn, I. 3.207, 3.212
Tyler-Kabara, E. 3.331
Tyrlik, M. 2.003
Tyrlikova, I. 2.003, 2.301
Tzvetanov, P. 3.295, 3.298
U
Uchida, C.P. 3.251
Uchio, H. 1.116
Ueda, Y. 1.297
Uematsu, M. 1.367
Ueno, M. 1.300, 2.353
Ugorec, I. 1.140
Ugur Yilmaz, C. 1.053
Ukitsu, S. 2.353
Ullmann, J. 1.035
Umezu, M. 1.373
Ünalp, A. 1.229
UnCheol, L. 3.040
Ung, H. 3.183
Unnwongse, K. 2.073
Unterberger, I. 2.121, 2.169, 2.245,
2.262
Upchurch, K. 1.184
Upreti, C. 1.295
Urrestarazu, E. 2.153
Uysal, U. 2.111
Uzun, M. 2.075
Uzuner, G. 3.305
V
Vago, D.R. 2.236
Vajjala, V.S. 1.134
Vakili, R. 3.257
Vale, F. 2.360, 2.361
Valencia, I. 1.203, 2.035, 3.312
Valente, K. 1.122, 2.259, 2.260,
2.306, 3.076, 3.082
Valiante, T. 1.016, 3.200
Valle-Dorado, M. 1.001
Valton, L. 2.226
Valujskikh, A. 1.008
Van Bebber, S. 2.058
Van Cott, A.C. 1.284
Van den Maagdenberg, A.M. C.01
van der Linden, Jr., H. 2.274, 3.199
van Gerven, J.M. 2.307
Van Grunderbeek, W. 1.067
Van Kampen, A. 1.333
van Kranen-Mastenbroek, V. 1.138
Van Ness, P. 1.316, 2.038, 2.189,
2.193, 2.209, 3.083
Van Nieuwenhuyse, B. 3.028, C.08
Van Orman, C. 2.134
van Rijckevorsel, K. 1.067
Van Straten, A.F. 2.042
Vanasse, C. C.01
VanCott, A. 2.257
VanHaerents, S. 1.188, 1.205
Vanli- Yavuz, E. 2.224
Vannasing, P. 1.072, 1.260
Vannest, J. 1.353, 2.024
Vargas, L. 2.101, 2.120
Varni, J. 1.090
Varvel, N. 3.116
Vasoli, V. 1.175, 2.156, 3.071
Vater, I. 1.115
Vaughan, D. 2.243
Vaughn, B. 2.057
Vazquez, B. 1.213
Vazquez, M. 3.101
Vázquez Gregorio, R. 3.154
Veenstra, A. 2.013
Vega, C. 1.098, 3.169, 2.017
Velez, A. 2.028
Velez, F. 1.342, 1.344, 2.044
Velez, F.F. 1.273, 1.287
Velisek, L. 3.025, 3.122
Veliskova, J. 3.025, 3.122
Velmurugan, J. 1.143
Velmurugan, M. 1.223
Vena, J.E. 3.142
Venkatesan, C. 1.222
Venkatraghavan, L. 3.200
Venkatraman, K. 1.066
Ver Hoef, L. 1.236, 1.247, 1.249,
2.338, B.09
Verity, K. 2.015
Verma, A. 2.254
Vernet, M. 1.154
Vernier, E. 1.340
Vernino, S. 2.189
Verpillat, P. 1.334, 1.335, 1.336
Verrier, R.L. 3.218
Vestergaard, M. 2.266
Vezina, G. 3.355, 3.364
Vezzani, A. 1.020
Vibhute, P. 3.343
Vickrey, B. 1.357, 2.045
Vidaurre, J. 2.112
Vigevano, F. 2.146, 3.360
Vignoli, A. 3.243
Villagran, A. 2.317, 2.326
Villalobos, R. 1.274, 1.356
Villalobos Chávez, F. 3.311
Villani, F. 2.184, 3.360
Villanueva, V. 1.332
Villeda Hernandez, J. 2.334
Villega, F. 2.263
Vincent, J. 1.141
Vincentiis, S. 1.122, 2.259, 2.260,
2.306
Virta, J. 1.052
Viteri Torres, C. 2.153
Vitko, L.R. 3.321
Vitkovskiy, P. 1.062, 1.076, 1.164
Vlachos, I. 3.107
Voets, N. 3.344
Voges, J. 3.045, 3.058, 3.349
Vollaro, T. 2.311
Vollmar, C. 2.165, 3.211, 3.273
Volpe, A. 3.302
von Deimling, M. 1.115
von Ellenrieder, N. 3.163, 3.184, 3.185
von Spiczak, S. 1.115, 3.090
Vonck, K. 1.017, 1.067, 3.028, C.08
Vossler, D.G. 2.144
Vulliemoz, S. 2.244
Vyas, M. 2.313
W
Waber, D.P. 2.017
Wada, T. 1.116
Wade, A.G. 1.334, 1.335, 1.336
Wade, R. 2.297
Wadhawan, A. 2.365
Wadman, W. 3.028, C.08
Wagenaar, J.B. 3.167
Wagley, P. 3.118
Wagner, G. 1.067
Wagner, J. 2.271
Wagnon, J. C.09
Wainwright, M. B.06
Waldman, W. 3.298
Waldman Zadeh, W. 3.295
Walker, I.M. 3.322
Walker, J. 3.351
Walker, M. 1.057
Wallace, E. 3.033
Waller, K. 1.194
Walsh, N. 2.318
Walters, B. 3.348
Wambacq, I. 1.183
Wamil, M. A.08
Wang, G. 2.161, 2.163
Wang, H. 1.041, 1.103, 3.074, 3.249
Wang, J.L. 1.162
Wang, L. 1.016
Wang, P. C.06
Wang, S. 2.104, 3.241
Wang, X. 1.167, 1.273, 1.287
Wang, Y. 3.002, 3.113
Wang, Z. 1.240, 3.004
Wang, Z.I. 1.040, 3.359
Wannamaker, B. 3.142
Ward-Mitchell, R. 2.136
Wark, J.D. 1.291
Warner, M. 3.282
Warren, A. 3.287
Warren, C. 1.066
Warren, P. 1.330
Wasade, V.S. 2.208, 2.215, 2.252
ABSTRACT AUTHOR INDEX
Thomas, G.P. 1.246
Thomas, P. 2.226
Thomas, R. 3.092
Thome, U. 3.359
Thome Costa, U. 1.144, 2.172
Thome-Souza, S. 1.098, 1.329, 2.213,
3.202, 3.235
Thompson, A.L. 1.139
Thompson, D. 1.066
Thompson, D.M. 2.034
Thompson, E. 3.351
Thompson, L. 3.335
Thompson, M. 2.267, C.07
Thompson, N. 3.075, 3.078
Thomson, J. 1.076
Thomson, K. 1.050
Thorne, N.P. 3.100
Thurman, D. 2.047, 2.074, 3.130
Tian, N. 2.074
Tilton, N. 2.309, 3.303
Timarova, G. 2.304
Timmings, P. 3.180
Ting, T. 2.330, 3.288
Tippin Davis, B. 1.194
Tirol, F. 2.200, 3.162
Titus, J.B. 2.354
Toda, K. 1.359, 1.361
Todaro, M. 1.231, 1.291
Togrol, E. 3.170
Tohma, S. 2.091, 2.093, 2.097
Tohyama, J. 1.105, 1.116
Toledo, M. 1.332, 3.237, 3.309
Toler, J. 1.345
Tom, M. 2.046
Tominaga, K. 2.202
Tominaga, T. 1.367, 3.159
Tominaga, Y. 1.116
Tomson, T. 2.231
Topjian, A. 1.182, B.06
Torello, A. 1.020
Tornes, L. 2.063
Toropova, K. 1.121
Torres-Barba, D. 1.278
Torrez-Corzo, J. 1.356
Tosun, D. 1.252, 1.254, 3.254
Toth, E. 1.157
Tovar Quiroga, D.F. 2.138
Tovar-Spinoza, Z. 3.194, 3.357, 3.363
Toyoda, I. 1.014
Toyoshima, D. 1.220
Tracy, J. 1.255, 2.237
Tran, B. 3.017
Tran, H. 2.227
Tran, P.T. 2.123
Tran, T. 3.274
Tran, T.T. 2.036
Tran, Y.T. 3.370
Tranel, D. 1.079
Traynelis, S.F. 3.014
Treiman, D.M. 1.042
Treiman, L.J. 1.042
Tremblay, J. 1.072, 1.260
Trenado, C. 3.154
Trent, C. 1.054
Trifonov, I. 1.059, 2.076
Trinka, E. 1.317, 1.319, 2.068, 2.245,
3.228
107
ABSTRACT AUTHOR INDEX
Waseem, H. 2.360, 2.361
Washington III, J. 1.289
Wassermann, E. 3.065
Watanabe, K. 1.224, 1.235, 1.243
Watanabe, S. 1.259, 2.239, 2.307
Watanabe, T. 1.116
Watson, R. 2.339
Weaver, K.
Weber, Y. 1.115
Webster, E. 2.320, 3.296
Webster, R. 3.087
Wechsler, R. 3.291, 3.292
Wechsler, R.T. 1.312, 2.291
Weckhuysen, S. 1.114
Wedberg, E. 2.131
Wei, S.P. 2.042
Weinand, M. 1.349, 2.256, 2.337,
2.339
Weinstein, S. 2.351
Weinstock, A. 1.214
Weir, C. 3.129
Weiss, S. 2.353
Weiss, S.A. 1.057
Welter, E. 1.084, 3.085, 3.127
Welty, T. 1.324, 2.285, 2.286, 2.287
Wempe, M.F. 3.003
Wen, J.H. 3.030
Wen, M. 2.322
Wen, P. 3.098
Wenzel, L. 3.156
Werhahn, K. 3.294, 3.297
Werhahn, K.J. 3.291, 3.292, 3.299
Wesselkamper, K. 3.324
West, P.J. 3.020
Westerveld, M. 2.014, 2.248, 2.255,
3.276
Weston, M. 1.013
Westover, M. 1.154, 3.054, 3.203,
3.226
Wetjen, N. 1.355
Whalen, H. 3.215
Whalley, B.J.
Wharen, R. 1.349, 2.212, 2.337,
2.339, 3.343
Whealy, M.A. 2.079
Wheatley, M. 2.178, 3.261
Whelan, P. 1.025
Wheless, J. 2.195
White, A. 1.267, 3.039, 3.279
White, H. 1.050, 3.095
White, J. 3.105
Whitehead, M. 1.354
Whitfield-Gabrieli, S. 1.154
Whitmire, L. 3.206
Wicks, P. 2.058
Widjaja, E. 1.127, 1.189, 2.353
Wiebe, S. 1.285, 2.051, 2.067, 2.071,
2.082, 2.150, 2.198, 2.223, 3.139
Wiggs, E. 3.065, 3.084, 3.278
Wild, I. 3.295
Wilfong, A. 2.299, 2.333, 2.347,
3.307, 3.353, 3.358, 3.371, B.06
Wilk, P. 2.056, 3.134
Wilkening, G. 1.098, 2.012, 2.103
Williams, B. 1.325, 2.276, 2.279,
2.288, 2.289, 2.291, 2.293, 2.294,
2.295
Williams, J. 3.033
108
Williams, K. 1.182, B.06
Williams, P. 3.296
Williams, S. 3.331
Williamson, J. 1.037, 3.115
Willie, J. 1.349, 2.256, 2.337, 2.339,
3.344
Willmore, L. 1.297
Wilman, A.H. 1.253
Wilner, A. 1.270
Wilson, D.A. 2.087, 3.142
Wilson, J.A. 1.353
Winawer, M. 2.275, 3.081, 3.135
Wirrell, E. 1.193, 1.206, 1.355,
1.364, 2.035, 2.079, 2.203, 3.145,
3.158, 3.229
Wise, C.A. 1.120
Wisnowski, J. 2.159
Wlodek, M.E. 1.047
Woldoff, S. 2.016
Wolf, E.G. 3.005
Wolf, S. 3.316, 3.356
Wolff, M. 1.118
Wollack, J.B. 1.134
Wolter-Warmerdam, K. 3.209
Wong, C.H. 3.286
Wong, J. 1.046, 3.106
Wong, M. 1.024, 3.013,
Wong, P. 3.304
Wong, S. 1.145, 2.325
Wong, S.M. 3.153
Wong, V.S. 1.209, 1.277, 2.118
Wong-Kisiel, L. 1.193, 1.355, 1.364,
2.079, 2.203, 3.148, 3.158, 3.214,
3.229
Woo, D. 1.036
Woo, Y. 1.117
Wood, R. 3.129
Woodard, V. 3.367
Woodrum, D. 2.339
Woodward, R. 2.136
Works, K. 2.084
Worrell, G. 1.169, 1.175, 1.374,
1.377, 2.156, 2.212, 2.256, 2.337,
2.339, 3.071, 3.158
Wrede, J. 3.245
Wright, C. 2.070
Wu, C. 2.256
Wu, E. 1.213
Wu, J. 1.245, 2.355, 3.249, 3.255,
3.262
Wu, J.Y. 2.358
Wu, R. 1.062
Wu, S. 2.102, 3.160
Wu, T. 3.221
Wu, X. 1.029, 1.031, 1.033
Wu, Y.W. 3.222
Wulsin, A.C. 3.010
Wulsin, D. 3.183
Wusthoff, C. 1.136, 1.182
Wyatt, K. 1.193
Wyllie, E. 1.149, 1.362
X
Xiao, W.R. B.01
Xie, J. 1.017
Xing, D. 1.325, 2.276, 2.279, 2.288,
2.291
Xiong, W. 1.155
Xu, D. 3.024
Xu, M. 3.017
Yue, C. C.06
Yum, M. 1.036, 1.328
Y
Z
Yacubian, E. 2.327, 3.251, 3.369
Yadav, A. 3.207, 3.212
Yaffe, R.B. 2.010
Yaghouby, F. 1.071, 1.077
Yagiri, E. 2.132
Yakovlev, A. 2.076
Yamada, M. 2.116
Yamagata, S. 2.080
Yamaguchi, T. 1.116
Yamamoto, H. 1.235, 1.243, 1.365,
2.158
Yamamoto, T. 1.371, 1.373
Yamao, Y. 1.350, 2.335
Yamashita, H. 1.110
Yamashita, S. 3.165
Yamauchi, K. 2.132
Yamazaki, E. 3.216
Yamazoe, T. 1.371
Yan, B. 3.285
Yan, C. 2.246
Yanagisawa, T. 1.060, 2.357
Yang, A. 1.182
Yang, G. 1.102
Yang, H. 1.325, 2.276, 2.279, 2.288,
2.289, 2.291, 2.293, 2.294, 2.295
Yang, M. 3.013
Yang, T. 1.170
Yang, X. 1.372
Yang Kao, Y. 2.094
Yao, D. 3.285
Yarbrough, C. 1.372
Yardi, R. 1.226
Yardi, R. 1.347, 1.377
Yasuda, C. 3.259, 3.260, 3.261
Yasuda, R. 1.269
Yates, S. 3.300
Yaun, A. 2.351
Ye, S. 1.126
Yelvington, K.H. 2.155, 3.238
Yeom, J. 1.170
Yerra, S. 1.231
Yildirim Capraz, I. 1.207
Yilmaz, C. 1.229
Yilmaz, U. 3.328
Ying, Z. 1.008, 1.012, 1.040
Yogi, A. 1.238, 1.245, 1.261, 3.255,
3.262
Yokoi, S. 1.235, 1.243
Yokota, T. 1.371
Yoon, J. 1.211
Yoon, J.W. 3.343
Yoong, M. 1.092, 2.015
Yoshimine, T. 1.060, 2.357
Yoshimura, K. 3.216
Young, G. 3.109
Youroukos, S. 2.187
Yozawitz, E. 3.214
Yu, H. 1.351
Yu, J. 2.314, 2.315
Yu, R. 3.354
Yu, W. 2.227
Yuan, H. 3.014
Yudovin, S. 1.245
Zack, M. 2.074
Zadeh, N. 1.106
Zaehle, T. 3.349
Zafar, H. 3.106
Zaghloul, K. 1.150
zaghloul, K. 3.084
Zaghloul, K.A. 2.010
Zaher, A. 2.272
Zaidi, S. 3.015
Zak, M. 1.208
Zamarian, L. 2.245
Zambrelli, E. 3.243
Zanelli, P. 3.097
Zanelli, S.A. 3.118
Zangen, A. 3.337
Zanotti-Fregonara, P. 1.002
Zanotto, F. 3.220
Zaveri, H. 1.041, 1.156, 2.151, 2.350,
3.074, 3.136
Zawadzki, L. 2.023, 3.267
Zeft, A. 1.192
Zeiger, M. A.09
Zelleke, T. 2.351, 3.141
Zelmann, R. 2.358
Zemblis, J. 3.215
Zeng, C. 1.023
Zeng, L. 2.323
Zeng, R. 1.088
Zerbs, A. 3.228
Zeuthen, T. 1.021
Zhan, H. 3.030
Zhan, Q. 1.044, 1.164
Zhang, B. 3.013
Zhang, C. 3.260
Zhang, G. 3.127
Zhang, H. 3.005, C.02
Zhang, L. 3.092
Zhang, M. 2.249
Zhang, S. 3.136
Zhang, W. 2.026, 2.235
Zhao, B. 1.057
Zhao, G.Q. 3.004
Zhao, J. 1.043
Zhao, Z. 3.286
Zheng, N. 3.288, 3.310
Zhou, C. 3.015
Zhou, D. 3.285
Zhou, J. C.06
Zhou, R. 3.222
Zhou, X. 3.166
Ziemba, K.S. 2.139
Zillgitt, A. 1.151, 2.215, 2.252
Zimmerman, A.M. 2.325
Ziobro, J. 2.351
Zoghbi, S. 1.002
Zohrevand, P. 2.222
Zou, J. 3.013
Zrik, A. 3.212
Zubair, M.N. 3.373
Zupanc, M. 2.013
Zutshi, D. 3.250
COMMERCIAL SUPPORTER RECOGNITION
All as of October 21, 2014
Benefactor Level
Special thanks to:
Sunovion
Pharmaceuticals Inc.
for supporting:
• Exhibit
• Program Book Ad
• Media Wall Spots (3 days)
• Footprints
• virtualTote Bag Banner Ad
• virtualTote Bag Insert
• Cell Phone Charging Station
(3 days)
• Networking Massage
Lounge (3 days)
• Airport Baggage Carousel
Display AD
• Passport to Prizes
• Innovation Pavilion
(Saturday / Sunday)
• Cyber Café (3 days)
Door Drops
Scientific Exhibit
Office Rental in Exhibit Hall
Epilepsy Currents Ads
Educational Grant Annual Fundamentals
Symposium, AET Symposium
• AES Fellows / EpiPORT
• SIGs (2)
SUPPORTER LEVELS
• Suds for Science Reception •
• Lunch in Exhibit Hall
•
(3 days)
•
• Poster Session Breakfast
•
(2 days)
•
• Coffee Break in Exhibit Hall
(3 days)
109
Leader Level
Special thanks to:
Eisai, Inc.
for supporting:
• Exhibit
• Program Book Ad
• Innovation Pavilion (Monday)
• virtualTote Bag Banner Ad
• Passport to Prizes
• Door Drops
• Epilepsy Currents Ads
• Named Fellowship (Sustained)
• Nurse / Young Investigator Awards
• AES Fellows / EpiPORT
• Educational Grant – Epilepsy Specialist Symposium,
Annual Fundamentals Symposium, AET Symposium,
Professionals in Epilepsy Care Symposium
110
Leader Level
Special thanks to:
UCB, Inc.
for supporting:
• Exhibit
• Program Book Ad
• Scientific Exhibits
• Educational Grant — Epilepsy Specialist Symposium,
Annual Fundamentals Symposium, AET Symposium
• AES Fellows / EpiPORT
• Cyber Café (3 days)
• Media Wall Spot (3 days)
• Coffee Break in Exhibit Hall (2 days)
SUPPORTER LEVELS
111
Partner Level
Special thanks to:
Lundbeck
Pharmaceuticals, Inc.
for supporting:
• Exhibit
• Program Book Ad
• Media Wall spot (2 days)
• Innovation Pavilion (Saturday / Sunday)
• Passport to Prizes
• Door Drops
• Scientific Exhibit
• Epilepsy Currents Ads
• Educational Grant — AET Symposium,
Annual Fundamentals Symposium
112
Partner Level
Special thanks to:
Upsher-Smith
Laboratories, Inc.
for supporting:
• Exhibit
• Hoyer Lecture
• Program Book Ad
• Passport to Prizes
• Door Drops
• Scientific Exhibits
• Epilepsy Currents Ads
• Seed Grant
• AES Fellows / EpiPORT
• Year Round Education
SUPPORTER LEVELS
113
Supporter Level
Special thanks to:
for supporting:
Cyberonics, Inc.
• Exhibit
• Innovation Pavilion
(Saturday / Sunday)
• Scientific Exhibit
• Named Fellowship (Sustained)
• Educational Grant — Annual
Fundamentals Symposium
Supporter Level
114
Special thanks to:
for supporting:
Natus Neurology
Incorporated
• Exhibit
• Auction of XLTEK LTM
System
Supporter Level
Special thanks to:
Supernus
Pharmaceuticals,
Inc.
for supporting:
•
•
•
•
•
•
Exhibit
Program Book Ad
Passport to Prizes
Door Drop
AES Fellows / EpiPORT
Educational Grant — Annual
Fundamentals Symposium
Supporter Level
for supporting:
Mallinckrodt
Pharmaceuticals
• Exhibit
• Epilepsy Currents Ads
• Educational Grant —
Pediatric State of the
Art Symposium
SUPPORTER LEVELS
Special thanks to:
115
Supporter Level
Special thanks to:
for supporting:
Acorda
Therapeutics
• Investigator Workshop
• SIGs (2)
• Program Book Ad
• virtualTotebag Banner Ad
• Epilepsy Currents Ads
• AES Fellows / EpiPORT
116
Contributor Level
Contributor Level
Special thanks to:
Special thanks to:
Nihon Kohden
America, Inc.
Cadwell
Laboratories, Inc.
for supporting:
for supporting:
• Exhibit
• Exhibit
• Media Wall Spot (2 days)
• Auction of EEG-1200
• Footprints
• Passport to Prizes
• Epilepsy Currents Ads
Contributor Level
Contributor Level
Special thanks to:
Compumedics
Limited
• Exhibit
• Epilepsy Currents Ad
Pfizer Inc.
for supporting:
• General Conference Grant
SUPPORTER LEVELS
for supporting:
Special thanks to:
117
Advocate Level
Special thanks to these companies for supporting:
NeuroPace, Inc.
• Exhibit
• Innovation Pavilion (Saturday/Sunday)
ELEKTA
• Exhibit
• Epilepsy Currents Ad
Electrical
Geodesics, Inc.
• Exhibit
• Epilepsy Currents Ad
• Educational Grant —
Annual Course
Medtronic, Inc.
• Exhibit
• Nurse/Young Investigator’s Awards
118
GW Pharmaceuticals
• Exhibit
• Investigator’s Workshop (1)
• SIG (1)
Blackrock
Microsystems, LLC
• Exhibit
Patron Level
Special thanks to these
companies for supporting:
Rhythm Link
• Exhibit
• Epilepsy Currents Ad
PMT Corporation
• Exhibit
Ripple LLC
Ad-Tech Medical
Instrument Corp.
• Exhibit
Monteris Medical, Inc.
• Exhibit
Medical Neurogenetics,
LLC
• Exhibit
• Exhibit
Lifelines Neurodiagnostics
Systems, Inc.
• Exhibit
The Jack Pribaz Foundation
• Exhibit
• Passport to Prizes
• Media Wall Spot (3 days)
Nexstim, Inc.
• Exhibit
Neurolynx, Inc.
• Exhibit
SUPPORTER LEVELS
119
GENERAL INFORMATION
AES 2014 Annual Meeting
The American Epilepsy Society (AES) is one of 108 Chapters of the
International League Against Epilepsy (ILAE). The Annual Meeting of the
American Epilepsy Society is the largest meeting and exhibition in the world
for those who share the common scientific and clinical interests of epilepsy
and clinical neurophysiology. The meeting attracts more than 4,000 attendees
dedicated to improving the quality of life for those dealing with epilepsy. This
meeting is the top forum to examine common concerns and to gain insight
from leading authorities.
Mission Statement
The American Epilepsy Society advances research and education for
professionals dedicated to the prevention, treatment and cure of epilepsy.
Target Audiences
Basic: Those new to epilepsy treatment or whose background is limited, e.g.,
students, residents, general physicians, general neurologists and
neurosurgeons, other professionals in epilepsy care, administrators.
Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons,
and other providers with experience in epilepsy care (e.g., advanced practice
nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic
and translational researchers.
Advanced: Symposia will address highly technical or complex topics
(e.g., neurophysiology, advanced imaging techniques or advanced treatment
modalities, including surgery).
Policy on Commercial Support and Conflict
of Interest
The American Epilepsy Society maintains a policy on the use of commercial
support, which ensures that all educational activities sponsored by the AES
provide in-depth presentations that are fair, balanced, independent and
scientifically rigorous. All faculty, planning committee members, editors,
and other individuals who are in a position to control content are required to
disclose any relevant relationships with any commercial interests related to
the activity. The existence of these interests or relationships is not viewed as
implying bias or decreasing the value of the presentations. All educational
materials are reviewed for fair balance, scientific objectivity and levels of
evidence. This information will also be made available through syllabus
materials and faculty presentations.
Disclosure of Unlabeled / Unapproved Uses
This educational program may include references to the use of products for
indications not approved by the FDA. These discussions are noted on the
faculty’s disclosure forms as well as during their presentations. Opinions
expressed with regard to unapproved uses of products are solely those of the
faculty and are not endorsed by the American Epilepsy Society or any
manufacturers of pharmaceuticals.
Abstracts
Abstracts from the 2014 Annual Meeting are available on the AES website
and will also be available as an online supplement to Epilepsy Currents.
Accreditation
The American Epilepsy Society is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to offer
continuing medical education for physicians.
Credit Designation
Physicians: The American Epilepsy Society designates this live activity for a
maximum of 32.75 AMA PRA Category 1 CreditsTM. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
Physician Assistant: AAPA accepts certificates of participation for
educational activities certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 32.75 hours of Category 1
credit for completing this program.
120
Nursing: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare
and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare
is accredited as a provider of continuing nursing education by the American
Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 30.75 contact hours.
Nurse Practitioners: Jointly provided by AKH Inc., Advancing Knowledge in
Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in
Healthcare is accredited by the American Association of Nurse Practitioners
as an approved provider of nurse practitioner continuing education. Provider
Number: 030803.
This program is accredited for 30.75 contact hours which includes 7.0 hours
of pharmacology. Program ID #21424
This program was planned in accordance with AANP CE Standards and
Policies and AANP Commercial Support Standards.
Pharmacy: Jointly provided by AKH Inc., Advancing Knowledge in
Healthcare and American Epilepsy Society. AKH Inc., Advancing
Knowledge in Healthcare is accredited by the Accreditation Council
for Pharmacy Education as a provider of continuing pharmacy education.
Select portions of this Annual Meeting are approved for pharmacy CE credit.
Specific hours of credit for approved presentations and Universal Activity
Numbers assigned to those presentations are found elsewhere in program
materials. Criteria for success: Credit is based on documented program
attendance and online completion of a program evaluation / assessment.
If you have any questions about this CE activity, please contact AKH Inc. at
[email protected].
International Credits: The American Medical Association has determined
that non-U.S. licensed physicians who participate in this CME activity are
eligible for AMA PRA Category 1 Credits TM.
CME / CE Certificates
The Medical Education Evaluator® is an online system that allows attendees
to complete course evaluations, track educational credits and print out the
appropriate certificate.
Once you have accessed the Medical Education Evaluator®, you will be
asked to enter your “myAES number” and password that you created. The
certificate(s) are saved to your personal account page and are cumulative.
You may print the certificate(s) at any time.
The following fees apply for obtaining educational credits:
Member Fees:
$50 through January 16, 2015
$75 January 17 – February 27, 2015
Non-member Fees:
$75 through January 16, 2015
$100 January 17 – February 27, 2015
The online Evaluator will be open through February 27, 2015. You
must complete the evaluations and credit tracking by that date.
Completing this information online also assists the Council on Education and
Annual Meeting Committee with important needs assessment data so AES
can further plan and address educational gaps to meet the needs of our
learners.
Attendance Certificate / International Attendees
A meeting attendance certificate will be available at the registration desk for
international meeting attendees on Tuesday, December 9.
Handouts
Handouts for the educational symposia will be available
via the virtualTotebag. For instructions: please refer to
the flyer provided in your meeting bag or go to the AES
website for details at www.AESnet.org.
Questions? Please contact virtualTotebag Support Desk at 410.402.1062
Email: [email protected]
GENERAL INFORMATION
Audience Response System
Press Room
Commercial Exhibits (page 82)
AES offers meeting information and assistance for journalists reporting on
epilepsy studies, educational presentations, and special reports at this
meeting. The AES on-site Press Room staff works with journalists to develop
stories, research facts and information, and connect with experts and
presenters. The on-site Press Room is also available to sponsors and
exhibitors for the display and distribution of relevant press releases and media
kits. For more information, contact Ellen Cupo at (203) 314-6545 and
[email protected], or Natalie Judd at (203) 605-9515 and
[email protected].
AES will be utilizing the Audience Response System (ARS) in several of the
symposia. Faculty will have ARS questions throughout their presentations with
multiple choice answers. To participate, you will use your cell phone to text
your reply. When a question appears in a presentation, simply text your
answer (a 5 or 6 digit code) to “22333.” Standard text rates will apply. The
ARS will allow for interactive audience participation as well as real time,
immediate feedback to enhance the learning environment and ensure that we
are meeting the learning objectives set forth by each symposium.
The Exhibit Hall is an integral part of the learning experience. Meeting
participants will have an ideal opportunity to learn about the latest in
pharmaceuticals, publications, scientific equipment, and technology relevant
to the fields of epilepsy and neurophysiology. Please check the AES website
for an updated listing of exhibiting companies and organizations. To ensure
safety and security, no children under 12 years of age, strollers, carriages,
wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall
during exhibit hours.
Saturday, December 6
Sunday, December 7
Monday, December 8
Noon - 6:00 p.m.
10:00 a.m. - 6:00 p.m.
10:00 a.m. - 3:00 p.m.
Scientific Exhibits (page 23)
AES has approved guidelines for industry-sponsored Scientific Exhibits at the
Annual Meeting. Scientific Exhibits differ from traditional poster presentations
in that a broad range of material can be presented as a collection of topics,
such as results of various clinical trials, or a thematic presentation of one
aspect of drug development. Scientific Exhibits will be displayed on Sunday,
December 7 and Monday, December 8. An application to register for a
Scientific Exhibit was emailed to interested companies in June. Reservations
will be reviewed and accepted on a first-come, first-served basis until space
is sold out. Send inquiries of interest to JoLynn Amsden at
[email protected].
Cyber Café
Convention Center – Exhibit Hall 4B, Level 4
Open during Exhibit Hall hours
The Cyber Café will be available during Exhibit Hall hours at the Convention
Center with email and Internet access. You will also be able to complete the
course evaluations and obtain your CME certificate online. For your convenience,
Wi-Fi will also be available in the Convention Center.
Photography and Recording of Programs
AES strictly prohibits all photography (flash, digital, or otherwise), audio and /
or videotaping during the Annual Meeting. Equipment will be confiscated.
Material presented at the AES Annual Meeting is not to be reproduced in any
format without the express written consent of the AES. Attendees acknowledge
and agree that commercial or promotional distribution, publishing or
exploitation of speaker sessions, content, or materials from the AES Annual
Meeting is strictly prohibited unless you have received the express prior
written permission from AES or the otherwise applicable rights holder.
Business Centers
Two full-service FedEx Office business centers are conveniently located in
Seattle for Annual Meeting attendees. Both offer a variety of services which
include shipping, mailing, faxing and photocopying. Please contact the office
directly for details.
Washington State Convention Center, Level 1 (Suite 11-13)
http://local.fedex.com/wa/seattle/office-5161/
Phone: 206.467.1767
Sheraton Seattle Hotel, Level 2
http://local.fedex.com/wa/seattle/office-5539/
Phone: 206.467.5885
Friday, December 5 ..................................................
Saturday, December 6 ..............................................
Sunday, December 7 ................................................
Monday, December 8 ..............................................
Tuesday, December 9................................................
11:00 a.m. - 6:30 p.m.
7:30 a.m. - 6:30 p.m.
7:30 a.m. - 6:30 p.m.
7:30 a.m. - 6:30 p.m.
7:30 a.m. - 1:00 p.m.
A series of media briefings on a select number of topics will be held in the
press room from Friday, December 5 through Monday, December 8. Details
will be posted in Room 304, Level 3 at the Washington State Convention
Center and in advance on the AES website Press Room after December 1.
Hotel Information
Early Departure Policy
Guests who check out of the hotel prior to their scheduled departure date will
be charged a penalty of one night’s room rate and tax.
Sheraton Seattle Hotel (Headquarters Hotel)
1400 Sixth Avenue, Seattle, Washington 98101
Telephone: 206.621.9000
Crown Plaza Hotel Seattle
1113 Sixth Avenue, Seattle, WA 98101
Telephone: 206.464.1980
Grand Hyatt Seattle
721 Pine Street, Seattle, WA 98101
Telephone: 206.774.1234
Hyatt at Olive 8 Seattle
1635 8th Avenue, Seattle, WA 98101
Telephone: 206.695.1234
Hilton Seattle
1301 Sixth Avenue, Seattle, WA 98101
Telephone: 206.624.0500
Mayflower Park Hotel
405 Olive Way, Seattle, WA 98101
Telephone: 206.623.8700
Motif Seattle Hotel (formerly the Red Lion)
1415 Fifth Avenue, Seattle, WA 98101
Telephone: 206.971.8000
Renaissance Seattle Hotel
515 Madison Street, Seattle, WA 98101
Telephone: 206.583.0300
The Fairmont Olympic Seattle
411 University Street, Seattle, WA 98101
Telephone: 206.621.170
The Paramount Hotel
724 Pine Street, Seattle, WA 98101
Telephone: 206.292.9500
The Roosevelt Hotel
1531 7th Avenue, Seattle, WA 98101
Telephone: 206.621.1200
Warwick Seattle Hotel
401 Lenora Street, Seattle, WA 98121
Telephone: 206.443.4300
Meeting Location
Washington State Convention Center
800 Convention Place, Seattle, WA 98101-2350
GENERAL INFORMATION
When you attend an approved AES event or program, you enter an area where
photography, audio, and video recording may occur. By entering the event
premises, you consent to photography and its release, publication, exhibition,
or reproduction to be used for news, newsletters, promotional purposes,
advertising, inclusion on websites, or any other purpose by AES and
representatives. You release AES, its officers and employees, and each and all
persons involved from any liability connected with the taking, digitizing, or
publication of photographs and computer images. You have been fully informed
of your consent, waiver of liability, and release before entering the event.
Convention Center – Room 304, Level 3
121
GENERAL INFORMATION
Program Changes
AES cannot assume liability for any changes in the program due to external or
unforeseen circumstances.
Language
The official language of the Annual Meeting is English.
Meeting Attire
Dress for the Annual Meeting is business casual. Consider bringing a light
jacket or sweater with you since meeting room temperatures and personal
comfort levels vary.
No Smoking Policy
For the comfort and health of all attendees, smoking is not permitted at any
AES function. This includes educational sessions, meetings and all food
functions. Both the Convention Center and the Sheraton Seattle are smokefree facilities. Also, smoking is not permitted in public buildings, restaurants
or bars.
Gratuities
Gratuities are not automatically added to the bill, except in some cases for
large groups. Waiters and waitresses are usually given 15% to 20% of the bill.
Taxi drivers usually receive 15% of the fare and doormen and $2 per night for
hotel housekeeping. Skycaps and porters are normally tipped $1 per bag.
Registration & Security
AES is committed to providing a secure meeting environment. A formal
security plan is developed in consultation with the Security Department at the
Convention Center. All meeting attendees will be required to produce
government-issued photo identification prior to receiving their badge and
registration materials. Appropriate badges must be worn at all times while in
attendance at the Annual Meeting and are required for admittance to all
meeting activities. Security procedures will also be in place for exhibition
materials and all deliveries to the Annual Meeting.
Insurance / Liabilities
AES cannot be held responsible for any personal injury, loss, damage,
accident to private property or additional expenses incurred as a result of
delays or changes in air, rail, sea, road, or other services, strikes, sickness,
weather, acts of terrorism and any other cause. All participants are
encouraged to make their own arrangements for health and travel insurance.
Contact Information
Safety and Security Information
The following security measures have been designed to further enhance your
personal and professional safety.
• Pick up any Convention Center house phone located in the facility and dial
5127 or 206.694.5127. Uniformed Convention Center employees have
radios and are ready to assist you. Advise the dispatcher of the exact
location within the Convention Center.
We respectfully request that you do NOT call 911 directly.
• An EMT will be on duty in the Convention Center throughout the meeting.
• A government-issued photo identification is required to receive a badge
and to replace a lost badge.
• Convention Center Security may randomly check packages and bags at the
Convention Center entrances, meeting rooms and in the Exhibit Hall.
• You will be asked to always clearly display your name badge and to use
only approved Convention Center entrances and exits.
• Appropriate badges will be required to enter all educational sessions,
Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire
regulations, doors will be closed to all session rooms that fill to capacity.
• Throughout the meeting, you will notice security staff presence to monitor
the safety of all participants.
• Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.)
in any area of the Convention Center or hotel.
• Please report any suspicious activity to security staff or to the AES
registration desk staff.
General Safety Tips
• Remove your badge once you leave the meeting facilities.
• Carry important telephone numbers with you.
• Do not display or carry large amounts of cash.
• Walk in groups, especially at night.
• Lock your hotel room door.
• Always verify hotel room repair or service calls.
• Do not disclose your room number to anyone.
• Never give your personal information (credit card, room number, etc.) over
the phone; instead, go to the front desk if the hotel calls with questions.
American Epilepsy Society
342 North Main Street, Suite 301
West Hartford, CT 06117-2507
Phone:
Meeting Fax:
Email:
Website:
860.586.7505, ext. 512
888.238.7428
[email protected]
www.AESnet.org
Faculty Ready Room and Photos
Location: Convention Center – Room 303, Level 3
Faculty need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint
presentations have already been uploaded through the AES Faculty Development Room. All faculty must stop by
to reconfirm their presentation with an audiovisual technician.
Thursday, December 4
Friday, December 5
..............................
..................................
4:00 p.m. - 8:00 p.m.
8:00 a.m. - 6:00 p.m.
Saturday, December 6 .............................. 8:00 a.m. - 6:00 p.m.
Sunday, December 7
................................
8:00 a.m. - 6:00 p.m.
Monday, December 8 ................................ 8:00 a.m. - 6:00 p.m.
Tuesday, December 9.............................. 8:00 a.m. - 11:00 a.m.
122
MAP OF SEATTLE, WA
8th
8
t h Av
ve
e. N.
N
.
St
d
oa
Br
.
St
St
ia
tS
t.
in
ew
ar
Vi
St
.
St
no
ra
Bl
Le
el
no
rA
.
no
rA
.
.
e.
rs
S
on
ve
ve
Av
f fe
sS
t.
r
f fe
so
nS
t.
Al
de
t.
rS
t.
Yesle
Y
Ye
es er W
Way
ay
SW
Washington
a s h n g to n S t .
S Main
M a n St .
S Jackson
J a c k s o n St .
on I
st S
Je
s
nA
We
ry
a
t tl e
Je
me
St .
n
sla n
ea t
t
CH
IN
’L ATO
SW
We
eller
er SDt IS W
TR N /
I
S Lane
L a n e St . C T
I
S King
K ng SN
t T
d
a
le W
te r
i
Ta x
Occidental
O
c c d e n t a Av
ve
e. S
Se
ash
to V
e r to
1st
1
s t Av
ve
e. S
ry
Fe r
B re m
Ja
St .
me
re
y to
Bo
Fe rr
ER
NE R E
PIO UA
SQ
F e r r y to B a i n b r i d g e I s l a n d
.
ry
.
St .
Ja
PIER
P
R 52
52
WA S
WA
STA
TAT
ATE
FERRIES
F
RR ES
r
Te
C
r
he
ve
ia
mb
ve
t.
hA
nS
lu
5
.
hA
St
.
Co
.
ve
e.
M
o
a ri
St
on
hA
Av
PI E R 5 5
ARGOS Y CRUISES/ TILLICUM VILL AGE
on
t.
is
ad
7t
rn
M
is
ad
M
gS
8t
.
ri n
ri n
9t
ve
Sp
t.
gS
St .
Mi
Sp
10
0 a St . 1
ec
n
Se
ca
.
.
S
3S
e
en
Broadway
Br
o a d w ay
ve
.
ve
r
Mi
ve
hA
e
niv
y
si t
U on
Unio
Un
n St .
t.
nTSE
WA
W
A SHIN
SH N GT
TO
ON STA
TAT
T
A
AT
nio
U
CONV
NVE
V NTIO
ON C
CENTER
R
6
ve
.
U
dA
te
e.
es
Av
T W
t
1s
KE
Fe r
P I E R 57
SE AT TLE GRE AT WHEEL
V illag e
ic u m
r y to T ill
St .
2n
AR
WATERFRONT PARK
A
S
U
n
nio
4
ve
M
PIER 59
SE AT TLE AQUARIUM
hA
dA
E
AC
E
4t
K
PI E R S 6 2 & 6 3
W
8
3r
W
ay
11
1
7
2
9
WE
W
E S TL
LAKE
AK
t.
St. PA
PARK ke S
e
n
Pi
Pi
PL
N
EI
N
PA BRU
RK E
C
e.
e.
KE
PI E R 6 6
BELL S T. CRUISE TERMINAL
n
Av
e.
e
hA
ST
ka
d
e.
5t
as
Av
Av
6t
Al
1s
t
e.12
1
PI
PIER 67
BELL HARBOR
CONFERENCE CENTER
2n
e.
rg
.
St
d
ar
ch
an
e.
Av
e.
Av
.
Av
Av
Av
Av
h
ve
tt
d
h
h
.
.
St
ll
Be
3r
lio
h
e.
9t
8t
w
.
St
y
er
tt
4t
e.
Ho
.
St
t.
W
al
lS
ne
e.
Av
Av
re
hA
El
Ba
Av
h
ry
lS
rS
t.
ay
rn
5t
h
7t
a B.C
.
P I E R 69
VIC TORIA CLIPPER
te
7t
6t
.
c to r i
e.
Vi
K
es
da
Cl
Av
Ce
oa
Br
R
PA
W
e.. N
ke Ave
Wes ttllake
DS
d
Ea
St
.
gl
AR
W
e
ED
St
.
E
1s
t
Bo
Crowne Plaza Hotel Seat tle
Grand Hyat t Seat tle
Hilton Seat tle
Motif Seat tle (formerly Red Lion)
Renaissance Seat tle Hotel
Sheraton Seat tle Hotel
The Paramount Hotel
May flower Park Hotel
The Roosevelt
The Fairmont Olympic Hotel
Hyat t at Olive 8
War wick Seat tle Hotel
C A L A N D E R SO N
PARK
A
TL
Denn
D
enn
Te
r
Ya
Y
a
YR
SC O L
U YM
PALPT PIC
RK UR
E
Ea
E
a
M
Denn
D
enny Wa
Way
ay
LEGEND
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
JJohn
ohn
DENN Y
PA
ARK
Po
P
o
JJohn
ohn S
St.
t
Min
M
n
Fairvi
Fa
r v e w Av
ve
e. N.
N
Boren
Bor
e n Av e
e.
Thoma
Th
homass St.
Terry
T
e r r y Av
ve
e. N.
N
Westlake
W
es t ake Av
ve
e. N.
N
6 t h Av e
e. N
N.
EMP MUSEUM
E.. M
E
Mercer
e rc e r St .
Harrison
H
arr son Stt..
Taylor
T
a y o r Av
ve
e. N .
CHIHULY
GARDEN
& G L A SS
PACIFIC
SCI E N CE
CENTER
Rep
epublican
ub c an St.
E . Ro
E.
oyy S
Stt.
9th
9
t h Av
ve
e. N.
N
SEAT TLE
CENTER
W J o h n St .
W.John
W.
M
MOH
AI
A
L AKE
K
UNION
I
PAR
ARK
Merce
M
ercer St.
5th
5
t h Av
ve
e. N.
N
W. Thomas
T h o m a s St .
D ex
xtte
err Av
ve
e. N .
Aurora
A
u r o r a Av
ve
e. N .
Ro
oyy St.
BILL
B
LL & MELIN
MEL NDA
GAT
G
ATE
AT
ES F
FOUN
OUN DAT
AT ON
ATION
Queen
Q
ueen Anne
A n n e Av
ve
e. N.
N
W. Harrison
H a r r s o n St .
to V i
Va
alley St.
Merce
M
ercerr St.
W. Rep
publican
u b c a n St .
Fe rr y
4 t h Av
ve
e. N.
N
2nd
2
n d Av
ve
e. N.
N
1sstt Av
ve
e. W.
W
Warren
W
a r r e n Av e
e. N.
1st
1
s t Av
ve
e. N.
N
2nd
2
n d Av
ve
e. W.
W
W.Ro
oyy St.
Aloh
A
oha
a St .
CENTURYLINK
FIELD
S Dearborn
D e a r b o r n St .
S Charles
C h a r e s St .
SP
Plumme
ummer St.
Pike Place Market to CenturyLink Event Center: 1 mi / 1.6 km
Pike Place Market to Space Needle: 1 mi / 1.6 km
Pike Place Market to Convention Center: ½ mi / 800 m
S . L A K E U N I O N S T R E E TC A R
PARK
BUS/LIGHT R AIL TUNNEL
BUS/LIGHT R AIL TUNNEL STAT
TION
SE AT TLE CENTER MONOR AIL
CONVENTION HOTEL
INFORMAT
TION CENTER
DR .
JOSE
R IZ AL
PARK
A
Ro
oyya
al B
Brougham
ro u g h a m W
Way
ay
S A F E CO F I E L D
Edgar
E
dgar Martinez
Ma r t n ez W
Way
ay
4 t h Av
ve
e.
MA JOR AT TR AC TION
CENTURYLINK
EVENT CENTER
123
WASHINGTON STATE CONVENTION CENTER
LEVEL 3
Faculty Ready Room (302)
Faculty Photo Room (303)
n Press Room (304)
n
n
Poster entrance when
exhibit hall is closed
LEVEL 4
Registration
Exhibit Hall
n Poster Sessions
n
n
124
WASHINGTON STATE CONVENTION CENTER
LEVEL 6
Ballrooms 6C and 6E
n Session Rooms
n Scientific Exhibits
n
125
SHERATON SEATTLE HOTEL
126
Seattle Children’s Epilepsy Program
Offers Unsurpassed Care
Seattle Children’s Epilepsy Program is the largest on the West Coast
dedicated to treating children and young adults up to age 21.
As part of the University of Washington’s Regional Epilepsy Center
and the Northwest Epilepsy Consortium, Seattle Children’s serves
patients in Washington, Alaska, Idaho and Montana.
Our six pediatric epileptologists collaborate with experts in
neurosurgery, neuropsychology and neuroradiology to provide
promising leading-edge options for children with epilepsy like laser
ablation. We have special expertise in neurogenetics, participated
in NIH sponsored EPGP and EPI-4K projects, and mitochondrial
disorders. We are active in epilepsy research and offer clinical trial
and study opportunities.
Learn more at www.seattlechildrens.org/epilepsy
127
127
THE MOST WIDELY READ AND HIGHLY
CITED PEER-REVIEWED NEUROLOGY JOURNAL
The Official Journal of the
American Academy of Neurology
One subscription...four ways to access
Neurology brings you:
ǦŠŠ—ǂ—Š›ŽŠœŠ‰—™Žˆ‘Š˜†“‰
Clinical/Scientific Notes
ǦŽŠœ˜ʮŠ›ŽŠœ˜ǩŽ“ˆ‘š‰Ž“Œ
Medical Hypothesis papers)
ǦŽ˜™”—Žˆ†‘Šš—”‘”Œž
Ǧ”“™Š’•”—†—ž˜˜šŠ˜
in Neurologic Practice
ǦŠš—”Images
Ǧ”‰ˆ†˜™˜
Ǧš’†“Ž™ŽŠ˜
Ǧ—Ž™Š‘Žˆ® – Online Correspondence
Ǧ””Š›ŽŠœ˜
Ǧ
‘”‡†‘Š—˜•Šˆ™Ž›Š˜
Ǧ”˜Ž™Ž”“•†•Š—˜†“‰ŒšŽ‰Š‘Ž“Š˜
‹—”’™Š
Enjoy full-text online access, including expedited e-pub, presentation downloads, search functions,
topic alerts, e-TOC service, RSS feeds of current issues and podcasts, mobile device downloads, and a
Resident & Fellow subsite. Plus, access Neurology on your iPad® for a print-like reading experience
enhanced with article-sharing features, links, and more!
Neurology.org
Visit Booth #400 for Meeting Discounts
4-R013
128
Neurology Clinical Practice
An Official Journal of the American Academy of Neurology
ǦAdditional Series Sections:™†™Ž˜™Žˆ˜Ž“‘Ž“Žˆ†‘
—†ˆ™ŽˆŠ†“‰—†ˆ™ŽˆŠˆ—”˜˜”—‰Š—˜
Ǧ••—”†ˆŠ˜™”•†™ŽŠ“™˜œŽ™›†—Ž”š˜“Šš—”‘”ŒŽˆ
ˆ”“‰Ž™Ž”“˜
Ǧ†˜Šǂ‡†˜Š‰†—™Žˆ‘Š˜”“Š™Žˆ†‘Ž˜˜šŠ˜
ǦǒŽ›ŠŠœŽ“Œ˜Ǔš•‰†™Š˜”“‰Ž˜Š†˜Š˜†“‰‰Ž˜”—‰Š—˜
Ǧ‹ʬˆŠǂ‡†˜Š‰Ž˜˜šŠ˜†“‰’†“†ŒŠ’Š“™™Ž•˜
ǦŠ†‘™•”‘Žˆž‰Ž˜ˆš˜˜Ž”“˜
Š’‡Š—˜”‹™Š’Š—Žˆ†“ˆ†‰Š’ž
”‹Šš—”‘”Œž—ŠˆŠŽ›ŠNeurology®
Clinical Practice†˜†‡Š“Šʬ™”‹
’Š’‡Š—˜Ž•ǀ“™Š—“†™Ž”“†‘Š’‡Š—˜
—ŠˆŠŽ›Š”“‘Ž“Šǂ”“‘ž†ˆˆŠ˜˜ǀ
”™†’Š’‡Š—lj
Š†—“’”—Š†‡”š™™Š†™
AAN.com/Membership.
Neurology.org/cp
Visit Booth #400 for Meeting Discounts
ȟǂțȜȟ
129
Indexed In: Biological Abstracts, BIOSIS, Current Contents/Clinical Medicine,
EMBASE, Excerpta Medica, Index Medicus, MEDLINE,
Neuroscience Citation Index, Research Alert, Scopus and Scisearch
Seminars in Neurology
Editor-in-Chief: D. Greer
2015/Volume 35/6 issues p.a./ISSN 0271-8235
USA and Canada
Individuals: $316 $253
Institutions: $1,054
Please contact [email protected]
For institutional licenses, please contact [email protected]
Mexico, Central and South America
Individuals: $343 $274
Institutions: $1,081
Please contact [email protected]
For institutional licenses, please contact [email protected]
Europe, Africa, Asia, Australia, New Zealand
Individuals: €336 €269
Institutions: €1,084
(Please add shipping charges: €57.00)
Please contact [email protected]
For institutional licenses, please contact [email protected]
Bangladesh, Bhutan, India, Nepal,
Pakistan, and Sri Lanka
For subscription rates in INR, please
contact [email protected]
SUBSCRIBE NOW AND STAY UP-TO-DATE IN 2015
Visit www.thieme.com/journals in order to subscribe or renew your subscription.
Take full advantage of your individual subscription by registering online at
www.thieme-connect.com/products:
• Individual subscribers get free online access to current and back issues of their journal(s)
• Advanced online access for select journals via the eFirst service
• Up-to-date Alerts via email or RSS-Feed
• Advanced search across our entire library of journals
ORDER TODAY
http://www.thieme.com
Become a fan at www.facebook.com/thiemepublishers.
130
Follow us @ThiemeNY
Exploring Critical Advances
in Brain Connection Research
Brain Connectivity is the premier peer-reviewed journal for cutting-edge
research in the expanding area of systems neuroscience.
Critical advancements in the
diagnosis and treatment of
neurodegenerative diseases
and psychiatric disorders
Vital information on brain
mapping, new imaging
modalities, and translating
research discoveries from
lab to clinic
Accepted in MEDLINE®
in its first year
Founding and Co-Editors-in-Chief:
Christopher P. Pawela, PhD
and Bharat B. Biswal, PhD
Subscribe Today!
www.liebertpub.com/brain
131
Adjunctive therapy for patients ages 12 and up
with partial-onset seizures1
NOVEL TARGET.
NOVEL POTENTIAL.
FYCOMPA®—the first and only non-competitive
AMPA receptor antagonist1-3
GET ON TARGET AT AES
Visit us at Booth #305
Indication
FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures
with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.
AES = American Epilepsy Society
132
Indication FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily
generalized seizures in patients with epilepsy aged 12 years and older.
Important Safety Information
WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS
• Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and
threats have been reported in patients taking FYCOMPA
• These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated
with hostility and aggression
• Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality
that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA
• Closely monitor patients particularly during the titration period and at higher doses
• FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening
Serious Psychiatric and Behavioral Reactions Hostility- and aggression-related
adverse reactions occurred in 12% and 20% of clinical trial patients randomized to
receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 6% of
patients in the placebo group. These effects were dose-related and generally appeared
within the first 6 weeks of treatment, although new events continued to be observed
through more than 37 weeks. These effects in FYCOMPA-treated patients led to
dose reduction, interruption, and discontinuation more frequently than placebotreated patients. The combination of alcohol and FYCOMPA significantly worsened mood
and increased anger. Patients taking FYCOMPA should avoid the use of alcohol.
Patients, their caregivers, and families should be informed that FYCOMPA may increase
the risk of psychiatric events. Patients should be monitored during treatment and for
at least one month after the last dose of FYCOMPA, and especially when taking higher
doses and during the initial few weeks of drug therapy (titration period) or at other times
of dose increases.
Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including
FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone
considering prescribing FYCOMPA or any other AED must balance the risk of suicidal
thoughts or behavior with the risk of untreated illness. Epilepsy and many other
illnesses for which AEDs are prescribed are themselves associated with morbidity
and mortality and an increased risk of suicidal thoughts and behavior. Patients, their
caregivers, and families should be informed of the risk and advised to monitor and
immediately report the emergence or worsening of depression, suicidal thoughts or
behavior, thoughts about self-harm, and/or any unusual changes in mood or behavior.
Should suicidal thoughts or behavior emerge during treatment, consider whether the
emergence of these symptoms in any given patient may be related to the illness
being treated.
Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in
events related to dizziness and disturbance in gait or coordination. Dizziness and
vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at
doses of 8 mg and 12 mg/day, respectively, compared to 10% of placebo-treated
patients. Gait disturbance related events were reported in 12% and 16% of patients
randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively,
compared to 2% of placebo-treated patients. These adverse reactions occurred
mostly during the titration phase.
Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence
and fatigue-related events. Somnolence was reported in 16% and 18% of patients
randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared
to 7% of placebo-treated patients. Fatigue-related events were reported in 12% and
15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day,
respectively, compared to 5% of placebo-treated patients. In the controlled Phase 3
epilepsy clinical trials, these adverse reactions occurred mostly during the titration
phase. Patients should be advised against engaging in hazardous activities requiring
mental alertness, such as operating motor vehicles or dangerous machinery, until the
effect of FYCOMPA is known.
Falls Falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at
doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated patients.
Withdrawal of AEDs A gradual withdrawal is generally recommended with
antiepileptic drugs to minimize the potential of increased seizure frequency.
Most Common Adverse Reactions In clinical trials, the most frequently reported
dose-related adverse reactions in patients receiving FYCOMPA 8 mg or 12 mg vs
placebo (≥4% and at least 1% higher than the placebo group) included dizziness
(36% vs 9%), somnolence (16% vs 7%), fatigue (10% vs 5%), irritability (9% vs 3%),
falls (7% vs 3%), nausea (7% vs 5%), ataxia (5% vs 0%), balance disorder (4% vs 1%),
gait disturbance (4% vs 1%), vertigo (4% vs 1%), and weight gain (4% vs 1%).
Drug Interactions FYCOMPA may decrease the efficacy of contraceptives containing
levonorgestrel. Plasma levels of FYCOMPA were decreased when administered with
carbamazepine, phenytoin and oxcarbazepine. Concomitant use with strong CYP3A
inducers such as St. John’s wort and rifampin should be avoided. Multiple dosing of
FYCOMPA 12 mg/day enhanced the effects of alcohol on vigilance and alertness, and
increased levels of anger, confusion, and depression. These effects may also be seen
when FYCOMPA is used in combination with other CNS depressants.
Pregnancy Category C and Lactation FYCOMPA should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus. Physicians are
advised to recommend that pregnant patients taking FYCOMPA enroll in the North
American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be
exercised when FYCOMPA is administered to a nursing woman.
Hepatic and Renal Impairment Use in patients with severe hepatic or severe
renal impairment is not recommended. Dosage adjustments are recommended in
patients with mild or moderate hepatic impairment. Use with caution in patients
with moderate renal impairment.
Drug Abuse and Dependence FYCOMPA is a Schedule III controlled drug substance
and has the potential to be abused or lead to drug dependence.
Please see Brief Summary of full Prescribing
Information on the next page for Boxed WARNING
and additional Important Safety Information.
References: 1. Fycompa Prescribing Information. Woodcliff Lake, NJ: Eisai
Inc.; June 2014. 2. Rogawski MA. Revisiting AMPA receptors as an antiepileptic
drug target. Epilepsy Curr. 2011;11:56-63. 3. Hanada T, Hashizume Y, Tokuhara
N, et al. Fycompa: a novel, orally active, noncompetitive AMPA-receptor
antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia.
2011;52:1331-1340.
FYCOMPA® is a registered trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc.
Manufactured and marketed by Eisai Inc., Woodcliff Lake, NJ 07677
© 2014 Eisai Inc. All rights reserved. FYCO0788 September 2014
133
NOTES
134
NOTES
135
NOTES
136
VISIT SUPERNUS PHARMACEUTICALS AT BOOTH #605
Get your Passport to Prizes
stamped at booth #605 each day
of the convention to be eligible
for the daily prize drawing
For more information visit
www.TrokendiXR.com and
www.OxtellarXR.com
Proudly Supports the American Epilepsy Society (AES) 2014 Annual Meeting
Trokendi XR and Oxtellar XR are registered trademarks of Supernus Pharmaceuticals, Inc.
©2014 Supernus Pharmaceuticals, Inc. All rights reserved. SPN.2014-0040
COME VISIT OUR BOOTH!
Learn more
about APTIOM
at Booth 105
Under license from
is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc., is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
©2014 Sunovion Pharmaceuticals Inc. All rights reserved. 09/14 APT435-14
AES
n
December 5 – 9, 2014
n
Seattle, Washington, USA